



IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION

1305 East Walnut – Des Moines, IA 50309 ☐ (515) 974-3131 ☐ Fax 1-866-626-0216

Holly Randleman, Pharm.D.
Melissa Klotz, Pharm.D.
Jason Kruse, D.O.
Rhea Hartley, M.D.

Caitlin Reinking, Pharm.D.
Charles Wadle, D.O.
Bryon Schaeffer, M.D.

Jennifer Johnson, Pharm.D.
Abby Cate, Pharm.D.
Jordan Thoman, Pharm.D.

Professional Staff:

Pam Smith, R.Ph.
DUR Project Coordinator

February 4, 2026

Abby Cate, Pharm.D.
Pharmacy Consultant
Iowa Medicaid
1305 East Walnut
Des Moines, Iowa 50309

Dear Abby:

The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, February 4, 2026. At this meeting, Commission members reviewed and discussed prior authorization (PA) criteria for Dupilumab (Dupixent); Finerenone (Kerendia); Janus Kinase Inhibitors; Remibrutinib (Rhapsido); and Tezepelumab-ekko (Tezspire). The following recommendations have been made by the DUR Commission:

Dupilumab (Dupixent)

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for Dupixent (dupilumab). Payment for non-preferred agents will be considered when there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered when patient has an FDA approved or compendia indication for the requested drug under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient's current weight in kilograms (kg) is provided; and
3. Patient has a diagnosis of moderate-to-severe atopic dermatitis; and
 - a. Patient has failed to respond to good skin care and regular use of emollients; and
 - b. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; and
 - c. Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
 - d. Patient will continue with skin care regimen and regular use of emollients; or
4. Patient has a diagnosis of moderate to severe asthma with an eosinophilic phenotype (with a pretreatment eosinophil count ≥ 150 cells/mcL within the previous 6 weeks) or

- with oral corticosteroid dependent asthma; and
- a. Has a pretreatment forced expiratory volume in 1 second (FEV_1) \leq 80% predicted in adults; $<$ 90% predicted in adolescents 12 to 17 years of age; and $<$ 95% predicted in children 6 to 11 years of age; and
 - b. Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (e.g. long-acting beta-2 agonist [LABA], or leukotriene receptor antagonist [LTRA]) for a minimum of 3 consecutive months. Patient must be compliant with therapy, based on pharmacy claims; and
 - c. Patient must have one of the following, in addition to the regular maintenance medications defined above:
 - i. One (1) or more exacerbations in the previous year or
 - ii. Require daily oral corticosteroids for at least 3 days; or
5. Patient has a diagnosis of inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP); and
 - a. Documentation dupilumab will be used as an add-on maintenance treatment; and
 - b. Documentation of an adequate trial and therapy failure with at least one preferred medication from each of the following categories:
 - i. Nasal corticosteroid spray; and
 - ii. Oral corticosteroid; or
 6. Patient has a diagnosis of eosinophilic esophagitis (EoE); and
 - a. Patient has \geq 15 intraepithelial eosinophils per high-power field (eos/hpf) as confirmed by endoscopic esophageal biopsy (attach results); and
 - b. Patient has signs and symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, food refusal, abdominal pain, heartburn regurgitation, chest pain and/or, odynophagia); and
 - c. Documentation of previous trials and therapy failures with all of the following:
 - i. High dose proton pump inhibitor (PPI) for at least 8 weeks; and
 - ii. Swallowed topical corticosteroid (e.g., fluticasone propionate, oral budesonide suspension); and
 - iii. Dietary therapy; or
 7. Patient has a diagnosis of moderate to severe prurigo nodularis (PN); and
 - a. Patient has experienced severe to very severe pruritus, as demonstrated by a current Worst Itch-Numeric Rating Scale (WI-NRS) \geq 7; and
 - b. Patient has \geq 20 nodular lesions (attach documentation); and
 - c. Documentation of a previous trial and therapy failure with a high or super high potency topical corticosteroid for at least 14 consecutive days; ~~and~~ **or**
 8. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype; and
 - a. Patient has moderate to severe airflow limitation, measured within the past 12 months, as evidenced by both of the following:
 - i. FEV_1/FVC ratio $<$ 0.7, and
 - ii. FEV_1 % predicted between 30% to 79%; and
 - b. Patient has a minimum blood eosinophil count of 300 cells/mcL, measured within the past 12 months; and
 - c. Patient has documentation of maximal inhaled therapy for 3 or more months and an inadequate response to:
 - i. Triple therapy with all of the following treatments:

1. Long-acting muscarinic antagonist/anticholinergic (LAMA); and
2. Long-acting beta-2 agonist (LABA); and
3. Inhaled corticosteroid (ICS); or
- ii. Double therapy with both of the following if ICS is contraindicated
 1. LABA; and
 2. LAMA; and
- d. Patient has history of at least 2 moderate or 1 severe exacerbation(s) in the previous 12 months despite receiving maximal triple therapy or double therapy (defined above). Moderate exacerbation is defined as patient required treatment with systemic corticosteroids and/or antibiotics and severe exacerbation is defined as hospitalization or observation for over 24 hours in an emergency department or urgent care facility; and
- e. Patient will continue to receive maintenance therapy (as documented above) concomitantly with dupilumab; or
9. Patient has a diagnosis of chronic spontaneous urticaria (CSU) with no known cause; and
 - a. Patient has documentation of an adequate trial and therapy failure with a preferred second generation H1 receptor antihistamine for at least 2 weeks.

If criteria for coverage are met, initial authorization will be given for 6 months for all the above indications, except for COPD and CSU, which will receive an initial authorization of 12 months to assess the response to treatment. Request for continuation of therapy will require documentation of a positive response to therapy and continued use of add-on maintenance therapy, where indicated.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Proposed Clinical Prior Authorization Criteria (changes italicized/highlighted, and/or stricken) Prior authorization (PA) is required for Dupixent (dupilumab). Payment for non-preferred agents will be considered when there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered when patient has an FDA approved or compendia indication for the requested drug under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient's current weight in kilograms (kg) is provided; and
3. Patient has a diagnosis of moderate-to-severe atopic dermatitis; and
 - a. Patient has failed to respond to good skin care and regular use of emollients; and
 - b. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; and
 - c. Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
 - d. Patient will continue with skin care regimen and regular use of emollients; or
4. Patient has a diagnosis of moderate to severe asthma with an eosinophilic phenotype (with a pretreatment eosinophil count ≥ 150 cells/mcL within the previous 6 weeks) or with oral corticosteroid dependent asthma; and

- a. Has a pretreatment forced expiratory volume in 1 second (FEV₁) ≤ 80% predicted in adults; < 90% predicted in adolescents 12 to 17 years of age; and < 95% predicted in children 6 to 11 years of age; and
 - b. Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (e.g. long-acting beta₂ agonist [LABA], or leukotriene receptor antagonist [LTRA]) for a minimum of 3 consecutive months. Patient must be compliant with therapy, based on pharmacy claims; and
 - c. Patient must have one of the following, in addition to the regular maintenance medications defined above:
 - i. One (1) or more exacerbations in the previous year or
 - ii. Require daily oral corticosteroids for at least 3 days; or
5. Patient has a diagnosis of inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP); and
- a. Documentation dupilumab will be used as an add-on maintenance treatment; and
 - b. Documentation of an adequate trial and therapy failure with at least one preferred medication from each of the following categories:
 - i. Nasal corticosteroid spray; and
 - ii. Oral corticosteroid; or
6. Patient has a diagnosis of eosinophilic esophagitis (EoE); and
- a. Patient has ≥ 15 intraepithelial eosinophils per high-power field (eos/hpf) as confirmed by endoscopic esophageal biopsy (attach results); and
 - b. Patient has signs and symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, food refusal, abdominal pain, heartburn regurgitation, chest pain and/or, odynophagia); and
 - c. Documentation of previous trials and therapy failures with all of the following:
 - i. High dose proton pump inhibitor (PPI) for at least 8 weeks; and
 - ii. Swallowed topical corticosteroid (e.g., fluticasone propionate, oral budesonide suspension): and
 - iii. Dietary therapy; or
7. Patient has a diagnosis of moderate to severe prurigo nodularis (PN); and
- a. Patient has experienced severe to very severe pruritus, as demonstrated by a current Worst Itch-Numeric Rating Scale (WI-NRS) ≥ 7; and
 - b. Patient has ≥ 20 nodular lesions (attach documentation); and
 - c. Documentation of a previous trial and therapy failure with a high or super high potency topical corticosteroid for at least 14 consecutive days; or
8. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype; and
- a. Patient has moderate to severe airflow limitation, measured within the past 12 months, as evidenced by both of the following:
 - i. FEV₁/FVC ratio < 0.7, and
 - ii. FEV₁ % predicted between 30% to 79%; and
 - b. Patient has a minimum blood eosinophil count of 300 cells/mcL, measured within the past 12 months; and
 - c. Patient has documentation of maximal inhaled therapy for 3 or more months and an inadequate response to:
 - i. Triple therapy with all of the following treatments:
 1. Long-acting muscarinic antagonist/anticholinergic (LAMA); and

2. Long-acting beta-2 agonist (LABA); and
3. Inhaled corticosteroid (ICS); or
- ii. Double therapy with both of the following if ICS is contraindicated
 1. LABA; and
 2. LAMA; and
- d. Patient has history of at least 2 moderate or 1 severe exacerbation(s) in the previous 12 months despite receiving maximal triple therapy or double therapy (defined above). Moderate exacerbation is defined as patient required treatment with systemic corticosteroids and/or antibiotics and severe exacerbation is defined as hospitalization or observation for over 24 hours in an emergency department or urgent care facility; and
- e. Patient will continue to receive maintenance therapy (as documented above) concomitantly with dupilumab; or
9. Patient has a diagnosis of chronic spontaneous urticaria (CSU) with no known cause; and
 - a. Patient has documentation of an adequate trial and therapy failure with a preferred second generation H1 receptor antihistamine for at least 2 weeks; or
10. Patient has a diagnosis of bullous pemphigoid (BP); and
 - a. Is initiated with a tapering course of oral corticosteroids.

If criteria for coverage are met, initial authorization will be given for 6 months for all the above indications, except for COPD, and CSU, and BP which will receive an initial authorization of 12 months to assess the response to treatment. Request for continuation of therapy will require documentation of a positive response to therapy and continued use of add-on maintenance therapy, where indicated.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Finerenone (Kerendia)

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for finerenone (Kerendia). Payment will be considered under the following conditions:

1. Request adheres to all FDA approved labeling, including age, dosing, contraindications, warnings and precautions, and drug interactions; and
2. Patient has a diagnosis of chronic kidney disease (CKD) associated with Type 2 Diabetes (T2D); and
3. Patient is currently receiving a maximally tolerated dose of an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB); and
4. Patient is currently receiving a maximally tolerated dose of a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease [i.e., dapagliflozin (Farxiga)]; and
5. Patient has the following baseline tests prior to initiation of treatment with finerenone:
 - a. Serum potassium is ≤ 5.0 mEq/L; and
 - b. Estimated glomerular filtration rate (eGFR) is ≥ 25 mL/min/1.73m²; and

- c. Urine albumin to creatinine ratio (UACR) is ≥ 30 mg/g.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Initial authorizations will be approved for six months. Additional PAs will be considered with the following documentation:

1. Patient's serum potassium is < 5.5 mEq/L; and
2. Patient's eGFR is ≥ 25 mL/min/1.73m²; and
3. Patient remains on a maximally tolerated dose of an ACEi or ARB; and
4. Patient remains on a maximally tolerated dose of an SGLT2 inhibitor.

Proposed Clinical Prior Authorization Criteria (changes italicized/highlighted, and/or stricken)
Prior authorization (PA) is required for finerenone (Kerendia). Payment will be considered under the following conditions:

1. Request adheres to all FDA approved labeling, including age, dosing, contraindications, warnings and precautions, and drug interactions; and
2. Patient has a diagnosis of chronic kidney disease (CKD) associated with Type 2 Diabetes (T2D); and
 - a. Patient is currently receiving a maximally tolerated dose of an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB); and
 - b. Patient is currently receiving a maximally tolerated dose of a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (i.e., dapagliflozin [Farxiga], empagliflozin [Jardiance]); ~~or and~~
3. *Patient has a diagnosis of heart failure; and*
 - a. *Patient has a left ventricular ejection fraction (LVEF) $\geq 40\%$; and*
 - b. *Patient is currently receiving a maximally tolerated dose of a SGLT2 inhibitor indicated for use in patients with heart failure (i.e., dapagliflozin [Farxiga], empagliflozin [Jardiance]); and*
4. Patient has the following baseline tests prior to initiation of treatment with finerenone:
 - a. Serum potassium is ≤ 5.0 mEq/L; and
 - b. Estimated glomerular filtration rate (eGFR) is ≥ 25 mL/min/1.73m²; and
 - c. Urine albumin to creatinine ratio (UACR) is ≥ 30 mg/g.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Initial authorizations will be approved for ~~one year~~ *one year* ~~six months~~. Additional PAs will be considered with the following documentation:

1. Patient's eGFR is ≥ 25 mL/min/1.73m²; and
2. *For a diagnosis of CKD associated with T2D:*
 - a. Patient's serum potassium is < 5.5 mEq/L; and
 - b. Patient remains on a maximally tolerated dose of an ACEi or ARB; and
 - c. Patient remains on a maximally tolerated dose of an SGLT2 inhibitor; ~~or~~
3. *For a diagnosis of heart failure:*
 - a. *Patient's serum potassium is < 6 mEq/L; and*

b. *Patient remains on a maximally tolerated dose of an SGLT2 inhibitor.*

Janus Kinase (JAK) Inhibitors

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for Janus kinase (JAK) inhibitors. Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agent(s) would be medically contraindicated. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug, excluding requests for the FDA approved indication of alopecia areata or other excluded medical use(s), as defined in Section 1927 (d)(2) of the Social Security Act, State Plan, and Rules when the following conditions are met:

1. Patient is not using or planning to use a JAK inhibitor in combination with other JAK inhibitors, biological therapies, or potent immunosuppressants (azathioprine or cyclosporine); and
2. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
3. Patient has a diagnosis of:
 - a. Moderate to severe rheumatoid arthritis; with
 - i. A documented trial and inadequate response, at a maximally tolerated dose, with methotrexate; and
 - ii. A documented trial and inadequate response to one preferred TNF inhibitor; OR
 - b. Psoriatic arthritis; with
 - i. A documented trial and inadequate response, at a maximally tolerated dose, with methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); and
 - ii. Documented trial and therapy failure with one preferred TNF inhibitor used for psoriatic arthritis; OR
 - c. Moderately to severely active ulcerative colitis; with
 - i. A documented trial and inadequate response with a preferred TNF inhibitor; OR
 - d. Moderately to severely active Crohn's disease; with
 - i. A documented trial and inadequate response with a preferred TNF inhibitor; OR
 - e. Polyarticular Course Juvenile Idiopathic Arthritis; with
 - i. A documented trial and inadequate response to the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); and
 - ii. A documented trial and inadequate response with a preferred TNF inhibitor; OR
 - f. Axial spondyloarthritis conditions (e.g., ankylosing spondylitis or nonradiographic axial spondyloarthritis); with
 - i. A documented trial and inadequate response to at least two preferred non-steroidal anti-inflammatories (NSAIDs) at a maximally tolerated dose for a minimum of at least one month; and
 - ii. A documented trial and inadequate response with at least one

- preferred TNF inhibitor; OR
- g. Atopic dermatitis; with
 - i. Documentation patient has failed to respond to good skin care and regular use of emollients; and
 - ii. A documented adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; or
 - iii. A documented trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
 - iv. For mild to moderate atopic dermatitis (topical treatments):
 - 1. Affected area is less than 20% of body surface area (BSA); and
 - 2. Patient has been instructed to use no more than 60 grams of topical ruxolitinib per week; or
 - v. For moderate to severe chronic hand eczema (topical treatments):
 - 1. Chronic hand eczema has persisted for more than 3 months or recurred two or more times within a 12-month time frame after the initial occurrence with complete clearances between relapses; and
 - 2. Patient has been instructed to use no more than 30 grams per 2 weeks or 60 grams per month of topical delgocitinib; or
 - vi. For moderate to severe atopic dermatitis (oral treatments):
 - 1. A documented trial and therapy failure with a systemic drug product for the treatment of moderate to severe atopic dermatitis, including biologics; and
 - 2. Requests for upadacitinib for pediatric patients 12 to less than 18 years of age must include the patient's weight in kg; or
 - h. Nonsegmental vitiligo; with
 - i. A documented trial and inadequate response with a potent topical corticosteroid; or
 - ii. A documented trial and inadequate response with a topical calcineurin inhibitor; and
 - iii. The patient's body surface area (BSA) is less than or equal to the affected BSA per FDA approved label, if applicable; or
 - i. Giant Cell Arteritis; with
 - i. Documentation patient is currently taking a glucocorticoid, with a tapering dose, or has discontinued use of glucocorticoids.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Proposed Clinical Prior Authorization Criteria (changes highlighted/italicized and/or stricken)
 Prior authorization (PA) is required for Janus kinase (JAK) inhibitors. Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agent(s) would be medically contraindicated. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug, excluding requests for the FDA approved indication of alopecia areata or other excluded medical use(s), as defined in Section 1927 (d)(2) of the Social Security Act, State Plan, and Rules when the following conditions are met:

1. Patient is not using or planning to use a JAK inhibitor in combination with

- other JAK inhibitors, biological therapies, or potent immunosuppressants (azathioprine or cyclosporine); and
2. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
 3. Patient has a diagnosis of:
 - a. Moderate to severe rheumatoid arthritis; with
 - i. A documented trial and inadequate response, at a maximally tolerated dose, with methotrexate; and
 - ii. A documented trial and inadequate response to one preferred TNF inhibitor; OR
 - b. Psoriatic arthritis; with
 - i. A documented trial and inadequate response, at a maximally tolerated dose, with methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); and
 - ii. Documented trial and therapy failure with one preferred TNF inhibitor used for psoriatic arthritis; OR
 - c. Moderately to severely active ulcerative colitis; with
 - i. A documented trial and inadequate response with a preferred TNF inhibitor; or
 - ii. *If TNF inhibitors are clinically inadvisable, documentation of at least one approved systemic therapy;* OR
 - d. Moderately to severely active Crohn's disease; with
 - i. A documented trial and inadequate response with a preferred TNF inhibitor; or
 - ii. *If TNF inhibitors are clinically inadvisable, documentation of at least one approved systemic therapy;* OR
 - e. Polyarticular Course Juvenile Idiopathic Arthritis; with
 - i. A documented trial and inadequate response to the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); and
 - ii. A documented trial and inadequate response with a preferred TNF inhibitor; OR
 - f. Axial spondyloarthritis conditions (e.g., ankylosing spondylitis or nonradiographic axial spondyloarthritis); with
 - i. A documented trial and inadequate response to at least two preferred non-steroidal anti-inflammatories (NSAIDs) at a maximally tolerated dose for a minimum of at least one month; and
 - ii. A documented trial and inadequate response with at least one preferred TNF inhibitor; OR
 - g. Atopic dermatitis; with
 - i. Documentation patient has failed to respond to good skin care and regular use of emollients; and
 - ii. A documented adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; or
 - iii. A documented trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and

- iv. For mild to moderate atopic dermatitis (topical treatments):
 1. Affected area is less than 20% of body surface area (BSA); and
 2. Patient has been instructed to use no more than 60 grams of topical ruxolitinib per week; or
- v. For moderate to severe chronic hand eczema (topical treatments):
 1. Chronic hand eczema has persisted for more than 3 months or recurred two or more times within a 12-month time frame after the initial occurrence with complete clearances between relapses; and
 2. Patient has been instructed to use no more than 30 grams per 2 weeks or 60 grams per month of topical delgocitinib; or
- vii. For moderate to severe atopic dermatitis (oral treatments):
 1. A documented trial and therapy failure with a systemic drug product for the treatment of moderate to severe atopic dermatitis, including biologics; and
 2. Requests for upadacitinib for pediatric patients 12 to less than 18 years of age must include the patient's weight in kg; or
- h. Nonsegmental vitiligo; with
 - i. A documented trial and inadequate response with a potent topical corticosteroid; or
 - ii. A documented trial and inadequate response with a topical calcineurin inhibitor; and
 - iii. The patient's body surface area (BSA) is less than or equal to the affected BSA per FDA approved label, if applicable; or
- i. Giant Cell Arteritis; with
 - i. Documentation patient is currently taking a glucocorticoid, with a tapering dose, or has discontinued use of glucocorticoids.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Remibrutinib (Rhapsido)

Newly Proposed Clinical Prior Authorization Criteria

Prior authorization (PA) is required for remibrutinib (Rhapsido). Payment for non-preferred agents will be considered when there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered when patient has an FDA approved or compendia indication for the requested drug under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of chronic spontaneous urticaria (CSU) with no known cause; and
3. Patient has documentation of an adequate trial and therapy failure with a preferred second generation H1 receptor antihistamine for at least 2 weeks.

If criteria for coverage are met, initial authorization will be given for 12 months to assess the response to treatment. Requests for continuation of therapy will require documentation of a positive response to therapy.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Tezepelumab-ekko (Tezspire)

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for tezepelumab-ekko (Tezspire) prefilled pen. Requests for tezepelumab-ekko (Tezspire) single dose vial or prefilled syringe will not be considered through the pharmacy benefit. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following conditions are met:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of severe asthma; and
 - a. Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (e.g., long-acting beta-2 agonist [LABA], leukotriene receptor antagonist [LTRA], oral theophylline) for a minimum of 3 consecutive months. Patient must be compliant with therapy, based on pharmacy claims; and
 - b. Patient must have one of the following, in addition to the regular maintenance medications defined above:
 - i. Two or more asthma exacerbations requiring oral or injectable corticosteroid treatment in the previous 12 months, or
 - ii. One or more asthma exacerbations resulting in hospitalization in the previous 12 months; and
 - c. This medication will be used as an add-on maintenance treatment; and
 - d. Patient/caregiver will administer medication in patient's home; and
 - e. Is not prescribed in combination with other biologics indicated for asthma.

If criteria for coverage are met, initial authorization will be given for 6 months to assess the response to treatment. Requests for continuation of therapy will require documentation of a positive response to therapy.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Proposed Clinical Prior Authorization Criteria (changes highlighted/italicized and/or stricken)

Prior authorization (PA) is required for tezepelumab-ekko (Tezspire) prefilled pen. Requests for tezepelumab-ekko (Tezspire) single dose vial or prefilled syringe will not be considered through the pharmacy benefit. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following conditions are met:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions,

- drug interactions, and use in specific populations; and
2. Patient has a diagnosis of severe asthma; and
 - a. Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (e.g., long-acting beta-2 agonist [LABA], leukotriene receptor antagonist [LTRA], oral theophylline) for a minimum of 3 consecutive months. Patient must be compliant with therapy, based on pharmacy claims; and
 - b. Patient must have one of the following, in addition to the regular maintenance medications defined above:
 - i. Two or more asthma exacerbations requiring oral or injectable corticosteroid treatment in the previous 12 months, or
 - ii. One or more asthma exacerbations resulting in hospitalization in the previous 12 months; and
 - c. This medication will be used as an add-on maintenance treatment; and
 - d. Patient/caregiver will administer medication in patient's home; and
 - e. Is not prescribed in combination with other biologics indicated for asthma;
or
 3. *Patient has a diagnosis of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP); and*
 - a. *Documentation that tezepelumab will be used as an add-on maintenance treatment; and*
 - b. *Documentation of an adequate trial and therapy failure with at least one preferred medication from each of the following categories:*
 - i. *Nasal corticosteroid spray; and*
 - ii. *Oral corticosteroid.*

If criteria for coverage are met, initial authorization will be given for 6 months to assess the response to treatment. Requests for continuation of therapy will require documentation of a positive response to therapy.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Thank you in advance for the Department's consideration of accepting the DUR Commission's recommendations regarding Dupilumab (Dupixent); Finerenone (Kerendia); Janus Kinase Inhibitors; Remibrutinib (Rhapsido); and Tezepelumab-ekko (Tezspire).

Sincerely,

Pamela Smith, R.Ph.
Drug Utilization Review Project Coordinator
Iowa Medicaid

Cc: Erin Halverson, R.Ph, Iowa Medicaid
Gina Kuebler, R.Ph, Iowa Medicaid

Quarterly Monthly Statistics

| CATEGORY | September 2025 / November 2025 | December 2025 / February 2026 | % CHANGE |
|-----------------------------------|--------------------------------|-------------------------------|----------|
| TOTAL PAID AMOUNT | \$108,138,140 | \$108,916,904 | 0.7% |
| UNIQUE USERS | 100,493 | 104,140 | 3.6% |
| COST PER USER | \$1,076.08 | \$1,045.87 | -2.8% |
| TOTAL PRESCRIPTIONS | 775,012 | 774,732 | 0.0% |
| AVERAGE PRESCRIPTIONS PER USER | 7.71 | 7.44 | -3.5% |
| AVERAGE COST PER PRESCRIPTION | \$139.53 | \$140.59 | 0.8% |
| # GENERIC PRESCRIPTIONS | 690,380 | 688,899 | -0.2% |
| % GENERIC | 89.08% | 88.92% | -0.2% |
| \$ GENERIC | \$13,996,409 | \$13,904,584 | -0.7% |
| AVERAGE GENERIC PRESCRIPTION COST | \$20.27 | \$20.18 | -0.4% |
| AVERAGE GENERIC DAYS SUPPLY | 28.82 | 29.83 | 3.5% |
| # BRAND PRESCRIPTIONS | 84,632 | 85,833 | 1.4% |
| % BRAND | 10.92% | 11.08% | 1.5% |
| \$ BRAND | \$94,141,731 | \$95,012,320 | 0.9% |
| AVERAGE BRAND PRESCRIPTION COST | \$1,112.37 | \$1,106.94 | -0.5% |
| AVERAGE BRAND DAYS SUPPLY | 27.82 | 27.75 | -0.3% |

| UTILIZATION BY AGE | | | |
|-------------------------------|--------------------------------|--------------------------------|-------------------------------|
| AGE | September 2025 / November 2025 | December 2025 / February 2026 | |
| 0-6 | 30,152 | 34,269 | |
| 7-12 | 56,518 | 59,225 | |
| 13-18 | 74,602 | 76,220 | |
| 19-64 | 613,679 | 604,942 | |
| 65+ | 7,748 | 7,520 | |
| TOTAL | 782,699 | 782,176 | |
| UTILIZATION BY GENDER AND AGE | | | |
| GENDER | AGE | September 2025 / November 2025 | December 2025 / February 2026 |
| F | | | |
| | 0-6 | 13,143 | 14,970 |
| | 7-12 | 21,972 | 23,044 |
| | 13-18 | 38,590 | 38,985 |
| | 19-64 | 409,011 | 401,701 |
| | 65+ | 4,848 | 4,762 |
| | Gender Total | 487,564 | 483,462 |
| M | | | |
| | 0-6 | 17,009 | 19,299 |
| | 7-12 | 34,546 | 36,181 |
| | 13-18 | 36,012 | 37,235 |
| | 19-64 | 204,668 | 203,241 |
| | 65+ | 2,900 | 2,758 |
| | Gender Total | 295,135 | 298,714 |
| Grand Total | 782,699 | 782,176 | |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
December 2025 / February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|--|----------------|-------|--------------------|----------------|-------------|---------------|
| 1 | U OF I HOSPITALS & CLINICS AMBULATORY CARE PHARM | IOWA CITY | IA | 12,039 | \$5,860,445.92 | \$486.79 | 1 |
| 2 | RIGHT DOSE PHARMACY | ANKENY | IA | 7,097 | \$253,757.25 | \$35.76 | 2 |
| 3 | WALGREENS #4405 | COUNCIL BLUFFS | IA | 6,481 | \$510,127.08 | \$78.71 | 3 |
| 4 | WALGREENS #5042 | CEDAR RAPIDS | IA | 5,825 | \$445,424.48 | \$76.47 | 4 |
| 5 | HY-VEE PHARMACY #5 (1109) | DAVENPORT | IA | 5,116 | \$492,841.04 | \$96.33 | 5 |
| 6 | HY-VEE PHARMACY #2 (1138) | DES MOINES | IA | 4,835 | \$419,771.79 | \$86.82 | 8 |
| 7 | WALGREENS #5239 | DAVENPORT | IA | 4,712 | \$281,772.86 | \$59.80 | 9 |
| 8 | HY-VEE PHARMACY #1 (1092) | COUNCIL BLUFFS | IA | 4,620 | \$498,658.13 | \$107.93 | 6 |
| 9 | HY-VEE PHARMACY (1075) | CLINTON | IA | 4,552 | \$409,909.13 | \$90.05 | 7 |
| 10 | HARTIG PHARMACY SERVICES | DUBUQUE | IA | 4,166 | \$355,741.44 | \$85.39 | 10 |
| 11 | DRILLING PHARMACY | SIOUX CITY | IA | 4,102 | \$342,046.28 | \$83.39 | 15 |
| 12 | HY-VEE DRUGSTORE (7060) | MUSCATINE | IA | 4,072 | \$308,891.97 | \$75.86 | 13 |
| 13 | HY-VEE PHARMACY #5 (1151) | DES MOINES | IA | 4,010 | \$289,535.97 | \$72.20 | 14 |
| 14 | HY-VEE PHARMACY (1403) | MARSHALLTOWN | IA | 3,965 | \$311,942.11 | \$78.67 | 12 |
| 15 | BROADLAWNS MEDICAL CENTER OUTPATIENT PHARMACY | DES MOINES | IA | 3,910 | \$280,499.95 | \$71.74 | 11 |
| 16 | HY-VEE PHARMACY #3 (1056) | CEDAR RAPIDS | IA | 3,768 | \$340,407.86 | \$90.34 | 16 |
| 17 | GREENWOOD DRUG ON KIMBALL AVE. | WATERLOO | IA | 3,742 | \$281,978.56 | \$75.36 | 19 |
| 18 | WAGNER PHARMACY | CLINTON | IA | 3,425 | \$297,406.56 | \$86.83 | 22 |
| 19 | HY-VEE PHARMACY (1074) | CHARLES CITY | IA | 3,407 | \$230,544.14 | \$67.67 | 17 |
| 20 | HY-VEE PHARMACY #5 (1061) | CEDAR RAPIDS | IA | 3,320 | \$310,562.37 | \$93.54 | 24 |

| | | | | | | | |
|----|---|----------------|----|-------|--------------|---------|----|
| 21 | HY-VEE PHARMACY #3 (1142) | DES MOINES | IA | 3,296 | \$243,067.92 | \$73.75 | 21 |
| 22 | NUCARA LTC PHARMACY #3 | IOWA CITY | IA | 3,283 | \$166,388.74 | \$50.68 | 18 |
| 23 | IMMC OUTPATIENT PHARMACY | DES MOINES | IA | 3,263 | \$189,916.98 | \$58.20 | 38 |
| 24 | WALGREENS #15647 | SIOUX CITY | IA | 3,229 | \$280,443.71 | \$86.85 | 20 |
| 25 | HY-VEE DRUGSTORE (7065) | OTTUMWA | IA | 3,217 | \$264,872.17 | \$82.34 | 27 |
| 26 | CVS PHARMACY #08658 | DAVENPORT | IA | 3,189 | \$241,538.41 | \$75.74 | 31 |
| 27 | WALMART PHARMACY 10-1509 | MAQUOKETA | IA | 3,177 | \$277,138.86 | \$87.23 | 32 |
| 28 | HY-VEE PHARMACY (1192) | FT DODGE | IA | 3,174 | \$251,963.84 | \$79.38 | 26 |
| 29 | WALMART PHARMACY 10-5115 | DAVENPORT | IA | 3,101 | \$246,389.50 | \$79.45 | 25 |
| 30 | HY-VEE PHARMACY (1449) | NEWTON | IA | 3,081 | \$256,171.91 | \$83.15 | 29 |
| 31 | HY-VEE PHARMACY (1396) | MARION | IA | 3,079 | \$253,601.24 | \$82.36 | 33 |
| 32 | HY-VEE PHARMACY #4 (1148) | DES MOINES | IA | 3,024 | \$237,173.59 | \$78.43 | 43 |
| 33 | MAIN AT LOCUST PHARMACY AND MEDICAL SUPPLY | DAVENPORT | IA | 3,022 | \$228,638.04 | \$75.66 | 23 |
| 34 | HY-VEE DRUGSTORE #1 (7020) | CEDAR RAPIDS | IA | 3,001 | \$235,932.93 | \$78.62 | 35 |
| 35 | UI HEALTHCARE - IOWA RIVER LANDING PHARMACY | CORALVILLE | IA | 2,958 | \$144,238.16 | \$48.76 | 40 |
| 36 | WALGREENS #359 | DES MOINES | IA | 2,904 | \$228,144.54 | \$78.56 | 36 |
| 37 | NELSON FAMILY PHARMACY | FORT MADISON | IA | 2,849 | \$157,729.47 | \$55.36 | 41 |
| 38 | WALGREENS #5721 | DES MOINES | IA | 2,841 | \$178,648.84 | \$62.88 | 28 |
| 39 | WALGREENS #3700 | COUNCIL BLUFFS | IA | 2,832 | \$238,882.85 | \$84.35 | 39 |
| 40 | HY-VEE PHARMACY #2 (1044) | BURLINGTON | IA | 2,832 | \$190,526.66 | \$67.28 | 42 |
| 41 | SIOUXLAND COMMUNITY HEALTH CENTER | SIOUX CITY | IA | 2,831 | \$172,371.20 | \$60.89 | 37 |
| 42 | COMMUNITY HEALTH CARE PHARMACY | DAVENPORT | IA | 2,778 | \$172,656.21 | \$62.15 | 57 |
| 43 | WALMART PHARMACY 10-2889 | CLINTON | IA | 2,749 | \$220,638.73 | \$80.26 | 49 |
| 44 | WALGREENS #11942 | DUBUQUE | IA | 2,701 | \$186,011.14 | \$68.87 | 45 |

| | | | | | | | |
|----|-------------------------------|-----------------|----|-------|--------------|----------|----|
| 45 | WALGREENS #7453 | DES MOINES | IA | 2,654 | \$220,904.26 | \$83.23 | 30 |
| 46 | SOUTH SIDE DRUG | OTTUMWA | IA | 2,651 | \$211,535.32 | \$79.79 | 55 |
| 47 | CVS PHARMACY #10282 | FORT DODGE | IA | 2,649 | \$175,665.69 | \$66.31 | 47 |
| 48 | HY-VEE PHARMACY (1058) | CENTERVILLE | IA | 2,647 | \$261,358.04 | \$98.74 | 54 |
| 49 | WALGREENS #7455 | WATERLOO | IA | 2,619 | \$170,104.97 | \$64.95 | 44 |
| 50 | MAHASKA DRUGS INC | OSKALOOSA | IA | 2,606 | \$251,160.76 | \$96.38 | 46 |
| 51 | CVS PHARMACY #08544 | WATERLOO | IA | 2,601 | \$173,886.41 | \$66.85 | 52 |
| 52 | HY-VEE DRUGSTORE (7056) | MASON CITY | IA | 2,598 | \$206,062.22 | \$79.32 | 71 |
| 53 | MEDICAP PHARMACY | KNOXVILLE | IA | 2,591 | \$283,526.69 | \$109.43 | 53 |
| 54 | WALMART PHARMACY 10-0797 | WEST BURLINGTON | IA | 2,580 | \$223,596.89 | \$86.67 | 77 |
| 55 | WALMART PHARMACY 10-0985 | FAIRFIELD | IA | 2,566 | \$172,613.85 | \$67.27 | 51 |
| 56 | MERCYONE FOREST PARK PHARMACY | MASON CITY | IA | 2,555 | \$242,048.74 | \$94.74 | 59 |
| 57 | HY-VEE PHARMACY #1 (1610) | SIOUX CITY | IA | 2,543 | \$227,645.38 | \$89.52 | 48 |
| 58 | UNION PHARMACY | COUNCIL BLUFFS | IA | 2,503 | \$262,181.56 | \$104.75 | 63 |
| 59 | SCOTT PHARMACY | FAYETTE | IA | 2,461 | \$144,836.55 | \$58.85 | 50 |
| 60 | PREFERRED CARE PHARMACY | CEDAR RAPIDS | IA | 2,444 | \$175,698.03 | \$71.89 | 68 |
| 61 | WALGREENS #4041 | DAVENPORT | IA | 2,437 | \$167,513.33 | \$68.74 | 34 |
| 62 | WALMART PHARMACY 10-0559 | MUSCATINE | IA | 2,412 | \$192,844.10 | \$79.95 | 61 |
| 63 | HY-VEE PHARMACY (1522) | PERRY | IA | 2,384 | \$243,669.57 | \$102.21 | 62 |
| 64 | HY-VEE PHARMACY (1065) | CHARITON | IA | 2,378 | \$172,229.21 | \$72.43 | 56 |
| 65 | HY-VEE PHARMACY (1459) | OELWEIN | IA | 2,366 | \$168,550.48 | \$71.24 | 67 |
| 66 | HERITAGE PARTNERS PHARMACY | WEST BURLINGTON | IA | 2,366 | \$146,635.97 | \$61.98 | 70 |
| 67 | HY-VEE PHARMACY (1180) | FAIRFIELD | IA | 2,364 | \$198,316.98 | \$83.89 | 66 |
| 68 | MEDICAP PHARMACY LTC | INDIANOLA | IA | 2,323 | \$69,273.72 | \$29.82 | 93 |

| | | | | | | | |
|----|---|-----------------|----|-------|--------------|----------|----|
| 69 | MEDICAP PHARMACY | NEWTON | IA | 2,304 | \$153,424.84 | \$66.59 | 69 |
| 70 | HY-VEE PHARMACY (1873) | WAUKEE | IA | 2,295 | \$199,100.77 | \$86.75 | 81 |
| 71 | CVS PHARMACY #10032 | MARION | IA | 2,293 | \$171,627.91 | \$74.85 | 74 |
| 72 | WALGREENS #9708 | DUBUQUE | IA | 2,283 | \$166,029.25 | \$72.72 | 60 |
| 73 | LAGRANGE PHARMACY | VINTON | IA | 2,270 | \$198,949.26 | \$87.64 | 58 |
| 74 | LEWIS FAMILY DRUG #28 | ONAWA | IA | 2,270 | \$194,094.97 | \$85.50 | 64 |
| 75 | HY-VEE PHARMACY (1437) | MUSCATINE | IA | 2,245 | \$165,649.63 | \$73.79 | 87 |
| 76 | CRESCENT COMMUNITY HEALTH CENTER PHARMACY | DUBUQUE | IA | 2,244 | \$121,704.86 | \$54.24 | 78 |
| 77 | WALGREENS #4714 | DES MOINES | IA | 2,233 | \$179,774.83 | \$80.51 | 73 |
| 78 | GENOA HEALTHCARE, LLC | DAVENPORT | IA | 2,230 | \$381,637.61 | \$171.14 | 80 |
| 79 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 2,230 | \$302,215.85 | \$135.52 | 76 |
| 80 | HY-VEE PHARMACY #3 (1866) | WATERLOO | IA | 2,230 | \$247,356.17 | \$110.92 | 88 |
| 81 | WALMART PHARMACY 10-3394 | ATLANTIC | IA | 2,216 | \$232,754.55 | \$105.03 | 85 |
| 82 | HARTIG DRUG CO | DUBUQUE | IA | 2,215 | \$172,896.63 | \$78.06 | 86 |
| 83 | HY-VEE PHARMACY (1895) | WINDSOR HEIGHTS | IA | 2,211 | \$148,733.64 | \$67.27 | 83 |
| 84 | HY-VEE PHARMACY (1530) | PLEASANT HILL | IA | 2,194 | \$149,749.95 | \$68.25 | 95 |
| 85 | EXACTCARE | VALLEY VIEW | OH | 2,186 | \$167,254.20 | \$76.51 | 84 |
| 86 | HY-VEE PHARMACY (1071) | CLARINDA | IA | 2,182 | \$236,767.54 | \$108.51 | 91 |
| 87 | HY-VEE PHARMACY (1241) | HARLAN | IA | 2,182 | \$204,138.50 | \$93.56 | 72 |
| 88 | OSTERHAUS PHARMACY | MAQUOKETA | IA | 2,181 | \$110,756.66 | \$50.78 | 79 |
| 89 | WALGREENS #7454 | ANKENY | IA | 2,167 | \$155,896.61 | \$71.94 | 65 |
| 90 | WALGREENS #7452 | DES MOINES | IA | 2,166 | \$130,463.50 | \$60.23 | 98 |
| 91 | MCMH PHARMACY | RED OAK | IA | 2,164 | \$206,370.69 | \$95.37 | 90 |
| 92 | HY-VEE PHARMACY #1 (1504) | OTTUMWA | IA | 2,154 | \$144,664.38 | \$67.16 | 75 |

| | | | | | | | |
|-----|---------------------------|--------------|----|-------|--------------|----------|-----|
| 93 | HY-VEE PHARMACY #6 (1155) | DES MOINES | IA | 2,090 | \$212,495.55 | \$101.67 | 89 |
| 94 | WALMART PHARMACY 10-0784 | MT PLEASANT | IA | 2,087 | \$172,265.40 | \$82.54 | 112 |
| 95 | THOMPSON DEAN DRUG | SIOUX CITY | IA | 2,080 | \$183,770.17 | \$88.35 | 92 |
| 96 | HY-VEE PHARMACY #3 (1107) | DAVENPORT | IA | 2,077 | \$184,807.31 | \$88.98 | 109 |
| 97 | HY-VEE PHARMACY #1 (1054) | CEDAR RAPIDS | IA | 2,074 | \$202,563.02 | \$97.67 | 82 |
| 98 | WALMART PHARMACY 10-1723 | DES MOINES | IA | 2,062 | \$196,901.28 | \$95.49 | 99 |
| 99 | HY-VEE PHARMACY (1224) | GRIMES | IA | 2,058 | \$127,591.79 | \$62.00 | 100 |
| 100 | HY-VEE PHARMACY #3 (1615) | SIOUX CITY | IA | 2,041 | \$190,776.99 | \$93.47 | 97 |

TOP 100 PHARMACIES BY PAID AMOUNT
December 2025 / February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|---|-------------------|-------|--------------------|----------------|-----------------|---------------|
| 1 | U OF I HOSPITALS & CLINICS AMBULATORY CARE PHARM | IOWA CITY | IA | 12,039 | \$5,860,445.92 | \$2,611.61 | 2 |
| 2 | CVS/SPECIALTY | MONROEVILLE | PA | 624 | \$5,604,498.18 | \$22,875.50 | 1 |
| 3 | UNITYPOINT AT HOME | URBANDALE | IA | 1,024 | \$3,927,735.49 | \$12,085.34 | 4 |
| 4 | WALGREENS SPECIALTY PHARMACY #16528 | DES MOINES | IA | 776 | \$3,896,298.25 | \$14,377.48 | 3 |
| 5 | CAREMARK ILLINOIS SPECIALTY PHARMACY, LLC DBA CVS/SPECIALTY | MT PROSPECT | IL | 305 | \$3,442,847.96 | \$34,428.48 | 5 |
| 6 | PANTHERX SPECIALTY PHARMACY | CORAOPOLIS | PA | 106 | \$2,761,256.04 | \$70,801.44 | 7 |
| 7 | BIOPLUS SPECIALTY PHARMACY SERVICES, LLC | ALTAMONTE SPRINGS | FL | 390 | \$2,744,554.22 | \$16,533.46 | 6 |
| 8 | WALGREENS SPECIALTY PHARMACY #21250 | IOWA CITY | IA | 394 | \$2,073,589.91 | \$12,491.51 | 8 |
| 9 | CAREMARK KANSAS SPECIALTY PHARMACY, LLC DBA CVS/SPECIALTY | LENEXA | KS | 230 | \$1,838,976.04 | \$15,853.24 | 34 |
| 10 | NUCARA SPECIALTY PHARMACY | PLEASANT HILL | IA | 1,235 | \$1,258,361.87 | \$9,390.76 | 10 |
| 11 | AMBER SPECIALTY PHARMACY | OMAHA | NE | 203 | \$1,235,981.99 | \$16,051.71 | 11 |
| 12 | CAREMARK LLC, DBA CVS/SPECIALTY | REDLANDS | CA | 95 | \$1,131,333.07 | \$31,425.92 | 9 |
| 13 | WALGREENS SPECIALTY PHARMACY #16280 | FRISCO | TX | 65 | \$1,097,435.06 | \$91,452.92 | 12 |
| 14 | SOLEO HEALTH INC. | WOODRIDGE | IL | 5 | \$1,063,451.39 | \$531,725.70 | 13 |
| 15 | CVS PHARMACY #00102 | AURORA | CO | 88 | \$752,240.37 | \$21,492.58 | 14 |
| 16 | ACCREDITO HEALTH GROUP INC | MEMPHIS | TN | 51 | \$731,341.39 | \$31,797.45 | 16 |
| 17 | BIOLOGICS BY MCKESSON | CARY | NC | 29 | \$604,601.29 | \$50,383.44 | 19 |
| 18 | CR CARE PHARMACY | CEDAR RAPIDS | IA | 1,910 | \$591,890.88 | \$3,115.22 | 21 |
| 19 | ACCREDITO HEALTH GROUP INC | WARRENDALE | PA | 27 | \$583,556.90 | \$64,839.66 | 24 |

| | | | | | | | |
|----|--|-------------------|----|-------|--------------|--------------|----|
| 20 | OPTUM PHARMACY 702, LLC | JEFFERSONVILLE | IN | 79 | \$575,463.59 | \$15,985.10 | 22 |
| 21 | EVERSANA LIFE SCIENCE SERVICES, LLC | CHESTERFIELD | MO | 13 | \$556,625.51 | \$111,325.10 | 31 |
| 22 | THE NEBRASKA MEDICAL CENTER CLINIC PHARMACY | OMAHA | NE | 730 | \$548,775.90 | \$3,810.94 | 33 |
| 23 | ANOVORX GROUP, LLC | MEMPHIS | TN | 53 | \$528,328.73 | \$25,158.51 | 18 |
| 24 | WALGREENS SPECIALTY PHARMACY #16270 | OMAHA | NE | 78 | \$522,382.31 | \$26,119.12 | 15 |
| 25 | MERCYONE GENESIS FIRSTMED SPECIALTY PHARMACY | DAVENPORT | IA | 878 | \$514,165.26 | \$2,840.69 | 17 |
| 26 | WALGREENS #4405 | COUNCIL BLUFFS | IA | 6,481 | \$510,127.08 | \$396.99 | 23 |
| 27 | EXPRESS SCRIPTS SPECIALTY DIST SVCS | SAINT LOUIS | MO | 31 | \$502,623.60 | \$38,663.35 | 29 |
| 28 | ORSINI PHARMACEUTICAL SERVICES LLC | ELK GROVE VILLAGE | IL | 24 | \$498,804.01 | \$49,880.40 | 20 |
| 29 | HY-VEE PHARMACY #1 (1092) | COUNCIL BLUFFS | IA | 4,620 | \$498,658.13 | \$1,141.09 | 26 |
| 30 | HY-VEE PHARMACY #5 (1109) | DAVENPORT | IA | 5,116 | \$492,841.04 | \$714.26 | 27 |
| 31 | WALGREENS #5042 | CEDAR RAPIDS | IA | 5,825 | \$445,424.48 | \$343.43 | 28 |
| 32 | HY-VEE PHARMACY #2 (1138) | DES MOINES | IA | 4,835 | \$419,771.79 | \$645.80 | 35 |
| 33 | HY-VEE PHARMACY (1075) | CLINTON | IA | 4,552 | \$409,909.13 | \$625.82 | 30 |
| 34 | GENOA HEALTHCARE, LLC | DAVENPORT | IA | 2,230 | \$381,637.61 | \$1,998.10 | 38 |
| 35 | HARTIG PHARMACY SERVICES | DUBUQUE | IA | 4,166 | \$355,741.44 | \$1,115.18 | 32 |
| 36 | DRILLING PHARMACY | SIOUX CITY | IA | 4,102 | \$342,046.28 | \$985.72 | 40 |
| 37 | ONCO360 | LOUISVILLE | KY | 20 | \$341,033.68 | \$42,629.21 | 25 |
| 38 | HY-VEE PHARMACY #3 (1056) | CEDAR RAPIDS | IA | 3,768 | \$340,407.86 | \$624.60 | 36 |
| 39 | AVERA SPECIALTY PHARMACY | SIOUX FALLS | SD | 77 | \$326,729.14 | \$10,890.97 | 41 |
| 40 | HY-VEE PHARMACY (1403) | MARSHALLTOWN | IA | 3,965 | \$311,942.11 | \$431.46 | 39 |
| 41 | HY-VEE PHARMACY #5 (1061) | CEDAR RAPIDS | IA | 3,320 | \$310,562.37 | \$651.07 | 42 |
| 42 | PARAGON PARTNERS | OMAHA | NE | 913 | \$309,657.61 | \$3,919.72 | 53 |

| | | | | | | | |
|----|---|----------------|----|-------|--------------|------------|----|
| 43 | HY-VEE DRUGSTORE (7060) | MUSCATINE | IA | 4,072 | \$308,891.97 | \$527.12 | 47 |
| 44 | GENOA HEALTHCARE, LLC | SIOUX CITY | IA | 1,833 | \$306,689.61 | \$1,742.55 | 52 |
| 45 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 2,230 | \$302,215.85 | \$997.41 | 44 |
| 46 | WAGNER PHARMACY | CLINTON | IA | 3,425 | \$297,406.56 | \$758.69 | 61 |
| 47 | FIFIELD PHARMACY | DES MOINES | IA | 1,670 | \$296,364.83 | \$1,818.19 | 54 |
| 48 | HY-VEE PHARMACY #5 (1151) | DES MOINES | IA | 4,010 | \$289,535.97 | \$500.93 | 50 |
| 49 | MEDICAP PHARMACY | KNOXVILLE | IA | 2,591 | \$283,526.69 | \$1,238.11 | 49 |
| 50 | GREENWOOD DRUG ON KIMBALL AVE. | WATERLOO | IA | 3,742 | \$281,978.56 | \$792.07 | 57 |
| 51 | WALGREENS #5239 | DAVENPORT | IA | 4,712 | \$281,772.86 | \$252.48 | 48 |
| 52 | BROADLAWNS MEDICAL CENTER OUTPATIENT PHARMACY | DES MOINES | IA | 3,910 | \$280,499.95 | \$437.60 | 63 |
| 53 | WALGREENS #15647 | SIOUX CITY | IA | 3,229 | \$280,443.71 | \$354.10 | 59 |
| 54 | WALMART PHARMACY 10-1509 | MAQUOKETA | IA | 3,177 | \$277,138.86 | \$554.28 | 62 |
| 55 | MERCYONE WATERLOO PHARMACY | WATERLOO | IA | 1,900 | \$266,119.11 | \$661.99 | 60 |
| 56 | HY-VEE DRUGSTORE (7065) | OTTUMWA | IA | 3,217 | \$264,872.17 | \$527.63 | 67 |
| 57 | UNION PHARMACY | COUNCIL BLUFFS | IA | 2,503 | \$262,181.56 | \$1,236.71 | 74 |
| 58 | HY-VEE PHARMACY (1058) | CENTERVILLE | IA | 2,647 | \$261,358.04 | \$794.40 | 83 |
| 59 | HARTIG DRUG CO | DUBUQUE | IA | 1,835 | \$260,963.60 | \$1,039.70 | 58 |
| 60 | HY-VEE PHARMACY (1449) | NEWTON | IA | 3,081 | \$256,171.91 | \$533.69 | 55 |
| 61 | HY-VEE PHARMACY #2 (1018) | AMES | IA | 1,943 | \$254,502.76 | \$839.94 | 84 |
| 62 | RIGHT DOSE PHARMACY | ANKENY | IA | 7,097 | \$253,757.25 | \$654.01 | 51 |
| 63 | HY-VEE PHARMACY (1396) | MARION | IA | 3,079 | \$253,601.24 | \$579.00 | 64 |
| 64 | ALLEN CLINIC PHARMACY | WATERLOO | IA | 956 | \$252,532.06 | \$774.64 | 37 |
| 65 | HY-VEE PHARMACY (1192) | FT DODGE | IA | 3,174 | \$251,963.84 | \$571.35 | 65 |
| 66 | MAHASKA DRUGS INC | OSKALOOSA | IA | 2,606 | \$251,160.76 | \$703.53 | 87 |

| | | | | | | | |
|----|--|-----------------|----|-------|--------------|-------------|-----|
| 67 | HY-VEE PHARMACY #3 (1866) | WATERLOO | IA | 2,230 | \$247,356.17 | \$721.16 | 95 |
| 68 | WALMART PHARMACY 10-5115 | DAVENPORT | IA | 3,101 | \$246,389.50 | \$509.07 | 43 |
| 69 | HY-VEE PHARMACY (1522) | PERRY | IA | 2,384 | \$243,669.57 | \$696.20 | 70 |
| 70 | HY-VEE PHARMACY #3 (1142) | DES MOINES | IA | 3,296 | \$243,067.92 | \$471.98 | 68 |
| 71 | MERCYONE FOREST PARK PHARMACY | MASON CITY | IA | 2,555 | \$242,048.74 | \$630.34 | 79 |
| 72 | CVS PHARMACY #08658 | DAVENPORT | IA | 3,189 | \$241,538.41 | \$522.81 | 75 |
| 73 | UI HEALTH CARE DES MOINES PHARMACY | DES MOINES | IA | 29 | \$241,071.08 | \$18,543.93 | 45 |
| 74 | RIVER HILLS PHARMACY | OTTUMWA | IA | 630 | \$239,720.16 | \$1,762.65 | 111 |
| 75 | WALGREENS #3700 | COUNCIL BLUFFS | IA | 2,832 | \$238,882.85 | \$392.25 | 73 |
| 76 | HY-VEE PHARMACY #4 (1148) | DES MOINES | IA | 3,024 | \$237,173.59 | \$536.59 | 77 |
| 77 | HY-VEE PHARMACY (1071) | CLARINDA | IA | 2,182 | \$236,767.54 | \$692.30 | 81 |
| 78 | HY-VEE DRUGSTORE #1 (7020) | CEDAR RAPIDS | IA | 3,001 | \$235,932.93 | \$572.65 | 56 |
| 79 | WALMART PHARMACY 10-3394 | ATLANTIC | IA | 2,216 | \$232,754.55 | \$619.03 | 112 |
| 80 | HY-VEE PHARMACY (1074) | CHARLES CITY | IA | 3,407 | \$230,544.14 | \$456.52 | 69 |
| 81 | MAIN AT LOCUST PHARMACY AND MEDICAL SUPPLY | DAVENPORT | IA | 3,022 | \$228,638.04 | \$933.22 | 66 |
| 82 | WALGREENS #359 | DES MOINES | IA | 2,904 | \$228,144.54 | \$289.16 | 91 |
| 83 | HY-VEE PHARMACY #1 (1610) | SIOUX CITY | IA | 2,543 | \$227,645.38 | \$516.20 | 72 |
| 84 | GREENWOOD COMPLIANCE PHARMACY | WATERLOO | IA | 1,374 | \$226,852.79 | \$2,246.07 | 71 |
| 85 | WALMART PHARMACY 10-0797 | WEST BURLINGTON | IA | 2,580 | \$223,596.89 | \$522.42 | 115 |
| 86 | L & M PHARMACY CARE | LE MARS | IA | 1,760 | \$223,361.91 | \$4,855.69 | 88 |
| 87 | PRIMARY HEALTHCARE PHARMACY | DES MOINES | IA | 895 | \$221,145.29 | \$1,332.20 | 90 |
| 88 | WALGREENS #7453 | DES MOINES | IA | 2,654 | \$220,904.26 | \$375.05 | 76 |
| 89 | WALMART PHARMACY 10-2889 | CLINTON | IA | 2,749 | \$220,638.73 | \$446.64 | 99 |
| 90 | HY-VEE PHARMACY #6 (1155) | DES MOINES | IA | 2,090 | \$212,495.55 | \$908.10 | 104 |

| | | | | | | | |
|-----|-----------------------------------|--------------|----|-------|--------------|-------------|-----|
| 91 | SOUTH SIDE DRUG | OTTUMWA | IA | 2,651 | \$211,535.32 | \$678.00 | 106 |
| 92 | BIOPLUS SPECIALTY PHARMACY, INC | LAKE MARY | FL | 22 | \$211,040.70 | \$15,074.34 | 128 |
| 93 | MCMH PHARMACY | RED OAK | IA | 2,164 | \$206,370.69 | \$825.48 | 82 |
| 94 | HY-VEE DRUGSTORE (7056) | MASON CITY | IA | 2,598 | \$206,062.22 | \$447.96 | 97 |
| 95 | OPTUM INFUSION SERVICES 550, LLC. | URBANDALE | IA | 13 | \$205,980.54 | \$68,660.18 | 784 |
| 96 | HY-VEE PHARMACY (1241) | HARLAN | IA | 2,182 | \$204,138.50 | \$563.92 | 89 |
| 97 | HY-VEE PHARMACY #1 (1054) | CEDAR RAPIDS | IA | 2,074 | \$202,563.02 | \$682.03 | 80 |
| 98 | HY-VEE PHARMACY (1873) | WAUKEE | IA | 2,295 | \$199,100.77 | \$444.42 | 113 |
| 99 | LAGRANGE PHARMACY | VINTON | IA | 2,270 | \$198,949.26 | \$688.41 | 85 |
| 100 | GENOA HEALTHCARE, LLC | MARSHALLTOWN | IA | 701 | \$198,462.69 | \$2,512.19 | 144 |

TOP 100 PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
December 2025 / February 2026

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS MEMBER | PREVIOUS RANK |
|------|------------|-------------------|--------------|--------------------|--------------------|---------------|
| 1 | 1982605762 | Jeffrey Wilharm | \$133,930.41 | 2,136 | 7.12 | 1 |
| 2 | 1063491645 | Allyson Wheaton | \$111,566.31 | 1,294 | 2.72 | 4 |
| 3 | 1215146055 | Rebecca Wolfe | \$73,430.55 | 1,219 | 2.86 | 3 |
| 4 | 1730849647 | Melanie Parrish | \$35,052.74 | 1,170 | 3.06 | 9 |
| 5 | 1356359871 | Rhea Hartley | \$102,545.24 | 1,160 | 2.48 | 2 |
| 6 | 1528365277 | Mina Salib | \$471,845.73 | 1,147 | 2.25 | 11 |
| 7 | 1043434525 | Robert Kent | \$86,583.15 | 1,127 | 4.05 | 7 |
| 8 | 1013115369 | Bobbita Nag | \$62,114.58 | 1,114 | 2.62 | 5 |
| 9 | 1902478811 | Joan Anderson | \$318,596.75 | 1,079 | 3.47 | 18 |
| 10 | 1467502286 | Charles Tilley | \$193,004.30 | 1,077 | 3.58 | 6 |
| 11 | 1902850845 | Deborah Bahe | \$97,416.86 | 1,005 | 3.95 | 10 |
| 12 | 1437238110 | Genevieve Nelson | \$273,376.04 | 993 | 3.16 | 14 |
| 13 | 1043418809 | Michael Ciliberto | \$442,840.69 | 989 | 2.63 | 16 |
| 14 | 1467907394 | Cynthia Coenen | \$109,429.95 | 983 | 3.67 | 8 |
| 15 | 1790163848 | Hesper Nowatzki | \$136,125.99 | 977 | 2.98 | 17 |
| 16 | 1770933046 | Shelby Biller | \$169,608.72 | 946 | 3.11 | 23 |
| 17 | 1306559786 | Roy Henry | \$66,118.16 | 940 | 3.48 | 19 |
| 18 | 1902574361 | Laura Owens | \$87,735.86 | 933 | 3.30 | 22 |
| 19 | 1902912538 | Christian Jones | \$83,516.34 | 930 | 3.23 | 13 |
| 20 | 1659358620 | Carlos Castillo | \$25,695.07 | 917 | 3.10 | 20 |

| | | | | | | |
|----|------------|------------------|--------------|-----|------|----|
| 21 | 1992402655 | Shane Eberhardt | \$156,966.60 | 909 | 3.03 | 24 |
| 22 | 1184657603 | Sara Rygol | \$166,739.76 | 882 | 3.14 | 33 |
| 23 | 1245960350 | Mary Welborn | \$57,317.25 | 862 | 2.85 | 39 |
| 24 | 1164538674 | Joseph Wanzek | \$72,719.12 | 844 | 4.09 | 28 |
| 25 | 1417214321 | Leah Brandon | \$22,328.20 | 842 | 5.07 | 45 |
| 26 | 1679573893 | Patty Hildreth | \$198,962.06 | 837 | 3.44 | 25 |
| 27 | 1609532373 | Erin Fox-Hammel | \$88,369.71 | 833 | 3.84 | 26 |
| 28 | 1154815330 | Bruce Pehl | \$54,141.14 | 810 | 3.40 | 29 |
| 29 | 1922455096 | Dean Guerdet | \$94,205.97 | 808 | 3.13 | 15 |
| 30 | 1649248378 | Kathleen Wild | \$27,212.69 | 800 | 3.16 | 44 |
| 31 | 1053630640 | Jennifer Donovan | \$112,026.86 | 791 | 2.95 | 60 |
| 32 | 1275763047 | Rebecca Bowman | \$125,547.49 | 791 | 3.74 | 42 |
| 33 | 1215125216 | Rebecca Walding | \$53,473.58 | 781 | 3.67 | 41 |
| 34 | 1134191018 | Dustin Smith | \$58,352.92 | 780 | 3.64 | 46 |
| 35 | 1801463245 | Ann Mojeiko | \$123,431.16 | 780 | 3.46 | 67 |
| 36 | 1215184726 | Babuji Gandra | \$25,082.78 | 771 | 2.77 | 32 |
| 37 | 1053963900 | Nicole Mcclavy | \$115,774.98 | 770 | 3.21 | 34 |
| 38 | 1457914657 | Seema Antony | \$96,232.09 | 765 | 2.91 | 47 |
| 39 | 1003470923 | Earlene Angell | \$102,663.25 | 762 | 4.01 | 21 |
| 40 | 1477199198 | Sajo Thomas | \$143,540.47 | 762 | 3.09 | 31 |
| 41 | 1992103386 | Melissa Larsen | \$90,922.32 | 760 | 3.07 | 30 |
| 42 | 1053398800 | Steven Scurr | \$42,627.71 | 755 | 4.12 | 68 |
| 43 | 1205393386 | Jessica Hudspeth | \$97,014.87 | 748 | 3.81 | 40 |
| 44 | 1922144088 | Thomas Hopkins | \$18,543.87 | 744 | 2.44 | 59 |

| | | | | | | |
|----|------------|---------------------|--------------|-----|------|-----|
| 45 | 1215981758 | Lisa Pisney | \$69,922.70 | 731 | 3.44 | 35 |
| 46 | 1982030946 | Jacklyn Besch | \$48,144.80 | 728 | 2.75 | 51 |
| 47 | 1538368170 | Christopher Matson | \$28,809.70 | 724 | 3.29 | 37 |
| 48 | 1023542271 | Flynn McCullough | \$71,365.31 | 719 | 3.47 | 101 |
| 49 | 1811419815 | Gretchen Wenger | \$88,832.63 | 719 | 2.47 | 38 |
| 50 | 1801998372 | Wendy Hansen-Penman | \$31,473.60 | 711 | 3.77 | 55 |
| 51 | 1821333774 | Brittni Benda | \$44,907.53 | 708 | 2.12 | 56 |
| 52 | 1649763079 | Kate Jarvis | \$120,487.13 | 703 | 3.39 | 49 |
| 53 | 1265841845 | Mary Schwering | \$52,362.05 | 700 | 3.15 | 60 |
| 54 | 1902358443 | Melissa Konken | \$159,053.05 | 700 | 3.19 | 36 |
| 55 | 1689077018 | Stacy Roth | \$102,177.32 | 697 | 2.93 | 51 |
| 56 | 1609946243 | Sina Linman | \$31,196.69 | 693 | 2.41 | 62 |
| 57 | 1144588476 | Rachel Filzer | \$83,288.30 | 686 | 2.92 | 53 |
| 58 | 1811960768 | Angela Veenstra | \$37,156.63 | 676 | 3.65 | 93 |
| 59 | 1598183493 | Jena Ellerhoff | \$36,826.86 | 672 | 4.53 | 54 |
| 60 | 1376926535 | Rebecca Devine | \$205,963.56 | 665 | 4.16 | 975 |
| 61 | 1306475413 | Autumn Anderson | \$36,507.86 | 662 | 3.43 | 91 |
| 62 | 1477142289 | Andrea Johnson | \$140,789.16 | 661 | 3.41 | 98 |
| 63 | 1528329398 | Erin Rowan | \$47,353.19 | 660 | 3.03 | 71 |
| 64 | 1356724405 | Beth Colon | \$74,530.64 | 659 | 2.42 | 66 |
| 65 | 1679669832 | Erin Hatcher | \$106,285.47 | 658 | 2.72 | 335 |
| 66 | 1376244954 | Cory Slusher | \$49,847.60 | 650 | 2.23 | 94 |
| 67 | 1215581251 | Anna Throckmorton | \$29,931.97 | 645 | 5.59 | 81 |
| 68 | 1699361949 | Nicholas Jensen | \$114,346.71 | 645 | 3.55 | 268 |

| | | | | | | |
|----|------------|-------------------|--------------|-----|------|-----|
| 69 | 1588746515 | Amy Badberg | \$30,818.67 | 639 | 2.73 | 78 |
| 70 | 1043703887 | Tenaea Jeppeson | \$37,493.61 | 637 | 3.53 | 65 |
| 71 | 1073156295 | Kasie Christensen | \$57,461.07 | 633 | 2.65 | 80 |
| 72 | 1760455083 | Thomas Schmadeke | \$80,724.49 | 631 | 3.26 | 108 |
| 73 | 1295967255 | Mary Robinson | \$38,840.88 | 630 | 4.44 | 77 |
| 74 | 1114681889 | Kelsey Bauer | \$62,372.03 | 629 | 4.15 | 84 |
| 75 | 1992573786 | Lashelle Goode | \$37,244.57 | 627 | 2.82 | 105 |
| 76 | 1942857529 | Amanda Renne | \$30,449.91 | 622 | 3.20 | 99 |
| 77 | 1457584740 | Eric Meyer | \$43,055.47 | 621 | 2.12 | 12 |
| 78 | 1871105916 | Lacie Theis | \$39,602.45 | 615 | 2.56 | 48 |
| 79 | 1477112688 | Felicia Hoerner | \$54,206.46 | 614 | 2.64 | 95 |
| 80 | 1790499648 | Maria Brickner | \$81,947.06 | 609 | 4.79 | 105 |
| 81 | 1881095503 | Karoweso Chipendo | \$69,826.15 | 608 | 3.14 | 149 |
| 82 | 1164823092 | Jamey Gregersen | \$47,213.56 | 606 | 3.21 | 114 |
| 83 | 1649209933 | Richard Blunk | \$34,302.85 | 606 | 1.98 | 74 |
| 84 | 1255405338 | Bryan Netolicky | \$74,157.64 | 605 | 3.10 | 63 |
| 85 | 1255058640 | Shelli Brown | \$114,046.94 | 604 | 2.96 | 76 |
| 86 | 1619153137 | Joada Best | \$53,497.21 | 601 | 2.82 | 69 |
| 87 | 1992314108 | Lynzee Makowski | \$524,685.77 | 600 | 2.40 | 104 |
| 88 | 1194425223 | Mary Boksa | \$58,546.39 | 599 | 2.57 | 49 |
| 89 | 1831731298 | Heather Wilson | \$36,781.50 | 599 | 2.63 | 88 |
| 90 | 1063792026 | Jill Miller | \$167,203.69 | 598 | 2.17 | 108 |
| 91 | 1023469798 | Shipeng Wei | \$43,754.52 | 597 | 7.13 | 105 |
| 92 | 1750867248 | Mikhail Shkiryak | \$109,709.16 | 597 | 2.66 | 87 |

| | | | | | | |
|-----|------------|------------------|--------------|-----|------|-----|
| 93 | 1043211303 | Ali Safdar | \$106,351.99 | 596 | 2.54 | 72 |
| 94 | 1316356496 | Kimberly Roberts | \$30,381.63 | 595 | 4.04 | 136 |
| 95 | 1396181012 | Heather Kruse | \$37,002.91 | 595 | 4.17 | 73 |
| 96 | 1417941188 | Debra Neuharth | \$35,903.31 | 591 | 3.20 | 56 |
| 97 | 1891707832 | Lisa Klock | \$39,458.02 | 591 | 2.78 | 82 |
| 98 | 1598786097 | Stephanie Gray | \$97,076.69 | 590 | 3.17 | 130 |
| 99 | 1205334570 | Trisha Kress | \$39,033.48 | 589 | 4.46 | 168 |
| 100 | 1639607757 | Michael Gerber | \$104,439.34 | 588 | 3.07 | 86 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
December 2025 / February 2026

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | AVG COST RX | PRESCRIPTION COUNT | PREVIOUS RANK |
|------|------------|---------------------|----------------|--------------|--------------------|---------------|
| 1 | 1841632965 | Ahmad Al-Huniti | \$1,234,974.16 | \$38,592.94 | 32 | 1 |
| 2 | 1437121407 | Linda Cadaret | \$898,778.86 | \$7,190.23 | 125 | 3 |
| 3 | 1477761328 | Amy Calhoun | \$769,538.68 | \$8,186.58 | 94 | 8 |
| 4 | 1023108701 | Ronald Zolty | \$754,150.71 | \$11,970.65 | 63 | 5 |
| 5 | 1326211889 | James Friedlander | \$652,079.00 | \$7,582.31 | 86 | 6 |
| 6 | 1942937388 | Carly Trausch | \$646,970.12 | \$1,216.11 | 532 | 4 |
| 7 | 1285626390 | Kathleen Gradoville | \$583,645.20 | \$2,411.76 | 242 | 14 |
| 8 | 1326034984 | Katherine Mathews | \$547,866.86 | \$8,301.01 | 66 | 2 |
| 9 | 1992314108 | Lynzee Makowski | \$524,685.77 | \$874.48 | 600 | 7 |
| 10 | 1891146999 | Becky Johnson | \$515,982.30 | \$1,183.45 | 436 | 11 |
| 11 | 1528365277 | Mina Salib | \$471,845.73 | \$411.37 | 1147 | 16 |
| 12 | 1700561826 | Pedro Hsieh | \$464,762.97 | \$9,682.56 | 48 | 10 |
| 13 | 1861277980 | Kathryn Ewoldt | \$453,985.08 | \$1,188.44 | 382 | 15 |
| 14 | 1356753859 | Katie Lutz | \$443,439.01 | \$3,236.78 | 137 | 30 |
| 15 | 1043418809 | Michael Ciliberto | \$442,840.69 | \$447.77 | 989 | 12 |
| 16 | 1750470118 | Laura Graeff-Armas | \$413,261.15 | \$103,315.29 | 4 | 17 |
| 17 | 1700417169 | Courtney Reints | \$401,352.94 | \$1,274.14 | 315 | 18 |
| 18 | 1376525196 | Randolph Rough | \$377,235.96 | \$3,224.24 | 117 | 13 |
| 19 | 1043565328 | Sara Moeller | \$357,711.05 | \$2,956.29 | 121 | 21 |
| 20 | 1417443953 | Rodney Clark | \$355,985.69 | \$1,275.93 | 279 | 19 |

| | | | | | | |
|----|------------|-------------------------|--------------|-------------|------|-----|
| 21 | 1295091510 | Rebecca Weiner | \$352,259.42 | \$1,104.26 | 319 | 22 |
| 22 | 1326410499 | Tara Eastvold | \$348,765.02 | \$1,010.91 | 345 | 32 |
| 23 | 1629415922 | Alyssa Lakin | \$344,844.21 | \$1,874.15 | 184 | 20 |
| 24 | 1750348496 | Vanessa Curtis | \$336,172.33 | \$2,049.83 | 164 | 851 |
| 25 | 1528334406 | Chittalsinh Raulji | \$335,134.92 | \$12,889.80 | 26 | 101 |
| 26 | 1649943689 | Jessica Wolfe | \$333,201.51 | \$1,781.83 | 187 | 24 |
| 27 | 1902478811 | Joan Anderson | \$318,596.75 | \$295.27 | 1079 | 43 |
| 28 | 1477765584 | Sangeeta Shah | \$300,957.90 | \$820.05 | 367 | 197 |
| 29 | 1649826140 | Taylor Myers | \$295,775.29 | \$1,607.47 | 184 | 23 |
| 30 | 1508091109 | Melissa Muff-Luett | \$287,478.14 | \$5,636.83 | 51 | 27 |
| 31 | 1285620583 | Michael Tansey | \$287,195.39 | \$2,815.64 | 102 | 28 |
| 32 | 1437238110 | Genevieve Nelson | \$273,376.04 | \$275.30 | 993 | 31 |
| 33 | 1386084747 | Jennifer Condon | \$272,604.49 | \$1,383.78 | 197 | 26 |
| 34 | 1952420705 | Eric Rush | \$263,572.74 | \$43,928.79 | 6 | 9 |
| 35 | 1932153830 | Michael Stephens | \$260,944.11 | \$21,745.34 | 12 | 25 |
| 36 | 1295054542 | Angela Delecaris | \$240,658.95 | \$4,911.41 | 49 | 29 |
| 37 | 1558673095 | Amanda Van Wyk | \$233,911.65 | \$1,613.18 | 145 | 156 |
| 38 | 1053520759 | Alicia Gerke | \$233,621.84 | \$5,698.09 | 41 | 50 |
| 39 | 1285331058 | Natalie Reitz | \$229,283.60 | \$4,585.67 | 50 | 62 |
| 40 | 1609131770 | Sreenath Thati Ganganna | \$226,665.36 | \$469.29 | 483 | 78 |
| 41 | 1730318205 | Diana Bayer-Bowstead | \$217,446.27 | \$1,941.48 | 112 | 115 |
| 42 | 1821046087 | Archana Verma | \$215,969.76 | \$2,511.28 | 86 | 42 |
| 43 | 1306823281 | Molly Franke | \$215,475.13 | \$1,766.19 | 122 | 54 |
| 44 | 1871868984 | Hana Niebur | \$213,778.33 | \$4,191.73 | 51 | 45 |

| | | | | | | |
|----|------------|---------------------|--------------|-------------|------|-----|
| 45 | 1851568703 | Mathew Davey | \$210,460.95 | \$3,141.21 | 67 | 84 |
| 46 | 1053456426 | Karen Agricola | \$210,051.36 | \$17,504.28 | 12 | 66 |
| 47 | 1376926535 | Rebecca Devine | \$205,963.56 | \$309.72 | 665 | 276 |
| 48 | 1841050986 | Smrithi Mani | \$199,157.57 | \$2,586.46 | 77 | 705 |
| 49 | 1114214541 | Dimah Saade | \$199,038.90 | \$8,293.29 | 24 | 141 |
| 50 | 1679573893 | Patty Hildreth | \$198,962.06 | \$237.71 | 837 | 57 |
| 51 | 1730406356 | Christina Warren | \$196,656.93 | \$1,512.75 | 130 | 52 |
| 52 | 1245468768 | Thomas Schmidt | \$195,549.78 | \$1,880.29 | 104 | 40 |
| 53 | 1447519038 | Erin Richardson | \$195,403.35 | \$745.81 | 262 | 36 |
| 54 | 1285710764 | Jitendrakumar Gupta | \$193,595.70 | \$771.30 | 251 | 80 |
| 55 | 1467502286 | Charles Tilley | \$193,004.30 | \$179.21 | 1077 | 68 |
| 56 | 1891952552 | Nicholas Fustino | \$189,759.10 | \$3,012.05 | 63 | 221 |
| 57 | 1730293705 | Robert Jackson | \$189,583.25 | \$3,213.28 | 59 | 46 |
| 58 | 1902191059 | Amber Tierney | \$189,432.41 | \$5,571.54 | 34 | 38 |
| 59 | 1851161228 | Kala Clark | \$188,619.00 | \$324.65 | 581 | 59 |
| 60 | 1669184511 | Chandra Miller | \$188,548.21 | \$8,570.37 | 22 | 60 |
| 61 | 1750913406 | Carrissa Riggs | \$188,531.29 | \$2,732.34 | 69 | 222 |
| 62 | 1629537576 | Jordan Evans | \$187,083.38 | \$1,005.82 | 186 | 70 |
| 63 | 1306071915 | Thomas Pietras | \$184,137.74 | \$1,898.33 | 97 | 55 |
| 64 | 1447373832 | Joshua Wilson | \$182,738.18 | \$4,153.14 | 44 | 33 |
| 65 | 1578132940 | Alec Steils | \$176,719.92 | \$652.10 | 271 | 47 |
| 66 | 1588616171 | Heather Thomas | \$176,522.24 | \$1,819.82 | 97 | 34 |
| 67 | 1437513520 | Sussette Szachowicz | \$176,091.24 | \$755.76 | 233 | 76 |
| 68 | 1609003011 | John Bernat | \$174,654.79 | \$14,554.57 | 12 | 65 |

| | | | | | | |
|----|------------|------------------------|--------------|------------|-----|-----|
| 69 | 1578958542 | Heidi Curtis | \$172,660.11 | \$903.98 | 191 | 85 |
| 70 | 1144455502 | Jennifer Petts | \$171,655.50 | \$837.34 | 205 | 77 |
| 71 | 1699018721 | Shilpi Relan | \$169,797.62 | \$912.89 | 186 | 49 |
| 72 | 1770933046 | Shelby Biller | \$169,608.72 | \$179.29 | 946 | 73 |
| 73 | 1932464971 | Kari Ernst | \$168,866.87 | \$1,723.13 | 98 | 51 |
| 74 | 1275836751 | Holly Kramer | \$168,491.37 | \$1,504.39 | 112 | 81 |
| 75 | 1063792026 | Jill Miller | \$167,203.69 | \$279.60 | 598 | 83 |
| 76 | 1558543595 | Gordon Buchanan | \$167,017.98 | \$971.03 | 172 | 82 |
| 77 | 1184657603 | Sara Rygol | \$166,739.76 | \$189.05 | 882 | 130 |
| 78 | 1811666118 | Jessiann Dryden-Parish | \$165,460.27 | \$1,323.68 | 125 | 53 |
| 79 | 1467449579 | Brian Wayson | \$163,670.04 | \$2,182.27 | 75 | 102 |
| 80 | 1649419219 | Heather Hunemuller | \$163,501.84 | \$1,248.11 | 131 | 39 |
| 81 | 1184056822 | Abby Kolthoff | \$163,194.09 | \$437.52 | 373 | 37 |
| 82 | 1134981038 | Cassidy Chalupa | \$160,374.85 | \$2,586.69 | 62 | 91 |
| 83 | 1104804053 | Winthrop Risk | \$159,900.64 | \$352.20 | 454 | 105 |
| 84 | 1902358443 | Melissa Konken | \$159,053.05 | \$227.22 | 700 | 75 |
| 85 | 1174584072 | Bradley Lair | \$157,439.29 | \$4,143.14 | 38 | 191 |
| 86 | 1992402655 | Shane Eberhardt | \$156,966.60 | \$172.68 | 909 | 104 |
| 87 | 1003315201 | Abigail Behrens | \$155,780.72 | \$1,770.24 | 88 | 89 |
| 88 | 1356752067 | Kelly Delaney-Nelson | \$155,734.52 | \$1,497.45 | 104 | 63 |
| 89 | 1003103383 | Greer Sutamtewagul | \$155,513.74 | \$4,712.54 | 33 | 177 |
| 90 | 1104029008 | Katie Larson Ode | \$155,077.96 | \$1,314.22 | 118 | 797 |
| 91 | 1093162075 | Meghan Ryan | \$154,519.75 | \$1,500.19 | 103 | 72 |
| 92 | 1134440886 | Melissa Chiston | \$152,376.51 | \$2,059.14 | 74 | 321 |

| | | | | | | |
|-----|------------|------------------|--------------|-------------|-----|-------|
| 93 | 1407065469 | Christoph Randak | \$149,137.28 | \$898.42 | 166 | 112 |
| 94 | 1013026798 | Stephen Grant | \$147,006.80 | \$3,500.16 | 42 | 88 |
| 95 | 1285946566 | Hazim Zaghoul | \$145,812.24 | \$1,415.65 | 103 | 126 |
| 96 | 1699765826 | Joseph Merchant | \$145,798.56 | \$2,513.77 | 58 | 122 |
| 97 | 1316934318 | Steven Lentz | \$144,318.57 | \$11,101.43 | 13 | 35 |
| 98 | 1477199198 | Sajo Thomas | \$143,540.47 | \$188.37 | 762 | 86 |
| 99 | 1538621818 | Cara Franey | \$142,791.60 | \$11,899.30 | 12 | 12437 |
| 100 | 1245737097 | Ashley Patrick | \$141,437.98 | \$1,704.07 | 83 | 44 |

TOP 20 THERAPEUTIC CLASS BY PAID AMOUNT

| CATEGORY DESCRIPTION | September 2025 / November 2025 | PREVIOUS RANK | % BUDGET | December 2025 / February 2026 | CURRENT RANK | % BUDGET | % CHANGE |
|---|-----------------------------------|------------------|-------------|----------------------------------|-----------------|-------------|-------------|
| DERMATOLOGICALS | \$13,362,116 | 2 | 12.4% | \$14,087,304 | 1 | 12.9% | 5.4% |
| ANTIDIABETICS | \$14,401,573 | 1 | 13.3% | \$14,078,707 | 2 | 12.9% | -2.2% |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | \$11,041,466 | 3 | 10.2% | \$11,348,201 | 3 | 10.4% | 2.8% |
| ANALGESICS - ANTI-INFLAMMATORY | \$7,490,114 | 4 | 6.9% | \$6,844,298 | 4 | 6.3% | -8.6% |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | \$6,087,952 | 5 | 5.6% | \$6,489,031 | 5 | 6.0% | 6.6% |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | \$5,873,538 | 6 | 5.4% | \$6,062,745 | 6 | 5.6% | 3.2% |
| ENDOCRINE AND METABOLIC AGENTS - MISC. | \$4,201,704 | 7 | 3.9% | \$4,486,659 | 7 | 4.1% | 6.8% |
| PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. | \$3,943,048 | 8 | 3.6% | \$4,046,160 | 8 | 3.7% | 2.6% |
| MIGRAINE PRODUCTS | \$3,616,781 | 10 | 3.3% | \$3,836,807 | 9 | 3.5% | 6.1% |
| ANTICONVULSANTS | \$3,742,183 | 9 | 3.5% | \$3,695,707 | 10 | 3.4% | -1.2% |
| ANTIVIRALS | \$3,397,411 | 12 | 3.1% | \$3,405,004 | 11 | 3.1% | 0.2% |
| CARDIOVASCULAR AGENTS - MISC. | \$3,305,354 | 13 | 3.1% | \$3,256,731 | 12 | 3.0% | -1.5% |
| ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES | \$3,450,217 | 11 | 3.2% | \$3,252,298 | 13 | 3.0% | -5.7% |
| HEMATOLOGICAL AGENTS - MISC. | \$3,250,793 | 14 | 3.0% | \$3,182,622 | 14 | 2.9% | -2.1% |
| RESPIRATORY AGENTS - MISC. | \$2,972,618 | 15 | 2.7% | \$2,876,048 | 15 | 2.6% | -3.2% |
| GASTROINTESTINAL AGENTS - MISC. | \$2,388,586 | 16 | 2.2% | \$2,350,644 | 16 | 2.2% | -1.6% |
| ANTIDEPRESSANTS | \$2,117,066 | 17 | 2.0% | \$2,166,686 | 17 | 2.0% | 2.3% |
| NEUROMUSCULAR AGENTS | \$1,392,150 | 19 | 1.3% | \$1,480,629 | 18 | 1.4% | 6.4% |
| ANTICOAGULANTS | \$1,758,978 | 18 | 1.6% | \$1,455,063 | 19 | 1.3% | -17.3% |
| MISCELLANEOUS THERAPEUTIC CLASSES | \$589,160 | 21 | 0.5% | \$944,849 | 20 | 0.9% | 60.4% |

TOP 20 THERAPEUTIC CLASS BY PRESCRIPTION COUNT

| CATEGORY DESCRIPTION | September 2025 / November 2025 | PREVIOUS RANK | December 2025 / February 2026 | CURRENT RANK | % CHANGE |
|---|--------------------------------|---------------|-------------------------------|--------------|----------|
| ANTIDEPRESSANTS | 96,213 | 1 | 95,343 | 1 | -0.9% |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | 48,911 | 2 | 50,564 | 2 | 3.4% |
| ANTICONVULSANTS | 48,507 | 3 | 48,460 | 3 | -0.1% |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | 44,296 | 4 | 43,869 | 4 | -1.0% |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | 37,904 | 5 | 38,045 | 5 | 0.4% |
| ANTIDIABETICS | 37,031 | 6 | 36,883 | 6 | -0.4% |
| ANTIANSXIETY AGENTS | 34,326 | 8 | 34,416 | 7 | 0.3% |
| ANTIHYPERTENSIVES | 33,590 | 9 | 33,060 | 8 | -1.6% |
| ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | 34,628 | 7 | 31,673 | 9 | -8.5% |
| ANTIHISTAMINES | 24,831 | 10 | 22,934 | 10 | -7.6% |
| DERMATOLOGICALS | 22,315 | 11 | 22,159 | 11 | -0.7% |
| ANTIHYPERLIPIDEMICS | 20,225 | 12 | 19,348 | 12 | -4.3% |
| PENICILLINS | 15,761 | 15 | 19,217 | 13 | 21.9% |
| ANALGESICS - ANTI-INFLAMMATORY | 17,127 | 13 | 16,656 | 14 | -2.8% |
| ANALGESICS - OPIOID | 16,505 | 14 | 16,279 | 15 | -1.4% |
| BETA BLOCKERS | 15,442 | 16 | 15,119 | 16 | -2.1% |
| MUSCULOSKELETAL THERAPY AGENTS | 13,092 | 17 | 13,011 | 17 | -0.6% |
| CORTICOSTEROIDS | 12,368 | 19 | 12,322 | 18 | -0.4% |
| THYROID AGENTS | 12,835 | 18 | 11,553 | 19 | -10.0% |
| ANALGESICS - NonNarcotic | 11,320 | 21 | 11,394 | 20 | 0.7% |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | September 2025 / November 2025 | PREVIOUS RANK | December 2025 / February 2026 | CURRENT RANK | % CHANGE |
|--------------------|-----------------------------------|------------------|----------------------------------|-----------------|----------|
| OZEMPIC | \$5,338,199 | 1 | \$5,570,701 | 1 | 4.4% |
| VRAYLAR | \$3,637,005 | 3 | \$3,589,784 | 2 | -1.3% |
| DUPIXENT PEN | \$3,008,189 | 4 | \$3,464,427 | 3 | 15.2% |
| HUMIRA(CF) PEN | \$3,656,447 | 2 | \$3,208,978 | 4 | -12.2% |
| MOUNJARO | \$2,576,611 | 5 | \$2,871,213 | 5 | 11.4% |
| SKYRIZI PEN | \$2,252,998 | 6 | \$2,122,451 | 6 | -5.8% |
| INVEGA SUSTENNA | \$1,904,618 | 9 | \$1,950,544 | 7 | 2.4% |
| TRIKAFTA | \$2,175,023 | 8 | \$1,867,155 | 8 | -14.2% |
| JARDIANCE | \$2,235,232 | 7 | \$1,691,457 | 9 | -24.3% |
| STELARA | \$1,820,050 | 10 | \$1,581,331 | 10 | -13.1% |
| BIKTARVY | \$1,490,361 | 11 | \$1,577,993 | 11 | 5.9% |
| ZEPBOUND | \$1,013,178 | 17 | \$1,393,509 | 12 | 37.5% |
| REXULTI | \$1,345,784 | 12 | \$1,389,658 | 13 | 3.3% |
| TRULICITY | \$1,147,541 | 14 | \$1,160,785 | 14 | 1.2% |
| TALTZ AUTOINJECTOR | \$1,084,003 | 15 | \$1,130,602 | 15 | 4.3% |
| NURTEC ODT | \$1,078,602 | 16 | \$1,103,108 | 16 | 2.3% |
| ALTUVIIIO | \$881,771 | 20 | \$997,219 | 17 | 13.1% |
| RINVOQ | \$837,328 | 22 | \$975,463 | 18 | 16.5% |
| ELIQUIS | \$1,258,718 | 13 | \$973,383 | 19 | -22.7% |
| DUPIXENT SYRINGE | \$906,374 | 19 | \$970,345 | 20 | 7.1% |
| WAKIX | \$851,663 | 21 | \$930,104 | 21 | 9.2% |

| | | | | | |
|-----------------------------|-----------|----|-----------|----|--------|
| CAPLYTA | \$800,220 | 23 | \$923,560 | 22 | 15.4% |
| COSENTYX UNOREADY PEN | \$777,797 | 28 | \$856,428 | 23 | 10.1% |
| BIMZELX AUTOINJECTOR | \$779,557 | 26 | \$855,899 | 24 | 9.8% |
| SKYRIZI ON-BODY | \$696,723 | 34 | \$840,019 | 25 | 20.6% |
| EVRYSDI | \$727,108 | 30 | \$821,305 | 26 | 13.0% |
| TRELEGY ELLIPTA | \$778,875 | 27 | \$807,309 | 27 | 3.7% |
| INGREZZA | \$772,207 | 29 | \$788,316 | 28 | 2.1% |
| UBRELVY | \$699,736 | 33 | \$770,206 | 29 | 10.1% |
| NORDITROPIN FLEXPRO | \$612,132 | 42 | \$745,992 | 30 | 21.9% |
| LYBALVI | \$649,313 | 38 | \$732,564 | 31 | 12.8% |
| AUSTEDO XR | \$652,738 | 37 | \$729,768 | 32 | 11.8% |
| EPIDIOLEX | \$657,019 | 36 | \$720,766 | 33 | 9.7% |
| ARISTADA | \$668,714 | 35 | \$715,551 | 34 | 7.0% |
| ABILIFY MAINTENA | \$713,952 | 31 | \$692,359 | 35 | -3.0% |
| AJOVY AUTOINJECTOR | \$624,571 | 40 | \$690,256 | 36 | 10.5% |
| STRENSIQ | \$933,653 | 18 | \$676,817 | 37 | -27.5% |
| ENBREL SURECLICK | \$784,835 | 25 | \$673,156 | 38 | -14.2% |
| SYMBICORT | \$625,306 | 39 | \$624,629 | 39 | -0.1% |
| LISDEXAMFETAMINE DIMESYLATE | \$788,005 | 24 | \$619,363 | 40 | -21.4% |
| TREMFYA ONE-PRESS | \$706,790 | 32 | \$617,065 | 41 | -12.7% |
| JORNAY PM | \$568,743 | 44 | \$598,343 | 42 | 5.2% |
| ORENITRAM ER | \$488,132 | 50 | \$559,795 | 43 | 14.7% |
| ALYFTREK | \$425,079 | 56 | \$557,836 | 44 | 31.2% |
| UPTRAVI | \$396,954 | 60 | \$554,791 | 45 | 39.8% |

| | | | | | |
|-----------------------|-----------|-----|-----------|----|--------|
| TYVASO DPI | \$536,174 | 47 | \$550,426 | 46 | 2.7% |
| TRINTELLIX | \$552,753 | 45 | \$543,856 | 47 | -1.6% |
| XOLAIR | \$433,197 | 55 | \$539,262 | 48 | 24.5% |
| INVEGA TRINZA | \$537,198 | 46 | \$532,272 | 49 | -0.9% |
| HEMLIBRA | \$599,672 | 43 | \$518,862 | 50 | -13.5% |
| FARXIGA | \$624,468 | 41 | \$499,440 | 51 | -20.0% |
| VYKAT XR | \$179,504 | 115 | \$462,129 | 52 | 157.4% |
| KESIMPTA PEN | \$519,826 | 49 | \$456,247 | 53 | -12.2% |
| QELBREE | \$434,357 | 54 | \$446,843 | 54 | 2.9% |
| XARELTO | \$450,208 | 53 | \$436,638 | 55 | -3.0% |
| CRYSVITA | \$486,507 | 51 | \$436,427 | 56 | -10.3% |
| OPSUMIT | \$415,245 | 58 | \$435,401 | 57 | 4.9% |
| FINTEPLA | \$480,582 | 52 | \$427,204 | 58 | -11.1% |
| QULIPTA | \$394,015 | 61 | \$420,010 | 59 | 6.6% |
| TAKHZYRO | \$342,671 | 70 | \$398,681 | 60 | 16.3% |
| WINREVAIR (2 PACK) | \$386,306 | 62 | \$393,435 | 61 | 1.8% |
| ALBUTEROL SULFATE HFA | \$406,533 | 59 | \$393,317 | 62 | -3.3% |
| ORFADIN | \$280,187 | 76 | \$372,154 | 63 | 32.8% |
| OTEZLA | \$417,576 | 57 | \$370,901 | 64 | -11.2% |
| LINZESS | \$528,371 | 48 | \$368,839 | 65 | -30.2% |
| AUSTEDO | \$365,431 | 66 | \$357,782 | 66 | -2.1% |
| UZEDY | \$276,503 | 79 | \$354,430 | 67 | 28.2% |
| KISQALI | \$355,743 | 67 | \$348,866 | 68 | -1.9% |
| VERZENIO | \$269,627 | 82 | \$346,397 | 69 | 28.5% |

| | | | | | |
|------------------------------|-----------|-----|-----------|----|--------|
| NUCALA | \$300,489 | 71 | \$346,184 | 70 | 15.2% |
| DUVYZAT | \$383,024 | 63 | \$344,719 | 71 | -10.0% |
| XYWAV | \$349,504 | 69 | \$336,912 | 72 | -3.6% |
| FASENRA PEN | \$261,662 | 83 | \$329,642 | 73 | 26.0% |
| ALPROLIX | \$258,750 | 85 | \$322,257 | 74 | 24.5% |
| ABILIFY ASIMTUFII | \$276,008 | 80 | \$317,346 | 75 | 15.0% |
| COSENTYX SENSOREADY (2 PENS) | \$300,394 | 72 | \$314,317 | 76 | 4.6% |
| EMGALITY PEN | \$278,157 | 78 | \$299,799 | 77 | 7.8% |
| GLYCEROL PHENYLBUTYRATE | \$99,366 | 194 | \$298,097 | 78 | 200.0% |
| TREMFYA PEN | \$132,443 | 155 | \$289,745 | 79 | 118.8% |
| PROCYSBI | \$278,740 | 77 | \$285,985 | 80 | 2.6% |
| LANTUS SOLOSTAR | \$289,505 | 74 | \$282,969 | 81 | -2.3% |
| BRIVIACT | \$247,772 | 89 | \$276,180 | 82 | 11.5% |
| MAVYRET | \$365,822 | 65 | \$274,595 | 83 | -24.9% |
| BREZTRI AEROSPHERE | \$272,508 | 81 | \$270,306 | 84 | -0.8% |
| TOLVAPTAN | \$354,520 | 68 | \$270,110 | 85 | -23.8% |
| SOGROYA | \$246,660 | 90 | \$268,100 | 86 | 8.7% |
| SPIRIVA RESPIMAT | \$290,836 | 73 | \$265,726 | 87 | -8.6% |
| TEZSPIRE | \$200,750 | 104 | \$263,665 | 88 | 31.3% |
| AIMOVIG AUTOINJECTOR | \$260,921 | 84 | \$263,412 | 89 | 1.0% |
| PULMOZYME | \$254,953 | 86 | \$262,219 | 90 | 2.9% |
| VALTOCO | \$285,870 | 75 | \$241,552 | 91 | -15.5% |
| CREON | \$243,133 | 91 | \$240,381 | 92 | -1.1% |
| NOVOSEVEN RT | \$253,832 | 87 | \$236,061 | 93 | -7.0% |

| | | | | | |
|-----------------------------|-----------|-----|-----------|-----|--------|
| SKYCLARYS | \$217,771 | 98 | \$235,512 | 94 | 8.1% |
| AZSTARYS | \$231,100 | 94 | \$235,036 | 95 | 1.7% |
| IMCIVREE | \$116,544 | 177 | \$234,668 | 96 | 101.4% |
| DEXTROAMPHETAMINE-AMPHET ER | \$228,741 | 95 | \$231,074 | 97 | 1.0% |
| VYVANSE | \$253,230 | 88 | \$230,433 | 98 | -9.0% |
| ADVAIR HFA | \$238,221 | 93 | \$228,872 | 99 | -3.9% |
| HIZENTRA | \$225,575 | 97 | \$225,236 | 100 | -0.2% |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | September 2025 / November 2025 | PREVIOUS RANK | December 2025 / February 2026 | CURRENT RANK | % CHANGE |
|-----------------------------|-----------------------------------|------------------|----------------------------------|-----------------|----------|
| TRAZODONE HCL | 14,797 | 1 | 14,582 | 1 | -1.5% |
| SERTRALINE HCL | 13,840 | 3 | 13,626 | 2 | -1.5% |
| ALBUTEROL SULFATE HFA | 13,490 | 4 | 13,521 | 3 | 0.2% |
| BUPROPION XL | 12,759 | 5 | 12,994 | 4 | 1.8% |
| AMOXICILLIN | 9,812 | 15 | 12,691 | 5 | 29.3% |
| OMEPRAZOLE | 14,199 | 2 | 12,601 | 6 | -11.3% |
| FLUOXETINE HCL | 11,738 | 6 | 11,690 | 7 | -0.4% |
| HYDROXYZINE HCL | 10,483 | 11 | 10,747 | 8 | 2.5% |
| GABAPENTIN | 10,772 | 8 | 10,540 | 9 | -2.2% |
| LEVOTHYROXINE SODIUM | 11,694 | 7 | 10,377 | 10 | -11.3% |
| ESCITALOPRAM OXALATE | 10,275 | 12 | 10,189 | 11 | -0.8% |
| ATORVASTATIN CALCIUM | 10,763 | 9 | 10,177 | 12 | -5.4% |
| CETIRIZINE HCL | 10,728 | 10 | 9,953 | 13 | -7.2% |
| BUSPIRONE HCL | 9,882 | 13 | 9,767 | 14 | -1.2% |
| MONTELUKAST SODIUM | 9,816 | 14 | 9,403 | 15 | -4.2% |
| CLONIDINE HCL | 8,173 | 16 | 8,274 | 16 | 1.2% |
| QUETIAPINE FUMARATE | 7,888 | 18 | 7,959 | 17 | 0.9% |
| DEXTROAMPHETAMINE-AMPHET ER | 7,702 | 20 | 7,947 | 18 | 3.2% |
| ARIPRAZOLE | 7,548 | 21 | 7,786 | 19 | 3.2% |
| LAMOTRIGINE | 7,462 | 22 | 7,526 | 20 | 0.9% |

| | | | | | |
|--------------------------------|-------|----|-------|----|-------|
| LISINOPRIL | 7,880 | 19 | 7,396 | 21 | -6.1% |
| PREDNISON | 7,399 | 23 | 7,239 | 22 | -2.2% |
| PANTOPRAZOLE SODIUM | 7,975 | 17 | 7,192 | 23 | -9.8% |
| DULOXETINE HCL | 7,310 | 24 | 7,014 | 24 | -4.0% |
| ONDANSETRON ODT | 5,601 | 37 | 6,935 | 25 | 23.8% |
| LISDEXAMFETAMINE DIMESYLATE | 6,599 | 25 | 6,736 | 26 | 2.1% |
| TOPIRAMATE | 6,438 | 27 | 6,425 | 27 | -0.2% |
| FLUTICASONE PROPIONATE | 6,547 | 26 | 6,225 | 28 | -4.9% |
| AMOXICILLIN-CLAVULANATE POTASS | 5,447 | 39 | 6,078 | 29 | 11.6% |
| METHYLPHENIDATE ER | 5,918 | 31 | 6,073 | 30 | 2.6% |
| AZITHROMYCIN | 5,636 | 35 | 6,057 | 31 | 7.5% |
| FAMOTIDINE | 6,423 | 28 | 6,031 | 32 | -6.1% |
| HYDROCODONE-ACETAMINOPHEN | 6,092 | 29 | 5,885 | 33 | -3.4% |
| OZEMPIC | 5,730 | 34 | 5,871 | 34 | 2.5% |
| CYCLOBENZAPRINE HCL | 5,791 | 32 | 5,733 | 35 | -1.0% |
| AMLODIPINE BESYLATE | 5,927 | 30 | 5,676 | 36 | -4.2% |
| DEXTROAMPHETAMINE-AMPHETAMINE | 5,454 | 38 | 5,558 | 37 | 1.9% |
| VENLAFAXINE HCL ER | 5,630 | 36 | 5,505 | 38 | -2.2% |
| RISPERIDONE | 5,174 | 41 | 5,308 | 39 | 2.6% |
| LORATADINE | 5,761 | 33 | 5,238 | 40 | -9.1% |
| METOPROLOL SUCCINATE | 5,264 | 40 | 5,086 | 41 | -3.4% |
| CLONAZEPAM | 5,058 | 42 | 5,045 | 42 | -0.3% |
| ALPRAZOLAM | 4,971 | 43 | 4,978 | 43 | 0.1% |
| LOSARTAN POTASSIUM | 4,768 | 44 | 4,550 | 44 | -4.6% |

| | | | | | |
|--------------------------|-------|-----|-------|----|---------|
| IBUPROFEN | 4,375 | 47 | 4,438 | 45 | 1.4% |
| ASPIRIN EC | 4,425 | 46 | 4,279 | 46 | -3.3% |
| JARDIANCE | 4,035 | 53 | 4,225 | 47 | 4.7% |
| METFORMIN HCL ER | 4,334 | 48 | 4,208 | 48 | -2.9% |
| GUANFACINE HCL ER | 4,066 | 52 | 4,119 | 49 | 1.3% |
| CEPHALEXIN | 4,436 | 45 | 4,070 | 50 | -8.3% |
| MIRTAZAPINE | 4,070 | 50 | 4,060 | 51 | -0.2% |
| METFORMIN HCL | 4,190 | 49 | 4,025 | 52 | -3.9% |
| PROPRANOLOL HCL | 3,984 | 55 | 3,998 | 53 | 0.4% |
| OSELTAMIVIR PHOSPHATE | 91 | 585 | 3,942 | 54 | 4231.9% |
| PRAZOSIN HCL | 3,953 | 56 | 3,928 | 55 | -0.6% |
| GUANFACINE HCL | 3,880 | 57 | 3,905 | 56 | 0.6% |
| ACETAMINOPHEN | 3,757 | 59 | 3,860 | 57 | 2.7% |
| POLYETHYLENE GLYCOL 3350 | 3,726 | 62 | 3,799 | 58 | 2.0% |
| ROSUVASTATIN CALCIUM | 3,780 | 58 | 3,784 | 59 | 0.1% |
| LEVETIRACETAM | 3,727 | 61 | 3,766 | 60 | 1.0% |
| ALLERGY RELIEF | 4,069 | 51 | 3,758 | 61 | -7.6% |
| LORAZEPAM | 3,731 | 60 | 3,754 | 62 | 0.6% |
| CEFDINIR | 2,934 | 80 | 3,724 | 63 | 26.9% |
| ALBUTEROL SULFATE | 3,412 | 69 | 3,694 | 64 | 8.3% |
| MELOXICAM | 3,996 | 54 | 3,687 | 65 | -7.7% |
| HYDROXYZINE PAMOATE | 3,550 | 64 | 3,509 | 66 | -1.2% |
| LANTUS SOLOSTAR | 3,562 | 63 | 3,500 | 67 | -1.7% |
| METHYLPHENIDATE HCL | 3,320 | 70 | 3,462 | 68 | 4.3% |

| | | | | | |
|---------------------------|-------|----|-------|----|-------|
| PREGABALIN | 3,440 | 68 | 3,422 | 69 | -0.5% |
| FOLIC ACID | 3,536 | 65 | 3,381 | 70 | -4.4% |
| TRIAMCINOLONE ACETONIDE | 3,491 | 66 | 3,367 | 71 | -3.6% |
| VALACYCLOVIR | 3,129 | 74 | 3,346 | 72 | 6.9% |
| SPIRONOLACTONE | 3,215 | 73 | 3,251 | 73 | 1.1% |
| FUROSEMIDE | 3,443 | 67 | 3,213 | 74 | -6.7% |
| FEROSUL | 3,300 | 71 | 3,210 | 75 | -2.7% |
| FLUCONAZOLE | 3,279 | 72 | 3,162 | 76 | -3.6% |
| TRAMADOL HCL | 3,082 | 75 | 3,016 | 77 | -2.1% |
| BACLOFEN | 2,952 | 79 | 2,965 | 78 | 0.4% |
| OXYCODONE HCL | 3,065 | 76 | 2,960 | 79 | -3.4% |
| OLANZAPINE | 2,924 | 81 | 2,943 | 80 | 0.6% |
| ATOMOXETINE HCL | 2,981 | 78 | 2,928 | 81 | -1.8% |
| METRONIDAZOLE | 3,053 | 77 | 2,925 | 82 | -4.2% |
| MOUNJARO | 2,569 | 87 | 2,859 | 83 | 11.3% |
| SYMBICORT | 2,846 | 83 | 2,843 | 84 | -0.1% |
| POTASSIUM CHLORIDE | 2,769 | 84 | 2,771 | 85 | 0.1% |
| DEXMETHYLPHENIDATE HCL ER | 2,565 | 88 | 2,715 | 86 | 5.8% |
| HYDROCHLOROTHIAZIDE | 2,882 | 82 | 2,677 | 87 | -7.1% |
| TIZANIDINE HCL | 2,681 | 85 | 2,636 | 88 | -1.7% |
| ONDANSETRON HCL | 2,225 | 95 | 2,550 | 89 | 14.6% |
| VRAYLAR | 2,608 | 86 | 2,511 | 90 | -3.7% |
| ELIQUIS | 2,362 | 90 | 2,405 | 91 | 1.8% |
| ZOLPIDEM TARTRATE | 2,277 | 91 | 2,268 | 92 | -0.4% |

| | | | | | |
|-----------------------------|-------|-----|-------|-----|--------|
| SUMATRIPTAN SUCCINATE | 2,244 | 93 | 2,146 | 93 | -4.4% |
| OXCARBAZEPINE | 2,168 | 96 | 2,096 | 94 | -3.3% |
| DESVENLAFAXINE SUCCINATE ER | 2,088 | 98 | 2,088 | 95 | 0.0% |
| AMITRIPTYLINE HCL | 1,996 | 100 | 2,055 | 96 | 3.0% |
| MUPIROCIN | 2,275 | 92 | 2,050 | 97 | -9.9% |
| KETOCONAZOLE | 1,953 | 102 | 2,021 | 98 | 3.5% |
| NYSTATIN | 2,135 | 97 | 2,002 | 99 | -6.2% |
| DOXYCYCLINE MONOHYDRATE | 2,536 | 89 | 1,972 | 100 | -22.2% |

Fee for Service Claims Quarterly Statistics

| | September through November 2025 | December through February 2026 | % CHANGE |
|-----------------------------------|---------------------------------|--------------------------------|----------|
| TOTAL PAID AMOUNT | \$2,924,447 | \$3,108,774 | 6.3% |
| UNIQUE USERS | 3,435 | 3,580 | 4.2% |
| COST PER USER | \$851.37 | \$868.37 | 2.0% |
| TOTAL PRESCRIPTIONS | 21,673 | 23,201 | 7.1% |
| AVERAGE PRESCRIPTIONS PER USER | 6.31 | 6.48 | 2.7% |
| AVERAGE COST PER PRESCRIPTION | \$134.94 | \$133.99 | -0.7% |
| # GENERIC PRESCRIPTIONS | 19,584 | 20,946 | 7.0% |
| % GENERIC | 90.4% | 90.3% | -0.1% |
| \$ GENERIC | \$1,013,337 | \$1,011,914 | -0.1% |
| AVERAGE GENERIC PRESCRIPTION COST | \$51.74 | \$48.31 | -6.6% |
| AVERAGE GENERIC DAYS SUPPLY | 27 | 28 | 3.7% |
| # BRAND PRESCRIPTIONS | 2,089 | 2,255 | 7.9% |
| % BRAND | 9.6% | 9.7% | 0.8% |
| \$ BRAND | \$1,911,110 | \$2,096,860 | 9.7% |
| AVERAGE BRAND PRESCRIPTION COST | \$914.84 | \$929.87 | 1.6% |
| AVERAGE BRAND DAYS SUPPLY | 28 | 28 | 0.0% |

| UTILIZATION BY AGE | | |
|--------------------|---------------------------------|--------------------------------|
| AGE | September through November 2025 | December through February 2026 |
| 0-6 | 202 | 195 |
| 7-12 | 366 | 360 |
| 13-18 | 622 | 626 |
| 19-64 | 2,225 | 2,357 |
| 65+ | 20 | 42 |
| | 3,435 | 3,580 |

| UTILIZATION BY GENDER AND AGE | | | |
|-------------------------------|-------|---------------------------------|--------------------------------|
| GENDER | AGE | September through November 2025 | December through February 2026 |
| F | 0-6 | 109 | 102 |
| | 7-12 | 158 | 163 |
| | 13-18 | 310 | 313 |
| | 19-64 | 1,396 | 1,477 |
| | 65+ | 11 | 21 |
| | | 1,984 | 2,076 |
| M | 0-6 | 93 | 93 |
| | 7-12 | 208 | 197 |
| | 13-18 | 312 | 313 |
| | 19-64 | 829 | 880 |
| | 65+ | 9 | 21 |
| | | 1,451 | 1,504 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|----------------------------------|----------------|-------|--------------------|--------------|-------------|---------------|
| 1 | UIHC AMBULATORY CARE PHARMACY | IOWA CITY | IA | 887 | \$137,810.01 | \$155.37 | 1 |
| 2 | MESKWAKI PHARMACY | TAMA | IA | 815 | \$657,790.00 | \$807.10 | 2 |
| 3 | SIOUXLAND COMMUNITY HEALTH CENTE | SIOUX CITY | IA | 806 | \$46,427.64 | \$57.60 | 3 |
| 4 | DRILLING MORNINGSIDE PHARMACY IN | SIOUX CITY | IA | 577 | \$30,758.26 | \$53.31 | 5 |
| 5 | WALGREENS #15647 | SIOUX CITY | IA | 531 | \$58,809.84 | \$110.75 | 4 |
| 6 | THOMPSON-DEAN DRUG | SIOUX CITY | IA | 412 | \$34,940.69 | \$84.81 | 6 |
| 7 | COVENANT FAMILY PHARMACY | WATERLOO | IA | 255 | \$8,553.50 | \$33.54 | 15 |
| 8 | RIGHT DOSE PHARMACY | ANKENY | IA | 234 | \$5,777.67 | \$24.69 | 7 |
| 9 | WALGREEN #04405 | COUNCIL BLUFFS | IA | 219 | \$13,489.76 | \$61.60 | 8 |
| 10 | GENOA HEALTHCARE LLC | SIOUX CITY | IA | 190 | \$16,457.41 | \$86.62 | 9 |
| 11 | HY-VEE PHARMACY #3 (1866) | WATERLOO | IA | 168 | \$7,808.13 | \$46.48 | 12 |
| 12 | HY-VEE STORE CLINIC 1023-039 | GRIMES | IA | 167 | \$8,532.60 | \$51.09 | 17 |
| 13 | COMMUNITY HEALTH CARE INC | DAVENPORT | IA | 165 | \$17,054.99 | \$103.36 | 10 |
| 14 | IMMC OUTPATIENT PHARMACY | DES MOINES | IA | 157 | \$6,868.72 | \$43.75 | 27 |
| 15 | MAIN AT LOCUST PHARMACY | DAVENPORT | IA | 154 | \$8,071.35 | \$52.41 | 11 |
| 16 | BROADLAWNS MEDICAL CENTER | DES MOINES | IA | 153 | \$12,618.14 | \$82.47 | 13 |
| 17 | HY-VEE PHARMACY (1075) | CLINTON | IA | 148 | \$16,584.69 | \$112.06 | 34 |
| 18 | CVS PHARMACY #17554 | CEDAR FALLS | IA | 147 | \$13,921.15 | \$94.70 | 14 |
| 19 | WAL MART PHARMACY 10-3590 | SIOUX CITY | IA | 147 | \$5,969.81 | \$40.61 | 24 |
| 20 | UNITY POINT HEALTH PHARMACY | CEDAR RAPIDS | IA | 144 | \$3,090.42 | \$21.46 | 18 |
| 21 | REUTZEL PHARMACY | CEDAR RAPIDS | IA | 134 | \$13,380.15 | \$99.85 | 19 |
| 22 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 128 | \$19,882.42 | \$155.33 | 44 |
| 23 | HY-VEE PHARMACY #3 (1615) | SIOUX CITY | IA | 126 | \$7,259.87 | \$57.62 | 21 |
| 24 | MEDICAP PHARMACY | INDIANOLA | IA | 124 | \$3,319.78 | \$26.77 | 56 |
| 25 | EASTERN IOWA HEALTH CENTER PHARM | CEDAR RAPIDS | IA | 124 | \$6,376.26 | \$51.42 | 135 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|----------------------------------|----------------|-------|--------------------|-------------|-------------|---------------|
| 26 | PRIMARY HEALTH CARE PHARMACY | DES MOINES | IA | 123 | \$15,270.93 | \$124.15 | 31 |
| 27 | HY-VEE PHARMACY (1403) | MARSHALLTOWN | IA | 121 | \$3,883.55 | \$32.10 | 42 |
| 28 | HY-VEE PHARMACY #4 (1148) | DES MOINES | IA | 117 | \$7,592.04 | \$64.89 | 45 |
| 29 | HY-VEE PHARMACY (1071) | CLARINDA | IA | 116 | \$6,297.76 | \$54.29 | 36 |
| 30 | PHARMACY MATTERS LTC | IOWA CITY | IA | 116 | \$875.32 | \$7.55 | 28 |
| 31 | WALGREEN COMPANY #05042 | CEDAR RAPIDS | IA | 115 | \$9,677.20 | \$84.15 | 16 |
| 32 | WALGREEN #05239 | DAVENPORT | IA | 113 | \$5,128.43 | \$45.38 | 35 |
| 33 | HY-VEE PHARMACY #1 (1610) | SIOUX CITY | IA | 112 | \$7,044.11 | \$62.89 | 26 |
| 34 | WALGREEN COMPANY #05470 | SIOUX CITY | IA | 111 | \$5,165.12 | \$46.53 | 22 |
| 35 | WCHS PHARMACY | WINNEBAGO | NE | 111 | \$89,561.00 | \$806.86 | 20 |
| 36 | ALL CARE HEALTH CENTER PHARMACY | COUNCIL BLUFFS | IA | 103 | \$5,000.39 | \$48.55 | 32 |
| 37 | HY-VEE PHARMACY 1068 | CHEROKEE | IA | 103 | \$3,934.22 | \$38.20 | 33 |
| 38 | GREENWOOD DRUG ON KIMBALL AVENUE | WATERLOO | IA | 101 | \$1,926.15 | \$19.07 | 25 |
| 39 | COMMUNITY PHARMACY OF LAKE CITY | LAKE CITY | IA | 100 | \$6,807.49 | \$68.07 | 152 |
| 40 | CHEROKEE MAIN STREET PHARMACY | CHEROKEE | IA | 99 | \$5,480.13 | \$55.35 | 68 |
| 41 | DRUGTOWN PHARMACY #1 (7020) | CEDAR RAPIDS | IA | 99 | \$4,575.43 | \$46.22 | 37 |
| 42 | NUCARA PHARMACY #27 | PLEASANT HILL | IA | 96 | \$3,528.54 | \$36.76 | 38 |
| 43 | WAL-MART PHARMACY #10-0646 | ANAMOSA | IA | 95 | \$2,848.05 | \$29.98 | 30 |
| 44 | HARTLEY HOMETOWN PHARMACY | HARTLEY | IA | 95 | \$7,923.32 | \$83.40 | 48 |
| 45 | CVS PHARMACY #8544 | WATERLOO | IA | 94 | \$8,500.42 | \$90.43 | 40 |
| 46 | TARRYTOWN EXPOCARE LLC | AUSTIN | TX | 93 | \$6,394.98 | \$68.76 | 39 |
| 47 | MERCY OUTPATIENT PHARMACY | DES MOINES | IA | 92 | \$3,277.52 | \$35.63 | 53 |
| 48 | HY-VEE PHARMACY #5 (1151) | DES MOINES | IA | 92 | \$1,883.85 | \$20.48 | 59 |
| 49 | WALGREEN #05721 | DES MOINES | IA | 92 | \$4,093.75 | \$44.50 | 29 |
| 50 | CVS PHARMACY #08658 | DAVENPORT | IA | 92 | \$14,519.74 | \$157.82 | 63 |
| 51 | GREENVILLE PHARMACY INC | SIOUX CITY | IA | 91 | \$5,510.34 | \$60.55 | 23 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|----------------------------------|-----------------|-------|--------------------|-------------|-------------|---------------|
| 52 | HY-VEE PHARMACY 1382 | LE MARS | IA | 91 | \$2,709.89 | \$29.78 | 67 |
| 53 | CVS PHARMACY #10282 | FORT DODGE | IA | 88 | \$2,918.95 | \$33.17 | 49 |
| 54 | NELSON FAMILY PHARMACY | FORT MADISON | IA | 87 | \$12,409.61 | \$142.64 | 65 |
| 55 | WAL-MART PHARMACY #10-0581 | MARSHALLTOWN | IA | 85 | \$3,208.41 | \$37.75 | 41 |
| 56 | HY-VEE PHARMACY (1052) | CEDAR FALLS | IA | 82 | \$896.43 | \$10.93 | 94 |
| 57 | HY-VEE PHARMACY (1895) | WINDSOR HEIGHTS | IA | 80 | \$2,444.12 | \$30.55 | 286 |
| 58 | MERCY MEDICAL CENTER NORTH IA DB | MASON CITY | IA | 79 | \$3,093.62 | \$39.16 | 66 |
| 59 | OSTERHAUS PHARMACY | MAQUOKETA | IA | 78 | \$5,391.76 | \$69.13 | 84 |
| 60 | NUCARA LTC PHARMACY 4 | WATERLOO | IA | 78 | \$981.17 | \$12.58 | 43 |
| 61 | HERITAGE PARK PHARMACY INC D/B/A | WEST BURLINGTON | IA | 76 | \$3,962.94 | \$52.14 | 122 |
| 62 | HERITAGE PARK PHARMACY | WEST BURLINGTON | IA | 76 | \$4,329.30 | \$56.96 | 50 |
| 63 | MEDICAP PHARMACY | BOONE | IA | 75 | \$8,676.84 | \$115.69 | 72 |
| 64 | WALGREENS #03876 | MARION | IA | 75 | \$12,469.61 | \$166.26 | 76 |
| 65 | LEWIS FAMILY DRUG #28 | ONAWA | IA | 74 | \$7,080.88 | \$95.69 | 46 |
| 66 | WAL-MART PHARMACY 10-1546 | IOWA FALLS | IA | 73 | \$10,006.94 | \$137.08 | 47 |
| 67 | MEDICAP PHARMACY #7 | GRINNELL | IA | 72 | \$6,374.64 | \$88.54 | 83 |
| 68 | WALGREENS #12393 | CEDAR RAPIDS | IA | 71 | \$1,650.18 | \$23.24 | 125 |
| 69 | MAIN STREET DRUG | CHARLES CITY | IA | 71 | \$2,320.69 | \$32.69 | 73 |
| 70 | HY-VEE DRUGSTORE #7026 | CEDAR RAPIDS | IA | 71 | \$5,433.22 | \$76.52 | 92 |
| 71 | PEOPLES CLINIC PHARMACY | WATERLOO | IA | 70 | \$951.76 | \$13.60 | |
| 72 | HY-VEE PHARMACY (1619) | SHENANDOAH | IA | 70 | \$5,050.63 | \$72.15 | 204 |
| 73 | HY-VEE DRUGSTORE # 1180 | FAIRFIELD | IA | 69 | \$3,265.88 | \$47.33 | 54 |
| 74 | UI HEALTHCARE RIVER LANDING PHAR | CORALVILLE | IA | 68 | \$3,990.39 | \$58.68 | 156 |
| 75 | HY VEE PHARMACY 1459 | OELWEIN | IA | 68 | \$3,153.27 | \$46.37 | 85 |
| 76 | WRIGHTWAY LTC PHARMACY | CLINTON | IA | 67 | \$3,786.55 | \$56.52 | 77 |
| 77 | HY-VEE PHARMACY (1022) | ANKENY | IA | 67 | \$4,718.74 | \$70.43 | 162 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|------------------------------|----------------|-------|--------------------|-------------|-------------|---------------|
| 78 | WAL-MART PHARMACY 10-2889 | CLINTON | IA | 66 | \$1,564.15 | \$23.70 | 144 |
| 79 | WAL-MART PHARMACY #10-0886 | FT DODGE | IA | 66 | \$3,367.81 | \$51.03 | 80 |
| 80 | WHITE DRUG ENTERPRISES INC | SPENCER | IA | 66 | \$8,252.40 | \$125.04 | 61 |
| 81 | WALGREEN #7452 | DES MOINES | IA | 65 | \$4,412.46 | \$67.88 | 82 |
| 82 | WALGREEN COMPANY #3700 | COUNCIL BLUFFS | IA | 65 | \$1,978.90 | \$30.44 | 52 |
| 83 | HY-VEE PHARMACY #2 (1614) | SIOUX CITY | IA | 65 | \$5,082.37 | \$78.19 | 81 |
| 84 | ELIZABETHS PHARMACY ON MAIN | BRITT | IA | 64 | \$4,802.07 | \$75.03 | 93 |
| 85 | HY-VEE PHARMACY (1396) | MARION | IA | 64 | \$7,009.38 | \$109.52 | 102 |
| 86 | LARRY'S PHARMACY | HUMBOLDT | IA | 63 | \$5,242.65 | \$83.22 | 90 |
| 87 | WALGREEN #05362 | DES MOINES | IA | 63 | \$4,324.26 | \$68.64 | 130 |
| 88 | WAL-MART PHARMACY #10-1415 | SPIRIT LAKE | IA | 62 | \$2,052.99 | \$33.11 | 131 |
| 89 | KOERNER WHIPPLE PHARMACY | HAMPTON | IA | 61 | \$4,290.95 | \$70.34 | 57 |
| 90 | PARAGON PARTNERS | OMAHA | NE | 61 | \$24,861.85 | \$407.57 | 115 |
| 91 | HY VEE PHARMACY #1449 | NEWTON | IA | 60 | \$6,415.77 | \$106.93 | 78 |
| 92 | WAL MART PHARMACY 10-1621 | CENTERVILLE | IA | 60 | \$11,672.19 | \$194.54 | 100 |
| 93 | WAL-MART PHARMACY #10-0797 | W. BURLINGTON | IA | 60 | \$5,506.88 | \$91.78 | 110 |
| 94 | IOWA VETERANS HOME | MARSHALLTOWN | IA | 60 | \$1,885.10 | \$31.42 | 55 |
| 95 | WALGREEN #359 | DES MOINES | IA | 60 | \$4,586.49 | \$76.44 | 117 |
| 96 | HY VEE PHARMACY 7072 | TOLEDO | IA | 59 | \$5,610.91 | \$95.10 | 113 |
| 97 | CVS PHARMACY #17056 | ALTOONA | IA | 59 | \$4,412.66 | \$74.79 | 218 |
| 98 | HY-VEE PHARMACY #3 (1142) | DES MOINES | IA | 59 | \$1,990.64 | \$33.74 | 60 |
| 99 | MEDICAP PHARMACY | CRESTON | IA | 58 | \$1,890.31 | \$32.59 | 91 |
| 100 | CENTER POINT FAMILY PHARMACY | CENTER POINT | IA | 58 | \$960.37 | \$16.56 | 154 |

TOP 100 PHARMACIES BY PAID AMOUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|----------------------------------|----------------|-------|--------------------|--------------|-----------------|---------------|
| 1 | MESKWAKI PHARMACY | TAMA | IA | 815 | \$657,790.00 | \$2,549.57 | 1 |
| 2 | UIHC AMBULATORY CARE PHARMACY | IOWA CITY | IA | 887 | \$137,810.01 | \$906.64 | 4 |
| 3 | WALGREENS SPECIALTY PHARMACY #16 | DES MOINES | IA | 13 | \$120,182.79 | \$15,022.85 | 2 |
| 4 | COMMUNITY A WALGREENS PHARMACY | IOWA CITY | IA | 15 | \$101,731.35 | \$16,955.23 | 7 |
| 5 | WCHS PHARMACY | WINNEBAGO | NE | 111 | \$89,561.00 | \$2,132.40 | 3 |
| 6 | ACCREDITO HEALTH GROUP INC | WARRENDALE | PA | 7 | \$88,487.57 | \$29,495.86 | 8 |
| 7 | ACCREDITO HEALTH GROUP INC | MEMPHIS | TN | 16 | \$73,761.35 | \$9,220.17 | 12 |
| 8 | CAREMARK KANSAS SPEC PHARMACY LL | LENEXA | KS | 24 | \$68,076.56 | \$6,807.66 | 5 |
| 9 | WALGREENS #15647 | SIOUX CITY | IA | 531 | \$58,809.84 | \$486.03 | 10 |
| 10 | SIOUXLAND COMMUNITY HEALTH CENTE | SIOUX CITY | IA | 806 | \$46,427.64 | \$357.14 | 19 |
| 11 | HY-VEE PHARMACY #2 (1106) | DAVENPORT | IA | 48 | \$45,766.29 | \$9,153.26 | 245 |
| 12 | ACCREDITO HEALTH GROUP INC | WHITESTOWN | IN | 10 | \$38,381.45 | \$7,676.29 | 18 |
| 13 | UNITY POINT AT HOME | URBANDALE | IA | 29 | \$36,763.43 | \$3,342.13 | 6 |
| 14 | THOMPSON-DEAN DRUG | SIOUX CITY | IA | 412 | \$34,940.69 | \$612.99 | 16 |
| 15 | WAL-MART PHARMACY #10-0892 | ANKENY | IA | 22 | \$32,828.08 | \$8,207.02 | 57 |
| 16 | PROCARE PHARMACY DIRECT LLC | MONROEVILLE | PA | 7 | \$31,123.03 | \$6,224.61 | 322 |
| 17 | DRILLING MORNINGSIDE PHARMACY IN | SIOUX CITY | IA | 577 | \$30,758.26 | \$559.24 | 20 |
| 18 | WAL-MART PHARMACY #10-0985 | FAIRFIELD | IA | 48 | \$28,863.47 | \$3,207.05 | 17 |
| 19 | ANOVORX GROUP INC | MEMPHIS | TN | 13 | \$28,361.23 | \$4,726.87 | 35 |
| 20 | PARAGON PARTNERS | OMAHA | NE | 61 | \$24,861.85 | \$6,215.46 | 26 |
| 21 | INFOCUS PHARMACY SERVICE | DUBUQUE | IA | 34 | \$23,692.91 | \$2,632.55 | 254 |
| 22 | FRED LEROY HEALTH & WELLNESS | OMAHA | NE | 27 | \$21,702.00 | \$3,100.29 | 15 |
| 23 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 128 | \$19,882.42 | \$2,840.35 | 28 |
| 24 | SENDERRA RX PHARMACY | PLANO | TX | 2 | \$19,160.85 | \$9,580.43 | 14 |
| 25 | COMMUNITY HEALTH CARE INC | DAVENPORT | IA | 165 | \$17,054.99 | \$1,137.00 | 39 |

TOP 100 PHARMACIES BY PAID AMOUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|----------------------------------|-----------------|-------|--------------------|-------------|-----------------|---------------|
| 26 | CARL T CURTIS HEALTH ED CENTER P | MACY | NE | 21 | \$16,871.00 | \$1,297.77 | 23 |
| 27 | HY-VEE PHARMACY (1075) | CLINTON | IA | 148 | \$16,584.69 | \$921.37 | 45 |
| 28 | GENOA HEALTHCARE LLC | SIOUX CITY | IA | 190 | \$16,457.41 | \$484.04 | 24 |
| 29 | CVS PHARMACY #17133 | DES MOINES | IA | 21 | \$16,009.18 | \$16,009.18 | 94 |
| 30 | PRIMARY HEALTH CARE PHARMACY | DES MOINES | IA | 123 | \$15,270.93 | \$282.80 | 130 |
| 31 | GENESIS FIRST MED PHARMACY | DAVENPORT | IA | 20 | \$14,796.61 | \$2,466.10 | 93 |
| 32 | CVS PHARMACY #08658 | DAVENPORT | IA | 92 | \$14,519.74 | \$1,037.12 | 36 |
| 33 | CVS PHARMACY #17554 | CEDAR FALLS | IA | 147 | \$13,921.15 | \$1,546.79 | 32 |
| 34 | MEDICAP PHARMACY | NEWTON | IA | 35 | \$13,905.61 | \$3,476.40 | 21 |
| 35 | NUCARA SPECIALTY PHARMACY | PLEASANT HILL | IA | 25 | \$13,829.94 | \$6,914.97 | 11 |
| 36 | WALGREEN #04405 | COUNCIL BLUFFS | IA | 219 | \$13,489.76 | \$329.02 | 40 |
| 37 | REUTZEL PHARMACY | CEDAR RAPIDS | IA | 134 | \$13,380.15 | \$557.51 | 22 |
| 38 | OPTUM PHARMACY 702 LLC | JEFFERSONVILLE | IN | 2 | \$13,214.43 | \$13,214.43 | 37 |
| 39 | WALGREEN #06623 | WEST DES MOINES | IA | 18 | \$13,180.51 | \$3,295.13 | 43 |
| 40 | OPTUM PHARMACY 701 LLC | FLINT | MI | 1 | \$13,114.43 | \$13,114.43 | |
| 41 | BROADLAWNS MEDICAL CENTER | DES MOINES | IA | 153 | \$12,618.14 | \$293.45 | 53 |
| 42 | WALGREENS #03876 | MARION | IA | 75 | \$12,469.61 | \$779.35 | 29 |
| 43 | NELSON FAMILY PHARMACY | FORT MADISON | IA | 87 | \$12,409.61 | \$1,240.96 | 72 |
| 44 | ALLEN MEMORIAL HOSPITAL | WATERLOO | IA | 44 | \$12,356.05 | \$686.45 | 215 |
| 45 | WAL MART PHARMACY 10-1621 | CENTERVILLE | IA | 60 | \$11,672.19 | \$3,890.73 | 34 |
| 46 | HY-VEE PHARMACY (1522) | PERRY | IA | 16 | \$10,063.12 | \$3,354.37 | 55 |
| 47 | WAL-MART PHARMACY 10-1546 | IOWA FALLS | IA | 73 | \$10,006.94 | \$1,111.88 | 51 |
| 48 | WALGREEN COMPANY #05042 | CEDAR RAPIDS | IA | 115 | \$9,677.20 | \$293.25 | 90 |
| 49 | CHILDRENS HOSPITAL & MEDICAL CEN | OMAHA | NE | 14 | \$9,374.27 | \$3,124.76 | 229 |
| 50 | ALLIANCERX WALGREENS PRIME #1628 | PITTSBURGH | PA | 2 | \$8,941.86 | \$4,470.93 | 84 |
| 51 | MEDICAP PHARMACY | BOONE | IA | 75 | \$8,676.84 | \$1,446.14 | 65 |

TOP 100 PHARMACIES BY PAID AMOUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|----------------------------------|----------------|-------|--------------------|------------|-----------------|---------------|
| 52 | COVENANT FAMILY PHARMACY | WATERLOO | IA | 255 | \$8,553.50 | \$137.96 | 106 |
| 53 | HY-VEE STORE CLINIC 1023-039 | GRIMES | IA | 167 | \$8,532.60 | \$501.92 | 41 |
| 54 | CVS PHARMACY #8544 | WATERLOO | IA | 94 | \$8,500.42 | \$386.38 | 69 |
| 55 | HARTIG DRUG CO #28 | MONTICELLO | IA | 6 | \$8,458.32 | \$8,458.32 | 500 |
| 56 | HY-VEE PHARMACY (1544) | RED OAK | IA | 36 | \$8,356.72 | \$1,671.34 | 109 |
| 57 | WHITE DRUG ENTERPRISES INC | SPENCER | IA | 66 | \$8,252.40 | \$1,375.40 | 58 |
| 58 | NELSON LONG TERM CARE PHARMACY | FORT MADISON | IA | 3 | \$8,122.13 | \$8,122.13 | 86 |
| 59 | MAIN AT LOCUST PHARMACY | DAVENPORT | IA | 154 | \$8,071.35 | \$1,008.92 | 54 |
| 60 | LEWIS FAMILY DRUG #69 | ROCK VALLEY | IA | 43 | \$7,964.21 | \$1,592.84 | 73 |
| 61 | HARTLEY HOMETOWN PHARMACY | HARTLEY | IA | 95 | \$7,923.32 | \$3,961.66 | 75 |
| 62 | HY-VEE PHARMACY #3 (1866) | WATERLOO | IA | 168 | \$7,808.13 | \$709.83 | 71 |
| 63 | HY-VEE PHARMACY #4 (1148) | DES MOINES | IA | 117 | \$7,592.04 | \$446.59 | 63 |
| 64 | GENOA HEALTHCARE LLC | FORT DODGE | IA | 55 | \$7,290.13 | \$1,458.03 | 154 |
| 65 | HY-VEE PHARMACY #3 (1615) | SIOUX CITY | IA | 126 | \$7,259.87 | \$403.33 | 44 |
| 66 | HY-VEE PHARMACY 1295 | IOWA FALLS | IA | 24 | \$7,231.41 | \$1,807.85 | 48 |
| 67 | WAL-MART PHARMACY #10-1965 | COUNCIL BLUFFS | IA | 40 | \$7,201.43 | \$1,800.36 | 47 |
| 68 | LEWIS FAMILY DRUG #28 | ONAWA | IA | 74 | \$7,080.88 | \$295.04 | 61 |
| 69 | SCOTT DRUG AN AFFILIATE OF GENES | DEWITT | IA | 50 | \$7,077.46 | \$1,769.37 | 116 |
| 70 | HY-VEE PHARMACY #1 (1610) | SIOUX CITY | IA | 112 | \$7,044.11 | \$220.13 | 59 |
| 71 | RIVER HILLS PHARMACY | OTTUMWA | IA | 17 | \$7,021.56 | \$2,340.52 | 91 |
| 72 | HY-VEE PHARMACY (1396) | MARION | IA | 64 | \$7,009.38 | \$876.17 | 31 |
| 73 | HY-VEE PHARMACY (1622) | SIOUX CENTER | IA | 13 | \$6,889.25 | \$2,296.42 | 77 |
| 74 | IMMC OUTPATIENT PHARMACY | DES MOINES | IA | 157 | \$6,868.72 | \$163.54 | 140 |
| 75 | COMMUNITY PHARMACY OF LAKE CITY | LAKE CITY | IA | 100 | \$6,807.49 | \$618.86 | 182 |
| 76 | CVS PHARMACY #00102 | AURORA | CO | 1 | \$6,714.15 | \$6,714.15 | 9 |
| 77 | HY VEE PHARMACY #1449 | NEWTON | IA | 60 | \$6,415.77 | \$1,069.30 | 96 |

TOP 100 PHARMACIES BY PAID AMOUNT
December through February 2026

| RANK | PHARMACY NAME | PHARMACY CITY | STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|----------------------------------|----------------|-------|--------------------|------------|-----------------|---------------|
| 78 | TARRYTOWN EXPOCARE LLC | AUSTIN | TX | 93 | \$6,394.98 | \$3,197.49 | 97 |
| 79 | EASTERN IOWA HEALTH CENTER PHARM | CEDAR RAPIDS | IA | 124 | \$6,376.26 | \$130.13 | 234 |
| 80 | MEDICAP PHARMACY #7 | GRINNELL | IA | 72 | \$6,374.64 | \$2,124.88 | 78 |
| 81 | HY-VEE PHARMACY #2 (1101) | COUNCIL BLUFFS | IA | 27 | \$6,313.28 | \$2,104.43 | 81 |
| 82 | HY-VEE PHARMACY (1071) | CLARINDA | IA | 116 | \$6,297.76 | \$699.75 | 30 |
| 83 | PRICE CHOPPER | DES MOINES | IA | 7 | \$5,999.63 | \$5,999.63 | 357 |
| 84 | WAL MART PHARMACY 10-3590 | SIOUX CITY | IA | 147 | \$5,969.81 | \$198.99 | 66 |
| 85 | HY-VEE PHARMACY #1 (1013) | AMES | IA | 45 | \$5,929.33 | \$658.81 | 136 |
| 86 | HY-VEE PHARMACY 1628-039 | MILFORD | IA | 48 | \$5,780.32 | \$1,926.77 | 127 |
| 87 | RIGHT DOSE PHARMACY | ANKENY | IA | 234 | \$5,777.67 | \$412.69 | 92 |
| 88 | SAMS PHARMACY 10-6344 | DES MOINES | IA | 15 | \$5,631.98 | \$5,631.98 | 122 |
| 89 | HY VEE PHARMACY 7072 | TOLEDO | IA | 59 | \$5,610.91 | \$701.36 | 88 |
| 90 | GREENVILLE PHARMACY INC | SIOUX CITY | IA | 91 | \$5,510.34 | \$367.36 | 67 |
| 91 | WAL-MART PHARMACY #10-0797 | W. BURLINGTON | IA | 60 | \$5,506.88 | \$323.93 | 101 |
| 92 | CHEROKEE MAIN STREET PHARMACY | CHEROKEE | IA | 99 | \$5,480.13 | \$1,096.03 | 49 |
| 93 | HY-VEE DRUGSTORE #7026 | CEDAR RAPIDS | IA | 71 | \$5,433.22 | \$776.17 | 79 |
| 94 | OSTERHAUS PHARMACY | MAQUOKETA | IA | 78 | \$5,391.76 | \$1,797.25 | 80 |
| 95 | LARRY'S PHARMACY | HUMBOLDT | IA | 63 | \$5,242.65 | \$873.78 | 143 |
| 96 | WALGREEN COMPANY #05470 | SIOUX CITY | IA | 111 | \$5,165.12 | \$178.11 | 64 |
| 97 | HY-VEE PHARMACY 1297 | JEFFERSON | IA | 43 | \$5,153.01 | \$1,288.25 | 87 |
| 98 | WALGREEN #05239 | DAVENPORT | IA | 113 | \$5,128.43 | \$213.68 | 85 |
| 99 | HY-VEE PHARMACY #2 (1614) | SIOUX CITY | IA | 65 | \$5,082.37 | \$338.82 | 102 |
| 100 | WAL-MART PHARMACY 10-5748 | GRIMES | IA | 21 | \$5,081.39 | \$1,270.35 | 104 |

TOP 100 PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
December through February 2026

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS MEMBER | PREVIOUS RANK |
|------|------------|-----------------------------|--------------|--------------------|--------------------|---------------|
| 1 | 1043418809 | MICHAEL CILIBERTO MD | \$27,172.67 | 210 | 5.53 | 4 |
| 2 | 1053340661 | LEIGHTON FROST MD | \$163,809.16 | 206 | 2.82 | 1 |
| 3 | 1982605762 | JEFFREY DEAN WILHARM MD | \$1,651.97 | 152 | 21.71 | 2 |
| 4 | 1194888024 | ALICIA D WAGER NP | \$91,393.94 | 130 | 2.03 | 3 |
| 5 | 1093141129 | LARRY MARTIN NEWMAN ARNP | \$97,771.00 | 121 | 2.33 | 5 |
| 6 | 1164481362 | MELISSA PEARSON ARNP | \$89,526.00 | 112 | 1.40 | 7 |
| 7 | 1780820860 | LAUREN GRAHAM MD | \$81,574.96 | 103 | 2.86 | 8 |
| 8 | 1902358443 | MELISSA KONKEN ARNP | \$10,497.00 | 98 | 7.54 | 19 |
| 9 | 1144214248 | KRISTI WALZ MD | \$13,249.14 | 95 | 9.50 | 6 |
| 10 | 1346557550 | ROBERT BRYAN BOYLE ARNP | \$5,460.04 | 91 | 7.00 | 30 |
| 11 | 1659358620 | CARLOS CASTILLO MD | \$1,547.34 | 82 | 8.20 | 11 |
| 12 | 1699658245 | AMY STRIM ANRP | \$2,194.02 | 81 | 7.36 | 250 |
| 13 | 1417214321 | LEAH BRANDON DO | \$2,756.30 | 81 | 7.36 | 16 |
| 14 | 1912991183 | MOLLY EARLEYWINE PA | \$5,961.31 | 80 | 6.15 | 10 |
| 15 | 1538671961 | JAMIE WRIGHT ARNP | \$1,213.30 | 75 | 6.82 | 18 |
| 16 | 1780877878 | CHRISTOPHER JACOBS ARNP | \$4,875.19 | 75 | 7.50 | 13 |
| 17 | 1013355759 | DYLAN C GREENE MD | \$2,923.05 | 71 | 5.92 | 9 |
| 18 | 1053376475 | DANIEL W GILLETTE MD | \$2,323.83 | 69 | 13.80 | 14 |
| 19 | 1619153137 | JOADA JEAN BEST ARNP | \$4,363.15 | 65 | 5.91 | 15 |
| 20 | 1033890918 | DINA IRWIN ARNP | \$3,490.20 | 64 | 3.37 | 21 |
| 21 | 1770933046 | SHELBY BILLER APRN | \$11,444.53 | 62 | 7.75 | 29 |
| 22 | 1811512064 | ADRIANNA DENISE MITCHELL MD | \$324.24 | 59 | 59.00 | 27 |
| 23 | 1760965032 | MELISSA MILLER ARNP | \$1,138.01 | 58 | 3.87 | 23 |
| 24 | 1154929230 | CHELSEA JONES ARNP | \$4,458.67 | 58 | 5.80 | 305 |
| 25 | 1083248256 | ERIN LYNNE REWERTS ARNP | \$3,921.60 | 57 | 57.00 | 12 |
| 26 | 1821268335 | JACQUELINE MCINNIS PAC | \$1,242.81 | 56 | 14.00 | 24 |

TOP 100 PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
December through February 2026

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS MEMBER | PREVIOUS RANK |
|------|------------|--------------------------------|-------------|--------------------|--------------------|---------------|
| 27 | 1215125216 | REBECCA EVELYN WALDING | \$5,684.24 | 54 | 6.00 | 17 |
| 28 | 1457584740 | ERIC MEYER ARNP | \$561.61 | 52 | 8.67 | 20 |
| 29 | 1407836513 | NATHAN R NOBLE DO | \$969.09 | 51 | 3.19 | 49 |
| 30 | 1053600296 | JESSICA MCCOOL MD | \$6,536.34 | 50 | 16.67 | 105 |
| 31 | 1174840656 | JOSEPHINE DUNN-JUNIES MD | \$1,830.72 | 50 | 12.50 | 34 |
| 32 | 1093272668 | RICARDO OSARIO ARNP | \$3,033.09 | 48 | 4.36 | 22 |
| 33 | 1932652757 | KELSIE JO SWISHER APRN | \$582.25 | 48 | 16.00 | 39 |
| 34 | 1073369070 | NICHOLAS BLIEU ARNP | \$753.30 | 47 | 4.27 | 326 |
| 35 | 1427617471 | SUSAN GRAVES PA | \$669.77 | 47 | 11.75 | 42 |
| 36 | 1891756128 | PHILIP JOSEPH MULLER DO | \$5,824.08 | 46 | 5.75 | 186 |
| 37 | 1578123915 | BRIANNA E BROWNLIE DO | \$3,809.71 | 45 | 9.00 | 36 |
| 38 | 1639134034 | ELIZABETH PRATT ARNP | \$1,195.84 | 44 | 2.10 | 53 |
| 39 | 1386938447 | THERESA CZECH MD | \$9,162.22 | 44 | 6.29 | 146 |
| 40 | 1013115369 | BOBBITA NAG MD | \$2,318.48 | 44 | 4.89 | 32 |
| 41 | 1649922410 | CASSANDRA MARIE ZIMMERMAN ARNP | \$812.46 | 44 | 44.00 | 87 |
| 42 | 1356337273 | LISA JAYNE MENZIES MD | \$810.60 | 44 | 5.50 | 26 |
| 43 | 1609131770 | SREENATH THATI GANGANNA MBBS | \$5,852.47 | 43 | 3.91 | 93 |
| 44 | 1528037082 | RODNEY J DEAN MD | \$842.71 | 43 | 8.60 | 165 |
| 45 | 1932943206 | ANDREW J KILGER DO | \$1,887.71 | 43 | 43.00 | 72 |
| 46 | 1477199198 | SAJO THOMAS ARNP | \$979.43 | 43 | 8.60 | 71 |
| 47 | 1548874688 | HEIDI MARIE HASSLER PA | \$536.66 | 43 | 6.14 | 65 |
| 48 | 1982630703 | JODI VANSICKLE MD | \$336.06 | 42 | 5.25 | 77 |
| 49 | 1215146055 | REBECCA JEAN MARIE WOLFE MD | \$702.38 | 42 | 10.50 | 47 |
| 50 | 1447519038 | ERIN E RICHARDSON MD | \$5,583.64 | 42 | 4.67 | 140 |
| 51 | 1972100618 | DAVID TILLMAN ANRP | \$590.14 | 41 | 4.10 | 1388 |
| 52 | 1205249562 | KELLY RYDER MD | \$2,916.90 | 41 | 3.73 | 50 |

TOP 100 PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
December through February 2026

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS MEMBER | PREVIOUS RANK |
|------|------------|---------------------------------|-------------|--------------------|--------------------|---------------|
| 53 | 1629265368 | HANNAH LOKENVITZ PA | \$2,487.46 | 41 | 41.00 | 52 |
| 54 | 1982699260 | SCOTT SHEETS DO | \$1,039.86 | 40 | 5.00 | 79 |
| 55 | 1659652568 | DANNIELE ANDERSON PA | \$4,275.97 | 40 | 13.33 | 1091 |
| 56 | 1881095503 | KAROWESO MARGARET CHIPENDO ARNP | \$491.55 | 40 | 6.67 | 58 |
| 57 | 1154666527 | NICOLE M BACCAM ARNP | \$506.89 | 39 | 2.44 | 185 |
| 58 | 1932531316 | BROOKE JOHNSON ARNP | \$2,864.18 | 39 | 9.75 | 67 |
| 59 | 1801439229 | CYNTHIA LYNN JAMES ARNP | \$496.91 | 39 | 1.50 | 241 |
| 60 | 1962418640 | BARCLAY MONASTER MD | \$5,529.08 | 39 | 9.75 | 31 |
| 61 | 1700080538 | EDUARDO CARLIN MD | \$4,998.37 | 39 | 3.55 | 78 |
| 62 | 1104498039 | BRENDA L CAIN ARNP | \$5,760.02 | 38 | 4.75 | 28 |
| 63 | 1104804053 | WINTHROP S RISK II MD | \$7,304.05 | 38 | 12.67 | 74 |
| 64 | 1043211493 | VIKRANT SALARIA MD | \$3,059.54 | 38 | 12.67 | 55 |
| 65 | 1306475413 | AUTUMN SAGE ANDERSON APRN | \$493.35 | 37 | 9.25 | 80 |
| 66 | 1699769794 | DAVE FALDMO PA | \$366.48 | 37 | 7.40 | 102 |
| 67 | 1891146999 | BECKY L JOHNSON ANRP | \$19,827.93 | 37 | 7.40 | 109 |
| 68 | 1790986925 | TAHUANTY PENA MD | \$26,826.60 | 37 | 12.33 | 62 |
| 69 | 1932582988 | DIANNE HUMPHREY ARNP | \$7,417.37 | 36 | 18.00 | 84 |
| 70 | 1821481045 | SHAWN T PLUNKETT PMHNP | \$410.13 | 36 | 6.00 | 38 |
| 71 | 1679920045 | BREANNE VOGEL ARNP | \$576.40 | 36 | 12.00 | 44 |
| 72 | 1538847181 | TYLER JON LESKO ARNP | \$11,124.82 | 35 | 3.89 | 812 |
| 73 | 1730135070 | JAMES W WALLACE MD | \$3,315.04 | 34 | 8.50 | 121 |
| 74 | 1346349388 | THOMAS BRENT HOEHNS MD | \$2,022.77 | 34 | 34.00 | 89 |
| 75 | 1871375543 | MONICA NUCKOLLS ARNP | \$614.53 | 34 | 6.80 | |
| 76 | 1619948023 | KAREN J KROGSTAD MD | \$1,187.54 | 34 | 11.33 | 91 |
| 77 | 1457346231 | DAWN EBACH MD | \$425.07 | 34 | 4.25 | 70 |
| 78 | 1467502286 | CHARLES R TILLEY PA | \$3,508.74 | 34 | 11.33 | 69 |

TOP 100 PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
December through February 2026

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS MEMBER | PREVIOUS RANK |
|------|------------|------------------------------|-------------|--------------------|--------------------|---------------|
| 79 | 1679545354 | KATHERINE COLLEEN NICKELS MD | \$6,897.12 | 34 | 6.80 | 66 |
| 80 | 1326013426 | PAUL DENNIS PETERSON DO | \$2,062.65 | 34 | 4.25 | 40 |
| 81 | 1629506829 | MARIAH SKELLEY APRN | \$22,997.56 | 33 | 16.50 | 533 |
| 82 | 1558147868 | JAMIE KARSTENS ARNP | \$588.56 | 33 | 3.67 | 92 |
| 83 | 1689077018 | STACY ROTH ARNP | \$11,314.61 | 33 | 8.25 | 76 |
| 84 | 1588920151 | AMANDA H CROXTON DO | \$8,075.05 | 33 | 5.50 | 99 |
| 85 | 1144240805 | DANIEL ROWLEY MD | \$3,590.32 | 33 | 16.50 | 75 |
| 86 | 1326080409 | JAMES OWENS MD | \$615.66 | 33 | 4.71 | 129 |
| 87 | 1619380680 | TARA BROCKMAN DO | \$1,326.87 | 33 | 8.25 | 94 |
| 88 | 1720698335 | DANIKA LEIGH HANSEN ARNP | \$2,192.53 | 32 | 3.20 | 33 |
| 89 | 1528796430 | RACHEL KLUG APRN | \$804.28 | 32 | 4.00 | 25 |
| 90 | 1588746515 | AMY BADBERG MD | \$373.09 | 32 | 10.67 | 288 |
| 91 | 1932493749 | NICHOLAS CHARLES BECHTOLD DO | \$1,598.07 | 31 | 7.75 | 57 |
| 92 | 1598750432 | CHRISTOPHER OKIISHI MD | \$976.34 | 31 | 6.20 | 63 |
| 93 | 1073235925 | KRISTINA L BECK ARNP | \$595.25 | 31 | 10.33 | 37 |
| 94 | 1699109595 | TONYA K FLAUGH ARNP | \$5,125.19 | 31 | 10.33 | 68 |
| 95 | 1427164789 | MICHAEL J OURADA MD | \$605.89 | 31 | 15.50 | 88 |
| 96 | 1588838841 | LEENU MISHRA MD | \$417.42 | 31 | 2.58 | 263 |
| 97 | 1174640528 | AMY JO PAYNE PA | \$5,242.47 | 30 | 2.31 | 437 |
| 98 | 1700356334 | BRIANNA J SCHAFFER ARNP | \$2,379.34 | 30 | 10.00 | 188 |
| 99 | 1649250390 | NATHANIEL A MEYER MD | \$6,698.34 | 30 | 15.00 | 108 |
| 100 | 1558039495 | SARAH HIETBRINK ARNP | \$10,689.62 | 30 | 15.00 | 95 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
December through February 2026

| RANK | DOCTOR NUM | PRESCRIBER NAME | PAID AMOUNT | AVG COST RX | PRESCRIPTION COUNT | PREVIOUS RANK |
|------|------------|--------------------------|--------------|-------------|--------------------|---------------|
| 1 | 1053340661 | LEIGHTON FROST MD | \$163,809.16 | \$795.19 | 206 | 1 |
| 2 | 1093141129 | LARRY MARTIN NEWMAN ARNP | \$97,771.00 | \$808.02 | 121 | 4 |
| 3 | 1194888024 | ALICIA D WAGER NP | \$91,393.94 | \$703.03 | 130 | 2 |
| 4 | 1164481362 | MELISSA PEARSON ARNP | \$89,526.00 | \$799.34 | 112 | 6 |
| 5 | 1780820860 | LAUREN GRAHAM MD | \$81,574.96 | \$791.99 | 103 | 5 |
| 6 | 1326034984 | KATHERINE MATHEWS MD | \$65,587.10 | \$8,198.39 | 8 | 966 |
| 7 | 1669184511 | CHANDRA MILLER ARNP | \$56,628.38 | \$14,157.10 | 4 | 3 |
| 8 | 1578958542 | HEIDI E CURTIS ARNP | \$49,592.87 | \$9,918.57 | 5 | 7 |
| 9 | 1225263833 | LINDSAY J ORRIS DO | \$44,994.07 | \$4,090.37 | 11 | 621 |
| 10 | 1629719737 | CLAIRE O WILLIAMS PA | \$40,434.20 | \$5,776.31 | 7 | 8 |
| 11 | 1043441264 | KATHERINE LEM PA-C | \$40,381.51 | \$10,095.38 | 4 | 13 |
| 12 | 1467449579 | BRIAN P WAYSON ARNP | \$36,744.43 | \$2,826.49 | 13 | 68 |
| 13 | 1245468768 | THOMAS SCHMIDT MD | \$32,523.47 | \$4,065.43 | 8 | 70 |
| 14 | 1265048870 | KELLY ALEXIS MERCHIE PA | \$28,850.84 | \$4,121.55 | 7 | 24 |
| 15 | 1184056822 | ABBY IRENE KOLTHOFF ARNP | \$27,298.01 | \$1,299.91 | 21 | 17 |
| 16 | 1043418809 | MICHAEL CILIBERTO MD | \$27,172.67 | \$129.39 | 210 | 9 |
| 17 | 1790986925 | TAHUANTY PENA MD | \$26,826.60 | \$725.04 | 37 | 27 |
| 18 | 1619021144 | CHRISTOPHER M GIBBS MD | \$26,621.85 | \$4,436.98 | 6 | |
| 19 | 1295091510 | REBECCA WEINER MD | \$24,346.46 | \$1,623.10 | 15 | 551 |
| 20 | 1114524378 | ROSA M MARQUEZ PA-C | \$24,255.78 | \$2,425.58 | 10 | 29 |
| 21 | 1730293705 | ROBERT JACKSON DO | \$24,223.30 | \$4,037.22 | 6 | 16 |
| 22 | 1417307497 | EMILY BOES DO | \$23,957.66 | \$2,177.97 | 11 | 28 |
| 23 | 1205504669 | JENNIFER SWANSON ARNP | \$23,254.00 | \$801.86 | 29 | 26 |
| 24 | 1992365894 | EMILY A WEIG MD | \$23,084.07 | \$23,084.07 | 1 | |
| 25 | 1629506829 | MARIAH SKELLEY APRN | \$22,997.56 | \$696.90 | 33 | 85 |
| 26 | 1750648275 | SARAH GROSS MD | \$21,560.93 | \$2,695.12 | 8 | 18 |
| 27 | 1518257047 | LAURA A WHITTINGTON DO | \$20,731.78 | \$6,910.59 | 3 | 40 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
December through February 2026

| RANK | DOCTOR NUM | PRESCRIBER NAME | PAID AMOUNT | AVG COST RX | PRESCRIPTION COUNT | PREVIOUS RANK |
|------|------------|----------------------------|-------------|-------------|--------------------|---------------|
| 28 | 1356752067 | KELLY DELANEY-NELSON MD | \$20,247.53 | \$2,249.73 | 9 | 20 |
| 29 | 1891146999 | BECKY L JOHNSON ANRP | \$19,827.93 | \$535.89 | 37 | 12 |
| 30 | 1619526076 | KATHRYN C HUBER PA C | \$17,847.65 | \$892.38 | 20 | 62 |
| 31 | 1730717968 | KATE ELIZABETH FERRELL MD | \$17,166.41 | \$3,433.28 | 5 | 2756 |
| 32 | 1114521721 | TARRAH HOLLIDAY ARNP | \$16,938.51 | \$584.09 | 29 | 34 |
| 33 | 1538664149 | LAURIE JORGENSEN ARNP | \$15,912.48 | \$1,768.05 | 9 | 103 |
| 34 | 1104088202 | PATRICK SAFO MD | \$15,305.39 | \$15,305.39 | 1 | 36 |
| 35 | 1598967291 | RADHIKA DHAMIJA MD | \$14,946.91 | \$1,494.69 | 10 | 56 |
| 36 | 1073852059 | AMBER HANSEN MD | \$13,792.00 | \$811.29 | 17 | 37 |
| 37 | 1225143316 | SUSAN MARIE JACOBI MD | \$13,502.96 | \$1,687.87 | 8 | 21 |
| 38 | 1144214248 | KRISTI WALZ MD | \$13,249.14 | \$139.46 | 95 | 94 |
| 39 | 1013585082 | BILAL HASAN BAIG DO | \$13,210.63 | \$13,210.63 | 1 | |
| 40 | 1194990945 | SANDEEP S GUPTA MD | \$12,631.68 | \$1,403.52 | 9 | 14 |
| 41 | 1235976374 | OLIVIA ANN HANSEN ARNP | \$12,545.77 | \$4,181.92 | 3 | 42 |
| 42 | 1629415922 | ALYSSA LAKIN PA | \$12,003.74 | \$1,714.82 | 7 | 31 |
| 43 | 1134249832 | STEVEN MICHAEL CRAIG MD | \$11,835.67 | \$1,479.46 | 8 | 45 |
| 44 | 1255658175 | ASHLEY DESCHAMP MD | \$11,742.55 | \$838.75 | 14 | 1556 |
| 45 | 1770933046 | SHELBY BILLER APRN | \$11,444.53 | \$184.59 | 62 | 50 |
| 46 | 1689077018 | STACY ROTH ARNP | \$11,314.61 | \$342.87 | 33 | 60 |
| 47 | 1538847181 | TYLER JON LESKO ARNP | \$11,124.82 | \$317.85 | 35 | 431 |
| 48 | 1558039495 | SARAH HIETBRINK ARNP | \$10,689.62 | \$356.32 | 30 | 55 |
| 49 | 1205859170 | MICHAEL WEI-CHIH CHEN DO | \$10,606.36 | \$441.93 | 24 | 372 |
| 50 | 1902358443 | MELISSA KONKEN ARNP | \$10,497.00 | \$107.11 | 98 | 43 |
| 51 | 1104251776 | ANTHONY ERIK GLYDWELL | \$10,438.00 | \$802.92 | 13 | 11 |
| 52 | 1508750761 | ROGERIO PASTORE BASSITT MD | \$10,229.23 | \$10,229.23 | 1 | |
| 53 | 1639157373 | CALVIN J HANSEN MD | \$10,105.47 | \$10,105.47 | 1 | 58 |
| 54 | 1811493679 | JUNE MYLER ARNP | \$9,650.72 | \$742.36 | 13 | 46 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
December through February 2026

| RANK | DOCTOR NUM | PRESCRIBER NAME | PAID AMOUNT | AVG COST RX | PRESCRIPTION COUNT | PREVIOUS RANK |
|------|------------|-------------------------------|-------------|-------------|--------------------|---------------|
| 55 | 1386938447 | THERESA CZECH MD | \$9,162.22 | \$208.23 | 44 | 78 |
| 56 | 1154504504 | AHMED M ABU AL-FOUL MD | \$8,458.32 | \$1,409.72 | 6 | 138 |
| 57 | 1417931700 | SUDHIR C KUMAR MD | \$8,270.86 | \$4,135.43 | 2 | 65 |
| 58 | 1407333065 | YACOUN M SALLAM MD | \$8,270.86 | \$4,135.43 | 2 | |
| 59 | 1568459329 | SHERRY L PARKS PA-C | \$8,163.89 | \$326.56 | 25 | 105 |
| 60 | 1497647937 | WESTON BIETZ ARNP | \$8,145.61 | \$1,629.12 | 5 | 212 |
| 61 | 1588920151 | AMANDA H CROXTON DO | \$8,075.05 | \$244.70 | 33 | 76 |
| 62 | 1639565328 | DEBRA HOAG APRN | \$8,035.00 | \$803.50 | 10 | 123 |
| 63 | 1124216882 | KELLY JESSICA PEARSON ARNP | \$8,029.95 | \$617.69 | 13 | 44 |
| 64 | 1932582988 | DIANNE HUMPHREY ARNP | \$7,417.37 | \$206.04 | 36 | 67 |
| 65 | 1104804053 | WINTHROP S RISK II MD | \$7,304.05 | \$192.21 | 38 | 81 |
| 66 | 1306349956 | KATIE LADEHOFF ARNP | \$7,259.00 | \$806.56 | 9 | 88 |
| 67 | 1760849343 | TIFFANY JEAN GRAMBLIN ARNP | \$7,222.80 | \$267.51 | 27 | 53 |
| 68 | 1821076753 | IRENA MARIA CHARYSZ-BIRSKI MD | \$7,208.03 | \$1,201.34 | 6 | 57 |
| 69 | 1942923339 | WILLY A GARCIA CNP | \$7,063.23 | \$784.80 | 9 | 1705 |
| 70 | 1811621865 | AMY COOPER | \$6,930.65 | \$770.07 | 9 | 72 |
| 71 | 1679545354 | KATHERINE COLLEEN NICKELS MD | \$6,897.12 | \$202.86 | 34 | 159 |
| 72 | 1821799362 | CARMINE NICHOLAS PALLADINO MD | \$6,841.67 | \$2,280.56 | 3 | 164 |
| 73 | 1265954804 | MARIUM JAMIL MD | \$6,725.51 | \$960.79 | 7 | 535 |
| 74 | 1992237960 | STEPHAN SLADE MD | \$6,715.15 | \$6,715.15 | 1 | |
| 75 | 1255319422 | DAVID STAUB MD | \$6,714.15 | \$6,714.15 | 1 | 22 |
| 76 | 1649250390 | NATHANIEL A MEYER MD | \$6,698.34 | \$223.28 | 30 | 74 |
| 77 | 1528365277 | MINA SALIB MD | \$6,687.95 | \$304.00 | 22 | 202 |
| 78 | 1063792026 | JILL NELLIE MILLER | \$6,685.98 | \$1,337.20 | 5 | 64 |
| 79 | 1972758126 | REBECCA BOLLIN DO | \$6,573.67 | \$386.69 | 17 | 90 |
| 80 | 1053600296 | JESSICA MCCOOL MD | \$6,536.34 | \$130.73 | 50 | 139 |
| 81 | 1821861840 | MAURICE ELLIS BLACKBIRD APRN | \$6,534.19 | \$653.42 | 10 | 496 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
December through February 2026

| RANK | DOCTOR NUM | PRESCRIBER NAME | PAID AMOUNT | AVG COST RX | PRESCRIPTION COUNT | PREVIOUS RANK |
|------|------------|------------------------------|-------------|-------------|--------------------|---------------|
| 82 | 1750348496 | VANESSA ANN CURTIS MD | \$6,246.61 | \$520.55 | 12 | 93 |
| 83 | 1881044089 | NATHAN THOMAS MD | \$6,226.90 | \$296.52 | 21 | 91 |
| 84 | 1912991183 | MOLLY EARLEYWINE PA | \$5,961.31 | \$74.52 | 80 | 86 |
| 85 | 1326798992 | JENNA MULLINS MD | \$5,869.03 | \$266.77 | 22 | 2859 |
| 86 | 1609131770 | SREENATH THATI GANGANNA MBBS | \$5,852.47 | \$136.10 | 43 | 132 |
| 87 | 1891756128 | PHILIP JOSEPH MULLER DO | \$5,824.08 | \$126.61 | 46 | 259 |
| 88 | 1366402505 | KUNAL KUMAR PATRA MD | \$5,781.66 | \$444.74 | 13 | 23 |
| 89 | 1104498039 | BRENDA L CAIN ARNP | \$5,760.02 | \$151.58 | 38 | 80 |
| 90 | 1215125216 | REBECCA EVELYN WALDING | \$5,684.24 | \$105.26 | 54 | 222 |
| 91 | 1902792856 | TIMOTHY HOFFMANN ARNP | \$5,646.96 | \$941.16 | 6 | |
| 92 | 1841603305 | SARA KING ARNP | \$5,599.96 | \$2,799.98 | 2 | |
| 93 | 1447519038 | ERIN E RICHARDSON MD | \$5,583.64 | \$132.94 | 42 | 376 |
| 94 | 1285710764 | JITENDRAKUMAR GUPTA MD | \$5,556.08 | \$198.43 | 28 | 97 |
| 95 | 1114704004 | AMANDA NOEL LAUER ARNP | \$5,554.81 | \$617.20 | 9 | |
| 96 | 1669056123 | KAMA AUSBORN ARNP | \$5,538.62 | \$291.51 | 19 | 229 |
| 97 | 1992103386 | MELISSA D LARSEN ARNP | \$5,531.94 | \$291.15 | 19 | 102 |
| 98 | 1962418640 | BARCLAY MONASTER MD | \$5,529.08 | \$141.77 | 39 | 89 |
| 99 | 1346557550 | ROBERT BRYAN BOYLE ARNP | \$5,460.04 | \$60.00 | 91 | 75 |
| 100 | 1801578646 | MICHELLE SWAN ARNP | \$5,278.67 | \$377.05 | 14 | 161 |

TOP 20 THERAPEUTIC CLASS BY PAID AMOUNT

| CATEGORY DESCRIPTION | September through November 2025 | RANK | % BUDGET | December through February 2026 | RANK | % BUDGET | % CHANGE |
|---|---------------------------------|------|----------|--------------------------------|------|----------|----------|
| ANTIDIABETICS | \$370,642 | 1 | 12.7% | \$380,354 | 1 | 12.2% | 2.6% |
| ANALGESICS - ANTI-INFLAMMATORY | \$243,955 | 3 | 8.3% | \$289,932 | 2 | 9.3% | 18.8% |
| DERMATOLOGICALS | \$243,176 | 4 | 8.3% | \$279,470 | 3 | 9.0% | 14.9% |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | \$276,005 | 2 | 9.4% | \$250,210 | 4 | 8.0% | -9.3% |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | \$148,372 | 7 | 5.1% | \$173,105 | 5 | 5.6% | 16.7% |
| ANTICONVULSANTS | \$166,196 | 5 | 5.7% | \$159,325 | 6 | 5.1% | -4.1% |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | \$151,755 | 6 | 5.2% | \$141,432 | 7 | 4.5% | -6.8% |
| ANTIVIRALS | \$110,896 | 8 | 3.8% | \$136,803 | 8 | 4.4% | 23.4% |
| NEUROMUSCULAR AGENTS | \$81,849 | 10 | 2.8% | \$126,148 | 9 | 4.1% | 54.1% |
| ANTIDEPRESSANTS | \$105,724 | 9 | 3.6% | \$116,375 | 10 | 3.7% | 10.1% |
| PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. | \$65,776 | 12 | 2.2% | \$104,653 | 11 | 3.4% | 59.1% |
| RESPIRATORY AGENTS - MISC. | \$31,938 | 21 | 1.1% | \$93,369 | 12 | 3.0% | 192.3% |
| MIGRAINE PRODUCTS | \$45,640 | 14 | 1.6% | \$66,920 | 13 | 2.2% | 46.6% |
| ANTIHYPERTENSIVES | \$48,212 | 13 | 1.6% | \$50,236 | 14 | 1.6% | 4.2% |
| ANALGESICS - OPIOID | \$35,262 | 18 | 1.2% | \$49,496 | 15 | 1.6% | 40.4% |
| ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | \$44,332 | 15 | 1.5% | \$43,281 | 16 | 1.4% | -2.4% |
| CORTICOSTEROIDS | \$33,771 | 19 | 1.2% | \$38,222 | 17 | 1.2% | 13.2% |
| ANTIANSIETY AGENTS | \$38,226 | 17 | 1.3% | \$35,021 | 18 | 1.1% | -8.4% |
| ANTICOAGULANTS | \$30,977 | 22 | 1.1% | \$34,349 | 19 | 1.1% | 10.9% |
| ENDOCRINE AND METABOLIC AGENTS - MISC. | \$22,737 | 29 | 0.8% | \$33,626 | 20 | 1.1% | 47.9% |

TOP 20 THERAPEUTIC CLASS BY PRESCRIPTION COUNT

| CATEGORY DESCRIPTION | September through November 2025 | PREV RANK | December through February 2026 | CURR RANK | PERC CHANGE |
|---|---------------------------------|-----------|--------------------------------|-----------|-------------|
| ANTIDEPRESSANTS | 2,336 | 1 | 2,513 | 1 | 7.6% |
| ANTICONVULSANTS | 1,490 | 2 | 1,759 | 2 | 18.1% |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | 1,426 | 3 | 1,539 | 3 | 7.9% |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | 1,159 | 4 | 1,193 | 4 | 2.9% |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | 1,066 | 6 | 1,187 | 5 | 11.4% |
| ANTIDIABETICS | 1,091 | 5 | 1,150 | 6 | 5.4% |
| ANTIHYPERTENSIVES | 1,049 | 7 | 1,066 | 7 | 1.6% |
| ANTIANSXIETY AGENTS | 979 | 8 | 1,013 | 8 | 3.5% |
| ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | 915 | 9 | 939 | 9 | 2.6% |
| ANALGESICS - OPIOID | 568 | 11 | 604 | 10 | 6.3% |
| ANTIHISTAMINES | 602 | 10 | 573 | 11 | -4.8% |
| DERMATOLOGICALS | 503 | 13 | 555 | 12 | 10.3% |
| ANALGESICS - ANTI-INFLAMMATORY | 498 | 14 | 546 | 13 | 9.6% |
| ANTIHYPERLIPIDEMICS | 509 | 12 | 543 | 14 | 6.7% |
| PENICILLINS | 444 | 15 | 474 | 15 | 6.8% |
| BETA BLOCKERS | 392 | 16 | 419 | 16 | 6.9% |
| MUSCULOSKELETAL THERAPY AGENTS | 368 | 17 | 403 | 17 | 9.5% |
| DIURETICS | 358 | 19 | 363 | 18 | 1.4% |
| LAXATIVES | 345 | 20 | 358 | 19 | 3.8% |
| THYROID AGENTS | 328 | 22 | 342 | 20 | 4.3% |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|---------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| HUMIRA PEN | \$131,323.12 | 2 | \$139,152.82 | 1 | 5.96% |
| OZEMPIC | \$154,969.87 | 1 | \$135,677.90 | 2 | -12.45% |
| EVRYSDI | \$81,849.21 | 4 | \$126,147.60 | 3 | 54.12% |
| VRAYLAR | \$86,122.97 | 3 | \$96,655.60 | 4 | 12.23% |
| SKYRIZI PEN | \$21,483.12 | 23 | \$88,800.72 | 5 | 313.35% |
| ENBREL SURECLICK | \$47,551.38 | 9 | \$80,866.02 | 6 | 70.06% |
| TRIKAFTA | \$24,186.67 | 20 | \$67,247.45 | 7 | 178.04% |
| BIKTARVY | \$68,367.97 | 6 | \$62,030.54 | 8 | -9.27% |
| DUPIXENT | \$79,399.50 | 5 | \$51,272.01 | 9 | -35.43% |
| JARDIANCE | \$63,220.14 | 7 | \$49,869.73 | 10 | -21.12% |
| COSENTYX UNOREADY | \$47,650.77 | 8 | \$48,761.87 | 11 | 2.33% |
| MOUNJARO | \$24,660.48 | 19 | \$45,810.77 | 12 | 85.77% |
| KESIMPTA | \$28,071.10 | 15 | \$38,923.34 | 13 | 38.66% |
| ARISTADA | \$28,146.69 | 14 | \$35,906.73 | 14 | 27.57% |
| RINVOQ | | 999 | \$33,393.90 | 15 | % |
| ALBUTEROL SULFATE | \$32,661.22 | 10 | \$32,774.21 | 16 | 0.35% |
| JORNAY PM | \$21,581.50 | 22 | \$26,715.76 | 17 | 23.79% |
| METHYLPHENIDATE HCL | \$20,343.84 | 27 | \$26,594.23 | 18 | 30.72% |
| VYVANSE | \$27,439.27 | 16 | \$26,413.92 | 19 | -3.74% |
| INGREZZA | \$16,706.93 | 38 | \$25,378.62 | 20 | 51.90% |
| EPIDIOLEX | \$15,169.94 | 46 | \$23,308.98 | 21 | 53.65% |
| NORDITROPIN FLEXPOR | \$13,141.04 | 60 | \$23,272.41 | 22 | 77.10% |
| INVEGA SUSTENNA | \$27,112.01 | 17 | \$22,986.08 | 23 | -15.22% |
| TALTZ | \$14,088.42 | 51 | \$21,788.46 | 24 | 54.66% |
| IBUPROFEN | \$22,091.27 | 21 | \$21,689.95 | 25 | -1.82% |
| CETIRIZINE HCL | \$21,039.03 | 25 | \$21,649.17 | 26 | 2.90% |
| REXULTI | \$30,612.41 | 11 | \$21,432.17 | 27 | -29.99% |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|-------------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| ELIQUIS | \$24,763.33 | 18 | \$20,997.25 | 28 | -15.21% |
| AGAMREE | \$12,709.46 | 65 | \$20,731.78 | 29 | 63.12% |
| LISINOPRIL | \$19,743.46 | 29 | \$20,683.33 | 30 | 4.76% |
| NURTEC | \$13,487.39 | 55 | \$19,483.03 | 31 | 44.45% |
| PYRETHRINS-PIPERONYL BUTOXIDE | \$15,219.00 | 45 | \$19,249.00 | 32 | 26.48% |
| ABILIFY MAINTENA | \$11,625.03 | 72 | \$19,140.28 | 33 | 64.65% |
| ORKAMBI | | 999 | \$18,890.44 | 34 | % |
| SYMBICORT | \$14,715.17 | 48 | \$18,076.15 | 35 | 22.84% |
| GENVOYA | \$12,344.67 | 67 | \$17,321.31 | 36 | 40.31% |
| LANTUS SOLOSTAR | \$18,781.55 | 30 | \$17,227.33 | 37 | -8.28% |
| TRULICITY | \$17,370.29 | 35 | \$17,143.89 | 38 | -1.30% |
| ZURZUVAE | | 999 | \$17,123.60 | 39 | % |
| AUSTEDO XR | | 999 | \$17,082.91 | 40 | % |
| ONDANSETRON | \$15,759.80 | 43 | \$16,762.01 | 41 | 6.36% |
| FARXIGA | \$15,940.10 | 42 | \$16,599.09 | 42 | 4.13% |
| ESCITALOPRAM OXALATE | \$20,364.91 | 26 | \$16,536.96 | 43 | -18.80% |
| TRAMADOL HCL | \$8,961.91 | 92 | \$16,202.93 | 44 | 80.80% |
| METFORMIN HCL | \$11,634.71 | 71 | \$15,949.67 | 45 | 37.09% |
| TREMFYA | \$14,577.07 | 49 | \$15,305.39 | 46 | 5.00% |
| PANTOPRAZOLE SODIUM | \$13,339.68 | 57 | \$15,227.18 | 47 | 14.15% |
| BUPROPION HCL | \$12,534.96 | 66 | \$15,205.43 | 48 | 21.30% |
| LYBALVI | \$16,976.05 | 37 | \$14,994.64 | 49 | -11.67% |
| EMGALITY | \$9,795.28 | 86 | \$14,653.97 | 50 | 49.60% |
| TRAZODONE HCL | \$16,488.23 | 39 | \$14,498.31 | 51 | -12.07% |
| APTIOM | \$14,518.95 | 50 | \$14,241.19 | 52 | -1.91% |
| NUCALA | \$12,342.33 | 68 | \$14,122.83 | 53 | 14.43% |
| KEPPRA | \$9,376.57 | 90 | \$13,679.27 | 54 | 45.89% |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|-------------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| MAVYRET | | 999 | \$13,210.63 | 55 | % |
| SERTRALINE HCL | \$13,247.03 | 58 | \$13,147.64 | 56 | -0.75% |
| ALPRAZOLAM | \$9,768.68 | 87 | \$12,961.85 | 57 | 32.69% |
| CAPLYTA | \$11,763.35 | 70 | \$12,942.33 | 58 | 10.02% |
| PAXLOVID | \$1,448.89 | 270 | \$12,857.36 | 59 | 787.39% |
| ZEPBOUND | \$5,326.67 | 131 | \$12,772.89 | 60 | 139.79% |
| ATORVASTATIN CALCIUM | \$15,537.10 | 44 | \$12,734.08 | 61 | -18.04% |
| LISDEXAMFETAMINE DIMESYLATE | \$13,919.04 | 52 | \$12,704.69 | 62 | -8.72% |
| AJOVY | \$10,353.30 | 80 | \$12,156.44 | 63 | 17.42% |
| ACETAMINOPHEN | \$17,545.13 | 34 | \$11,975.67 | 64 | -31.74% |
| AMPHETAMINE-DEXTROAMPHETAMINE | \$12,311.43 | 69 | \$11,733.00 | 65 | -4.70% |
| OMEPRAZOLE | \$17,182.82 | 36 | \$11,597.74 | 66 | -32.50% |
| AMOXICILLIN | \$12,971.55 | 62 | \$11,597.29 | 67 | -10.59% |
| UBRELVY | \$4,834.95 | 138 | \$11,595.94 | 68 | 139.84% |
| ONFI | \$16,105.55 | 41 | \$11,461.56 | 69 | -28.83% |
| CREON | \$18,020.45 | 33 | \$11,235.70 | 70 | -37.65% |
| XCOPRI | \$3,625.39 | 172 | \$10,973.96 | 71 | 202.70% |
| HYDROCODONE-ACETAMINOPHEN | \$13,420.38 | 56 | \$10,955.62 | 72 | -18.37% |
| WESTAB PLUS | \$13,881.03 | 53 | \$10,871.10 | 73 | -21.68% |
| AMLODIPINE BESYLATE | \$13,002.14 | 61 | \$10,795.32 | 74 | -16.97% |
| NAYZILAM | \$10,246.62 | 83 | \$10,595.67 | 75 | 3.41% |
| OXYCODONE HCL | \$4,286.61 | 154 | \$10,399.03 | 76 | 142.59% |
| PREDNISONE | \$7,576.55 | 106 | \$10,361.19 | 77 | 36.75% |
| FELBATOL | \$4,708.22 | 140 | \$10,311.22 | 78 | 119.00% |
| INVEGA TRINZA | \$10,319.92 | 82 | \$10,304.78 | 79 | -0.15% |
| GUANFACINE HCL (ADHD) | \$4,478.55 | 148 | \$10,256.86 | 80 | 129.02% |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|--------------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| BENEFIX | | 999 | \$10,229.23 | 81 | % |
| ASPIRIN | \$7,829.37 | 101 | \$10,179.05 | 82 | 30.01% |
| BENLYSTA | \$9,996.82 | 85 | \$10,146.45 | 83 | 1.50% |
| MONTELUKAST SODIUM | \$10,320.72 | 81 | \$9,640.39 | 84 | -6.59% |
| NOVOLOG | \$6,588.00 | 117 | \$9,268.65 | 85 | 40.69% |
| POLYETHYLENE GLYCOL 3350 | \$4,220.47 | 157 | \$9,086.28 | 86 | 115.29% |
| OSELTAMIVIR PHOSPHATE | \$60.36 | 585 | \$8,991.97 | 87 | 14,797.23% |
| QELBREE | \$10,396.13 | 79 | \$8,949.27 | 88 | -13.92% |
| NOVOLOG FLEXPEN | \$1,854.58 | 243 | \$8,899.83 | 89 | 379.88% |
| CEPHALEXIN | \$12,937.60 | 63 | \$8,822.07 | 90 | -31.81% |
| QUILLICHEW ER | \$5,389.94 | 129 | \$8,737.52 | 91 | 62.11% |
| INSULIN ASPART | \$11,084.09 | 76 | \$8,715.18 | 92 | -21.37% |
| LOSARTAN POTASSIUM | \$6,992.47 | 114 | \$8,698.10 | 93 | 24.39% |
| NORGESTIMATE-ETHINYL ESTRADIOL | \$4,301.14 | 153 | \$8,489.07 | 94 | 97.37% |
| TRELEGY ELLIPTA | \$8,430.62 | 94 | \$8,423.42 | 95 | -0.09% |
| ROSUVASTATIN CALCIUM | \$16,181.08 | 40 | \$8,420.99 | 96 | -47.96% |
| AMOXICILLIN & POT CLAVULANATE | \$11,431.34 | 73 | \$8,411.26 | 97 | -26.42% |
| FLUOXETINE HCL | \$7,882.40 | 98 | \$8,405.47 | 98 | 6.64% |
| BUSPIRONE HCL | \$6,052.65 | 124 | \$8,327.00 | 99 | 37.58% |
| INSULIN LISPRO | \$7,878.55 | 99 | \$8,223.37 | 100 | 4.38% |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|-----------------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| ALBUTEROL SULFATE | 505 | 1 | 511 | 1 | 1.19% |
| TRAZODONE HCL | 388 | 3 | 423 | 2 | 9.02% |
| CETIRIZINE HCL | 436 | 2 | 385 | 3 | -11.70% |
| METHYLPHENIDATE HCL | 367 | 5 | 377 | 4 | 2.72% |
| GABAPENTIN | 349 | 6 | 370 | 5 | 6.02% |
| FLUOXETINE HCL | 314 | 11 | 365 | 6 | 16.24% |
| SERTRALINE HCL | 376 | 4 | 356 | 7 | -5.32% |
| ATORVASTATIN CALCIUM | 311 | 12 | 340 | 8 | 9.32% |
| HYDROXYZINE HCL | 323 | 10 | 336 | 9 | 4.02% |
| ESCITALOPRAM OXALATE | 341 | 8 | 329 | 10 | -3.52% |
| AMPHETAMINE- DEXTROAMPHETAMINE | 302 | 13 | 325 | 11 | 7.62% |
| OMEPRAZOLE | 349 | 7 | 325 | 12 | -6.88% |
| CLONIDINE HCL | 325 | 9 | 315 | 13 | -3.08% |
| LEVOTHYROXINE SODIUM | 291 | 14 | 307 | 14 | 5.50% |
| QUETIAPINE FUMARATE | 254 | 16 | 285 | 15 | 12.20% |
| METFORMIN HCL | 260 | 15 | 275 | 16 | 5.77% |
| BUPROPION HCL | 245 | 18 | 271 | 17 | 10.61% |
| ARIPIRAZOLE | 226 | 20 | 256 | 18 | 13.27% |
| BUSPIRONE HCL | 253 | 17 | 248 | 19 | -1.98% |
| AMOXICILLIN | 231 | 19 | 246 | 20 | 6.49% |
| MONTELUKAST SODIUM | 222 | 21 | 235 | 21 | 5.86% |
| PANTOPRAZOLE SODIUM | 208 | 26 | 226 | 22 | 8.65% |
| LISINOPRIL | 219 | 22 | 219 | 23 | 0.00% |
| LAMOTRIGINE | 183 | 34 | 216 | 24 | 18.03% |
| LEVETIRACETAM | 169 | 39 | 210 | 25 | 24.26% |
| DULOXETINE HCL | 171 | 38 | 208 | 26 | 21.64% |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|--------------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| HYDROCODONE-ACETAMINOPHEN | 209 | 25 | 207 | 27 | -0.96% |
| FLUTICASONE PROPIONATE (NASAL) | 216 | 23 | 207 | 28 | -4.17% |
| IBUPROFEN | 199 | 27 | 206 | 29 | 3.52% |
| AMOXICILLIN & POT CLAVULANATE | 191 | 29 | 204 | 30 | 6.81% |
| ONDANSETRON | 192 | 28 | 201 | 31 | 4.69% |
| RISPERIDONE | 182 | 35 | 199 | 32 | 9.34% |
| POLYETHYLENE GLYCOL 3350 | 189 | 31 | 193 | 33 | 2.12% |
| AMLODIPINE BESYLATE | 190 | 30 | 191 | 34 | 0.53% |
| AZITHROMYCIN | 151 | 46 | 189 | 35 | 25.17% |
| GUANFACINE HCL (ADHD) | 175 | 36 | 188 | 36 | 7.43% |
| FERROUS SULFATE | 188 | 33 | 182 | 37 | -3.19% |
| PREDNISONE | 210 | 24 | 177 | 38 | -15.71% |
| HYDROXYZINE PAMOATE | 159 | 42 | 171 | 39 | 7.55% |
| FAMOTIDINE | 164 | 41 | 171 | 40 | 4.27% |
| OXYCODONE HCL | 136 | 48 | 167 | 41 | 22.79% |
| OZEMPIC | 189 | 32 | 163 | 42 | -13.76% |
| LISDEXAMFETAMINE DIMESYLATE | 129 | 50 | 160 | 43 | 24.03% |
| ASPIRIN | 174 | 37 | 159 | 44 | -8.62% |
| TOPIRAMATE | 154 | 44 | 158 | 45 | 2.60% |
| ACETAMINOPHEN | 166 | 40 | 153 | 46 | -7.83% |
| CYCLOBENZAPRINE HCL | 154 | 45 | 147 | 47 | -4.55% |
| LANTUS SOLOSTAR | 139 | 47 | 144 | 48 | 3.60% |
| PROPRANOLOL HCL | 110 | 55 | 139 | 49 | 26.36% |
| LOSARTAN POTASSIUM | 131 | 49 | 138 | 50 | 5.34% |
| VENLAFAXINE HCL | 115 | 53 | 132 | 51 | 14.78% |
| BACLOFEN | 102 | 61 | 130 | 52 | 27.45% |
| JARDIANCE | 123 | 52 | 129 | 53 | 4.88% |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|-----------------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| CEPHALEXIN | 155 | 43 | 128 | 54 | -17.42% |
| METOPROLOL SUCCINATE | 115 | 54 | 126 | 55 | 9.57% |
| MELOXICAM | 97 | 69 | 124 | 56 | 27.84% |
| GUANFACINE HCL | 128 | 51 | 123 | 57 | -3.91% |
| PRAZOSIN HCL | 106 | 58 | 120 | 58 | 13.21% |
| MIRTAZAPINE | 105 | 59 | 119 | 59 | 13.33% |
| SPIRONOLACTONE | 98 | 67 | 116 | 60 | 18.37% |
| OSELTAMIVIR PHOSPHATE | 3 | 457 | 113 | 61 | 3,666.67% |
| ROSUVASTATIN CALCIUM | 102 | 62 | 109 | 62 | 6.86% |
| CLONAZEPAM | 86 | 74 | 109 | 63 | 26.74% |
| PREGABALIN | 95 | 71 | 105 | 64 | 10.53% |
| DEXMETHYLPHENIDATE HCL | 97 | 70 | 105 | 65 | 8.25% |
| LORATADINE | 110 | 56 | 102 | 66 | -7.27% |
| ATOMOXETINE HCL | 108 | 57 | 100 | 67 | -7.41% |
| TRAMADOL HCL | 100 | 64 | 98 | 68 | -2.00% |
| OLANZAPINE | 79 | 77 | 96 | 69 | 21.52% |
| ALPRAZOLAM | 98 | 65 | 94 | 70 | -4.08% |
| TRIAMCINOLONE ACETONIDE (TOPICAL) | 100 | 63 | 93 | 71 | -7.00% |
| LORAZEPAM | 91 | 73 | 92 | 72 | 1.10% |
| SYMBICORT | 77 | 78 | 90 | 73 | 16.88% |
| FLUCONAZOLE | 103 | 60 | 90 | 74 | -12.62% |
| ONDANSETRON HCL | 74 | 79 | 87 | 75 | 17.57% |
| CEFDINIR | 74 | 80 | 87 | 76 | 17.57% |
| FUROSEMIDE | 98 | 68 | 84 | 77 | -14.29% |
| SULFAMETHOXAZOLE-TRIMETHOPRIM | 94 | 72 | 84 | 78 | -10.64% |
| DIVALPROEX SODIUM | 72 | 84 | 84 | 79 | 16.67% |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | September through November 2025 | PREVIOUS RANK | December through February 2026 | RANK | PERCENT CHANGE |
|---------------------------|---------------------------------|---------------|--------------------------------|------|----------------|
| VALACYCLOVIR HCL | 52 | 103 | 83 | 80 | 59.62% |
| OXYBUTYNIN CHLORIDE | 73 | 83 | 83 | 81 | 13.70% |
| METRONIDAZOLE | 98 | 66 | 83 | 82 | -15.31% |
| GLYCOPYRROLATE | 71 | 85 | 82 | 83 | 15.49% |
| CLOBAZAM | 40 | 118 | 82 | 84 | 105.00% |
| ZOLPIDEM TARTRATE | 73 | 81 | 82 | 85 | 12.33% |
| SENNOSIDES | 63 | 91 | 78 | 86 | 23.81% |
| AMITRIPTYLINE HCL | 65 | 89 | 76 | 87 | 16.92% |
| HYDROCHLOROTHIAZIDE | 86 | 75 | 75 | 88 | -12.79% |
| NALTREXONE HCL | 73 | 82 | 74 | 89 | 1.37% |
| FOLIC ACID | 51 | 105 | 74 | 90 | 45.10% |
| JORNAY PM | 57 | 96 | 73 | 91 | 28.07% |
| TIZANIDINE HCL | 55 | 101 | 72 | 92 | 30.91% |
| INSULIN LISPRO | 58 | 94 | 71 | 93 | 22.41% |
| VRAYLAR | 59 | 93 | 67 | 94 | 13.56% |
| OXCARBAZEPINE | 56 | 97 | 67 | 95 | 19.64% |
| KETOCONAZOLE (TOPICAL) | 48 | 110 | 67 | 96 | 39.58% |
| VYVANSE | 68 | 86 | 66 | 97 | -2.94% |
| CARVEDILOL | 66 | 87 | 66 | 98 | 0.00% |
| DOXYCYCLINE (MONOHYDRATE) | 82 | 76 | 63 | 99 | -23.17% |
| ELIQUIS | 50 | 107 | 61 | 100 | 22.00% |



**Iowa Total Care Claims
Quarterly Statistics**

| REPORT_DATE | Sep 2025 through Nov 2025 | Dec 2025 through Feb 2026 | % CHANGE |
|-----------------------------------|---------------------------|---------------------------|----------|
| TOTAL PAID AMOUNT | \$84,747,136.93 | \$87,459,108.67 | 3.20% |
| UNIQUE USERS | 92,401 | 97,346 | 5.35% |
| COST PER USER | \$917.17 | \$898.44 | -2.04% |
| TOTAL PRESCRIPTIONS | 634,164 | 645,443 | 1.78% |
| AVERAGE PRESCRIPTION PER USER | 6.86 | 6.63 | -3.39% |
| AVERAGE COST PER PRESCRIPTION | \$133.64 | \$135.50 | 1.40% |
| # GENERIC PRESCRIPTIONS | 568,487 | 579,736 | 1.98% |
| % GENERIC | 90.00% | 90.00% | 0.20% |
| \$ GENERIC | \$10,636,461.03 | \$10,724,585.54 | 0.83% |
| AVERAGE GENERIC PRESCRIPTION COST | \$18.71 | \$18.50 | -1.13% |
| AVERAGE GENERIC DAYS SUPPLY | 29 | 30 | 3.74% |
| # BRAND PRESCRIPTIONS | 64,647 | 64,679 | 0.05% |
| % BRAND | 10.00% | 10.00% | -1.73% |
| \$ BRAND | \$74,085,364.07 | \$76,707,625.04 | 3.54% |
| AVERAGE BRAND PRESCRIPTION COST | \$1,146.00 | \$1,185.97 | 3.49% |
| AVERAGE BRAND DAYS SUPPLY | 29 | 29 | 0.57% |

UTILIZATION BY AGE

| AGE | Sep 2025 through Nov 2025 | Dec 2025 through Feb 2026 |
|-------|---------------------------|---------------------------|
| 0-6 | 33,093 | 38,189 |
| 7-12 | 48,697 | 50,860 |
| 13-18 | 61,282 | 62,827 |
| 19-64 | 482,802 | 486,952 |
| 65+ | 5,921 | 5,696 |

UTILIZATION BY GENDER AND AGE

| GENDER | AGE | Sep 2025 through Nov 2025 | Dec 2025 through Feb 2026 |
|--------|-------|---------------------------|---------------------------|
| F | 0-6 | 14,464 | 16,847 |
| | 7-12 | 19,153 | 20,272 |
| | 13-18 | 32,526 | 33,120 |
| | 19-64 | 311,967 | 315,453 |
| | 65+ | 3,648 | 3,413 |
| M | 0-6 | 18,629 | 21,342 |
| | 7-12 | 29,544 | 30,588 |
| | 13-18 | 28,756 | 29,707 |
| | 19-64 | 170,835 | 171,499 |
| | 65+ | 2,273 | 2,283 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
202512 - 202602

| RANK | PHARMACY NAME | PHARMACY CITY | PHARMACY STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|--|----------------|----------------|--------------------|----------------|-------------|---------------|
| 1 | U OF I HOSPITALS & CLINICS AMBULATORY CARE PHARM | IOWA CITY | IA | 10,300 | \$6,924,642.49 | \$672.30 | 1 |
| 2 | RIGHT DOSE PHARMACY | ANKENY | IA | 5,840 | \$304,361.40 | \$52.12 | 2 |
| 3 | WALGREENS #4405 | COUNCIL BLUFFS | IA | 5,081 | \$381,045.35 | \$74.99 | 3 |
| 4 | BROADLAWNS MEDICAL CENTER OUTPATIENT PHARMACY | DES MOINES | IA | 4,660 | \$355,295.26 | \$76.24 | 4 |
| 5 | WALGREENS #5042 | CEDAR RAPIDS | IA | 4,333 | \$257,352.81 | \$59.39 | 5 |
| 6 | HY-VEE PHARMACY #2 (1138) | DES MOINES | IA | 4,329 | \$401,118.94 | \$92.66 | 7 |
| 7 | DRILLING PHARMACY | SIOUX CITY | IA | 4,010 | \$240,145.76 | \$59.89 | 6 |
| 8 | SIOUXLAND COMMUNITY HEALTH CENTER | SIOUX CITY | IA | 3,902 | \$209,939.25 | \$53.80 | 10 |
| 9 | GREENWOOD DRUG ON KIMBALL AVE. | WATERLOO | IA | 3,736 | \$402,855.63 | \$107.83 | 9 |
| 10 | HY-VEE PHARMACY (1403) | MARSHALLTOWN | IA | 3,710 | \$293,078.05 | \$79.00 | 8 |
| 11 | WALGREENS #5239 | DAVENPORT | IA | 3,517 | \$191,664.20 | \$54.50 | 11 |
| 12 | HY-VEE DRUGSTORE (7060) | MUSCATINE | IA | 3,311 | \$293,901.54 | \$88.77 | 13 |
| 13 | HY-VEE PHARMACY #5 (1109) | DAVENPORT | IA | 3,281 | \$290,203.80 | \$88.45 | 15 |
| 14 | IMMC OUTPATIENT PHARMACY | DES MOINES | IA | 3,207 | \$150,124.82 | \$46.81 | 33 |
| 15 | HY-VEE PHARMACY #5 (1151) | DES MOINES | IA | 3,072 | \$251,258.34 | \$81.79 | 12 |
| 16 | HY-VEE DRUGSTORE (7065) | OTTUMWA | IA | 3,047 | \$224,633.30 | \$73.72 | 14 |
| 17 | HY-VEE PHARMACY #1 (1092) | COUNCIL BLUFFS | IA | 2,939 | \$280,406.64 | \$95.41 | 16 |
| 18 | WALMART PHARMACY 10-0559 | MUSCATINE | IA | 2,877 | \$250,528.88 | \$87.08 | 23 |
| 19 | WAGNER PHARMACY | CLINTON | IA | 2,868 | \$211,323.55 | \$73.68 | 18 |
| 20 | WALGREENS #15647 | SIOUX CITY | IA | 2,838 | \$174,952.76 | \$61.65 | 17 |
| 21 | NELSON FAMILY PHARMACY | FORT MADISON | IA | 2,793 | \$125,719.43 | \$45.01 | 26 |
| 22 | HY-VEE PHARMACY (1192) | FT DODGE | IA | 2,748 | \$207,196.91 | \$75.40 | 19 |
| 23 | MEDICAP PHARMACY LTC | INDIANOLA | IA | 2,677 | \$96,637.96 | \$36.10 | 37 |
| 24 | HY-VEE PHARMACY (1075) | CLINTON | IA | 2,669 | \$207,522.64 | \$77.75 | 27 |
| 25 | HY-VEE PHARMACY #2 (1044) | BURLINGTON | IA | 2,656 | \$195,286.40 | \$73.53 | 24 |
| 26 | HY-VEE DRUGSTORE #1 (7020) | CEDAR RAPIDS | IA | 2,637 | \$284,997.53 | \$108.08 | 32 |
| 27 | HY-VEE PHARMACY (1449) | NEWTON | IA | 2,615 | \$226,020.20 | \$86.43 | 21 |
| 28 | MAHASKA DRUGS INC | OSKALOOSA | IA | 2,595 | \$209,982.06 | \$80.92 | 29 |
| 29 | WALGREENS #7455 | WATERLOO | IA | 2,559 | \$178,756.89 | \$69.85 | 22 |
| 30 | HY-VEE PHARMACY #3 (1056) | CEDAR RAPIDS | IA | 2,546 | \$193,740.34 | \$76.10 | 41 |
| 31 | CVS PHARMACY #10282 | FORT DODGE | IA | 2,529 | \$119,378.91 | \$47.20 | 31 |
| 32 | GREENWOOD COMPLIANCE PHARMACY | WATERLOO | IA | 2,528 | \$290,359.76 | \$114.86 | 34 |
| 33 | COMMUNITY HEALTH CARE PHARMACY | DAVENPORT | IA | 2,516 | \$140,244.12 | \$55.74 | 30 |
| 34 | HY-VEE PHARMACY #1 (1610) | SIOUX CITY | IA | 2,515 | \$192,258.68 | \$76.44 | 25 |
| 35 | NUCARA LTC PHARMACY #3 | IOWA CITY | IA | 2,515 | \$84,600.34 | \$33.64 | 20 |
| 36 | EXACTCARE | VALLEY VIEW | OH | 2,504 | \$234,800.21 | \$93.77 | 49 |
| 37 | WALMART PHARMACY 10-2889 | CLINTON | IA | 2,458 | \$166,469.32 | \$67.73 | 45 |
| 38 | HY-VEE PHARMACY #4 (1148) | DES MOINES | IA | 2,458 | \$163,906.32 | \$66.68 | 36 |
| 39 | WALGREENS #5721 | DES MOINES | IA | 2,455 | \$154,321.65 | \$62.86 | 28 |
| 40 | WALGREENS #359 | DES MOINES | IA | 2,344 | \$159,943.91 | \$68.24 | 39 |
| 41 | SOUTH SIDE DRUG | OTTUMWA | IA | 2,332 | \$142,243.14 | \$61.00 | 38 |
| 42 | WALGREENS #3700 | COUNCIL BLUFFS | IA | 2,330 | \$132,264.46 | \$56.77 | 43 |
| 43 | HY-VEE PHARMACY #3 (1142) | DES MOINES | IA | 2,315 | \$198,734.13 | \$85.85 | 35 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
202512 - 202602

| RANK | PHARMACY NAME | PHARMACY CITY | PHARMACY STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|---|-----------------|----------------|--------------------|--------------|-------------|---------------|
| 44 | CVS PHARMACY #08544 | WATERLOO | IA | 2,312 | \$223,089.38 | \$96.49 | 48 |
| 45 | HY-VEE PHARMACY #1 (1504) | OTTUMWA | IA | 2,309 | \$135,482.40 | \$58.68 | 46 |
| 46 | HY-VEE PHARMACY #3 (1866) | WATERLOO | IA | 2,292 | \$194,642.11 | \$84.92 | 47 |
| 47 | HY-VEE PHARMACY (1396) | MARION | IA | 2,254 | \$203,018.86 | \$90.07 | 44 |
| 48 | HY-VEE PHARMACY (1530) | PLEASANT HILL | IA | 2,254 | \$173,410.82 | \$76.93 | 50 |
| 49 | WALMART PHARMACY 10-3590 | SIOUX CITY | IA | 2,254 | \$156,517.49 | \$69.44 | 62 |
| 50 | WALMART PHARMACY 10-1509 | MAQUOKETA | IA | 2,246 | \$154,498.55 | \$68.79 | 55 |
| 51 | HY-VEE PHARMACY (1459) | OELWEIN | IA | 2,226 | \$151,044.91 | \$67.85 | 42 |
| 52 | HY-VEE PHARMACY (1071) | CLARINDA | IA | 2,222 | \$204,078.68 | \$91.84 | 53 |
| 53 | CVS PHARMACY #08658 | DAVENPORT | IA | 2,197 | \$168,901.81 | \$76.88 | 63 |
| 54 | UI HEALTHCARE - IOWA RIVER LANDING PHARMACY | CORALVILLE | IA | 2,181 | \$113,507.99 | \$52.04 | 51 |
| 55 | HY-VEE PHARMACY (1058) | CENTERVILLE | IA | 2,171 | \$215,951.09 | \$99.47 | 56 |
| 56 | HY-VEE PHARMACY #5 (1061) | CEDAR RAPIDS | IA | 2,136 | \$160,757.62 | \$75.26 | 54 |
| 57 | LEWIS FAMILY DRUG #28 | ONAWA | IA | 2,124 | \$198,868.80 | \$93.63 | 57 |
| 58 | HY-VEE PHARMACY (1074) | CHARLES CITY | IA | 2,110 | \$134,594.08 | \$63.79 | 65 |
| 59 | WALGREENS #7453 | DES MOINES | IA | 2,084 | \$149,608.21 | \$71.79 | 40 |
| 60 | HY-VEE PHARMACY (1522) | PERRY | IA | 2,082 | \$128,666.03 | \$61.80 | 60 |
| 61 | WALGREENS #4714 | DES MOINES | IA | 2,077 | \$148,851.44 | \$71.67 | 71 |
| 62 | WALMART PHARMACY 10-0797 | WEST BURLINGTON | IA | 2,069 | \$134,286.59 | \$64.90 | 87 |
| 63 | TOWNCREST LTC | IOWA CITY | IA | 2,042 | \$114,493.79 | \$56.07 | 61 |
| 64 | HY-VEE DRUGSTORE (7056) | MASON CITY | IA | 2,010 | \$169,284.37 | \$84.22 | 52 |
| 65 | GENOA HEALTHCARE, LLC | SIOUX CITY | IA | 1,987 | \$379,147.97 | \$190.81 | 75 |
| 66 | MERCYONE WATERLOO PHARMACY | WATERLOO | IA | 1,962 | \$219,893.05 | \$112.08 | 84 |
| 67 | WALMART PHARMACY 10-5115 | DAVENPORT | IA | 1,957 | \$133,402.39 | \$68.17 | 67 |
| 68 | PREFERRED CARE PHARMACY | CEDAR RAPIDS | IA | 1,957 | \$119,988.07 | \$61.31 | 70 |
| 69 | MAIN AT LOCUST PHARMACY AND MEDICAL SUPPLY | DAVENPORT | IA | 1,954 | \$156,743.46 | \$80.22 | 68 |
| 70 | MEDICAP PHARMACY | CRESTON | IA | 1,952 | \$114,418.19 | \$58.62 | 73 |
| 71 | UNION PHARMACY | COUNCIL BLUFFS | IA | 1,949 | \$136,350.96 | \$69.96 | 66 |
| 72 | HY-VEE PHARMACY (1180) | FAIRFIELD | IA | 1,933 | \$165,476.38 | \$85.61 | 74 |
| 73 | WALMART PHARMACY 10-0985 | FAIRFIELD | IA | 1,926 | \$130,816.82 | \$67.92 | 59 |
| 74 | SCOTT PHARMACY | FAYETTE | IA | 1,916 | \$134,584.66 | \$70.24 | 64 |
| 75 | DANIEL PHARMACY | FT DODGE | IA | 1,883 | \$126,961.45 | \$67.43 | 77 |
| 76 | MEDICAP PHARMACY | NEWTON | IA | 1,878 | \$212,378.16 | \$113.09 | 101 |
| 77 | WALMART PHARMACY 10-1723 | DES MOINES | IA | 1,871 | \$155,848.48 | \$83.30 | 99 |
| 78 | HY-VEE PHARMACY #1 (1281) | IOWA CITY | IA | 1,849 | \$103,759.40 | \$56.12 | 85 |
| 79 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 1,840 | \$151,829.75 | \$82.52 | 82 |
| 80 | HY-VEE PHARMACY (1895) | WINDSOR HEIGHTS | IA | 1,828 | \$124,561.33 | \$68.14 | 89 |
| 81 | WALMART PHARMACY 10-1431 | KEOKUK | IA | 1,815 | \$97,334.36 | \$53.63 | 93 |
| 82 | HY-VEE PHARMACY (1241) | HARLAN | IA | 1,805 | \$210,693.06 | \$116.73 | 80 |
| 83 | HY-VEE PHARMACY #3 (1615) | SIOUX CITY | IA | 1,798 | \$131,636.89 | \$73.21 | 69 |
| 84 | HY-VEE PHARMACY (1022) | ANKENY | IA | 1,790 | \$121,375.71 | \$67.81 | 94 |
| 85 | WALGREENS #11942 | DUBUQUE | IA | 1,787 | \$159,106.51 | \$89.04 | 100 |
| 86 | LAGRANGE PHARMACY | VINTON | IA | 1,781 | \$116,573.06 | \$65.45 | 72 |

TOP 100 PHARMACIES BY PRESCRIPTION COUNT
202512 - 202602

| RANK | PHARMACY NAME | PHARMACY CITY | PHARMACY STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST RX | PREVIOUS RANK |
|------|---|---------------|----------------|--------------------|--------------|-------------|---------------|
| 87 | HY-VEE PHARMACY (1011) | ALTOONA | IA | 1,778 | \$132,896.33 | \$74.74 | 79 |
| 88 | WALGREENS #5470 | SIOUX CITY | IA | 1,773 | \$124,693.79 | \$70.33 | 83 |
| 89 | WALMART PHARMACY 10-0646 | ANAMOSA | IA | 1,772 | \$147,762.20 | \$83.39 | 78 |
| 90 | WALMART PHARMACY 10-1393 | OSKALOOSA | IA | 1,758 | \$161,829.02 | \$92.05 | 76 |
| 91 | CRESCENT COMMUNITY HEALTH CENTER PHARMACY | DUBUQUE | IA | 1,745 | \$87,744.73 | \$50.28 | 86 |
| 92 | THOMPSON DEAN DRUG | SIOUX CITY | IA | 1,734 | \$154,719.02 | \$89.23 | 90 |
| 93 | WALGREENS #7454 | ANKENY | IA | 1,710 | \$97,560.89 | \$57.05 | 81 |
| 94 | WALGREENS #7452 | DES MOINES | IA | 1,698 | \$137,671.05 | \$81.08 | 107 |
| 95 | WALMART PHARMACY 10-3394 | ATLANTIC | IA | 1,698 | \$131,554.07 | \$77.48 | 98 |
| 96 | MCMH PHARMACY | RED OAK | IA | 1,692 | \$142,976.64 | \$84.50 | 103 |
| 97 | WALGREENS #3875 | CEDAR RAPIDS | IA | 1,682 | \$142,520.26 | \$84.73 | 91 |
| 98 | WALGREENS #4041 | DAVENPORT | IA | 1,656 | \$97,770.45 | \$59.04 | 58 |
| 99 | HY-VEE PHARMACY #3 (1107) | DAVENPORT | IA | 1,643 | \$147,207.04 | \$89.60 | 117 |
| 100 | HY-VEE PHARMACY (1382) | LEMARS | IA | 1,631 | \$140,247.51 | \$85.99 | 88 |

**TOP 100 PHARMACIES BY PAID AMOUNT
202512 - 202602**

| RANK | PHARMACY NAME | PHARMACY CITY | PHARMACY STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|---|-------------------|----------------|--------------------|----------------|-----------------|---------------|
| 1 | U OF I HOSPITALS & CLINICS AMBULATORY CARE PHARM | IOWA CITY | IA | 10,300 | \$6,924,642.49 | \$3,300.59 | 1 |
| 2 | CAREMARK KANSAS SPECIALTY PHARMACY, LLC DBA CVS/SPECIALTY | LENEXA | KS | 446 | \$3,654,853.60 | \$18,004.20 | 3 |
| 3 | WALGREENS SPECIALTY PHARMACY #16528 | DES MOINES | IA | 614 | \$3,296,259.68 | \$13,564.85 | 2 |
| 4 | UNITYPOINT AT HOME | URBANDALE | IA | 667 | \$2,565,793.04 | \$11,011.99 | 5 |
| 5 | ACCREDO HEALTH GROUP INC | MEMPHIS | TN | 213 | \$2,311,422.61 | \$26,877.01 | 6 |
| 6 | PANTHERX SPECIALTY PHARMACY | CORAOPOLIS | PA | 75 | \$2,174,405.00 | \$72,480.17 | 4 |
| 7 | NUCARA SPECIALTY PHARMACY | PLEASANT HILL | IA | 1,083 | \$1,258,011.74 | \$9,182.57 | 7 |
| 8 | ACARIAHEALTH PHARMACY #11 | HOUSTON | TX | 159 | \$1,204,314.98 | \$15,640.45 | 8 |
| 9 | CVS/SPECIALTY | MONROEVILLE | PA | 141 | \$1,008,715.20 | \$20,586.02 | 9 |
| 10 | AMBER PHARMACY | OMAHA | NE | 155 | \$891,116.25 | \$14,372.84 | 12 |
| 11 | OPTUM PHARMACY 702, LLC | JEFFERSONVILLE | IN | 97 | \$888,261.56 | \$18,899.18 | 10 |
| 12 | WALGREENS SPECIALTY PHARMACY #21250 | IOWA CITY | IA | 190 | \$888,082.11 | \$9,062.06 | 11 |
| 13 | ANOVORX GROUP, LLC | MEMPHIS | TN | 61 | \$665,266.46 | \$24,639.50 | 19 |
| 14 | WALGREENS SPECIALTY PHARMACY #16270 | OMAHA | NE | 64 | \$659,328.29 | \$24,419.57 | 15 |
| 15 | ACCREDO HEALTH GROUP INC | WARRENDALE | PA | 31 | \$635,975.51 | \$63,597.55 | 14 |
| 16 | THE NEBRASKA MED CENTER CLINIC PHCY | OMAHA | NE | 802 | \$628,019.42 | \$4,272.24 | 16 |
| 17 | WALGREENS SPECIALTY PHARMACY #16280 | FRISCO | TX | 23 | \$549,914.95 | \$91,652.49 | 17 |
| 18 | ONCO360 | LOUISVILLE | KY | 27 | \$504,970.39 | \$42,080.87 | 43 |
| 19 | MERCYONE GENESIS FIRSTMED SPECIALTY PHARMACY | DAVENPORT | IA | 498 | \$470,436.14 | \$3,178.62 | 26 |
| 20 | BIOLOGICS BY MCKESSON | FORT WORTH | TX | 20 | \$462,592.71 | \$57,824.09 | 18 |
| 21 | PARAGON PARTNERS | OMAHA | NE | 966 | \$459,982.32 | \$5,287.15 | 21 |
| 22 | EXPRESS SCRIPTS SPECIALTY DIST SVCS | SAINT LOUIS | MO | 26 | \$458,616.07 | \$45,861.61 | 24 |
| 23 | CR CARE PHARMACY | CEDAR RAPIDS | IA | 1,601 | \$445,222.51 | \$2,714.77 | 20 |
| 24 | CVS PHARMACY #00102 | AURORA | CO | 52 | \$430,183.71 | \$17,924.32 | 13 |
| 25 | ORSINI PHARMACEUTICAL SERVICES INC | ELK GROVE VILLAGE | IL | 21 | \$413,643.83 | \$51,705.48 | 34 |
| 26 | GREENWOOD DRUG ON KIMBALL AVE. | WATERLOO | IA | 3,736 | \$402,855.63 | \$1,209.78 | 28 |
| 27 | HY-VEE PHARMACY #2 (1138) | DES MOINES | IA | 4,329 | \$401,118.94 | \$645.92 | 30 |
| 28 | EVERSANA LIFE SCIENCE SERVICES, LLC | CHESTERFIELD | MO | 9 | \$400,416.14 | \$133,472.05 | 29 |
| 29 | WALGREENS #4405 | COUNCIL BLUFFS | IA | 5,081 | \$381,045.35 | \$332.21 | 27 |
| 30 | ACCREDO HEALTH GROUP, INC. | WHITESTOWN | IN | 33 | \$379,787.46 | \$21,099.30 | 48 |
| 31 | GENOA HEALTHCARE, LLC | SIOUX CITY | IA | 1,987 | \$379,147.97 | \$1,895.74 | 32 |
| 32 | BROADLAWNS MEDICAL CENTER OUTPATIENT PHARMACY | DES MOINES | IA | 4,660 | \$355,295.26 | \$462.02 | 25 |
| 33 | PANTHERX SPECIALTY PHARMACY | COLLIERVILLE | TN | 8 | \$352,571.73 | \$50,367.39 | |
| 34 | ALLEN CLINIC PHARMACY | WATERLOO | IA | 919 | \$344,027.96 | \$1,068.41 | 23 |
| 35 | SENDERRA RX PHARMACY | PLANO | TX | 43 | \$336,352.96 | \$18,686.28 | 85 |
| 36 | GENOA HEALTHCARE, LLC | DAVENPORT | IA | 1,444 | \$334,914.16 | \$2,342.06 | 33 |
| 37 | GENOA HEALTHCARE, LLC | MARSHALLTOWN | IA | 1,157 | \$305,645.39 | \$2,996.52 | 61 |
| 38 | RIGHT DOSE PHARMACY | ANKENY | IA | 5,840 | \$304,361.40 | \$747.82 | 42 |
| 39 | HY-VEE DRUGSTORE (7060) | MUSCATINE | IA | 3,311 | \$293,901.54 | \$525.76 | 38 |
| 40 | HY-VEE PHARMACY (1403) | MARSHALLTOWN | IA | 3,710 | \$293,078.05 | \$387.16 | 37 |
| 41 | GREENWOOD COMPLIANCE PHARMACY | WATERLOO | IA | 2,528 | \$290,359.76 | \$2,088.92 | 39 |
| 42 | HY-VEE PHARMACY #5 (1109) | DAVENPORT | IA | 3,281 | \$290,203.80 | \$555.95 | 60 |
| 43 | HY-VEE DRUGSTORE #1 (7020) | CEDAR RAPIDS | IA | 2,637 | \$284,997.53 | \$748.03 | 54 |
| 44 | HY-VEE PHARMACY #1 (1092) | COUNCIL BLUFFS | IA | 2,939 | \$280,406.64 | \$862.79 | 36 |

**TOP 100 PHARMACIES BY PAID AMOUNT
202512 - 202602**

| RANK | PHARMACY NAME | PHARMACY CITY | PHARMACY STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|---|---------------|----------------|--------------------|--------------|-----------------|---------------|
| 45 | AVERA SPECIALTY PHARMACY | SIOUX FALLS | SD | 79 | \$268,778.70 | \$8,144.81 | 47 |
| 46 | WALGREENS #5042 | CEDAR RAPIDS | IA | 4,333 | \$257,352.81 | \$264.49 | 40 |
| 47 | HY-VEE PHARMACY #5 (1151) | DES MOINES | IA | 3,072 | \$251,258.34 | \$470.52 | 45 |
| 48 | UI HEALTH CARE DES MOINES PHARMACY | DES MOINES | IA | 26 | \$250,852.35 | \$27,872.48 | 35 |
| 49 | WALMART PHARMACY 10-0559 | MUSCATINE | IA | 2,877 | \$250,528.88 | \$519.77 | 41 |
| 50 | CAREMARK ILLINOIS SPECIALTY PHARMACY, LLC DBA CVS/SPECIALTY | MT PROSPECT | IL | 40 | \$242,290.81 | \$15,143.18 | 51 |
| 51 | DRILLING PHARMACY | SIOUX CITY | IA | 4,010 | \$240,145.76 | \$704.24 | 44 |
| 52 | SOLEO HEALTH INC. | WOODRIDGE | IL | 2 | \$237,283.66 | \$237,283.66 | 171 |
| 53 | EXACTCARE | VALLEY VIEW | OH | 2,504 | \$234,800.21 | \$2,324.75 | 70 |
| 54 | HY-VEE PHARMACY SOLUTIONS | OMAHA | NE | 33 | \$227,607.24 | \$14,225.45 | 31 |
| 55 | HY-VEE PHARMACY (1449) | NEWTON | IA | 2,615 | \$226,020.20 | \$478.86 | 52 |
| 56 | HY-VEE DRUGSTORE (7065) | OTTUMWA | IA | 3,047 | \$224,633.30 | \$455.65 | 46 |
| 57 | CVS PHARMACY #08544 | WATERLOO | IA | 2,312 | \$223,089.38 | \$450.69 | 63 |
| 58 | MEDICAP PHARMACY | DES MOINES | IA | 1,501 | \$222,183.91 | \$2,290.56 | 82 |
| 59 | MERCYONE WATERLOO PHARMACY | WATERLOO | IA | 1,962 | \$219,893.05 | \$522.31 | 77 |
| 60 | PRIMARY HEALTHCARE PHARMACY | DES MOINES | IA | 1,011 | \$216,485.22 | \$1,066.43 | 75 |
| 61 | HY-VEE PHARMACY (1058) | CENTERVILLE | IA | 2,171 | \$215,951.09 | \$853.56 | 49 |
| 62 | MEDICAP PHARMACY | NEWTON | IA | 1,878 | \$212,378.16 | \$1,025.98 | 69 |
| 63 | WAGNER PHARMACY | CLINTON | IA | 2,868 | \$211,323.55 | \$709.14 | 55 |
| 64 | HY-VEE PHARMACY (1241) | HARLAN | IA | 1,805 | \$210,693.06 | \$598.56 | 71 |
| 65 | MAHASKA DRUGS INC | OSKALOOSA | IA | 2,595 | \$209,982.06 | \$562.95 | 68 |
| 66 | SIOUXLAND COMMUNITY HEALTH CENTER | SIOUX CITY | IA | 3,902 | \$209,939.25 | \$287.19 | 91 |
| 67 | HY-VEE PHARMACY (1075) | CLINTON | IA | 2,669 | \$207,522.64 | \$440.60 | 72 |
| 68 | HY-VEE PHARMACY (1192) | FT DODGE | IA | 2,748 | \$207,196.91 | \$473.05 | 53 |
| 69 | WALGREENS SPECIALTY PHARMACY #15443 | FRISCO | TX | 26 | \$204,212.64 | \$12,012.51 | 469 |
| 70 | HY-VEE PHARMACY (1071) | CLARINDA | IA | 2,222 | \$204,078.68 | \$711.08 | 76 |
| 71 | HY-VEE PHARMACY (1396) | MARION | IA | 2,254 | \$203,018.86 | \$507.55 | 64 |
| 72 | LEWIS FAMILY DRUG #28 | ONAWA | IA | 2,124 | \$198,868.80 | \$759.04 | 58 |
| 73 | HY-VEE PHARMACY #3 (1142) | DES MOINES | IA | 2,315 | \$198,734.13 | \$505.68 | 59 |
| 74 | OPTUM INFUSION SERVICES 550, LLC. | URBANDALE | IA | 70 | \$196,524.49 | \$19,652.45 | 56 |
| 75 | HY-VEE PHARMACY #2 (1044) | BURLINGTON | IA | 2,656 | \$195,286.40 | \$446.88 | 73 |
| 76 | HY-VEE PHARMACY #3 (1866) | WATERLOO | IA | 2,292 | \$194,642.11 | \$559.32 | 66 |
| 77 | HY-VEE PHARMACY #3 (1056) | CEDAR RAPIDS | IA | 2,546 | \$193,740.34 | \$403.63 | 65 |
| 78 | HY-VEE PHARMACY #1 (1610) | SIOUX CITY | IA | 2,515 | \$192,258.68 | \$403.90 | 57 |
| 79 | WALGREENS #5239 | DAVENPORT | IA | 3,517 | \$191,664.20 | \$208.33 | 62 |
| 80 | CHILDRENS HOME HEALTHCARE | OMAHA | NE | 33 | \$184,188.53 | \$15,349.04 | 22 |
| 81 | WALGREENS #7455 | WATERLOO | IA | 2,559 | \$178,756.89 | \$225.99 | 81 |
| 82 | RIVER HILLS PHARMACY | OTTUMWA | IA | 738 | \$178,103.29 | \$1,079.41 | 106 |
| 83 | VYTLONE SPECIALTY PHARMACY | LUBBOCK | TX | 20 | \$175,298.76 | \$87,649.38 | 87 |
| 84 | WALGREENS #15647 | SIOUX CITY | IA | 2,838 | \$174,952.76 | \$218.69 | 78 |
| 85 | WALMART PHARMACY 10-1496 | WATERLOO | IA | 1,464 | \$174,539.09 | \$519.46 | 100 |
| 86 | HY-VEE PHARMACY (1530) | PLEASANT HILL | IA | 2,254 | \$173,410.82 | \$476.40 | 93 |
| 87 | ARJ INFUSION SERVICES, LLC | CEDAR RAPIDS | IA | 14 | \$171,752.46 | \$85,876.23 | 50 |
| 88 | HY-VEE DRUGSTORE (7056) | MASON CITY | IA | 2,010 | \$169,284.37 | \$438.56 | 80 |

**TOP 100 PHARMACIES BY PAID AMOUNT
202512 - 202602**

| RANK | PHARMACY NAME | PHARMACY CITY | PHARMACY STATE | PRESCRIPTION COUNT | PAID AMT | AVG COST MEMBER | PREVIOUS RANK |
|------|--|---------------|----------------|--------------------|--------------|-----------------|---------------|
| 89 | CVS PHARMACY #08658 | DAVENPORT | IA | 2,197 | \$168,901.81 | \$464.02 | 105 |
| 90 | WALMART PHARMACY 10-2889 | CLINTON | IA | 2,458 | \$166,469.32 | \$389.86 | 89 |
| 91 | GENOA HEALTHCARE, LLC | MASON CITY | IA | 779 | \$165,797.33 | \$1,842.19 | 74 |
| 92 | WALMART PHARMACY 10-0581 | MARSHALLTOWN | IA | 1,590 | \$165,609.41 | \$495.84 | 99 |
| 93 | HY-VEE PHARMACY (1180) | FAIRFIELD | IA | 1,933 | \$165,476.38 | \$622.09 | 84 |
| 94 | HY-VEE PHARMACY #4 (1148) | DES MOINES | IA | 2,458 | \$163,906.32 | \$433.61 | 92 |
| 95 | WALMART PHARMACY 10-1393 | OSKALOOSA | IA | 1,758 | \$161,829.02 | \$603.84 | 88 |
| 96 | HY-VEE PHARMACY #5 (1061) | CEDAR RAPIDS | IA | 2,136 | \$160,757.62 | \$444.08 | 98 |
| 97 | WALGREENS #359 | DES MOINES | IA | 2,344 | \$159,943.91 | \$226.23 | 94 |
| 98 | WALGREENS #11942 | DUBUQUE | IA | 1,787 | \$159,106.51 | \$425.42 | 161 |
| 99 | GENOA HEALTHCARE, LLC | SIOUX CITY | IA | 686 | \$156,889.85 | \$2,659.15 | 123 |
| 100 | MAIN AT LOCUST PHARMACY AND MEDICAL SUPPLY | DAVENPORT | IA | 1,954 | \$156,743.46 | \$880.58 | 95 |

TOP PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
202512 - 202602

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS PER MEMBER | PREVIOUS RANK |
|------|------------|---------------------|--------------|--------------------|------------------------|---------------|
| 1 | 1982605762 | Jeffrey Wilharm | \$63,779.54 | 1,265 | 19.77 | 1 |
| 2 | 1528365277 | Mina Salib | \$342,214.88 | 1,110 | 4.49 | 3 |
| 3 | 1013115369 | Bobbita Nag | \$35,840.71 | 1,087 | 6.21 | 4 |
| 4 | 1356359871 | Rhea Hartley | \$58,999.20 | 995 | 5.18 | 2 |
| 5 | 1659358620 | Carlos Castillo | \$23,055.96 | 961 | 7.12 | 9 |
| 6 | 1730849647 | Melanie Parrish | \$34,130.05 | 950 | 7.31 | 8 |
| 7 | 1811419815 | Gretchen Wenger | \$76,532.02 | 829 | 5.92 | 6 |
| 8 | 1306559786 | Roy Henry | \$31,294.79 | 820 | 8.20 | 19 |
| 9 | 1417941188 | Debra Neuharth | \$62,259.14 | 805 | 7.12 | 15 |
| 10 | 1053630640 | Jennifer Donovan | \$138,813.49 | 801 | 6.21 | 28 |
| 11 | 1992402655 | Shane Eberhardt | \$174,209.98 | 790 | 5.68 | 10 |
| 12 | 1902478811 | Joan Anderson | \$140,101.81 | 783 | 7.99 | 20 |
| 13 | 1770933046 | Shelby Biller | \$92,026.78 | 769 | 7.61 | 11 |
| 14 | 1215125216 | Rebecca Walding | \$71,288.00 | 760 | 8.35 | 18 |
| 15 | 1619153137 | Joada Best | \$64,664.12 | 757 | 7.01 | 13 |
| 16 | 1811960768 | Angela Veenstra | \$43,452.58 | 725 | 9.93 | 34 |
| 17 | 1699361949 | Nicholas Jensen | \$92,758.62 | 719 | 9.34 | 74 |
| 18 | 1275763047 | Rebecca Bowman | \$105,216.10 | 716 | 8.95 | 21 |
| 19 | 1649248378 | Kathleen Wild | \$18,419.95 | 713 | 8.70 | 30 |
| 20 | 1467907394 | Cynthia Coenen | \$81,763.01 | 712 | 10.17 | 12 |
| 21 | 1609532373 | Erin Fox-Hammel | \$51,944.56 | 711 | 10.46 | 27 |
| 22 | 1801998372 | Wendy Hansen-Penman | \$34,082.75 | 698 | 8.84 | 16 |
| 23 | 1821268335 | Jacqueline Mcinnis | \$102,718.30 | 690 | 13.02 | 14 |
| 24 | 1598183493 | Jena Ellerhoff | \$39,642.57 | 683 | 11.38 | 26 |
| 25 | 1538368170 | Christopher Matson | \$37,441.41 | 681 | 8.62 | 17 |
| 26 | 1679573893 | Patty Hildreth | \$117,646.44 | 680 | 7.73 | 47 |
| 27 | 1457914657 | Seema Antony | \$58,017.24 | 679 | 6.53 | 42 |
| 28 | 1245960350 | Mary Welborn | \$41,668.37 | 678 | 5.75 | 53 |
| 29 | 1205393386 | Jessica Hudspeth | \$68,146.83 | 675 | 8.54 | 45 |
| 30 | 1538149042 | Eric Petersen | \$25,966.81 | 673 | 5.70 | 29 |
| 31 | 1043434525 | Robert Kent | \$49,195.74 | 672 | 6.86 | 24 |
| 32 | 1265841845 | Mary Schwering | \$79,232.50 | 670 | 7.61 | 48 |
| 33 | 1184056822 | Abby Kolthoff | \$352,877.00 | 664 | 6.64 | 5 |
| 34 | 1801463245 | Ann Mojeiko | \$81,719.11 | 663 | 6.70 | 59 |
| 35 | 1477199198 | Sajo Thomas | \$127,570.53 | 657 | 7.82 | 23 |
| 36 | 1992103386 | Melissa Larsen | \$82,352.15 | 654 | 8.07 | 22 |
| 37 | 1689077018 | Stacy Roth | \$111,433.32 | 637 | 6.37 | 35 |
| 38 | 1154815330 | Bruce Pehl | \$33,113.78 | 637 | 6.85 | 31 |
| 39 | 1902358443 | Melissa Konken | \$114,931.86 | 632 | 7.90 | 32 |
| 40 | 1164538674 | Joseph Wanzek | \$102,657.26 | 628 | 10.30 | 25 |
| 41 | 1023542271 | Flynn McCullough | \$93,234.49 | 621 | 7.76 | 49 |
| 42 | 1992314108 | Lynzee Makowski | \$929,218.33 | 610 | 5.55 | 50 |
| 43 | 1053963900 | Nicole McClavy | \$91,335.66 | 609 | 6.77 | 52 |
| 44 | 1114681889 | Kelsey Bauer | \$50,378.13 | 608 | 8.44 | 44 |

TOP PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
202512 - 202602

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS PER MEMBER | PREVIOUS RANK |
|------|------------|-----------------------|--------------|--------------------|------------------------|---------------|
| 45 | 1902912538 | Christian Jones | \$38,180.55 | 605 | 5.99 | 40 |
| 46 | 1528329398 | Erin Rowan | \$36,805.84 | 587 | 6.52 | 39 |
| 47 | 1407415128 | Sondra Philips | \$34,112.03 | 585 | 7.41 | 94 |
| 48 | 1255823506 | Nicole Delagardelle | \$102,882.98 | 583 | 6.14 | 43 |
| 49 | 1467092049 | Heidi Pedersen | \$77,185.52 | 582 | 8.43 | 93 |
| 50 | 1760965032 | Melissa Miller | \$41,551.84 | 581 | 7.09 | 61 |
| 51 | 1306475413 | Autumn Anderson | \$19,977.82 | 580 | 7.84 | 83 |
| 52 | 1215581251 | Anna Throckmorton | \$33,154.25 | 577 | 11.10 | 73 |
| 53 | 1720698335 | Danika Hansen | \$73,270.10 | 575 | 6.05 | 46 |
| 54 | 1457584740 | Eric Meyer | \$37,692.75 | 570 | 4.42 | 7 |
| 55 | 1891306452 | Jennifer Tomlin | \$38,903.96 | 567 | 5.91 | 64 |
| 56 | 1073156295 | Kasie Christensen | \$41,729.43 | 566 | 6.66 | 117 |
| 57 | 1215981758 | Lisa Pisney | \$73,056.02 | 563 | 6.70 | 37 |
| 58 | 1477926434 | Jackie Shipley | \$31,298.98 | 557 | 5.06 | 54 |
| 59 | 1689325524 | Brian Ayersman | \$70,713.57 | 553 | 6.83 | 226 |
| 60 | 1679669832 | Erin Hatcher | \$114,616.11 | 552 | 5.87 | 491 |
| 61 | 1841220290 | Kent Kunze | \$11,151.40 | 547 | 7.60 | 58 |
| 62 | 1467502286 | Charles Tilley | \$48,640.03 | 544 | 6.55 | 38 |
| 63 | 1992573786 | Lashelle Goode | \$29,583.46 | 544 | 6.04 | 67 |
| 64 | 1649763079 | Kate Jarvis | \$80,410.02 | 543 | 5.90 | 33 |
| 65 | 1942721584 | Shawna Fury | \$30,644.07 | 543 | 5.22 | 60 |
| 66 | 1831710987 | Margaret White | \$51,013.22 | 537 | 7.90 | 110 |
| 67 | 1043703887 | Tenaea Jeppeson | \$50,552.45 | 532 | 7.82 | 55 |
| 68 | 1821333774 | Brittni Benda | \$47,022.24 | 526 | 4.42 | 65 |
| 69 | 1891146999 | Becky Johnson | \$528,413.56 | 522 | 7.57 | 86 |
| 70 | 1477045797 | Chantal Rozmus | \$67,815.57 | 519 | 6.11 | 84 |
| 71 | 1184657603 | Sara Rygol | \$56,587.51 | 519 | 6.11 | 68 |
| 72 | 1417241621 | Ashley Mathes | \$25,180.10 | 519 | 5.77 | 56 |
| 73 | 1144214248 | Kristi Walz | \$101,527.93 | 515 | 7.57 | 71 |
| 74 | 1588746515 | Amy Badberg | \$35,026.45 | 514 | 7.14 | 63 |
| 75 | 1891422606 | Emily Clawson | \$52,987.24 | 513 | 5.83 | 66 |
| 76 | 1144588476 | Rachel Filzer | \$67,716.34 | 511 | 6.55 | 75 |
| 77 | 1619380680 | Tara Brockman | \$45,640.29 | 509 | 6.61 | 72 |
| 78 | 1881095503 | Karoweso Chipendo | \$36,788.64 | 507 | 6.58 | 157 |
| 79 | 1437238110 | Genevieve Nelson | \$106,020.41 | 506 | 9.04 | 51 |
| 80 | 1750845954 | Stephanie Giesler | \$101,227.31 | 506 | 8.16 | 69 |
| 81 | 1245227099 | Donna Dobson Tobin | \$69,151.14 | 499 | 9.60 | 78 |
| 82 | 1922455096 | Dean Guerdet | \$62,163.55 | 492 | 6.15 | 36 |
| 83 | 1356724405 | Beth Colon | \$29,218.30 | 490 | 4.95 | 77 |
| 84 | 1871021543 | Susan Wilson | \$45,751.04 | 489 | 7.30 | 116 |
| 85 | 1871598557 | Christopher Vandelune | \$19,875.36 | 489 | 5.26 | 251 |
| 86 | 1336853415 | Katherine Lowary | \$37,665.38 | 488 | 13.94 | 95 |
| 87 | 1134191018 | Dustin Smith | \$32,337.91 | 488 | 5.30 | 92 |
| 88 | 1609946243 | Sina Linman | \$23,552.41 | 488 | 5.81 | 88 |

**TOP PRESCRIBING PROVIDERS BY PRESCRIPTION COUNT
202512 - 202602**

| RANK | NPI NUM | PRESCRIBER NAME | PAID AMOUNT | PRESCRIPTION COUNT | AVG SCRIPTS PER MEMBER | PREVIOUS RANK |
|------|------------|-------------------|--------------|--------------------|------------------------|---------------|
| 89 | 1477534279 | Edmund Piasecki | \$40,227.26 | 487 | 6.32 | 123 |
| 90 | 1891707832 | Lisa Klock | \$29,436.81 | 487 | 5.53 | 96 |
| 91 | 1043418809 | Michael Ciliberto | \$266,998.77 | 485 | 7.46 | 81 |
| 92 | 1437345857 | Danielle Wendel | \$19,412.85 | 484 | 4.75 | 118 |
| 93 | 1922144088 | Thomas Hopkins | \$16,061.32 | 483 | 4.51 | 98 |
| 94 | 1326443342 | Sharon Pitt | \$31,811.61 | 481 | 7.52 | 97 |
| 95 | 1427766559 | Korie Eischeid | \$24,010.50 | 479 | 5.91 | 103 |
| 96 | 1053398800 | Steven Scurr | \$22,926.59 | 477 | 6.19 | 90 |
| 97 | 1821600594 | Carrie Goodwin | \$94,781.12 | 475 | 9.69 | 135 |
| 98 | 1902384118 | Nichole O'brien | \$58,739.24 | 475 | 6.09 | 87 |
| 99 | 1831731298 | Heather Wilson | \$31,146.77 | 475 | 6.60 | 89 |
| 100 | 1790135176 | Emily Reiter | \$46,855.75 | 473 | 5.77 | 131 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
202512 - 202602

| RANK | DOCTOR NUM | PRESCRIBER NAME | PRESCRIPTION COUNT | PAID AMOUNT | AVG COST RX | PREVIOUS RANK |
|------|------------|---------------------|--------------------|--------------|-------------|---------------|
| 1 | 1992314108 | Lynzee Makowski | 610 | \$929,218.33 | \$1,523.31 | 2 |
| 2 | 1326034984 | Katherine Mathews | 68 | \$814,694.45 | \$11,980.80 | 1 |
| 3 | 1316934318 | Steven Lentz | 34 | \$722,302.87 | \$21,244.20 | 4 |
| 4 | 1780788844 | Tammy Wichman | 46 | \$599,945.13 | \$13,042.29 | 3 |
| 5 | 1477761328 | Amy Calhoun | 50 | \$563,137.85 | \$11,262.76 | 17 |
| 6 | 1295091510 | Rebecca Weiner | 266 | \$535,647.26 | \$2,013.71 | 5 |
| 7 | 1942937388 | Carly Trausch | 444 | \$532,944.54 | \$1,200.33 | 7 |
| 8 | 1891146999 | Becky Johnson | 522 | \$528,413.56 | \$1,012.29 | 8 |
| 9 | 1285626390 | Kathleen Gradoville | 187 | \$507,393.32 | \$2,713.33 | 12 |
| 10 | 1417443953 | Rodney Clark | 343 | \$489,956.78 | \$1,428.45 | 9 |
| 11 | 1013126705 | Janice Staber | 39 | \$450,185.43 | \$11,543.22 | 13 |
| 12 | 1437121407 | Linda Cadaret | 99 | \$437,229.06 | \$4,416.46 | 14 |
| 13 | 1114214541 | Dimah Saade | 26 | \$393,749.03 | \$15,144.19 | 11 |
| 14 | 1700561826 | Pedro Hsieh | 51 | \$382,252.54 | \$7,495.15 | 42 |
| 15 | 1033221916 | Adrian Letz | 55 | \$380,548.65 | \$6,919.07 | 20 |
| 16 | 1952539447 | Anthony Fischer | 169 | \$373,924.00 | \$2,212.57 | 26 |
| 17 | 1184056822 | Abby Kolthoff | 664 | \$352,877.00 | \$531.44 | 10 |
| 18 | 1528365277 | Mina Salib | 1,110 | \$342,214.88 | \$308.30 | 33 |
| 19 | 1215333091 | Nadia Naz | 205 | \$332,817.05 | \$1,623.50 | 16 |
| 20 | 1700417169 | Courtney Reints | 216 | \$325,852.46 | \$1,508.58 | 15 |
| 21 | 1376777383 | Jonathon Hennings | 51 | \$312,316.34 | \$6,123.85 | 18 |
| 22 | 1669184511 | Chandra Miller | 27 | \$298,104.24 | \$11,040.90 | 6270 |
| 23 | 1356753859 | Katie Lutz | 122 | \$291,045.53 | \$2,385.62 | 22 |
| 24 | 1326211889 | James Friedlander | 55 | \$285,605.96 | \$5,192.84 | 64 |
| 25 | 1861277980 | Kathryn Ewoldt | 319 | \$280,824.65 | \$880.33 | 23 |
| 26 | 1043418809 | Michael Ciliberto | 485 | \$266,998.77 | \$550.51 | 19 |
| 27 | 1467449579 | Brian Wayson | 93 | \$264,422.32 | \$2,843.25 | 47 |
| 28 | 1609131770 | Sreenath Ganganna | 266 | \$248,524.12 | \$934.30 | 35 |
| 29 | 1275836751 | Holly Kramer | 119 | \$247,980.97 | \$2,083.87 | 59 |
| 30 | 1558808501 | Jessica Braksiek | 31 | \$247,760.51 | \$7,992.27 | 29 |
| 31 | 1568097244 | Elizabeth Dassow | 112 | \$244,594.72 | \$2,183.88 | 31 |
| 32 | 1225263833 | Lindsay Orris | 73 | \$216,141.99 | \$2,960.85 | 30 |
| 33 | 1588616171 | Heather Thomas | 101 | \$214,022.64 | \$2,119.04 | 24 |
| 34 | 1407065469 | Christoph Randak | 259 | \$211,459.48 | \$816.45 | 45 |
| 35 | 1326410499 | Tara Eastvold | 295 | \$210,411.77 | \$713.26 | 6 |
| 36 | 1134981038 | Cassidy Chalupa | 82 | \$208,262.34 | \$2,539.78 | 51 |
| 37 | 1649943689 | Jessica Wolfe | 159 | \$208,121.44 | \$1,308.94 | 32 |
| 38 | 1235792912 | Faraaz Zafar | 95 | \$205,458.12 | \$2,162.72 | 52 |
| 39 | 1134249832 | Steven Craig | 86 | \$199,529.51 | \$2,320.11 | 37 |
| 40 | 1043565328 | Sara Moeller | 62 | \$197,118.38 | \$3,179.33 | 53 |
| 41 | 1366065047 | Brittania Schoon | 92 | \$196,880.49 | \$2,140.01 | 48 |
| 42 | 1508148511 | Yogesh Reddy | 14 | \$193,858.42 | \$13,847.03 | 109 |
| 43 | 1538693700 | Kamel Shibbani | 42 | \$190,790.48 | \$4,542.63 | 219 |
| 44 | 1437147386 | Douglas Hornick | 78 | \$189,041.32 | \$2,423.61 | 50 |

**TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
202512 - 202602**

| RANK | DOCTOR NUM | PRESCRIBER NAME | PRESCRIPTION COUNT | PAID AMOUNT | AVG COST RX | PREVIOUS RANK |
|------|------------|-----------------------|--------------------|--------------|-------------|---------------|
| 45 | 1649419219 | Heather Hunemuller | 144 | \$188,238.37 | \$1,307.21 | 55 |
| 46 | 1447519038 | Erin Richardson | 158 | \$181,573.32 | \$1,149.20 | 49 |
| 47 | 1578958542 | Heidi Curtis | 156 | \$181,432.16 | \$1,163.03 | 54 |
| 48 | 1306071915 | Thomas Pietras | 63 | \$178,343.57 | \$2,830.85 | 77 |
| 49 | 1730406356 | Christina Warren | 133 | \$178,139.37 | \$1,339.39 | 39 |
| 50 | 1356445886 | Megan Eisel | 131 | \$177,644.41 | \$1,356.06 | 57 |
| 51 | 1891158275 | Andrew Groves | 31 | \$177,080.77 | \$5,712.28 | 651 |
| 52 | 1649826140 | Taylor Myers | 166 | \$175,590.74 | \$1,057.78 | 72 |
| 53 | 1235518507 | Adekunle Ajisebutu | 16 | \$175,331.96 | \$10,958.25 | 40 |
| 54 | 1598786097 | Stephanie Gray | 449 | \$174,973.84 | \$389.70 | 83 |
| 55 | 1093162075 | Meghan Ryan | 93 | \$174,849.54 | \$1,880.10 | 28 |
| 56 | 1992402655 | Shane Eberhardt | 790 | \$174,209.98 | \$220.52 | 44 |
| 57 | 1255658175 | Ashley Deschamp | 70 | \$164,514.08 | \$2,350.20 | 38 |
| 58 | 1841548161 | Crystal Meyer | 62 | \$158,623.94 | \$2,558.45 | 68 |
| 59 | 1356752067 | Kelly Delaney-Nelson | 45 | \$157,676.35 | \$3,503.92 | 63 |
| 60 | 1376525196 | Randolph Rough | 59 | \$157,428.58 | \$2,668.28 | 58 |
| 61 | 1780029090 | Divya Pati | 168 | \$155,382.55 | \$924.90 | 41 |
| 62 | 1356577951 | Christopher Mulder | 47 | \$153,147.02 | \$3,258.45 | 27 |
| 63 | 1144110909 | Julia Baray Alvarado | 326 | \$149,900.08 | \$459.82 | 528 |
| 64 | 1851568703 | Mathew Davey | 39 | \$149,002.45 | \$3,820.58 | 69 |
| 65 | 1043429087 | Kayelyn Wagner | 15 | \$145,860.41 | \$9,724.03 | 360 |
| 66 | 1417449570 | Alex Sieg | 25 | \$144,884.59 | \$5,795.38 | 46 |
| 67 | 1477968303 | Joseph Larson | 237 | \$144,437.65 | \$609.44 | 25 |
| 68 | 1386084747 | Jennifer Condon | 124 | \$143,505.65 | \$1,157.30 | 66 |
| 69 | 1912208323 | Lisa Meyer | 330 | \$142,750.36 | \$432.58 | 61 |
| 70 | 1336346352 | Hanna Zembrzuska | 52 | \$141,042.11 | \$2,712.35 | 70 |
| 71 | 1871979823 | Molly Garber | 78 | \$140,357.61 | \$1,799.46 | 730 |
| 72 | 1902478811 | Joan Anderson | 783 | \$140,101.81 | \$178.93 | 62 |
| 73 | 1962497438 | Sheryl Mulder | 30 | \$139,918.13 | \$4,663.94 | 284 |
| 74 | 1003315201 | Abigail Behrens | 49 | \$139,108.95 | \$2,838.96 | 56 |
| 75 | 1053630640 | Jennifer Donovan | 801 | \$138,813.49 | \$173.30 | 119 |
| 76 | 1780995506 | Quanhathai Kaewpoowat | 55 | \$138,226.31 | \$2,513.21 | 112 |
| 77 | 1114521721 | Tarrah Holliday | 438 | \$137,557.75 | \$314.06 | 85 |
| 78 | 1093382632 | Gail Dooley | 139 | \$137,398.94 | \$988.48 | 76 |
| 79 | 1366809923 | Kelly Hoover | 432 | \$136,220.99 | \$315.33 | 125 |
| 80 | 1245353242 | Sandy Hong | 82 | \$133,715.85 | \$1,630.68 | 92 |
| 81 | 1164630216 | Andrea Swenson | 14 | \$133,390.25 | \$9,527.88 | 106 |
| 82 | 1972560597 | Bernard Leman | 27 | \$133,324.45 | \$4,937.94 | 105 |
| 83 | 1952423071 | Sakeer Hussain | 24 | \$132,452.28 | \$5,518.85 | 178 |
| 84 | 1912979261 | David Visokey | 100 | \$129,488.49 | \$1,294.88 | 79 |
| 85 | 1578132940 | Alec Steils | 283 | \$128,918.59 | \$455.54 | 84 |
| 86 | 1629342662 | Rosa Stocker | 65 | \$127,804.36 | \$1,966.22 | 82 |
| 87 | 1477199198 | Sajo Thomas | 657 | \$127,570.53 | \$194.17 | 88 |
| 88 | 1669443230 | Kenneth Adams | 50 | \$126,604.67 | \$2,532.09 | 140 |

TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
202512 - 202602

| RANK | DOCTOR NUM | PRESCRIBER NAME | PRESCRIPTION COUNT | PAID AMOUNT | AVG COST RX | PREVIOUS RANK |
|------|------------|--------------------|--------------------|--------------|-------------|---------------|
| 89 | 1477765584 | Sangeeta Shah | 340 | \$126,575.62 | \$372.28 | 74 |
| 90 | 1841182052 | Aksana Tharp | 427 | \$124,468.42 | \$291.50 | 465 |
| 91 | 1023108701 | Ronald Zolty | 69 | \$123,940.56 | \$1,796.24 | 182 |
| 92 | 1427464379 | Akhila Ramakrishna | 93 | \$122,958.87 | \$1,322.14 | 622 |
| 93 | 1992921779 | Radha Andukuri | 29 | \$122,006.78 | \$4,207.13 | 174 |
| 94 | 1871892455 | David Claassen | 95 | \$121,407.17 | \$1,277.97 | 161 |
| 95 | 1790005064 | Christopher Sales | 23 | \$120,363.40 | \$5,233.19 | 7041 |
| 96 | 1659108090 | Teresa Hanson | 346 | \$120,312.70 | \$347.72 | 304 |
| 97 | 1255058640 | Shelli Brown | 458 | \$118,521.24 | \$258.78 | 115 |
| 98 | 1679573893 | Patty Hildreth | 680 | \$117,646.44 | \$173.01 | 98 |
| 99 | 1891955423 | Leah Siegfried | 249 | \$116,985.73 | \$469.82 | 97 |
| 100 | 1386938447 | Theresa Czech | 209 | \$116,226.17 | \$556.11 | 172 |

TOP 20 THERAPEUTIC CLASS BY PAID AMOUNT

| CATEGORY DESCRIPTION | 202509 - 202511 | | | 202512 - 202602 | | | % CHANGE |
|--|---------------------|---------------|-------------------|--------------------|--------------|------------------|----------|
| | PREVIOUS TOTAL COST | PREVIOUS RANK | PREVIOUS % BUDGET | CURRENT TOTAL COST | CURRENT RANK | CURRENT % BUDGET | |
| ANTIDIABETICS | \$11,532,508.45 | 1 | 13.61 % | \$11,097,445.83 | 1 | 12.69 % | -0.92 % |
| DERMATOLOGICALS | \$9,955,662.31 | 2 | 11.75 % | \$10,007,026.58 | 2 | 11.44 % | -0.31 % |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | \$9,287,298.78 | 3 | 10.96 % | \$9,637,588.43 | 3 | 11.02 % | 0.06 % |
| ANALGESICS - ANTI-INFLAMMATORY | \$6,535,063.56 | 4 | 7.71 % | \$6,446,400.31 | 4 | 7.37 % | -0.34 % |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | \$4,187,413.50 | 6 | 4.94 % | \$4,532,625.93 | 5 | 5.18 % | 0.24 % |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | \$4,347,271.91 | 5 | 5.13 % | \$4,516,735.95 | 6 | 5.16 % | 0.03 % |
| RESPIRATORY AGENTS - MISC. | \$3,704,905.80 | 7 | 4.37 % | \$3,718,759.17 | 7 | 4.25 % | -0.12 % |
| ANTIVIRALS | \$3,071,232.46 | 9 | 3.62 % | \$3,571,332.43 | 8 | 4.08 % | 0.46 % |
| PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC | \$3,163,339.11 | 8 | 3.73 % | \$3,434,826.68 | 9 | 3.93 % | 0.19 % |
| ENDOCRINE AND METABOLIC AGENTS - MISC. | \$2,580,907.25 | 11 | 3.05 % | \$2,747,002.53 | 10 | 3.14 % | 0.10 % |
| ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES | \$2,760,774.06 | 10 | 3.26 % | \$2,732,081.86 | 11 | 3.12 % | -0.13 % |
| HEMATOLOGICAL AGENTS - MISC. | \$2,144,733.37 | 14 | 2.53 % | \$2,573,676.07 | 12 | 2.94 % | 0.41 % |
| ANTICONVULSANTS | \$2,476,522.37 | 12 | 2.92 % | \$2,570,843.25 | 13 | 2.94 % | 0.02 % |
| MIGRAINE PRODUCTS | \$2,292,589.44 | 13 | 2.71 % | \$2,363,364.61 | 14 | 2.70 % | 0.00 % |
| CARDIOVASCULAR AGENTS - MISC. | \$1,998,680.21 | 15 | 2.36 % | \$2,132,909.82 | 15 | 2.44 % | 0.08 % |
| NEUROMUSCULAR AGENTS | \$1,497,260.88 | 19 | 1.77 % | \$1,831,109.93 | 16 | 2.09 % | 0.33 % |
| ANTIDEPRESSANTS | \$1,733,296.10 | 16 | 2.05 % | \$1,669,644.95 | 17 | 1.91 % | -0.14 % |
| GASTROINTESTINAL AGENTS - MISC. | \$1,542,344.63 | 17 | 1.82 % | \$1,664,805.28 | 18 | 1.90 % | 0.08 % |
| ANTICOAGULANTS | \$1,519,275.63 | 18 | 1.79 % | \$1,264,887.67 | 19 | 1.45 % | -0.35 % |
| CORTICOSTEROIDS | \$542,099.66 | 20 | 0.64 % | \$672,332.19 | 20 | 0.77 % | 0.13 % |

TOP 20 THERAPEUTIC CLASS BY PRESCRIPTION COUNT

| CURRENT CATEGORY DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | % CHANGE |
|---|-----------------|---------------|-----------------|--------------|----------|
| | PREVIOUS CLAIMS | PREVIOUS RANK | CURRENT CLAIMS | CURRENT RANK | |
| ANTIDEPRESSANTS | 78,051 | 1 | 78,645 | 1 | 0.76 % |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | 38,206 | 3 | 40,322 | 2 | 5.54 % |
| ANTICONVULSANTS | 38,466 | 2 | 38,626 | 3 | 0.42 % |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | 36,377 | 4 | 36,064 | 4 | -0.86 % |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | 30,429 | 5 | 31,180 | 5 | 2.47 % |
| ANTIDIABETICS | 30,425 | 6 | 30,576 | 6 | 0.50 % |
| ANTIANSXIETY AGENTS | 28,053 | 8 | 28,828 | 7 | 2.76 % |
| ANTIHYPERTENSIVES | 28,122 | 7 | 28,072 | 8 | -0.18 % |
| ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | 26,191 | 9 | 24,539 | 9 | -6.31 % |
| PENICILLINS | 15,470 | 13 | 19,294 | 10 | 24.72 % |
| DERMATOLOGICALS | 18,850 | 11 | 18,388 | 11 | -2.45 % |
| ANTIHISTAMINES | 18,929 | 10 | 17,611 | 12 | -6.96 % |
| ANTIHYPERTENSIVES | 16,647 | 12 | 16,310 | 13 | -2.02 % |
| ANALGESICS - ANTI-INFLAMMATORY | 14,782 | 14 | 14,703 | 14 | -0.53 % |
| ANALGESICS - OPIOID | 13,955 | 15 | 14,053 | 15 | 0.70 % |
| BETA BLOCKERS | 13,326 | 16 | 12,969 | 16 | -2.68 % |
| CORTICOSTEROIDS | 11,026 | 17 | 11,103 | 17 | 0.70 % |
| MUSCULOSKELETAL THERAPY AGENTS | 10,659 | 18 | 10,829 | 18 | 1.59 % |
| ANALGESICS - NonNarcotic | 9,674 | 20 | 10,061 | 19 | 4.00 % |
| DIURETICS | 9,466 | 21 | 9,438 | 20 | -0.30 % |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | PERCENT CHANGE |
|------------------|----------------------|---------------|---------------------|--------------|----------------|
| | PREVIOUS PAID AMOUNT | PREVIOUS RANK | CURRENT PAID AMOUNT | CURRENT RANK | |
| Ozempic | \$4,322,697.84 | 1 | \$4,574,706.36 | 1 | 5.83 % |
| Dupixent | \$3,548,934.60 | 2 | \$3,856,720.94 | 2 | 8.67 % |
| Humira Pen | \$3,227,376.48 | 3 | \$3,280,086.35 | 3 | 1.63 % |
| Vraylar | \$2,824,240.65 | 4 | \$2,977,143.27 | 4 | 5.41 % |
| Trikafta | \$2,740,516.27 | 5 | \$2,712,965.37 | 5 | -1.01 % |
| Mounjaro | \$1,540,211.57 | 10 | \$1,689,326.86 | 6 | 9.68 % |
| Invega Sust | \$1,764,874.61 | 7 | \$1,633,917.67 | 7 | -7.42 % |
| Skyrizi Pen | \$1,560,845.13 | 8 | \$1,633,258.16 | 8 | 4.64 % |
| Biktarvy | \$1,557,382.55 | 9 | \$1,616,719.64 | 9 | 3.81 % |
| Jardiance | \$2,042,143.21 | 6 | \$1,536,022.72 | 10 | -24.78 % |
| Duvyzat | \$842,649.45 | 16 | \$1,067,724.39 | 11 | 26.71 % |
| Rexulti | \$997,694.69 | 14 | \$1,013,217.59 | 12 | 1.56 % |
| Ingrezza | \$832,338.04 | 17 | \$1,006,318.44 | 13 | 20.90 % |
| Tremfya | \$702,335.57 | 20 | \$948,809.35 | 14 | 35.09 % |
| Taltz | \$1,049,690.30 | 12 | \$946,330.09 | 15 | -9.85 % |
| Trulicity | \$946,680.21 | 15 | \$908,908.58 | 16 | -3.99 % |
| Eliquis | \$1,095,546.36 | 11 | \$866,157.57 | 17 | -20.94 % |
| Caplyta | \$668,850.94 | 24 | \$809,993.52 | 18 | 21.10 % |
| Zepbound | \$539,359.51 | 33 | \$766,341.81 | 19 | 42.08 % |
| Stelara | \$1,035,974.98 | 13 | \$743,685.12 | 20 | -28.21 % |
| Aristada | \$711,788.98 | 19 | \$736,927.12 | 21 | 3.53 % |
| Rinvoq | \$631,798.50 | 26 | \$710,522.94 | 22 | 12.46 % |
| Nurtec | \$691,074.72 | 22 | \$677,875.06 | 23 | -1.91 % |
| Cosentyx Uno | \$670,513.72 | 23 | \$635,047.35 | 24 | -5.29 % |
| Altuviiio | \$702,005.79 | 21 | \$622,593.62 | 25 | -11.31 % |
| Abilify Main | \$546,046.32 | 31 | \$593,266.29 | 26 | 8.65 % |
| Symbicort | \$579,161.01 | 28 | \$588,758.58 | 27 | 1.66 % |
| Skyrizi | \$390,335.65 | 43 | \$558,473.85 | 28 | 43.08 % |
| Invega Trinz | \$539,391.04 | 32 | \$550,740.16 | 29 | 2.10 % |
| Winrevair | \$505,254.15 | 34 | \$543,892.21 | 30 | 7.65 % |
| Ilaris | \$640,885.90 | 25 | \$525,137.04 | 31 | -18.06 % |
| Trelegy | \$454,881.03 | 37 | \$523,977.57 | 32 | 15.19 % |
| Lisdexanfeta | \$628,921.77 | 27 | \$522,746.79 | 33 | -16.88 % |
| Austedo Xr | \$469,079.88 | 36 | \$521,316.29 | 34 | 11.14 % |
| Enbrel Srcl | \$555,097.86 | 30 | \$504,995.47 | 35 | -9.03 % |
| Jornay Pm | \$471,185.95 | 35 | \$495,542.41 | 36 | 5.17 % |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | PERCENT CHANGE |
|------------------|----------------------|---------------|---------------------|--------------|----------------|
| | PREVIOUS PAID AMOUNT | PREVIOUS RANK | CURRENT PAID AMOUNT | CURRENT RANK | |
| Lybalvi | \$443,214.36 | 39 | \$487,962.25 | 37 | 10.10 % |
| Wakix | \$396,642.61 | 42 | \$485,931.91 | 38 | 22.51 % |
| Mavyret | \$294,299.52 | 60 | \$483,073.21 | 39 | 64.14 % |
| Trintellix | \$446,564.48 | 38 | \$454,472.26 | 40 | 1.77 % |
| Ubrelvy | \$381,673.38 | 45 | \$451,179.08 | 41 | 18.21 % |
| Epidiolex | \$373,315.82 | 47 | \$444,638.46 | 42 | 19.11 % |
| Farxiga | \$567,677.22 | 29 | \$441,036.90 | 43 | -22.31 % |
| Kisqali | \$351,615.77 | 53 | \$435,670.86 | 44 | 23.91 % |
| Ajovy | \$423,761.49 | 41 | \$425,804.47 | 45 | 0.48 % |
| Norditropin | \$343,129.55 | 55 | \$425,338.44 | 46 | 23.96 % |
| Strensiq | \$720,826.30 | 18 | \$421,098.15 | 47 | -41.58 % |
| Albuterol | \$431,970.21 | 40 | \$416,409.80 | 48 | -3.60 % |
| Xywav | \$349,482.60 | 54 | \$403,389.49 | 49 | 15.42 % |
| Hemlibra | \$117,665.67 | 132 | \$380,963.34 | 50 | 223.77 % |
| Qelbree | \$364,502.35 | 49 | \$380,707.27 | 51 | 4.45 % |
| Kesimpta | \$358,057.97 | 51 | \$370,455.35 | 52 | 3.46 % |
| Fintepla | \$306,237.22 | 58 | \$369,370.54 | 53 | 20.62 % |
| Xarelto | \$382,137.31 | 44 | \$361,444.95 | 54 | -5.41 % |
| Crenessity | \$351,992.67 | 52 | \$355,442.67 | 55 | 0.98 % |
| Takhzyro | \$369,012.63 | 48 | \$346,612.82 | 56 | -6.07 % |
| Opsumit | \$376,002.69 | 46 | \$339,450.12 | 57 | -9.72 % |
| Xolair | \$231,373.70 | 77 | \$332,525.44 | 58 | 43.72 % |
| Qulipta | \$334,588.58 | 57 | \$330,774.88 | 59 | -1.14 % |
| Bimzelx | \$269,526.93 | 65 | \$327,822.45 | 60 | 21.63 % |
| Evrysdi | \$269,330.70 | 66 | \$315,072.14 | 61 | 16.98 % |
| Skyclarys | \$341,412.98 | 56 | \$302,648.73 | 62 | -11.35 % |
| Insulin Lisp | \$259,163.26 | 68 | \$301,346.16 | 63 | 16.28 % |
| Methylphenid | \$279,621.94 | 61 | \$292,807.98 | 64 | 4.72 % |
| Abilify Asim | \$272,001.70 | 63 | \$289,863.98 | 65 | 6.57 % |
| Livmarli | \$271,731.09 | 64 | \$288,825.50 | 66 | 6.29 % |
| Uptravi | \$155,241.79 | 111 | \$288,427.29 | 67 | 85.79 % |
| Skytrofa | \$234,194.89 | 76 | \$287,914.88 | 68 | 22.94 % |
| Tezspire | \$177,168.52 | 95 | \$264,366.36 | 69 | 49.22 % |
| Spiriva Resp | \$262,887.92 | 67 | \$264,279.64 | 70 | 0.53 % |
| Ruconest | \$129,210.63 | 123 | \$262,341.26 | 71 | 103.03 % |
| Advair Hfa | \$254,876.10 | 70 | \$256,282.81 | 72 | 0.55 % |

TOP 100 DRUGS BY PAID AMOUNT

| DRUG DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | PERCENT CHANGE |
|------------------|----------------------|---------------|---------------------|--------------|----------------|
| | PREVIOUS PAID AMOUNT | PREVIOUS RANK | CURRENT PAID AMOUNT | CURRENT RANK | |
| Alyftrek | \$255,733.65 | 69 | \$255,733.65 | 73 | 0.00 % |
| Lantus Solos | \$249,849.31 | 71 | \$255,410.20 | 74 | 2.23 % |
| Uzedy | \$188,281.75 | 90 | \$242,734.28 | 75 | 28.92 % |
| Amphet/dextr | \$239,553.40 | 74 | \$241,878.22 | 76 | 0.97 % |
| Adynovate | \$115,516.71 | 136 | \$237,283.66 | 77 | 105.41 % |
| Valtoco | \$236,131.61 | 75 | \$237,180.59 | 78 | 0.44 % |
| Pulmozyme | \$195,197.05 | 86 | \$232,656.06 | 79 | 19.19 % |
| Otezla | \$178,877.05 | 94 | \$225,456.15 | 80 | 26.04 % |
| Emgality | \$197,531.43 | 84 | \$223,262.92 | 81 | 13.03 % |
| Quillichew | \$205,387.64 | 82 | \$202,940.69 | 82 | -1.19 % |
| Voxzogo | \$230,234.41 | 78 | \$202,275.78 | 83 | -12.14 % |
| Briviact | \$178,925.38 | 93 | \$196,206.23 | 84 | 9.66 % |
| Orkambi | \$223,777.76 | 79 | \$196,168.98 | 85 | -12.34 % |
| Linzess | \$272,988.91 | 62 | \$194,600.54 | 86 | -28.71 % |
| Agamree | \$90,672.52 | 168 | \$194,458.69 | 87 | 114.46 % |
| Promacta | \$197,447.08 | 85 | \$191,278.15 | 88 | -3.12 % |
| Kalydeco | \$173,708.09 | 98 | \$190,737.14 | 89 | 9.80 % |
| Enbrel Mini | \$246,140.10 | 72 | \$187,298.55 | 90 | -23.91 % |
| Benlysta | \$161,302.87 | 108 | \$186,706.16 | 91 | 15.75 % |
| Sephience | \$60,010.63 | 229 | \$180,031.89 | 92 | 200.00 % |
| Lenvima | \$199,949.04 | 83 | \$177,951.41 | 93 | -11.00 % |
| Amoxicillin | \$130,315.15 | 122 | \$175,305.16 | 94 | 34.52 % |
| Creon | \$181,451.30 | 92 | \$172,858.27 | 95 | -4.74 % |
| Dovato | \$189,999.70 | 88 | \$172,628.52 | 96 | -9.14 % |
| Azstarys | \$172,079.43 | 100 | \$171,880.32 | 97 | -0.12 % |
| Descovy | \$165,220.23 | 104 | \$170,207.25 | 98 | 3.02 % |
| Breztri Aero | \$163,689.46 | 105 | \$169,322.38 | 99 | 3.44 % |
| Vyvanse | \$189,444.42 | 89 | \$166,235.91 | 100 | -12.25 % |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | PERCENT CHANGE |
|------------------|-----------------------------|---------------|----------------------------|--------------|----------------|
| | PREVIOUS PRESCRIPTION COUNT | PREVIOUS RANK | CURRENT PRESCRIPTION COUNT | CURRENT RANK | |
| Albuterol | 15,077 | 1 | 15,118 | 1 | 0.27 % |
| Amoxicillin | 9,912 | 6 | 12,989 | 2 | 31.04 % |
| Bupropion | 11,714 | 3 | 12,179 | 3 | 3.97 % |
| Trazodone | 11,854 | 2 | 12,110 | 4 | 2.16 % |
| Sertraline | 11,346 | 4 | 11,208 | 5 | -1.22 % |
| Amphet/dextr | 9,818 | 7 | 10,327 | 6 | 5.18 % |
| Fluoxetine | 9,652 | 8 | 9,871 | 7 | 2.27 % |
| Omeprazole | 10,865 | 5 | 9,860 | 8 | -9.25 % |
| Hydroxyz Hcl | 8,985 | 13 | 9,082 | 9 | 1.08 % |
| Methylphenid | 8,717 | 15 | 9,079 | 10 | 4.15 % |
| Escitalopram | 8,947 | 14 | 8,897 | 11 | -0.56 % |
| Atorvastatin | 9,102 | 11 | 8,805 | 12 | -3.26 % |
| Gabapentin | 8,994 | 12 | 8,716 | 13 | -3.09 % |
| Ondansetron | 6,729 | 22 | 8,532 | 14 | 26.79 % |
| Cetirizine | 9,157 | 10 | 8,373 | 15 | -8.56 % |
| Levothyroxin | 9,254 | 9 | 8,285 | 16 | -10.47 % |
| Bupirone | 7,994 | 16 | 8,255 | 17 | 3.26 % |
| Montelukast | 7,757 | 17 | 7,416 | 18 | -4.40 % |
| Quetiapine | 7,258 | 19 | 7,337 | 19 | 1.09 % |
| Metformin | 7,303 | 18 | 7,234 | 20 | -0.94 % |
| Clonidine | 6,949 | 20 | 7,106 | 21 | 2.26 % |
| Guanfacine | 6,602 | 23 | 6,880 | 22 | 4.21 % |
| Aripiprazole | 6,273 | 25 | 6,634 | 23 | 5.75 % |
| Lisinopril | 6,840 | 21 | 6,491 | 24 | -5.10 % |
| Prednisone | 6,311 | 24 | 6,410 | 25 | 1.57 % |
| Lamotrigine | 6,135 | 27 | 6,390 | 26 | 4.16 % |
| Amox/k Clav | 5,057 | 35 | 5,813 | 27 | 14.95 % |
| Duloxetine | 5,874 | 28 | 5,803 | 28 | -1.21 % |
| Pantoprazole | 6,146 | 26 | 5,797 | 29 | -5.68 % |
| Lisdexamfeta | 5,286 | 31 | 5,659 | 30 | 7.06 % |
| Azithromycin | 5,066 | 34 | 5,418 | 31 | 6.95 % |
| Ibuprofen | 4,699 | 41 | 5,136 | 32 | 9.30 % |
| Amlodipine | 5,166 | 32 | 5,111 | 33 | -1.06 % |
| Hydroco/apap | 5,129 | 33 | 5,060 | 34 | -1.35 % |
| Famotidine | 5,299 | 30 | 5,035 | 35 | -4.98 % |
| Cyclobenzapr | 4,947 | 37 | 4,994 | 36 | 0.95 % |
| Fluticasone | 5,328 | 29 | 4,956 | 37 | -6.98 % |
| Topiramate | 4,953 | 36 | 4,926 | 38 | -0.55 % |
| Ozempic | 4,637 | 42 | 4,801 | 39 | 3.54 % |
| Venlafaxine | 4,856 | 38 | 4,620 | 40 | -4.86 % |
| Metoprol Suc | 4,801 | 39 | 4,493 | 41 | -6.42 % |
| Loratadine | 4,792 | 40 | 4,372 | 42 | -8.76 % |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | PERCENT CHANGE |
|------------------|-----------------------------|---------------|----------------------------|--------------|----------------|
| | PREVIOUS PRESCRIPTION COUNT | PREVIOUS RANK | CURRENT PRESCRIPTION COUNT | CURRENT RANK | |
| Alprazolam | 4,108 | 46 | 4,197 | 43 | 2.17 % |
| Propranolol | 4,202 | 45 | 4,174 | 44 | -0.67 % |
| Risperidone | 4,103 | 47 | 4,165 | 45 | 1.51 % |
| Clonazepam | 4,233 | 44 | 4,143 | 46 | -2.13 % |
| Losartan Pot | 4,052 | 48 | 4,076 | 47 | 0.59 % |
| Aspirin Low | 4,380 | 43 | 4,075 | 48 | -6.96 % |
| Oseltamivir | 85 | 481 | 3,972 | 49 | 4572.94 % |
| Jardiance | 3,736 | 50 | 3,867 | 50 | 3.51 % |
| Cephalexin | 4,034 | 49 | 3,832 | 51 | -5.01 % |
| Cefdinir | 2,896 | 59 | 3,737 | 52 | 29.04 % |
| Rosuvastatin | 3,381 | 52 | 3,388 | 53 | 0.21 % |
| Mirtazapine | 3,269 | 53 | 3,378 | 54 | 3.33 % |
| Levetiraceta | 3,251 | 54 | 3,348 | 55 | 2.98 % |
| Meloxicam | 3,464 | 51 | 3,242 | 56 | -6.41 % |
| Prazosin Hcl | 3,187 | 55 | 3,222 | 57 | 1.10 % |
| Lorazepam | 3,147 | 57 | 3,168 | 58 | 0.67 % |
| Triamcinolon | 3,180 | 56 | 3,074 | 59 | -3.33 % |
| Folic Acid | 3,059 | 58 | 2,960 | 60 | -3.24 % |
| Hydroxyz Pam | 2,686 | 67 | 2,934 | 61 | 9.23 % |
| Oxycodone | 2,696 | 66 | 2,917 | 62 | 8.20 % |
| Pregabalin | 2,770 | 62 | 2,808 | 63 | 1.37 % |
| Lantus Solos | 2,771 | 61 | 2,795 | 64 | 0.87 % |
| Allergy Relf | 2,858 | 60 | 2,767 | 65 | -3.18 % |
| Furosemide | 2,741 | 63 | 2,702 | 66 | -1.42 % |
| Spirolact | 2,570 | 72 | 2,673 | 67 | 4.01 % |
| Symbicort | 2,619 | 70 | 2,656 | 68 | 1.41 % |
| Tramadol Hcl | 2,721 | 65 | 2,621 | 69 | -3.68 % |
| Metronidazol | 2,650 | 69 | 2,619 | 70 | -1.17 % |
| Fluconazole | 2,730 | 64 | 2,610 | 71 | -4.40 % |
| Ferosul | 2,585 | 71 | 2,603 | 72 | 0.70 % |
| Valacyclovir | 2,325 | 76 | 2,579 | 73 | 10.92 % |
| Prednisolone | 2,661 | 68 | 2,513 | 74 | -5.56 % |
| Atomoxetine | 2,414 | 73 | 2,479 | 75 | 2.69 % |
| Divalproex | 2,409 | 74 | 2,418 | 76 | 0.37 % |
| Olanzapine | 2,275 | 78 | 2,378 | 77 | 4.53 % |
| Acetamin | 2,266 | 79 | 2,331 | 78 | 2.87 % |
| Tizanidine | 2,342 | 75 | 2,303 | 79 | -1.67 % |
| Baclofen | 2,151 | 82 | 2,290 | 80 | 6.46 % |
| Dexmethylphe | 2,189 | 80 | 2,273 | 81 | 3.84 % |
| Insulin Lisp | 1,990 | 87 | 2,268 | 82 | 13.97 % |
| Hydrochlorot | 2,287 | 77 | 2,264 | 83 | -1.01 % |
| Eliquis | 2,084 | 84 | 2,176 | 84 | 4.41 % |

TOP 100 DRUGS BY PRESCRIPTION COUNT

| DRUG DESCRIPTION | 202509 - 202511 | | 202512 - 202602 | | PERCENT CHANGE |
|------------------|-----------------------------|---------------|----------------------------|--------------|----------------|
| | PREVIOUS PRESCRIPTION COUNT | PREVIOUS RANK | CURRENT PRESCRIPTION COUNT | CURRENT RANK | |
| Polyeth Glyc | 1,916 | 88 | 2,164 | 85 | 12.94 % |
| Vraylar | 2,030 | 86 | 2,095 | 86 | 3.20 % |
| Amitriptylin | 2,077 | 85 | 2,063 | 87 | -0.67 % |
| Clindamycin | 1,856 | 90 | 1,944 | 88 | 4.74 % |
| Mupirocin | 2,126 | 83 | 1,885 | 89 | -11.34 % |
| Desvenlafax | 1,688 | 96 | 1,807 | 90 | 7.05 % |
| Doxycyc Mono | 2,158 | 81 | 1,778 | 91 | -17.61 % |
| Naltrexone | 1,720 | 93 | 1,761 | 92 | 2.38 % |
| Sumatriptan | 1,707 | 94 | 1,760 | 93 | 3.10 % |
| Mounjaro | 1,597 | 100 | 1,724 | 94 | 7.95 % |
| Nystatin | 1,902 | 89 | 1,722 | 95 | -9.46 % |
| Oxcarbazepin | 1,734 | 92 | 1,693 | 96 | -2.36 % |
| Zolpidem | 1,702 | 95 | 1,648 | 97 | -3.17 % |
| Clopidogrel | 1,581 | 101 | 1,629 | 98 | 3.04 % |
| Citalopram | 1,635 | 99 | 1,555 | 99 | -4.89 % |
| Tamsulosin | 1,738 | 91 | 1,545 | 100 | -11.10 % |

| MOLINA HEALTHCARE OF IOWA CLAIMS QUARTERLY STATISTICS | | | |
|--|------------------------------|-----------------------------|-----------------|
| Category | Sept 2025 to Nov 2025 | Dec 2025 to Feb 2026 | % Change |
| Total paid Amount | \$61,634,913.39 | \$63,230,774.23 | 2.59% |
| Unique users | 76,623 | 81,854 | 6.83% |
| Cost Per user | \$804.39 | \$772.48 | -3.97% |
| Total prescriptions | 473,689 | 489,860 | 3.41% |
| Average Prescriptions per user | 6.18 | 5.98 | -3.19% |
| Average cost per prescription | \$130.12 | \$129.08 | -0.80% |
| # Generic Prescriptions | 427,724 | 442,453 | 3.44% |
| % Generic | 90.3% | 90.3% | 0.03% |
| \$ Generic | \$8,057,244.25 | \$8,319,688.47 | 3.26% |
| Average Generic Prescription Cost | \$18.84 | \$18.80 | -0.18% |
| Average Generic Days' Supply | 28.30 | 29.75 | 5.12% |
| # Brand Prescriptions | 45,965 | 47,407 | 3.14% |
| % Brand | 9.70% | 9.68% | -0.27% |
| \$ Brand | \$53,577,669 | \$54,911,086 | 2.49% |
| Average Brand Prescription cost | \$1,165.62 | \$1,158.29 | -0.63% |
| Average Brand Days' Supply | 28.25 | 28.28 | 0.12% |

| UTILIZATION BY AGE | | |
|--------------------|-----------------------|----------------------|
| Age | Sept 2025 to Nov 2025 | Dec 2025 to Feb 2026 |
| 0 to 6 | 11,723 | 13,712 |
| 7 to 12 | 9,864 | 10,922 |
| 13 to 18 | 10,196 | 10,625 |
| 19 to 64 | 44,334 | 45,851 |
| 65+ | 898 | 1,152 |
| Total | 76,623 | 82,262 |

| UTILIZATION BY GENDER AND AGE | | | |
|-------------------------------|---------------------|-----------------------|----------------------|
| Gender | Age | Sept 2025 to Nov 2025 | Dec 2025 to Feb 2026 |
| F | 0 to 6 | 5,448 | 6,473 |
| | 7 to 12 | 4,340 | 4,906 |
| | 13 to 18 | 5,741 | 5,957 |
| | 19 to 64 | 28,442 | 29,410 |
| | 65+ | 549 | 698 |
| | Gender Total | 44,520 | 47,444 |
| M | 0 to 6 | 6,272 | 7,235 |
| | 7 to 12 | 5,521 | 6,015 |
| | 13 to 18 | 4,454 | 4,664 |
| | 19 to 64 | 15,890 | 16,439 |
| | 65+ | 349 | 454 |
| | Gender Total | 32,486 | 34,807 |
| Grand Total | | 77,079 | 82,251 |

Top 100 Pharmacies by Prescription Count

Dec 2025 to Feb 2026

| RANK | Pharmacy NAME | Pharmacy City | State | Prescription Count | Paid Amount | Average Cost RX | Previous RANK |
|------|--------------------------|----------------|-------|--------------------|----------------|-----------------|---------------|
| 1 | UIHC AMBULATORY CARE PHC | IOWA CITY | IA | 7,286 | \$4,987,203.26 | \$684.49 | 1 |
| 2 | BROADLAWNS MED CTR OP PH | DES MOINES | IA | 4,709 | \$321,573.82 | \$68.29 | 2 |
| 3 | WALGREENS 04405 | COUNCIL BLUFFS | IA | 4,567 | \$296,701.77 | \$64.97 | 3 |
| 4 | WALGREENS 05042 | CEDAR RAPIDS | IA | 3,990 | \$226,129.01 | \$56.67 | 4 |
| 5 | HY-VEE PHARMACY 1403 | MARSHALLTOWN | IA | 3,396 | \$271,336.85 | \$79.90 | 6 |
| 6 | RIGHT DOSE PHARMACY | ANKENY | IA | 3,394 | \$165,545.52 | \$48.78 | 5 |
| 7 | SIOUXLAND COMM HLTH CTR | SIOUX CITY | IA | 3,382 | \$180,169.45 | \$53.27 | 7 |
| 8 | HY-VEE PHARMACY 1138 | DES MOINES | IA | 3,213 | \$255,042.62 | \$79.38 | 9 |
| 9 | WALGREENS 05239 | DAVENPORT | IA | 3,125 | \$158,802.92 | \$50.82 | 8 |
| 10 | HY-VEE PHARMACY 1075 | CLINTON | IA | 2,828 | \$220,473.17 | \$77.96 | 10 |
| 11 | COMMUNITY HEALTH CARE PH | DAVENPORT | IA | 2,720 | \$92,738.40 | \$34.09 | 19 |
| 12 | HY-VEE PHARMACY 1109 | DAVENPORT | IA | 2,671 | \$208,370.87 | \$78.01 | 14 |
| 13 | HY-VEE PHARMACY 1056 | CEDAR RAPIDS | IA | 2,619 | \$176,579.37 | \$67.42 | 12 |
| 14 | IMMC OUTPATIENT PHARMACY | DES MOINES | IA | 2,527 | \$134,082.22 | \$53.06 | 24 |
| 15 | WALGREENS 15647 | SIOUX CITY | IA | 2,514 | \$166,846.76 | \$66.37 | 20 |
| 16 | HY-VEE DRUGSTORE 7060 | MUSCATINE | IA | 2,501 | \$167,614.50 | \$67.02 | 11 |
| 17 | WALGREENS 03700 | COUNCIL BLUFFS | IA | 2,457 | \$199,961.25 | \$81.38 | 13 |
| 18 | HY-VEE PHARMACY 1092 | COUNCIL BLUFFS | IA | 2,440 | \$228,761.96 | \$93.75 | 18 |
| 19 | HY-VEE DRUGSTORE 7020 | CEDAR RAPIDS | IA | 2,334 | \$159,249.77 | \$68.23 | 22 |
| 20 | WALGREENS 05721 | DES MOINES | IA | 2,318 | \$151,818.04 | \$65.50 | 15 |
| 21 | HY-VEE DRUGSTORE 7065 | OTTUMWA | IA | 2,230 | \$155,749.38 | \$69.84 | 21 |
| 22 | HY-VEE PHARMACY 1151 | DES MOINES | IA | 2,220 | \$138,512.25 | \$62.39 | 25 |
| 23 | WALGREENS 07455 | WATERLOO | IA | 2,203 | \$119,934.39 | \$54.44 | 16 |

| | | | | | | | |
|----|---------------------------|-----------------|----|-------|--------------|----------|----|
| 24 | GREENWOOD DRUG ON KIMBAL | WATERLOO | IA | 2,192 | \$178,804.79 | \$81.57 | 33 |
| 25 | WALGREENS 00359 | DES MOINES | IA | 2,191 | \$138,959.88 | \$63.42 | 36 |
| 26 | HY-VEE PHARMACY 1192 | FORT DODGE | IA | 2,187 | \$138,612.11 | \$63.38 | 23 |
| 27 | CVS PHARMACY 08544 | WATERLOO | IA | 2,165 | \$151,678.93 | \$70.06 | 32 |
| 28 | NELSON FAMILY PHARMACY | FORT MADISON | IA | 2,135 | \$125,930.39 | \$58.98 | 35 |
| 29 | WALGREENS 07453 | DES MOINES | IA | 2,132 | \$163,488.42 | \$76.68 | 17 |
| 30 | HY-VEE PHARMACY 1142 | DES MOINES | IA | 2,107 | \$164,334.37 | \$77.99 | 27 |
| 31 | HY-VEE PHARMACY 1044 | BURLINGTON | IA | 2,073 | \$135,183.85 | \$65.21 | 29 |
| 32 | DRILLING PHARMACY 67 | SIOUX CITY | IA | 2,060 | \$143,602.57 | \$69.71 | 28 |
| 33 | HY-VEE PHARMACY 1610 | SIOUX CITY | IA | 2,029 | \$196,776.59 | \$96.98 | 26 |
| 34 | CVS PHARMACY 10282 | FORT DODGE | IA | 2,015 | \$161,585.85 | \$80.19 | 30 |
| 35 | WALMART PHARMACY 10-5115 | DAVENPORT | IA | 1,948 | \$154,190.96 | \$79.15 | 31 |
| 36 | HY-VEE PHARMACY 1061 | CEDAR RAPIDS | IA | 1,938 | \$114,930.89 | \$59.30 | 40 |
| 37 | CVS PHARMACY 08658 | DAVENPORT | IA | 1,872 | \$121,603.25 | \$64.96 | 41 |
| 38 | WALMART PHARMACY 10-2889 | CLINTON | IA | 1,869 | \$123,026.50 | \$65.82 | 37 |
| 39 | HY-VEE PHARMACY 1530 | PLEASANT HILL | IA | 1,862 | \$131,903.76 | \$70.84 | 45 |
| 40 | NUCARA LTC PHARMACY 3 | IOWA CITY | IA | 1,849 | \$51,663.00 | \$27.94 | 57 |
| 41 | HY-VEE PHARMACY 1522 | PERRY | IA | 1,812 | \$130,716.83 | \$72.14 | 38 |
| 42 | HY-VEE PHARMACY 1074 | CHARLES CITY | IA | 1,794 | \$124,268.63 | \$69.27 | 39 |
| 43 | WALMART PHARMACY 10-0797 | WEST BURLINGTON | IA | 1,773 | \$70,945.60 | \$40.01 | 56 |
| 44 | HY-VEE PHARMACY 1396 | MARION | IA | 1,767 | \$132,697.32 | \$75.10 | 51 |
| 45 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 1,750 | \$194,316.73 | \$111.04 | 43 |
| 46 | MAHASKA DRUGS | OSKALOOSA | IA | 1,743 | \$165,288.34 | \$94.83 | 42 |
| 47 | MEDICAP PHARMACY LTC 8405 | INDIANOLA | IA | 1,733 | \$52,294.95 | \$30.18 | 67 |
| 48 | HY-VEE PHARMACY 1180 | FAIRFIELD | IA | 1,692 | \$126,831.35 | \$74.96 | 46 |
| 49 | HY-VEE PHARMACY 1281 | IOWA CITY | IA | 1,683 | \$92,795.59 | \$55.14 | 50 |
| 50 | WALMART PHARMACY 10-0559 | MUSCATINE | IA | 1,680 | \$98,579.84 | \$58.68 | 54 |

| | | | | | | | |
|----|--------------------------|--------------|----|-------|--------------|----------|----|
| 51 | WALMART PHARMACY 10-3590 | SIoux CITY | IA | 1,667 | \$99,743.04 | \$59.83 | 44 |
| 52 | HY VEE PHARMACY 1459 | OELWEIN | IA | 1,653 | \$104,380.29 | \$63.15 | 58 |
| 53 | WALMART PHARMACY 10-3394 | ATLANTIC | IA | 1,650 | \$137,857.57 | \$83.55 | 53 |
| 54 | HY-VEE PHARMACY 1504 | OTTUMWA | IA | 1,618 | \$80,229.17 | \$49.59 | 55 |
| 55 | SCOTT PHARMACY INC | FAYETTE | IA | 1,614 | \$109,881.12 | \$68.08 | 49 |
| 56 | HY-VEE PHARMACY 1148 | DES MOINES | IA | 1,591 | \$149,435.27 | \$93.93 | 69 |
| 57 | WALGREENS 05852 | DES MOINES | IA | 1,577 | \$107,750.28 | \$68.33 | 59 |
| 58 | WALGREENS 04041 | DAVENPORT | IA | 1,574 | \$112,382.25 | \$71.40 | 34 |
| 59 | UI HEALTHCARE | CORALVILLE | IA | 1,568 | \$69,023.68 | \$44.02 | 63 |
| 60 | HY-VEE PHARMACY 1866 | WATERLOO | IA | 1,568 | \$134,193.70 | \$85.58 | 65 |
| 61 | HY-VEE PHARMACY 1058 | CENTERVILLE | IA | 1,555 | \$176,299.00 | \$113.38 | 48 |
| 62 | HY-VEE PHARMACY 1241 | HARLAN | IA | 1,553 | \$101,945.83 | \$65.64 | 73 |
| 63 | LEWIS FAMILY DRUG 28 | ONAWA | IA | 1,541 | \$160,801.56 | \$104.35 | 64 |
| 64 | WALMART PHARMACY 10-1723 | DES MOINES | IA | 1,513 | \$97,164.16 | \$64.22 | 66 |
| 65 | HY-VEE PHARMACY 1873 | WAUKEE | IA | 1,496 | \$104,138.00 | \$69.61 | 85 |
| 66 | WALMART PHARMACY 10-0581 | MARSHALLTOWN | IA | 1,479 | \$154,277.45 | \$104.31 | 70 |
| 67 | WALGREENS 03875 | CEDAR RAPIDS | IA | 1,479 | \$89,887.19 | \$60.78 | 76 |
| 68 | HY-VEE PHARMACY 1615 | SIoux CITY | IA | 1,478 | \$122,247.96 | \$82.71 | 47 |
| 69 | WALMART PHARMACY 10-0985 | FAIRFIELD | IA | 1,468 | \$91,695.42 | \$62.46 | 62 |
| 70 | HY-VEE PHARMACY 1202 | FORT MADISON | IA | 1,466 | \$142,615.77 | \$97.28 | 98 |
| 71 | WAGNER PHARMACY | CLINTON | IA | 1,457 | \$69,882.29 | \$47.96 | 61 |
| 72 | WALGREENS 07454 | ANKENY | IA | 1,453 | \$86,106.96 | \$59.26 | 52 |
| 73 | HY-VEE PHARMACY 1065 | CHARITON | IA | 1,447 | \$100,908.66 | \$69.74 | 82 |
| 74 | COVENANT FAMILY PHARMACY | WATERLOO | IA | 1,445 | \$221,541.69 | \$153.32 | 84 |
| 75 | WALMART PHARMACY 10-0646 | ANAMOSA | IA | 1,435 | \$123,171.64 | \$85.83 | 72 |
| 76 | SOUTH SIDE DRUG, INC. | OTTUMWA | IA | 1,434 | \$93,940.36 | \$65.51 | 81 |
| 77 | WALMART PHARMACY 10-1431 | KEOKUK | IA | 1,426 | \$96,004.75 | \$67.32 | 74 |

| | | | | | | | |
|-----|---------------------------|----------------|----|-------|--------------|----------|------|
| 78 | ALL CARE HEALTH CENTER | COUNCIL BLUFFS | IA | 1,419 | \$83,911.41 | \$59.13 | 68 |
| 79 | HY-VEE PHARMACY 1759 | URBANDALE | IA | 1,404 | \$91,608.61 | \$65.25 | 93 |
| 80 | HY-VEE PHARMACY 1107 | DAVENPORT | IA | 1,374 | \$102,258.83 | \$74.42 | 104 |
| 81 | WALGREENS 07452 | DES MOINES | IA | 1,369 | \$94,495.07 | \$69.02 | 86 |
| 82 | OMNICARE OF URBANDA 48236 | URBANDALE | IA | 1,360 | \$36,894.60 | \$27.13 | 60 |
| 83 | WELLS HOMETOWN DRUG KEOS | KEOSAUQUA | IA | 1,344 | \$99,558.91 | \$74.08 | 101 |
| 84 | FOREST PARK CLINIC PHCY | MASON CITY | IA | 1,340 | \$75,823.22 | \$56.58 | 92 |
| 85 | HY-VEE DRUGSTORE 7056 | MASON CITY | IA | 1,331 | \$120,568.85 | \$90.59 | 75 |
| 86 | MEDICAP PHARMACY 8023 | NEWTON | IA | 1,316 | \$103,004.16 | \$78.27 | 99 |
| 87 | WALMART PHARMACY 10-1621 | CENTERVILLE | IA | 1,304 | \$128,658.62 | \$98.66 | 89 |
| 88 | HY-VEE PHARMACY 1013 | AMES | IA | 1,304 | \$73,557.23 | \$56.41 | 78 |
| 89 | CVS PHARMACY 10032 | MARION | IA | 1,302 | \$79,484.52 | \$61.05 | 131 |
| 90 | HY-VEE PHARMACY 1071 | CLARINDA | IA | 1,299 | \$91,101.59 | \$70.13 | 108 |
| 91 | WALGREENS 05470 | SIOUX CITY | IA | 1,288 | \$72,662.36 | \$56.41 | 77 |
| 92 | HY-VEE PHARMACY 1052 | CEDAR FALLS | IA | 1,287 | \$93,432.47 | \$72.60 | 83 |
| 93 | PEOPLES CLINIC PHARMACY | WATERLOO | IA | 1,280 | \$15,264.88 | \$11.93 | #N/A |
| 94 | MAIN AT LOCUST PHARMACY | DAVENPORT | IA | 1,279 | \$83,982.90 | \$65.66 | 94 |
| 95 | HY-VEE PHARMACY 1009 | ALBIA | IA | 1,279 | \$119,249.69 | \$93.24 | 90 |
| 96 | LEWIS FAMILY DRUG 52 | SHELDON | IA | 1,272 | \$72,914.56 | \$57.32 | 123 |
| 97 | WALMART PHARMACY 10-0810 | MASON CITY | IA | 1,269 | \$125,679.24 | \$99.04 | 88 |
| 98 | WALMART PHARMACY 10-1496 | WATERLOO | IA | 1,263 | \$183,391.87 | \$145.20 | 87 |
| 99 | WALMART PHARMACY 10-2716 | CEDAR RAPIDS | IA | 1,251 | \$113,529.23 | \$90.75 | 105 |
| 100 | MEDICAP PHARMACY 8034 | CRESTON | IA | 1,247 | \$80,318.32 | \$64.41 | 117 |

**Top 100 Pharmacies by Paid Amount
Dec 2025 to Feb 2026**

| RANK | Pharmacy NAME | Pharmacy City | State | Prescription Count | Paid Amount | Average Cost Member | Previous RANK |
|------|----------------------------|----------------|-------|--------------------|----------------|---------------------|---------------|
| 1 | CAREMARK SPECIALTY P 1702 | LENEXA | KS | 765 | \$5,797,201.68 | \$7,578.04 | 1 |
| 2 | UIHC AMBULATORY CARE PHC | IOWA CITY | IA | 7,286 | \$4,987,203.26 | \$684.49 | 2 |
| 3 | COMMUNITY, A WALGRE 16528 | DES MOINES | IA | 581 | \$3,309,555.41 | \$5,696.31 | 3 |
| 4 | UNITYPOINT AT HOME | URBANDALE | IA | 486 | \$1,576,117.11 | \$3,243.04 | 4 |
| 5 | CVS SPECIALTY 02921 | MONROEVILLE | PA | 193 | \$1,179,066.67 | \$6,109.15 | 5 |
| 6 | NUCARA SPECIALTY PHARMAC | PLEASANT HILL | IA | 1,081 | \$1,157,054.70 | \$1,070.36 | 7 |
| 7 | PANTHERX SPECIALTY PHARM | CORAOPOLIS | PA | 32 | \$941,837.56 | \$29,432.42 | 6 |
| 8 | ACCREDITO HEALTH GROUP INC | MEMPHIS | TN | 62 | \$711,500.70 | \$11,475.82 | 8 |
| 9 | CAREMARK SPECIALTY 48031 | MOUNT PROSPECT | IL | 76 | \$697,451.79 | \$9,177.00 | 9 |
| 10 | COMMUNITY A WALGREE 21250 | IOWA CITY | IA | 141 | \$672,693.93 | \$4,770.88 | 10 |
| 11 | OPTUM PHARMACY | JEFFERSONVILLE | IN | 52 | \$444,691.95 | \$8,551.77 | 11 |
| 12 | EVERSANA LIFE SCIENCE SE | CHESTERFIELD | MO | 11 | \$424,033.49 | \$38,548.50 | 14 |
| 13 | ANOVORX GROUP LLC | MEMPHIS | TN | 36 | \$411,420.86 | \$11,428.36 | 16 |
| 14 | AVERA SPECIALTY PHARMACY | SIOUX FALLS | SD | 84 | \$384,311.58 | \$4,575.14 | 13 |
| 15 | BIOLOGICS BY MCKESSON | CARY | NC | 21 | \$376,256.90 | \$17,917.00 | 19 |
| 16 | ARJ INFUSION SERVICES LL | CEDAR RAPIDS | IA | 39 | \$363,914.37 | \$9,331.14 | 23 |
| 17 | CARE PLUS CVS/PHARM 00102 | AURORA | CO | 40 | \$351,030.57 | \$8,775.76 | 12 |
| 18 | CR CARE PHARMACY | CEDAR RAPIDS | IA | 1,070 | \$332,294.81 | \$310.56 | 20 |
| 19 | AMBER PHARMACY | OMAHA | NE | 50 | \$322,628.23 | \$6,452.56 | 32 |
| 20 | BROADLAWNS MED CTR OP PH | DES MOINES | IA | 4,709 | \$321,573.82 | \$68.29 | 21 |
| 21 | WALGREENS 04405 | COUNCIL BLUFFS | IA | 4,567 | \$296,701.77 | \$64.97 | 26 |
| 22 | GENOA HEALTHCARE LL 20171 | DAVENPORT | IA | 1,080 | \$295,328.91 | \$273.45 | 22 |
| 23 | EXPRESS SCRIPTS SPECIALT | ST. LOUIS | MO | 17 | \$294,596.99 | \$17,329.23 | 17 |

| | | | | | | | |
|----|---------------------------|-------------------|----|-------|--------------|-------------|-----|
| 24 | HY-VEE PHARMACY 1403 | MARSHALLTOWN | IA | 3,396 | \$271,336.85 | \$79.90 | 25 |
| 25 | HY-VEE PHARMACY 1138 | DES MOINES | IA | 3,213 | \$255,042.62 | \$79.38 | 30 |
| 26 | ALLEN CLINIC PHARMACY | WATERLOO | IA | 740 | \$250,267.25 | \$338.20 | 24 |
| 27 | GENOA HEALTHCARE LL 20304 | SIOUX CITY | IA | 986 | \$233,002.51 | \$236.31 | 42 |
| 28 | HY-VEE PHARMACY 1092 | COUNCIL BLUFFS | IA | 2,440 | \$228,761.96 | \$93.75 | 27 |
| 29 | GENOA HEALTHCARE LL 20459 | MARSHALLTOWN | IA | 577 | \$228,624.06 | \$396.23 | 37 |
| 30 | WALGREENS 05042 | CEDAR RAPIDS | IA | 3,990 | \$226,129.01 | \$56.67 | 35 |
| 31 | NEBRASKA MED CTR CLINIC | OMAHA | NE | 385 | \$225,867.89 | \$586.67 | 309 |
| 32 | COVENANT FAMILY PHARMACY | WATERLOO | IA | 1,445 | \$221,541.69 | \$153.32 | 39 |
| 33 | HY-VEE PHARMACY 1075 | CLINTON | IA | 2,828 | \$220,473.17 | \$77.96 | 33 |
| 34 | PRIMARY HEALTHCARE PHARM | DES MOINES | IA | 827 | \$213,885.42 | \$258.63 | 50 |
| 35 | S-S PHARMACY | COUNCIL BLUFFS | IA | 663 | \$213,575.72 | \$322.14 | 64 |
| 36 | HY-VEE PHARMACY 1109 | DAVENPORT | IA | 2,671 | \$208,370.87 | \$78.01 | 45 |
| 37 | CVS/SPECIALTY 1703 | REDLANDS | CA | 16 | \$201,398.90 | \$12,587.43 | 15 |
| 38 | PARAGON PARTNERS | OMAHA | NE | 157 | \$200,290.04 | \$1,275.73 | 48 |
| 39 | WALGREENS 03700 | COUNCIL BLUFFS | IA | 2,457 | \$199,961.25 | \$81.38 | 44 |
| 40 | HY-VEE PHARMACY 1610 | SIOUX CITY | IA | 2,029 | \$196,776.59 | \$96.98 | 38 |
| 41 | WALMART PHARMACY 10-3150 | COUNCIL BLUFFS | IA | 1,750 | \$194,316.73 | \$111.04 | 43 |
| 42 | ORSINI PHARMACEUTICAL SE | ELK GROVE VILLAGE | IL | 11 | \$189,132.78 | \$17,193.89 | 29 |
| 43 | WALMART PHARMACY 10-1496 | WATERLOO | IA | 1,263 | \$183,391.87 | \$145.20 | 89 |
| 44 | SIOUXLAND COMM HLTH CTR | SIOUX CITY | IA | 3,382 | \$180,169.45 | \$53.27 | 40 |
| 45 | FIFIELD DRUG STORE | DES MOINES | IA | 885 | \$179,011.00 | \$202.27 | 61 |
| 46 | GREENWOOD DRUG ON KIMBAL | WATERLOO | IA | 2,192 | \$178,804.79 | \$81.57 | 53 |
| 47 | HY-VEE PHARMACY 1056 | CEDAR RAPIDS | IA | 2,619 | \$176,579.37 | \$67.42 | 46 |
| 48 | HY-VEE PHARMACY 1058 | CENTERVILLE | IA | 1,555 | \$176,299.00 | \$113.38 | 31 |
| 49 | MAYO CLINIC PHARMACY | ROCHESTER | MN | 94 | \$174,359.34 | \$1,854.89 | 63 |
| 50 | HY-VEE DRUGSTORE 7060 | MUSCATINE | IA | 2,501 | \$167,614.50 | \$67.02 | 36 |

| | | | | | | | |
|----|----------------------------|--------------|----|-------|--------------|-------------|-----|
| 51 | WALGREENS 15647 | SIoux CITY | IA | 2,514 | \$166,846.76 | \$66.37 | 47 |
| 52 | FIRST MED EAST PHARMACY | DAVENPORT | IA | 407 | \$165,974.86 | \$407.80 | 28 |
| 53 | RIGHT DOSE PHARMACY | ANKENY | IA | 3,394 | \$165,545.52 | \$48.78 | 56 |
| 54 | MAHASKA DRUGS | OSKALOOSA | IA | 1,743 | \$165,288.34 | \$94.83 | 59 |
| 55 | HY-VEE PHARMACY 1142 | DES MOINES | IA | 2,107 | \$164,334.37 | \$77.99 | 58 |
| 56 | WALGREENS 07453 | DES MOINES | IA | 2,132 | \$163,488.42 | \$76.68 | 54 |
| 57 | ACCREDITO HEALTH GROUP INC | WHITESTOWN | IN | 11 | \$162,422.29 | \$14,765.66 | 318 |
| 58 | CVS PHARMACY 10282 | FORT DODGE | IA | 2,015 | \$161,585.85 | \$80.19 | 108 |
| 59 | LEWIS FAMILY DRUG 28 | ONAWA | IA | 1,541 | \$160,801.56 | \$104.35 | 67 |
| 60 | HY-VEE DRUGSTORE 7020 | CEDAR RAPIDS | IA | 2,334 | \$159,249.77 | \$68.23 | 57 |
| 61 | WALGREENS 05239 | DAVENPORT | IA | 3,125 | \$158,802.92 | \$50.82 | 41 |
| 62 | HY-VEE DRUGSTORE 7065 | OTTUMWA | IA | 2,230 | \$155,749.38 | \$69.84 | 62 |
| 63 | WALMART PHARMACY 10-0581 | MARSHALLTOWN | IA | 1,479 | \$154,277.45 | \$104.31 | 75 |
| 64 | WALMART PHARMACY 10-5115 | DAVENPORT | IA | 1,948 | \$154,190.96 | \$79.15 | 51 |
| 65 | WALGREENS 05721 | DES MOINES | IA | 2,318 | \$151,818.04 | \$65.50 | 71 |
| 66 | CVS PHARMACY 08544 | WATERLOO | IA | 2,165 | \$151,678.93 | \$70.06 | 84 |
| 67 | HY-VEE PHARMACY 1148 | DES MOINES | IA | 1,591 | \$149,435.27 | \$93.93 | 77 |
| 68 | ACARIAHEALTH PHARMACY 11 | HOUSTON | TX | 11 | \$146,995.88 | \$13,363.26 | 60 |
| 69 | DRILLING PHARMACY 67 | SIoux CITY | IA | 2,060 | \$143,602.57 | \$69.71 | 55 |
| 70 | HY-VEE PHARMACY 1202 | FORT MADISON | IA | 1,466 | \$142,615.77 | \$97.28 | 105 |
| 71 | GREENWOOD COMPLIANCE PHA | WATERLOO | IA | 885 | \$139,679.36 | \$157.83 | 66 |
| 72 | WALGREENS 00359 | DES MOINES | IA | 2,191 | \$138,959.88 | \$63.42 | 103 |
| 73 | HY-VEE PHARMACY 1192 | FORT DODGE | IA | 2,187 | \$138,612.11 | \$63.38 | 68 |
| 74 | HY-VEE PHARMACY 1151 | DES MOINES | IA | 2,220 | \$138,512.25 | \$62.39 | 74 |
| 75 | WALMART PHARMACY 10-3394 | ATLANTIC | IA | 1,650 | \$137,857.57 | \$83.55 | 73 |
| 76 | OPTIME CARE INC | EARTH CITY | MO | 3 | \$137,488.47 | \$45,829.49 | 83 |
| 77 | HY-VEE PHARMACY 1044 | BURLINGTON | IA | 2,073 | \$135,183.85 | \$65.21 | 72 |

| | | | | | | | |
|-----|---------------------------|-------------------|----|-------|--------------|------------|-----|
| 78 | HY-VEE PHARMACY 1866 | WATERLOO | IA | 1,568 | \$134,193.70 | \$85.58 | 90 |
| 79 | IMMC OUTPATIENT PHARMACY | DES MOINES | IA | 2,527 | \$134,082.22 | \$53.06 | 102 |
| 80 | GENOA HEALTHCARE LL 20246 | MASON CITY | IA | 672 | \$132,783.11 | \$197.59 | 80 |
| 81 | HY-VEE PHARMACY 1396 | MARION | IA | 1,767 | \$132,697.32 | \$75.10 | 91 |
| 82 | HY-VEE PHARMACY 1530 | PLEASANT HILL | IA | 1,862 | \$131,903.76 | \$70.84 | 96 |
| 83 | HY-VEE PHARMACY 1522 | PERRY | IA | 1,812 | \$130,716.83 | \$72.14 | 78 |
| 84 | BIOPLUS SPECIALTY PHCY S | ALTAMONTE SPRINGS | FL | 18 | \$130,595.71 | \$7,255.32 | 188 |
| 85 | WALGREENS 16270 | OMAHA | NE | 24 | \$130,170.95 | \$5,423.79 | 141 |
| 86 | SANFORD PHARMACY BROADWA | FARGO | ND | 14 | \$130,071.40 | \$9,290.81 | 184 |
| 87 | WALMART PHARMACY 10-1621 | CENTERVILLE | IA | 1,304 | \$128,658.62 | \$98.66 | 81 |
| 88 | RIVER HILLS PHARMACY | OTTUMWA | IA | 494 | \$128,039.06 | \$259.19 | 120 |
| 89 | HY-VEE PHARMACY 1180 | FAIRFIELD | IA | 1,692 | \$126,831.35 | \$74.96 | 76 |
| 90 | NELSON FAMILY PHARMACY | FORT MADISON | IA | 2,135 | \$125,930.39 | \$58.98 | 113 |
| 91 | HY-VEE PHARMACY 1042 | BURLINGTON | IA | 1,231 | \$125,732.31 | \$102.14 | 98 |
| 92 | WALMART PHARMACY 10-0810 | MASON CITY | IA | 1,269 | \$125,679.24 | \$99.04 | 97 |
| 93 | HY-VEE PHCY SOLUTIONS | OMAHA | NE | 21 | \$124,543.50 | \$5,930.64 | 70 |
| 94 | HY-VEE PHARMACY 1074 | CHARLES CITY | IA | 1,794 | \$124,268.63 | \$69.27 | 82 |
| 95 | WALMART PHARMACY 10-0646 | ANAMOSA | IA | 1,435 | \$123,171.64 | \$85.83 | 99 |
| 96 | WALMART PHARMACY 10-2889 | CLINTON | IA | 1,869 | \$123,026.50 | \$65.82 | 49 |
| 97 | HY-VEE PHARMACY 1615 | SIOUX CITY | IA | 1,478 | \$122,247.96 | \$82.71 | 86 |
| 98 | CVS PHARMACY 08658 | DAVENPORT | IA | 1,872 | \$121,603.25 | \$64.96 | 92 |
| 99 | HY-VEE DRUGSTORE 7056 | MASON CITY | IA | 1,331 | \$120,568.85 | \$90.59 | 85 |
| 100 | WALGREENS 07455 | WATERLOO | IA | 2,203 | \$119,934.39 | \$54.44 | 79 |

**Top 100 Prescribing Providers by Prescription Count
Dec 2025 to Feb 2026**

| RANK | NPI Num | Prescriber Name | Paid Amount | Prescription Count | Average Scripts Member | Previous Rank |
|------|------------|-----------------|--------------|--------------------|------------------------|---------------|
| 1 | 1982605762 | JEFFREY WILHARM | \$29,732.26 | 1,010 | 17.4 | 1 |
| 2 | 1811419815 | GRETCHEN WENGER | \$65,265.94 | 801 | 5.7 | 2 |
| 3 | 1013115369 | BOBBITA NAG | \$42,222.96 | 780 | 5.5 | 5 |
| 4 | 1528365277 | MINA SALIB | \$298,233.59 | 752 | 4.6 | 4 |
| 5 | 1356359871 | RHEA HARTLEY | \$66,009.82 | 699 | 5.1 | 3 |
| 6 | 1992402655 | SHANE EBERHARDT | \$88,989.75 | 631 | 5.4 | 7 |
| 7 | 1477199198 | SAJO THOMAS | \$115,301.23 | 624 | 7.5 | 19 |
| 8 | 1730849647 | MELANIE PARRISH | \$19,166.11 | 618 | 7.5 | 6 |
| 9 | 1982030946 | JACKLYN BESCH | \$18,527.44 | 596 | 7.8 | 8 |
| 10 | 1306559786 | ROY HENRY | \$86,382.88 | 579 | 7.4 | 9 |
| 11 | 1164538674 | JOSEPH WANZEK | \$40,751.59 | 573 | 8.0 | 18 |
| 12 | 1477926434 | JACKIE SHIPLEY | \$59,762.54 | 569 | 5.0 | 10 |
| 13 | 1811960768 | ANGELA VEENSTRA | \$59,008.28 | 556 | 10.1 | 39 |
| 14 | 1598183493 | JENA ELLERHOFF | \$16,626.89 | 553 | 9.5 | 12 |
| 15 | 1770933046 | SHELBY BILLER | \$58,868.23 | 541 | 6.0 | 11 |
| 16 | 1245960350 | MARY WELBORN | \$26,788.29 | 541 | 5.5 | 47 |
| 17 | 1609218304 | AMANDA GARR | \$77,828.65 | 535 | 5.6 | 59 |
| 18 | 1689077018 | STACY ROTH | \$45,314.89 | 532 | 7.4 | 16 |
| 19 | 1992573786 | LASHELLE GOODE | \$37,672.23 | 529 | 5.9 | 32 |
| 20 | 1942721584 | SHAWNA FURY | \$27,649.73 | 515 | 5.3 | 13 |
| 21 | 1659358620 | CARLOS CASTILLO | \$15,233.41 | 507 | 6.5 | 20 |
| 22 | 1265841845 | MARY SCHWERING | \$39,951.62 | 502 | 6.3 | 24 |
| 23 | 1164823092 | JAMEY GREGERSEN | \$22,408.12 | 497 | 8.1 | 27 |

| | | | | | | |
|----|------------|------------------|-------------|-----|------|-----|
| 24 | 1417941188 | DEBRA NEUHARTH | \$46,976.64 | 496 | 6.3 | 15 |
| 25 | 1801463245 | ANN MOJEIKO | \$25,886.07 | 488 | 6.5 | 107 |
| 26 | 1831731298 | HEATHER WILSON | \$36,520.62 | 481 | 7.2 | 22 |
| 27 | 1902912538 | CHRISTIAN JONES | \$39,109.66 | 480 | 5.5 | 33 |
| 28 | 1144588476 | RACHEL FILZER | \$76,882.27 | 477 | 6.7 | 26 |
| 29 | 1275763047 | REBECCA BOWMAN | \$78,961.24 | 475 | 7.2 | 29 |
| 30 | 1679573893 | PATTY HILDRETH | \$71,067.78 | 470 | 7.0 | 83 |
| 31 | 1467431445 | SUSAN CASADY | \$19,365.53 | 470 | 15.2 | 58 |
| 32 | 1649763079 | KATE JARVIS | \$79,773.13 | 465 | 5.7 | 23 |
| 33 | 1053963900 | NICOLE MCCLAVY | \$72,007.77 | 465 | 7.3 | 28 |
| 34 | 1053630640 | JENNIFER DONOVAN | \$44,927.68 | 462 | 4.5 | 53 |
| 35 | 1467092049 | HEIDI PEDERSEN | \$42,260.08 | 461 | 7.3 | 64 |
| 36 | 1699361949 | NICHOLAS JENSEN | \$40,206.77 | 452 | 7.9 | 123 |
| 37 | 1205393386 | JESSICA HUDSPETH | \$59,171.14 | 448 | 7.7 | 31 |
| 38 | 1184657603 | SARA RYGOL | \$60,294.50 | 442 | 5.9 | 71 |
| 39 | 1992562458 | ALISON FAUBLE | \$31,583.06 | 441 | 5.9 | 54 |
| 40 | 1437238110 | GENEVIEVE NELSON | \$46,133.96 | 439 | 9.0 | 30 |
| 41 | 1114681889 | KELSEY BAUER | \$31,280.33 | 434 | 6.5 | 21 |
| 42 | 1215981758 | LISA PISNEY | \$74,530.81 | 431 | 8.8 | 76 |
| 43 | 1043434525 | ROBERT KENT | \$35,726.93 | 430 | 6.2 | 14 |
| 44 | 1821333774 | BRITTON BENDA | \$36,932.57 | 427 | 4.8 | 46 |
| 45 | 1619153137 | JOADA BEST | \$36,648.01 | 426 | 6.3 | 49 |
| 46 | 1437209434 | JON THOMAS | \$34,664.89 | 426 | 6.1 | 51 |
| 47 | 1508844465 | MICHELE FRIEDMAN | \$24,872.44 | 424 | 15.1 | 43 |
| 48 | 1013355759 | DYLAN GREENE | \$25,186.97 | 422 | 5.1 | 40 |
| 49 | 1225089287 | JULIE HANSON | \$8,084.89 | 420 | 1.8 | 272 |
| 50 | 1689325524 | BRIAN AYERSMAN | \$79,557.60 | 418 | 6.5 | 267 |

| | | | | | | |
|----|------------|---------------------|-------------|-----|------|-----|
| 51 | 1003053653 | STANLEY MATHEW | \$15,677.64 | 417 | 12.3 | 70 |
| 52 | 1861634008 | NATHANIEL ALVIS | \$19,321.07 | 416 | 7.7 | 195 |
| 53 | 1871021543 | SUSAN WILSON | \$30,960.09 | 413 | 7.8 | 75 |
| 54 | 1891707832 | LISA KLOCK | \$26,438.58 | 408 | 4.9 | 57 |
| 55 | 1093272668 | RICARDO OSORIO | \$54,443.41 | 408 | 5.8 | 86 |
| 56 | 1306124557 | STACY STEWART | \$30,150.07 | 406 | 6.9 | 38 |
| 57 | 1538368170 | CHRISTOPHER MATSON | \$15,669.29 | 405 | 6.1 | 42 |
| 58 | 1619380680 | TARA BROCKMAN | \$18,486.95 | 404 | 4.9 | 102 |
| 59 | 1891306452 | JENNIFER TOMLIN | \$40,688.64 | 402 | 5.6 | 35 |
| 60 | 1467502286 | CHARLES TILLEY | \$94,248.24 | 402 | 7.3 | 45 |
| 61 | 1134191018 | DUSTIN SMITH | \$26,218.79 | 402 | 5.8 | 99 |
| 62 | 1023469798 | WEI SHIPENG | \$27,909.56 | 397 | 13.2 | 176 |
| 63 | 1255823506 | NICOLE DELAGARDELLE | \$67,876.40 | 392 | 5.2 | 91 |
| 64 | 1457914657 | SEEMA ANTONY | \$15,150.73 | 389 | 4.7 | 150 |
| 65 | 1881095503 | KAROWESO CHIPENDO | \$29,105.16 | 388 | 6.0 | 174 |
| 66 | 1891422606 | EMILY CLAWSON | \$65,972.73 | 387 | 6.0 | 63 |
| 67 | 1679986350 | JENNIFER SPOERL | \$48,563.78 | 385 | 6.4 | 67 |
| 68 | 1598345415 | LAUREN MANCIERI | \$17,255.83 | 385 | 5.3 | 119 |
| 69 | 1417241621 | ASHLEY MATHES | \$23,056.37 | 385 | 5.2 | 66 |
| 70 | 1326798992 | JENNA MULLINS | \$33,538.30 | 385 | 4.1 | 237 |
| 71 | 1316510324 | SANDY MARCUS | \$21,549.52 | 385 | 6.4 | 90 |
| 72 | 1306475413 | AUTUMN ANDERSON | \$18,180.20 | 384 | 8.0 | 138 |
| 73 | 1780877878 | CHRISTOPHER JACOBS | \$52,815.49 | 382 | 5.4 | 88 |
| 74 | 1346621059 | MARK ZACHARJASZ | \$26,437.45 | 381 | 10.0 | 48 |
| 75 | 1912345992 | AMY WINGERT | \$12,279.89 | 380 | 5.1 | 106 |
| 76 | 1801998372 | WENDY HANSEN-PENMAN | \$12,732.05 | 380 | 7.0 | 98 |
| 77 | 1679669832 | ERIN HATCHER | \$63,456.03 | 377 | 5.0 | 260 |

| | | | | | | |
|-----|------------|-----------------------|--------------|-----|------|-----|
| 78 | 1588746515 | AMY BADBERG | \$14,620.01 | 376 | 5.2 | 34 |
| 79 | 1760965032 | MELISSA MILLER | \$19,354.04 | 374 | 6.1 | 55 |
| 80 | 1467465716 | JEFFREY BRADY | \$22,540.99 | 374 | 5.3 | 87 |
| 81 | 1194425223 | MARY BOKSA | \$47,790.15 | 374 | 4.7 | 25 |
| 82 | 1902478811 | JOAN ANDERSON | \$43,377.86 | 371 | 5.5 | 78 |
| 83 | 1215184726 | BABUJI GANDRA | \$8,186.51 | 371 | 5.8 | 125 |
| 84 | 1063277671 | AMANDA FRY | \$39,539.21 | 371 | 6.3 | 79 |
| 85 | 1891955423 | LEAH SIEGFRIED | \$147,178.85 | 369 | 10.0 | 74 |
| 86 | 1215581251 | ANNA THROCKMORTON | \$23,725.19 | 369 | 8.4 | 103 |
| 87 | 1871598557 | CHRISTOPHER VANDELUNE | \$15,773.26 | 368 | 4.8 | 41 |
| 88 | 1275874273 | AMY MCCORMICK | \$49,771.69 | 365 | 5.4 | 117 |
| 89 | 1023542271 | FLYNN MCCULLOUGH | \$31,148.80 | 364 | 6.3 | 50 |
| 90 | 1891146999 | BECKY JOHNSON | \$463,401.76 | 363 | 5.8 | 116 |
| 91 | 1831710987 | MARGARET WHITE | \$41,789.55 | 362 | 5.9 | 141 |
| 92 | 1619416013 | HEATHER JACOBS | \$10,738.74 | 361 | 5.6 | 147 |
| 93 | 1437692803 | CASSANDRA DUNLAVY | \$33,933.39 | 361 | 5.3 | 73 |
| 94 | 1841071727 | CAROLYN NGUYEN | \$19,164.55 | 360 | 5.8 | 118 |
| 95 | 1972758126 | REBECCA BOLLIN | \$23,135.27 | 359 | 5.5 | 148 |
| 96 | 1134854128 | DZEVIDA PANDZIC | \$18,708.73 | 359 | 4.2 | 17 |
| 97 | 1003470923 | EARLENE ANGELL | \$87,247.64 | 358 | 11.2 | 82 |
| 98 | 1104498039 | BRENDA CAIN | \$45,482.07 | 352 | 6.8 | 128 |
| 99 | 1083439145 | AMANDA MONROE | \$10,985.94 | 350 | 7.1 | 218 |
| 100 | 1245227099 | DONNA DOBSON TOBIN | \$56,402.21 | 348 | 8.9 | 56 |

| Top 100 Prescribing Providers by Paid Amount Dec 2025 to Feb 2026 | | | | | | |
|--|------------|---------------------|--------------|-------------|--------------------|---------------|
| RANK | NPI Num | Prescriber Name | Paid Amount | Avg cost RX | Prescription Count | Previous Rank |
| 1 | 1114214541 | DIMAH SAADE | \$680,708.30 | \$17,454.06 | 39 | 1 |
| 2 | 1861277980 | KATHRYN EWOLDT | \$499,167.41 | \$1,663.89 | 300 | 3 |
| 3 | 1295091510 | REBECCA WEINER | \$492,276.71 | \$2,168.62 | 227 | 5 |
| 4 | 1013126705 | JANICE STABER | \$477,453.13 | \$15,401.71 | 31 | 10 |
| 5 | 1700561826 | PEDRO HSIEH | \$472,392.33 | \$19,683.01 | 24 | 12 |
| 6 | 1891146999 | BECKY JOHNSON | \$463,401.76 | \$1,276.59 | 363 | 4 |
| 7 | 1477761328 | AMY CALHOUN | \$451,479.74 | \$10,749.52 | 42 | 8 |
| 8 | 1942937388 | CARLY TRAUSCH | \$401,606.68 | \$1,174.29 | 342 | 6 |
| 9 | 1417443953 | RODNEY CLARK | \$348,862.52 | \$1,047.64 | 333 | 11 |
| 10 | 1316934318 | STEVEN LENTZ | \$339,830.74 | \$15,446.85 | 22 | 2 |
| 11 | 1932831971 | KRISTEN EMODI | \$338,134.05 | \$5,635.57 | 60 | 13 |
| 12 | 1760562466 | ARTHUR BEISANG | \$325,098.78 | \$54,183.13 | 6 | 15 |
| 13 | 1528365277 | MINA SALIB | \$298,233.59 | \$396.59 | 752 | 7 |
| 14 | 1467449579 | BRIAN WAYSON | \$273,112.74 | \$3,330.64 | 82 | 22 |
| 15 | 1821046087 | ARCHANA VERMA | \$267,355.88 | \$4,609.58 | 58 | 16 |
| 16 | 1649943689 | JESSICA WOLFE | \$254,217.38 | \$1,650.76 | 148 | 24 |
| 17 | 1669137832 | TIFFANY NAVRKAL | \$250,510.92 | \$2,197.46 | 6 | 1,459 |
| 18 | 1700417169 | COURTNEY REINTS | \$235,963.10 | \$1,396.23 | 114 | 18 |
| 19 | 1245353242 | SANDY HONG | \$224,997.20 | \$6,617.56 | 169 | 19 |
| 20 | 1952423071 | SAKEER HUSSAIN | \$214,759.40 | \$11,303.13 | 34 | 17 |
| 21 | 1588616171 | HEATHER THOMAS | \$213,861.26 | \$2,138.61 | 19 | 21 |
| 22 | 1437121407 | LINDA CADARET | \$207,463.39 | \$3,006.72 | 100 | 9 |
| 23 | 1437533130 | KATIE BROSHUIS | \$202,547.39 | \$2,665.10 | 69 | 31 |
| 24 | 1285626390 | KATHLEEN GRADOVILLE | \$196,467.35 | \$2,425.52 | 76 | 34 |

| | | | | | | |
|----|------------|----------------------|--------------|-------------|-----|-------|
| 25 | 1578958542 | HEIDI CURTIS | \$194,935.62 | \$1,392.40 | 81 | 72 |
| 26 | 1184056822 | ABBY KOLTHOFF | \$187,910.21 | \$618.13 | 140 | 41 |
| 27 | 1992314108 | LYNZEE MAKOWSKI | \$175,295.18 | \$524.84 | 304 | 20 |
| 28 | 1366065047 | BRITTANIA SCHOON | \$167,636.26 | \$2,361.07 | 334 | 23 |
| 29 | 1821866856 | LAUREN CRAWFORD | \$161,749.50 | \$1,263.67 | 71 | 76 |
| 30 | 1801405832 | SARAH HIEMER | \$159,518.32 | \$1,217.70 | 128 | 28 |
| 31 | 1063792026 | JILL MILLER | \$157,364.08 | \$512.59 | 131 | 46 |
| 32 | 1841607900 | SHAYLA SANDERS | \$157,111.53 | \$2,618.53 | 307 | 32 |
| 33 | 1003315201 | ABIGAIL BEHRENS | \$150,391.76 | \$3,342.04 | 60 | 33 |
| 34 | 1437513520 | SUSSETTE GONZALEZ | \$148,979.34 | \$1,432.49 | 45 | 50 |
| 35 | 1184989428 | SANTIAGO ENCALADA | \$147,359.66 | \$3,203.47 | 104 | 14 |
| 36 | 1891955423 | LEAH SIEGFRIED | \$147,178.85 | \$398.86 | 46 | 2,106 |
| 37 | 1093382632 | GAIL DOOLEY | \$146,073.75 | \$1,227.51 | 369 | 44 |
| 38 | 1215333091 | NADIA NAZ | \$146,064.95 | \$1,115.00 | 119 | 61 |
| 39 | 1013585082 | BILAL BAIG | \$144,528.94 | \$1,521.36 | 131 | 25 |
| 40 | 1356752067 | KELLY DELANEY-NELSON | \$141,386.93 | \$2,667.68 | 95 | 222 |
| 41 | 1649419219 | HEATHER HUNEMULLER | \$141,100.70 | \$1,331.14 | 53 | 38 |
| 42 | 1598438095 | LALaura LOGAN | \$140,101.41 | \$459.35 | 106 | 110 |
| 43 | 1073811352 | KYLE ROSE | \$139,312.21 | \$13,931.22 | 305 | 36 |
| 44 | 1700080538 | EDUARDO CARLIN | \$139,008.26 | \$2,242.07 | 10 | 99 |
| 45 | 1902191059 | AMBER TIERNEY | \$137,472.50 | \$5,728.02 | 62 | 70 |
| 46 | 1306071915 | THOMAS PIETRAS | \$135,091.31 | \$5,873.54 | 24 | 39 |
| 47 | 1972560597 | BERNARD LEMAN | \$133,968.21 | \$5,152.62 | 23 | 114 |
| 48 | 1720430184 | AMANDEEP RAKHRA | \$130,950.53 | \$4,365.02 | 26 | 75 |
| 49 | 1194945691 | ANJALI SHARATHKUMAR | \$126,536.98 | \$2,433.40 | 30 | 35 |
| 50 | 1538111356 | THANAI PONGDEE | \$125,576.28 | \$20,929.38 | 52 | 91 |
| 51 | 1144214248 | KRISTI WALZ | \$124,306.49 | \$408.90 | 6 | 104 |

| | | | | | | |
|----|------------|-----------------------|--------------|-------------|-----|-------|
| 52 | 1376525196 | RANDOLPH ROUGH | \$121,924.29 | \$2,488.25 | 304 | 62 |
| 53 | 1710463708 | MARY MILLS | \$121,477.77 | \$30,369.44 | 49 | 54 |
| 54 | 1295263010 | ZACHARY LANCASTER | \$120,201.35 | \$8,585.81 | 4 | 29 |
| 55 | 1194797449 | DIANNA PROKUPEK | \$117,131.77 | \$1,802.03 | 14 | 58 |
| 56 | 1801831870 | SEEMA HARICHAND-HERDT | \$116,483.57 | \$8,960.27 | 65 | 93 |
| 57 | 1649826140 | TAYLOR MYERS | \$115,310.77 | \$929.93 | 13 | 5,200 |
| 58 | 1477199198 | SAJO THOMAS | \$115,301.23 | \$184.78 | 124 | 42 |
| 59 | 1316942212 | JEFFREY GOLDMAN | \$114,678.63 | \$2,666.94 | 624 | 106 |
| 60 | 1790986925 | TAHUANTY PENA | \$111,074.00 | \$5,846.00 | 43 | 67 |
| 61 | 1730318205 | DIANA BAYER-BOWSTEAD | \$109,186.86 | \$933.22 | 19 | 27 |
| 62 | 1356655336 | AASIYA MATIN | \$108,148.98 | \$27,037.25 | 117 | 65 |
| 63 | 1134440886 | MELISSA WELLS | \$105,415.62 | \$2,242.89 | 4 | 63 |
| 64 | 1780995506 | QUANHATHAI KAEWPOOWAT | \$105,369.02 | \$2,026.33 | 47 | 128 |
| 65 | 1831855485 | AARON MARTIN | \$104,772.38 | \$518.68 | 52 | 73 |
| 66 | 1184044398 | ERIC MOU | \$104,644.48 | \$4,983.07 | 202 | 68 |
| 67 | 1467716027 | AMIR ORANDI | \$102,810.19 | \$12,851.27 | 21 | 425 |
| 68 | 1427685791 | DELANEY SCHARA | \$101,553.98 | \$1,450.77 | 8 | 142 |
| 69 | 1073336392 | GUSTAVO GODOY ALMEIDA | \$99,089.24 | \$11,009.92 | 70 | 82 |
| 70 | 1558028852 | CARRIE O'CONNELL | \$98,635.25 | \$296.20 | 9 | 95 |
| 71 | 1306230230 | SONAM PATEL | \$98,263.79 | \$2,977.69 | 333 | 102 |
| 72 | 1245643519 | JOSHUA BIES | \$97,847.05 | \$24,461.76 | 33 | 45 |
| 73 | 1235894122 | KRISHNA HUGHES | \$97,603.47 | \$1,251.33 | 4 | 1,308 |
| 74 | 1144829300 | KATIE SHANNON | \$96,685.00 | \$2,302.02 | 78 | 55 |
| 75 | 1467502286 | CHARLES TILLEY | \$94,248.24 | \$234.45 | 42 | 100 |
| 76 | 1407065469 | CHRISTOPH RANDAK | \$93,695.57 | \$794.03 | 402 | 53 |
| 77 | 1720698335 | DANIKA HANSEN | \$93,001.66 | \$334.54 | 118 | 109 |
| 78 | 1225266364 | SARAH BLIGH | \$92,386.39 | \$2,008.40 | 278 | 123 |

| | | | | | | |
|-----|------------|---------------------|-------------|-------------|-----|--------|
| 79 | 1659108090 | TERESA HANSON | \$91,820.75 | \$295.24 | 46 | 79 |
| 80 | 1336602846 | DRAKE BOUZEK | \$91,068.64 | \$1,718.28 | 311 | 103 |
| 81 | 1386084747 | JENNIFER CONDON | \$89,039.39 | \$899.39 | 53 | 2,418 |
| 82 | 1992402655 | SHANE EBERHARDT | \$88,989.75 | \$141.03 | 99 | 132 |
| 83 | 1720086523 | MARK CLEVELAND | \$88,745.72 | \$2,862.77 | 631 | 64 |
| 84 | 1730135070 | JAMES WALLACE | \$87,748.20 | \$3,656.18 | 31 | 185 |
| 85 | 1861463275 | DONALD WENDER | \$87,665.24 | \$6,743.48 | 24 | 96 |
| 86 | 1528000940 | SHELBY DAMES | \$87,641.65 | \$4,173.41 | 13 | 47 |
| 87 | 1003470923 | EARLENE ANGELL | \$87,247.64 | \$243.71 | 21 | 113 |
| 88 | 1407836513 | NATHAN NOBLE | \$86,879.22 | \$376.10 | 358 | 159 |
| 89 | 1306559786 | ROY HENRY | \$86,382.88 | \$149.19 | 231 | 160 |
| 90 | 1609268762 | JORDAN MEEKER | \$85,931.26 | \$3,305.05 | 579 | 270 |
| 91 | 1497101919 | ALEXANDER STALLER | \$85,926.42 | \$12,275.20 | 26 | 400 |
| 92 | 1982248589 | SAMANTHA CARON | \$85,830.04 | \$7,152.50 | 7 | 10,476 |
| 93 | 1386938447 | THERESA CZECH | \$85,602.86 | \$629.43 | 12 | 98 |
| 94 | 1225263833 | LINDSAY ORRIS | \$85,230.16 | \$1,495.27 | 136 | 101 |
| 95 | 1073007894 | ELISE DUWE | \$85,112.82 | \$417.22 | 57 | 85 |
| 96 | 1609003433 | DANIEL FULTON | \$84,514.26 | \$1,965.45 | 204 | 118 |
| 97 | 1265420095 | ELIZABETH COOPER | \$83,948.44 | \$3,649.93 | 43 | 77 |
| 98 | 1851568703 | MATHEW DAVEY | \$83,227.06 | \$1,770.79 | 23 | 26 |
| 99 | 1558882670 | PAVIDA PACHARIYANON | \$82,447.29 | \$634.21 | 47 | 56 |
| 100 | 1093162075 | MEGHAN RYAN | \$82,216.53 | \$1,284.63 | 130 | 92 |

| Top 20 Therapeutic Class by Paid Amount | | | | | | | |
|---|----------------------------------|---------------|-------------------|---------------------------------|--------------|------------------|----------|
| Category Description | Sept 2025 to Nov 2025 Total Cost | Previous Rank | Previous % Budget | Dec 2025 to Feb 2026 Total Cost | Current Rank | Current % Budget | % Change |
| DERMATOLOGICALS | \$8,293,701.62 | 1 | 13.46% | \$8,311,108.05 | 1 | 13.14% | 0.21% |
| ANTIDIABETICS | \$8,166,173.94 | 2 | 13.25% | \$8,142,884.50 | 2 | 12.88% | -0.29% |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | \$6,184,685.57 | 3 | 10.03% | \$6,854,673.18 | 3 | 10.84% | 10.83% |
| ANALGESICS - ANTI-INFLAMMATORY | \$4,418,689.19 | 4 | 7.17% | \$4,157,129.46 | 4 | 6.57% | -5.92% |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | \$3,142,810.82 | 6 | 5.10% | \$3,408,955.35 | 5 | 5.39% | 8.47% |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | \$3,163,193.30 | 5 | 5.13% | \$3,326,512.79 | 6 | 5.26% | 5.16% |
| ANTIVIRALS | \$2,620,325.31 | 7 | 4.25% | \$3,069,368.78 | 7 | 4.85% | 17.14% |
| ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES | \$2,289,867.61 | 8 | 3.72% | \$2,372,152.93 | 8 | 3.75% | 3.59% |
| HEMATOLOGICAL AGENTS - MISC. | \$2,020,799.49 | 9 | 3.28% | \$2,194,132.74 | 9 | 3.47% | 8.58% |
| PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. | \$1,939,068.89 | 11 | 3.15% | \$2,106,535.98 | 10 | 3.33% | 8.64% |
| RESPIRATORY AGENTS - MISC. | \$1,951,792.62 | 10 | 3.17% | \$1,927,330.69 | 11 | 3.05% | -1.25% |
| MIGRAINE PRODUCTS | \$1,518,401.63 | 13 | 2.46% | \$1,667,227.12 | 12 | 2.64% | 9.80% |
| GASTROINTESTINAL AGENTS - MISC. | \$1,852,454.47 | 12 | 3.01% | \$1,637,787.64 | 13 | 2.59% | -11.59% |
| ENDOCRINE AND METABOLIC AGENTS - MISC. | \$1,493,350.36 | 14 | 2.42% | \$1,612,233.15 | 14 | 2.55% | 7.96% |
| NEUROMUSCULAR AGENTS | \$1,412,319.09 | 15 | 2.29% | \$1,448,695.90 | 15 | 2.29% | 2.58% |
| ANTIDEPRESSANTS | \$1,324,360.34 | 16 | 2.15% | \$1,347,162.97 | 16 | 2.13% | 1.72% |
| ANTICONVULSANTS | \$1,299,139.99 | 17 | 2.11% | \$1,294,246.13 | 17 | 2.05% | -0.38% |
| ANTICOAGULANTS | \$1,188,349.23 | 18 | 1.93% | \$1,007,735.03 | 18 | 1.59% | -15.20% |
| CARDIOVASCULAR AGENTS - MISC. | \$999,238.72 | 19 | 1.62% | \$822,749.91 | 19 | 1.30% | -17.66% |
| MISCELLANEOUS THERAPEUTIC CLASSES | \$413,388.40 | 20 | 0.67% | \$601,323.40 | 20 | 0.95% | 45.46% |

Top 20 Therapeutic Class by Prescription Count

| Category Description | Sept 2025 to Nov 2025 Total Claims | Previous Rank | Dec 2025 to Feb 2026 Total Claims | Current Rank | % Change |
|---|---------------------------------------|---------------|--------------------------------------|--------------|----------|
| ANTIDEPRESSANTS | 59,647 | 1 | 60,345 | 1 | 1.17% |
| ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | 29,011 | 2 | 30,670 | 2 | 5.72% |
| ANTICONVULSANTS | 27,221 | 3 | 28,033 | 3 | 2.98% |
| ANTIASTHMATIC AND BRONCHODILATOR AGENTS | 27,187 | 4 | 27,406 | 4 | 0.81% |
| ANTIDIABETICS | 23,421 | 5 | 24,084 | 5 | 2.83% |
| ANTIPSYCHOTICS/ANTIMANIC AGENTS | 20,537 | 8 | 21,764 | 6 | 5.97% |
| ANTIANKXIETY AGENTS | 20,767 | 7 | 21,575 | 7 | 3.89% |
| ANTIHYPERTENSIVES | 20,928 | 6 | 21,157 | 8 | 1.09% |
| ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | 18,852 | 9 | 17,822 | 9 | -5.46% |
| PENICILLINS | 13,330 | 11 | 16,762 | 10 | 25.75% |
| DERMATOLOGICALS | 14,971 | 10 | 14,824 | 11 | -0.98% |
| ANTIHYPERLIPIDEMICS | 12,198 | 12 | 12,109 | 12 | -0.73% |
| ANALGESICS - OPIOID | 11,285 | 14 | 11,654 | 13 | 3.27% |
| ANALGESICS - ANTI-INFLAMMATORY | 11,558 | 13 | 11,636 | 14 | 0.67% |
| ANTIHISTAMINES | 11,068 | 15 | 10,306 | 15 | -6.88% |
| BETA BLOCKERS | 9,777 | 16 | 9,870 | 16 | 0.95% |
| CORTICOSTEROIDS | 9,159 | 17 | 9,216 | 17 | 0.62% |
| MUSCULOSKELETAL THERAPY AGENTS | 8,047 | 18 | 8,099 | 18 | 0.65% |
| ANTIEMETICS | 6,312 | 21 | 7,679 | 19 | 21.66% |
| DIURETICS | 7,363 | 20 | 7,254 | 20 | -1.48% |

| Top 100 Drugs by Paid Amount | | | | | |
|------------------------------|----------------------------------|---------------|---------------------------------|--------------|----------|
| Drug Description | Sept 2025 to Nov 2025 Total Cost | Previous Rank | Dec 2025 to Feb 2026 Total cost | Current Rank | % Change |
| Ozempic | \$3,180,335.30 | 1 | \$3,403,724.32 | 1 | 7.02% |
| Dupixent | \$2,692,483.17 | 2 | \$2,863,429.58 | 2 | 6.35% |
| Vraylar | \$1,961,421.42 | 3 | \$2,132,180.87 | 3 | 8.71% |
| Humira (2 Pen) | \$1,851,723.84 | 4 | \$1,728,554.10 | 4 | -6.65% |
| Biktarvy | \$1,500,702.81 | 6 | \$1,577,791.07 | 5 | 5.14% |
| Skyrizi Pen | \$1,739,755.62 | 5 | \$1,413,973.26 | 6 | -18.73% |
| Trikafta | \$1,238,026.09 | 8 | \$1,383,137.31 | 7 | 11.72% |
| Invega Sustenna | \$1,147,309.98 | 9 | \$1,217,948.58 | 8 | 6.16% |
| Mounjaro | \$959,267.75 | 11 | \$1,160,178.89 | 9 | 20.94% |
| Jardiance | \$1,490,619.18 | 7 | \$1,145,868.96 | 10 | -23.13% |
| Cosentyx UnoReady | \$664,738.98 | 16 | \$891,605.31 | 11 | 34.13% |
| Zepbound | \$642,773.77 | 18 | \$866,632.06 | 12 | 34.83% |
| Duvyzat | \$957,545.08 | 12 | \$849,832.46 | 13 | -11.25% |
| Taltz | \$688,241.52 | 15 | \$802,033.86 | 14 | 16.53% |
| Hemlibra | \$720,449.70 | 14 | \$726,613.59 | 15 | 0.86% |
| Stelara | \$1,052,486.02 | 10 | \$711,565.15 | 16 | -32.39% |
| Altuviiio | \$541,205.96 | 23 | \$700,234.94 | 17 | 29.38% |
| Eliquis | \$847,790.65 | 13 | \$669,094.81 | 18 | -21.08% |
| Trulicity | \$663,834.19 | 17 | \$662,086.78 | 19 | -0.26% |
| Caplyta | \$432,071.56 | 31 | \$621,858.35 | 20 | 43.92% |
| Rexulti | \$560,538.07 | 19 | \$593,406.34 | 21 | 5.86% |
| Skyrizi | \$548,595.79 | 22 | \$586,754.63 | 22 | 6.96% |

| | | | | | |
|-----------------------------|--------------|-----|--------------|----|---------|
| Rinvoq | \$556,236.78 | 20 | \$552,236.92 | 23 | -0.72% |
| Nurtec | \$475,147.17 | 29 | \$520,961.84 | 24 | 9.64% |
| Abilify Maintena | \$496,834.02 | 26 | \$490,594.20 | 25 | -1.26% |
| Aristada | \$502,648.26 | 24 | \$486,858.45 | 26 | -3.14% |
| Symbicort | \$456,130.22 | 30 | \$470,184.76 | 27 | 3.08% |
| Norditropin FlexPro | \$349,171.28 | 34 | \$461,187.82 | 28 | 32.08% |
| Ingrezza | \$479,819.51 | 28 | \$450,379.45 | 29 | -6.14% |
| Lisdexamfetamine Dimesylate | \$497,964.67 | 25 | \$413,451.14 | 30 | -16.97% |
| Invega Trinza | \$394,434.93 | 33 | \$411,039.02 | 31 | 4.21% |
| Farxiga | \$492,913.96 | 27 | \$409,151.40 | 32 | -16.99% |
| Enbrel SureClick | \$550,288.37 | 21 | \$407,078.88 | 33 | -26.02% |
| Trelegy Ellipta | \$338,600.52 | 35 | \$406,954.79 | 34 | 20.19% |
| Humira (2 Syringe) | \$307,786.02 | 38 | \$334,767.32 | 35 | 8.77% |
| Ubrelvy | \$280,957.69 | 44 | \$333,256.64 | 36 | 18.61% |
| Ilaris | \$332,009.59 | 36 | \$330,655.50 | 37 | -0.41% |
| Daybue | \$266,253.15 | 46 | \$325,098.78 | 38 | 22.10% |
| Jornay PM | \$269,124.88 | 45 | \$319,907.25 | 39 | 18.87% |
| Trintellix | \$289,984.43 | 42 | \$316,178.06 | 40 | 9.03% |
| Lybalvi | \$262,129.04 | 47 | \$313,338.28 | 41 | 19.54% |
| Xarelto | \$299,493.02 | 40 | \$301,590.73 | 42 | 0.70% |
| Mavyret | \$161,632.10 | 68 | \$297,363.97 | 43 | 83.98% |
| Albuterol Sulfate HFA | \$296,129.24 | 41 | \$284,610.09 | 44 | -3.89% |
| Ajovy | \$255,873.57 | 49 | \$282,468.44 | 45 | 10.39% |
| Austedo XR | \$215,410.58 | 53 | \$274,431.01 | 46 | 27.40% |
| Alyftrek | \$429,485.22 | 32 | \$267,405.20 | 47 | -37.74% |
| Kesimpta | \$61,709.07 | 183 | \$261,595.01 | 48 | 323.92% |
| Livmarli | \$260,452.81 | 48 | \$259,207.51 | 49 | -0.48% |

| | | | | | |
|-----------------------|--------------|-----|--------------|----|---------|
| Xywav | \$303,310.08 | 39 | \$245,888.19 | 50 | -18.93% |
| Evryydi | \$188,520.86 | 58 | \$242,376.36 | 51 | 28.57% |
| Bimzelx | \$158,553.37 | 69 | \$238,949.45 | 52 | 50.71% |
| Qelbree | \$209,931.56 | 54 | \$224,074.08 | 53 | 6.74% |
| Tremfya One-Press | \$233,233.12 | 52 | \$221,569.33 | 54 | -5.00% |
| Creon | \$238,933.16 | 51 | \$207,557.49 | 55 | -13.13% |
| Fasenra Pen | \$185,570.61 | 60 | \$206,987.06 | 56 | 11.54% |
| Uzedy | \$120,844.62 | 96 | \$201,407.63 | 57 | 66.67% |
| Lantus SoloStar | \$200,490.76 | 56 | \$201,023.83 | 58 | 0.27% |
| Wakix | \$251,383.01 | 50 | \$199,499.77 | 59 | -20.64% |
| Alprolix | \$146,358.46 | 77 | \$192,228.52 | 60 | 31.34% |
| Abilify Asimtufii | \$137,209.44 | 84 | \$192,078.98 | 61 | 39.99% |
| Kisqali (400 MG Dose) | \$198,341.30 | 57 | \$191,637.24 | 62 | -3.38% |
| Advair HFA | \$202,600.89 | 55 | \$188,777.29 | 63 | -6.82% |
| Nemludio | \$118,953.86 | 99 | \$180,981.99 | 64 | 52.14% |
| Emgality | \$161,682.03 | 66 | \$175,364.33 | 65 | 8.46% |
| Lenalidomide | \$165,460.88 | 64 | \$173,600.69 | 66 | 4.92% |
| Kisqali (600 MG Dose) | \$104,141.57 | 118 | \$171,997.47 | 67 | 65.16% |
| Tremfya Pen | \$140,907.04 | 80 | \$171,693.95 | 68 | 21.85% |
| Xolair | \$139,123.86 | 82 | \$169,444.31 | 69 | 21.79% |
| Qulipta | \$165,361.99 | 65 | \$168,538.98 | 70 | 1.92% |
| Spiriva Respimat | \$157,709.39 | 70 | \$168,480.78 | 71 | 6.83% |
| Dovato | \$98,455.35 | 128 | \$168,475.04 | 72 | 71.12% |
| Cholbam | \$118,297.53 | 101 | \$164,825.98 | 73 | 39.33% |
| Ebglyss | \$105,370.74 | 116 | \$164,038.78 | 74 | 55.68% |
| Austedo | \$124,761.39 | 94 | \$162,752.96 | 75 | 30.45% |
| Adempas | \$149,528.27 | 75 | \$161,598.53 | 76 | 8.07% |

| | | | | | |
|------------------------------|--------------|-----|--------------|-----|---------|
| Opsumit | \$132,866.82 | 86 | \$160,287.00 | 77 | 20.64% |
| Sogroya | \$103,201.48 | 119 | \$157,781.89 | 78 | 52.89% |
| Zenpep | \$108,141.22 | 111 | \$154,752.24 | 79 | 43.10% |
| Insulin Lispro (1 Unit Dial) | \$127,179.90 | 91 | \$153,989.36 | 80 | 21.08% |
| Adynovate | \$73,358.78 | 161 | \$152,967.80 | 81 | 108.52% |
| Amoxicillin | \$112,894.21 | 107 | \$152,479.71 | 82 | 35.06% |
| Epidiolex | \$146,234.18 | 78 | \$150,196.43 | 83 | 2.71% |
| Tezspire | \$110,675.44 | 108 | \$149,896.94 | 84 | 35.44% |
| Sofosbuvir-Velpatasvir | \$150,472.13 | 72 | \$148,308.91 | 85 | -1.44% |
| Gattex | \$281,419.92 | 43 | \$143,054.60 | 86 | -49.17% |
| Linzess | \$187,275.00 | 59 | \$140,134.20 | 87 | -25.17% |
| Orladeyo | \$130,707.33 | 88 | \$137,488.47 | 88 | 5.19% |
| Briviact | \$127,666.00 | 90 | \$134,307.75 | 89 | 5.20% |
| Jakafi | \$167,306.30 | 63 | \$131,382.17 | 90 | -21.47% |
| Vyvanse | \$149,959.07 | 74 | \$131,307.75 | 91 | -12.44% |
| Methylphenidate HCl ER (OSM) | \$129,322.63 | 89 | \$130,254.23 | 92 | 0.72% |
| Wegovy | \$70,215.18 | 167 | \$129,775.14 | 93 | 84.82% |
| Breztri Aerosphere | \$126,749.20 | 93 | \$129,493.42 | 94 | 2.17% |
| Enbrel | \$48,327.17 | 214 | \$129,312.89 | 95 | 167.58% |
| Paxlovid (300/100) | \$40,147.09 | 248 | \$125,959.87 | 96 | 213.75% |
| Ayvakit | \$81,695.26 | 147 | \$125,576.28 | 97 | 53.71% |
| Voranigo | \$81,617.78 | 148 | \$124,058.61 | 98 | 52.00% |
| Amphetamine-Dextroamphet ER | \$119,317.27 | 98 | \$123,436.45 | 99 | 3.45% |
| Descovy | \$140,813.35 | 81 | \$122,810.71 | 100 | -12.78% |

Top 100 Drugs by Prescription Count

| Drug Description | Sept 2025 to Nov 2025 Total Claims | Previous Rank | Dec 2025 to Feb 2026 Total Claims | Current Rank | % Change |
|-----------------------------|------------------------------------|---------------|-----------------------------------|--------------|----------|
| Amoxicillin | 8,630 | 4 | 11,427 | 1 | 32.41% |
| Albuterol Sulfate HFA | 9,966 | 1 | 10,002 | 2 | 0.36% |
| traZODone HCl | 8,763 | 3 | 8,935 | 3 | 1.96% |
| buPROPion HCl ER (XL) | 8,474 | 5 | 8,808 | 4 | 3.94% |
| Sertraline HCl | 8,849 | 2 | 8,732 | 5 | -1.32% |
| FLUoxetine HCl | 7,254 | 7 | 7,435 | 6 | 2.50% |
| Omeprazole | 7,835 | 6 | 7,229 | 7 | -7.73% |
| Gabapentin | 6,944 | 9 | 7,039 | 8 | 1.37% |
| Escitalopram Oxalate | 7,021 | 8 | 6,925 | 9 | -1.37% |
| hydrOXYzine HCl | 6,734 | 12 | 6,924 | 10 | 2.82% |
| Atorvastatin Calcium | 6,796 | 10 | 6,639 | 11 | -2.31% |
| busPIRone HCl | 6,095 | 13 | 6,316 | 12 | 3.63% |
| Levothyroxine Sodium | 6,795 | 11 | 5,966 | 13 | -12.20% |
| predniSONE | 5,190 | 14 | 5,344 | 14 | 2.97% |
| Ondansetron | 4,183 | 26 | 5,234 | 15 | 25.13% |
| QUETiapine Fumarate | 4,828 | 18 | 5,136 | 16 | 6.38% |
| Lisinopril | 5,172 | 15 | 5,062 | 17 | -2.13% |
| Amphetamine-Dextroamphet ER | 4,833 | 17 | 5,047 | 18 | 4.43% |
| Amoxicillin-Pot Clavulanate | 4,216 | 24 | 4,940 | 19 | 17.17% |
| Montelukast Sodium | 4,995 | 16 | 4,820 | 20 | -3.50% |
| cloNIDine HCl | 4,693 | 19 | 4,801 | 21 | 2.30% |
| ARIPiprazole | 4,493 | 21 | 4,782 | 22 | 6.43% |
| Lisdexamfetamine Dimesylate | 4,129 | 27 | 4,475 | 23 | 8.38% |

| | | | | | |
|-------------------------------|-------|-----|-------|----|----------|
| DULoxetine HCl | 4,423 | 22 | 4,456 | 24 | 0.75% |
| lamoTRigine | 4,218 | 23 | 4,440 | 25 | 5.26% |
| Azithromycin | 4,030 | 29 | 4,240 | 26 | 5.21% |
| amLODIPine Besylate | 4,195 | 25 | 4,225 | 27 | 0.72% |
| Pantoprazole Sodium | 4,525 | 20 | 4,207 | 28 | -7.03% |
| HYDROcodone-Acetaminophen | 4,023 | 30 | 4,129 | 29 | 2.63% |
| Cyclobenzaprine HCl | 3,966 | 31 | 3,920 | 30 | -1.16% |
| Cetirizine HCl | 4,121 | 28 | 3,870 | 31 | -6.09% |
| Amphetamine-Dextroamphetamine | 3,631 | 33 | 3,837 | 32 | 5.67% |
| Methylphenidate HCl ER (OSM) | 3,613 | 34 | 3,655 | 33 | 1.16% |
| Ozempic | 3,467 | 37 | 3,628 | 34 | 4.64% |
| Losartan Potassium | 3,409 | 39 | 3,547 | 35 | 4.05% |
| Famotidine | 3,530 | 36 | 3,501 | 36 | -0.82% |
| Fluticasone Propionate | 3,737 | 32 | 3,495 | 37 | -6.48% |
| Venlafaxine HCl ER | 3,583 | 35 | 3,487 | 38 | -2.68% |
| Oseltamivir Phosphate | 76 | 467 | 3,453 | 39 | 4443.42% |
| Metoprolol Succinate ER | 3,423 | 38 | 3,408 | 40 | -0.44% |
| Topiramate | 3,355 | 41 | 3,371 | 41 | 0.48% |
| Ibuprofen | 3,197 | 42 | 3,323 | 42 | 3.94% |
| Cephalexin | 3,404 | 40 | 3,187 | 43 | -6.37% |
| clonazepam | 3,066 | 43 | 3,180 | 44 | 3.72% |
| Cefdinir | 2,427 | 54 | 3,089 | 45 | 27.28% |
| ALPRAZolam | 2,956 | 44 | 3,052 | 46 | 3.25% |
| Jardiance | 2,793 | 45 | 2,964 | 47 | 6.12% |
| metFORMIN HCl ER | 2,676 | 48 | 2,781 | 48 | 3.92% |
| metFORMIN HCl | 2,717 | 46 | 2,670 | 49 | -1.73% |
| risperiDONE | 2,535 | 51 | 2,663 | 50 | 5.05% |

| | | | | | |
|-------------------------|-------|----|-------|----|--------|
| Lantus SoloStar | 2,631 | 49 | 2,663 | 51 | 1.22% |
| Triamcinolone Acetonide | 2,578 | 50 | 2,572 | 52 | -0.23% |
| Meloxicam | 2,683 | 47 | 2,534 | 53 | -5.55% |
| Rosuvastatin Calcium | 2,483 | 53 | 2,495 | 54 | 0.48% |
| Propranolol HCl | 2,415 | 55 | 2,489 | 55 | 3.06% |
| Albuterol Sulfate | 2,369 | 56 | 2,472 | 56 | 4.35% |
| oxyCODONE HCl | 2,331 | 57 | 2,467 | 57 | 5.83% |
| Mirtazapine | 2,233 | 60 | 2,407 | 58 | 7.79% |
| guanFACINE HCl ER | 2,220 | 62 | 2,370 | 59 | 6.76% |
| Aspirin Low Dose | 2,522 | 52 | 2,351 | 60 | -6.78% |
| Prazosin HCl | 2,291 | 58 | 2,299 | 61 | 0.35% |
| metroNIDAZOLE | 2,253 | 59 | 2,284 | 62 | 1.38% |
| hydrOXYzine Pamoate | 2,117 | 64 | 2,281 | 63 | 7.75% |
| levETIRAcetam | 2,183 | 63 | 2,222 | 64 | 1.79% |
| Pregabalin | 1,981 | 73 | 2,169 | 65 | 9.49% |
| Symbicort | 2,102 | 65 | 2,155 | 66 | 2.52% |
| LORazepam | 2,033 | 69 | 2,123 | 67 | 4.43% |
| Spironolactone | 2,094 | 67 | 2,112 | 68 | 0.86% |
| traMADol HCl | 2,097 | 66 | 2,083 | 69 | -0.67% |
| Folic Acid | 2,040 | 68 | 2,078 | 70 | 1.86% |
| valACYclovir HCl | 1,814 | 77 | 2,062 | 71 | 13.67% |
| Fluconazole | 2,221 | 61 | 2,037 | 72 | -8.28% |
| guanFACINE HCl | 2,011 | 72 | 2,011 | 73 | 0.00% |
| Furosemide | 2,012 | 71 | 2,004 | 74 | -0.40% |
| Methylphenidate HCl | 1,886 | 75 | 1,996 | 75 | 5.83% |
| Ondansetron HCl | 1,692 | 79 | 1,971 | 76 | 16.49% |
| Loratadine | 2,025 | 70 | 1,912 | 77 | -5.58% |

| | | | | | |
|-------------------------------|-------|-----|-------|-----|---------|
| hydroCHLOROthiazide | 1,926 | 74 | 1,818 | 78 | -5.61% |
| Atomoxetine HCl | 1,655 | 81 | 1,745 | 79 | 5.44% |
| Eliquis | 1,636 | 84 | 1,726 | 80 | 5.50% |
| OLANzapine | 1,626 | 86 | 1,665 | 81 | 2.40% |
| Amitriptyline HCl | 1,667 | 80 | 1,662 | 82 | -0.30% |
| tiZANidine HCl | 1,633 | 85 | 1,660 | 83 | 1.65% |
| Allergy Relief Cetirizine | 1,713 | 78 | 1,590 | 84 | -7.18% |
| FeroSul | 1,509 | 89 | 1,557 | 85 | 3.18% |
| Mupirocin | 1,644 | 83 | 1,522 | 86 | -7.42% |
| prednisoLONE Sodium Phosphate | 1,569 | 88 | 1,517 | 87 | -3.31% |
| Baclofen | 1,444 | 90 | 1,512 | 88 | 4.71% |
| Sulfamethoxazole-Trimethoprim | 1,648 | 82 | 1,501 | 89 | -8.92% |
| Dexmethylphenidate HCl ER | 1,426 | 91 | 1,490 | 90 | 4.49% |
| Vraylar | 1,393 | 92 | 1,478 | 91 | 6.10% |
| Doxycycline Monohydrate | 1,832 | 76 | 1,470 | 92 | -19.76% |
| Desvenlafaxine Succinate ER | 1,369 | 95 | 1,439 | 93 | 5.11% |
| Nystatin | 1,587 | 87 | 1,432 | 94 | -9.77% |
| Naltrexone HCl | 1,369 | 94 | 1,398 | 95 | 2.12% |
| SUMAtriptan Succinate | 1,345 | 96 | 1,334 | 96 | -0.82% |
| Acetaminophen Extra Strength | 1,300 | 97 | 1,323 | 97 | 1.77% |
| Naproxen | 1,379 | 93 | 1,318 | 98 | -4.42% |
| Polyethylene Glycol 3350 | 1,134 | 102 | 1,257 | 99 | 10.85% |
| Zolpidem Tartrate | 1,219 | 100 | 1,249 | 100 | 2.46% |

**Medicaid Statistics for Prescription Claims
December 2025 through February 2026**

Tri-Monthly Statistics

| | FFS | Wellpoint | Iowa Total Care | Molina Healthcare | Total** |
|------------------------------------|-------------|------------------|------------------------|--------------------------|----------------|
| Total Dollars Paid | \$3,108,774 | \$108,916,904 | \$87,459,109 | \$63,230,774 | \$262,715,561 |
| Users | 3,580 | 104,140 | 97,346 | 81,854 | 286,920 |
| Cost Per User | \$868.37 | \$1,045.87 | \$898.44 | \$772.48 | |
| Total Prescriptions | 23,201 | 774,732 | 645,443 | 489,860 | 1,933,236 |
| Average Rx/User | 6.48 | 7.44 | 6.63 | 5.98 | |
| Average Cost/Rx | \$133.99 | \$140.59 | \$135.50 | \$129.08 | |
| # Generic Prescriptions | 20,946 | 688,899 | 579,736 | 442,453 | |
| % Generic | 90.3% | 88.9% | 90.0% | 90.3% | |
| \$ Generic | \$1,011,914 | \$13,904,584 | \$10,724,586 | \$8,319,688 | |
| Average Generic Rx Cost | \$48.31 | \$20.18 | \$18.50 | \$18.80 | |
| Average Generic Days Supply | 28 | 29.83 | 30 | 29.75 | |
| # Brand Prescriptions | 2,255 | 85,833 | 64,679 | 47,407 | |
| % Brand | 9.7% | 11.1% | 10.0% | 9.7% | |
| \$ Brand | \$2,096,860 | \$95,012,320 | \$76,707,625 | \$54,911,068 | |
| Average Brand Rx Cost | \$929.87 | \$1,106.94 | \$1,185.97 | \$1,158.29 | |
| Average Brand Days Supply | 28 | 27.8 | 29 | 28.3 | |

**All reported dollars are pre-rebate

Top 20 Therapeutic Class by Paid Amount*

December 2025 through February 2026

| | FFS | Wellpoint | Iowa Total Care | Molina Healthcare |
|----|---|---|---|--|
| 1 | ANTIDIABETICS | DERMATOLOGICALS | ANTIDIABETICS | DERMATOLOGICALS |
| 2 | ANALGESICS - ANTI-INFLAMMATORY | ANTIDIABETICS | DERMATOLOGICALS | ANTIDIABETICS |
| 3 | DERMATOLOGICALS | ANTIPSYCHOTICS/ANTIMANIC AGENTS | ANTIPSYCHOTICS/ANTIMANIC AGENTS | ANTIPSYCHOTICS/ANTIMANIC AGENTS |
| 4 | ANTIPSYCHOTICS/ANTIMANIC AGENTS | ANALGESICS - ANTI-INFLAMMATORY | ANALGESICS - ANTI-INFLAMMATORY | ANALGESICS - ANTI-INFLAMMATORY |
| 5 | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | ADHD/ANTI-NARCOLEPSY AGENTS/ANTI-OBESITY-ANOREXIANTS |
| 6 | ANTICONVULSANTS | ANTIASTHMATIC AND BRONCHODILATOR AGENTS | ANTIASTHMATIC AND BROCHODILATOR AGENTS | ANTIASTHMATIC AND BRONCHODILATOR AGENTS |
| 7 | ANTIASTHMATIC AND BRONCHODILATOR AGENTS | ENDOCRINE AND METABOLIC AGENTS - MISC. | RESPIRATORY AGENTS - MISC. | ANTIVIRALS |
| 8 | ANTIVIRALS | PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. | ANTIVIRALS | ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES |
| 9 | NEUROMUSCULAR AGENTS | MIGRAINE PRODUCTS | PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. | HEMATOLOGICAL AGENTS - MISC. |
| 10 | ANTIDEPRESSANTS | ANTICONVULSANTS | ENDOCRINE AND METABOLIC AGENTS - MISC. | PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. |
| 11 | PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS - MISC. | ANTIVIRALS | ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES | RESPIRATORY AGENTS - MISC. |
| 12 | RESPIRATORY AGENTS - MISC. | CARDIOVASCULAR AGENTS - MISC. | HEMATOLOGICAL AGENTS - MISC. | MIGRAINE PRODUCTS |
| 13 | MIGRANE PRODUCTS | ANTINEOPLASTICS AND ADJUNCTIVE THERAPIES | ANTICONVULSANTS | GASTROINTESTINAL AGENTS - MISC. |
| 14 | ANTIHYPERTENSIVES | HEMATOLOGICAL AGENTS - MISC. | MIGRAINE PRODUCTS | ENDOCRINE AND METABOLIC AGENTS - MISC. |
| 15 | ANALGESICS - OPIOID | RESPIRATORY AGENTS - MISC. | CARDIOVASCULAR AGENTS - MISC. | NEUROMUSCULAR AGENTS |
| 16 | ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | GASTROINTESTINAL AGENTS - MISC. | NEUROMUSCULAR AGENTS | ANTIDEPRESSANTS |
| 17 | CORTICOSTEROIDS | ANTIDEPRESSANTS | ANTIDEPRESSANTS | ANTICONVULSANTS |
| 18 | ANTIANSIETY AGENTS | NEUROMUSCULAR AGENTS | GASTROINTESTINAL AGENTS - MISC. | ANTICOAGULANTS |
| 19 | ANTICOAGULANTS | ANTICOAGULANTS | ANTICOAGULANTS | CARDIOVASCULAR AGENTS - MISC. |
| 20 | ENDOCRINE AND METABOLIC AGENTS - MISC. | MISCELLANEOUS THERAPEUTIC CLASSES | CORTICOSTEROIDS | MISCELLANEOUS THERAPEUTIC CLASSES |

* Pre-rebate

Top 20 Therapeutic Class by Prescription Count

December 2025 through February 2026

| | FFS | Wellpoint | Iowa Total Care | Molina Healthcare |
|----|---|---|---|---|
| 1 | ANTIDEPRESSANTS | ANTIDEPRESSANTS | ANTIDEPRESSANTS | ANTIDEPRESSANTS |
| 2 | ANTICONVULSANTS | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS |
| 3 | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | ANTICONVULSANTS | ANTICONVULSANTS | ANTICONVULSANTS |
| 4 | ANTIASTHMATIC AND BRONCHODILATOR AGENTS | ANTIASTHMATIC AND BRONCHODILATOR AGENTS | ANTIASTHMATIC AND BRONCHODILATOR AGENTS | ANTIASTHMATIC AND BRONCHODILATOR AGENTS |
| 5 | ANTIPSYCHOTICS/ANTIMANIC AGENTS | ANTIPSYCHOTICS/ANTIMANIC AGENTS | ANTIPSYCHOTICS/ANTIMANIC AGENTS | ANTIDIABETICS |
| 6 | ANTIDIABETICS | ANTIDIABETICS | ANTIDIABETICS | ANTIPSYCHOTICS/ANTIMANIC AGENTS |
| 7 | ANTIHYPERTENSIVES | ANTIAXIETY AGENTS | ANTIAXIETY AGENTS | ANTIAXIETY AGENTS |
| 8 | ANTIAXIETY AGENTS | ANTIHYPERTENSIVES | ANTIHYPERTENSIVES | ANTIHYPERTENSIVES |
| 9 | ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS | ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS |
| 10 | ANALGESICS - OPIOID | ANTIHISTAMINES | PENICILLINS | PENICILLINS |
| 11 | ANTIHISTAMINES | DERMATOLOGICALS | DERMATOLOGICALS | DERMATOLOGICALS |
| 12 | DERMATOLOGICALS | ANTHYPERLIPIDEMICS | ANTIHISTAMINES | ANTHYPERLIPIDEMICS |
| 13 | ANALGESICS - ANTI-INFLAMMATORY | PENICILLINS | ANTHYPERLIPIDEMICS | ANALGESICS - OPIOID |
| 14 | ANTHYPERLIPIDEMICS | ANALGESICS - ANTI-INFLAMMATORY | ANALGESICS - ANTI-INFLAMMATORY | ANALGESICS - ANTI-INFLAMMATORY |
| 15 | PENICILLINS | ANALGESICS - OPIOID | ANALGESICS - OPIOID | ANTIHISTAMINES |
| 16 | BETA BLOCKERS | BETA BLOCKERS | BETA BLOCKERS | BETA BLOCKERS |
| 17 | MUSCULOSKELETAL THERAPY AGENTS | MUSCULOSKELETAL THERAPY AGENTS | CORTICOSTEROIDS | CORTICOSTEROIDS |
| 18 | DIURETICS | CORTICOSTEROIDS | MUSCULOSKELETAL THERAPY AGENTS | MUSCULOSKELETAL THERAPY AGENTS |
| 19 | LAXATIVES | THYROID AGENTS | ANALGESICS - NONNARCOTIC | ANTIEMETICS |
| 20 | THYROID AGENTS | DIURETICS | DIURETICS | DIURETICS |

Top 25 Drugs by Paid Amount**

December 2025 through February 2026

| | FFS | Wellpoint | Iowa Total Care | Molina Healthcare |
|----|---------------------|----------------------|-------------------|-------------------|
| 1 | HUMIRA PEN | OZEMPIC | OZEMPIC | OZEMPIC |
| 2 | OZEMPIC | VRAYLAR | DUPIXENT | DUPIXENT |
| 3 | EVRYSDI | DUPIXENT PEN | HUMIRA PEN | VRAYLAR |
| 4 | VRAYLAR | HUMIRA (CF) PEN | VRAYLAR | HUMIRA (2 PEN) |
| 5 | SKYRIZI PEN | MOUNJARO | TRIKAFTA | BIKTARVY |
| 6 | ENBREL SURECLICK | SKYRIZI PEN | MOUNJARO | SKYRIZI PEN |
| 7 | TRIKAFTA | INVEGA SUSTENNA | INVEGA SUSTENNA | TRIKAFTA |
| 8 | BIKTARVY | TRIKAFTA | SKYRIZI PEN | INVEGA SUSTENNA |
| 9 | DUPIXENT | JARDIANCE | BIKTARVY | MOUNJARO |
| 10 | JARDIANCE | STELARA | JARDIANCE | JARDIANCE |
| 11 | COSENTYX UNOREADY | BIKTARVY | DUVYZAT | COSENTYX UNOREADY |
| 12 | MOUNJARO | ZEPBOUND | REXULTI | ZEPBOUND |
| 13 | KESIMPTA | REXULTI | INGREZZA | DUVYZAT |
| 14 | ARISTADA | TRULICITY | TREMFYA | TALTZ |
| 15 | RINVOQ | TALTZ AUTOINJECTOR | TALTZ | HEMLIBRA |
| 16 | ALBUTEROL SULFATE | NURTEC ODT | TRULICITY | STELARA |
| 17 | JORNAY PM | ALTUVIIIIO | ELIQUIS | ALTUVIIIIO |
| 18 | METHYLPHENIDATE | RINVOQ | CAPLYTA | ELIQUIS |
| 19 | VYVANSE | ELIQUIS | ZEPBOUND | TRULICITY |
| 20 | INGREZZA | DUPIXENT SYRINGE | STELARA | CAPLYTA |
| 21 | EPIDIOLEX | WAKIX | ARISTADA | REXULTI |
| 22 | NORDITROPIN FLEXPRO | CAPLYTA | RINVOQ | SKYRIZI |
| 23 | INVEGA SUSTENNA | COSENTYX UNOREADY | NURTEC | RINVOQ |
| 24 | TALTZ | BIMZELX AUTOINJECTOR | COSENTYX UNOREADY | NURTEC |
| 25 | IBUPROFEN | SKYRIZI ON-BODY | ALTUVIIIIO | ABILIFY MAINTENA |

** Pre-rebate

Top 25 Drugs by Prescription Count

December 2025 through February 2026

| | FFS | Wellpoint | Iowa Total Care | Molina Healthcare |
|----|--------------------------|------------------------|---------------------|-------------------------|
| 1 | ALBUTEROL | TRAZODONE | ALBUTEROL | AMOXICILLIN |
| 2 | TRAZODONE | SERTRALINE | AMOXICILLIN | ALBUTEROL HFA |
| 3 | CETIRIZINE | ALBUTEROL HFA | BUPROPION | TRAZODONE |
| 4 | METHYLPHENIDATE | BUPROPION XL | TRAZODONE | BUPROPION XL |
| 5 | GABAPENTIN | AMOXICILLIN | SERTRALINE | SERTRALINE |
| 6 | FLUOXETINE | OMEPRAZOLE | AMPHET/DEXTROAMPHET | FLUOXETINE |
| 7 | SERTRALINE | FLUOXETINE | FLUOXETINE | OMEPRAZOLE |
| 8 | ATORVASTATIN | HYDROXYZINE HCL | OMEPRAZOLE | GABAPENTIN |
| 9 | HYDROXYZINE HCL | GABAPENTIN | HYDROXYZINE HCL | ESCITALOPRAM |
| 10 | ESCITALOPRAM | LEVOTHYROXINE | METHYLPHENIDATE | HYDROXYZINE HCL |
| 11 | AMPHETAMINE/DEXTROAMPHET | ESCITALOPRAM | ESCITALOPRAM | ATORVASTATIN |
| 12 | OMEPRAZOLE | ATORVASTATIN | ATORVASTATIN | BUSPIRONE |
| 13 | CLONIDINE | CETIRIZINE | GABAPENTIN | LEVOTHYROXINE |
| 14 | LEVOTHYROXINE | BUSPIRONE | ONDANSETRON | PREDNISONE |
| 15 | QUETIAPINE | MONTELUKAST | CETIRIZINE | ONDANSETRON |
| 16 | METFORMIN | CLONIDINE | LEVOTHYROXINE | QUETIAPINE |
| 17 | BUPROPION | QUETIAPINE | BUSPIRONE | LISINOPRIL |
| 18 | ARIPIRAZOLE | AMPHET/DEXTROAMPHET ER | MONTELUKAST | AMPHET/DEXTROAMPHET ER |
| 19 | BUSPIRONE | ARIPIRAZOLE | QUETIAPINE | AMOXICILLIN/CLAVULANATE |
| 20 | AMOXICILLIN | LAMOTRIGINE | METFORMIN | MONTELUKAST |
| 21 | MONTELUKAST | LISINOPRIL | CLONIDINE | CLONIDINE |
| 22 | PANTOPRAZOLE | PREDNISONE | GUANFACINE | ARIPIRAZOLE |
| 23 | LISINOPRIL | PANTOPRAZOLE | ARIPIRAZOLE | LISDEXAMFETAMINE |
| 24 | LAMOTRIGINE | DULOXETINE | LISINOPRIL | DULOXETINE |
| 25 | LEVETIRACETAM | ONDANSETRON ODT | PREDNISONE | LAMOTRIGINE |

Adherence to Antipsychotic Medications in Patients with Schizophrenia RetroDUR Data

Purpose

- Evaluate the adherence of antipsychotic medications among members diagnosed with schizophrenia or schizoaffective disorder.

Background

- Schizophrenia and schizoaffective disorder require long-term antipsychotic therapy.
- Non-adherence is common among these patients and is associated with relapse, hospitalization, functional decline, and increased mortality.
- This proposal aligns with the HEDIS measure: *Adherence to Antipsychotic Medications for Individuals with Schizophrenia*.
- Medications include oral and injectable first- and second-generation antipsychotics.

RDUR Criteria

- Members \geq 18 years of age
- Diagnosis of schizophrenia (F20.*) or schizoaffective disorder (F25.*)
- At least 2 claims for an antipsychotic during the time period
- Members must have continuous eligibility during the pharmacy claim lookback period
- Time period
 - Pharmacy claims: August 1, 2025 – January 31, 2026
 - Medical Claims: February 1, 2024 – January 31, 2026
- Report
 - Total number of members meeting the above criteria
 - Number of members with a proportion of days covered (PDC) \geq 80% and $<$ 80% during the time period.

Data

| | ITC | MHC | WLP | FFS |
|---------------------------|--------------|--------------|----------------|-------------|
| Members with PDC ≥ 80% | 837 (66%) | 648 (76%) | 1,371 (74%) | 23 (58%) |
| Members with PDC < 80% | 464 (34%) | 206 (24%) | 494 (26%) | 17 (42%) |
| Total Members | 1,301 | 854 | 1,865 | 40 |
| Total Prescribers | 708 | 556 | 805 | 46 |

Next Steps

1. Send letters to prescribers for patients with a PDC < 80% to share adherence findings and suggest follow-up care.
2. Other.
3. Nothing.

Evaluation of the Use of Duplicate Therapy For Autoimmune Disorders RetroDUR Data

Purpose

- Identify those members who are taking more than one immunomodulatory agent, such as a biological, a Janus Kinase (JAK) inhibitor, an interleukin-1 receptor antagonist, or a phosphodiesterase 4 inhibitor agent, to determine whether concurrent therapy is occurring and if it is clinically appropriate.

Background

- Recent literature suggests that some patients may benefit from more than one therapy with conditions such as inflammatory bowel disease, atopic dermatitis, psoriasis, or psoriatic arthritis. However, there is no definitive guidance about how and when to initiate additional agents.
- Current Iowa Medicaid criteria is directed at the use of single agents only. The JAK inhibitor criteria specify that patients should not use or plan to use a JAK inhibitor in combination with other JAK inhibitors, biologics, or potent immunosuppressants (azathioprine or cyclosporine).
- Risk of infection exists with immunomodulatory agents in general, including risk of activation of latent infections of Hepatitis B or C, or Tuberculosis.
- Pre-treatment testing for latent infections, and pretreatment administration of vaccinations, is one way to mitigate this risk.
- Fabisiak et al propose that dual biologic therapy for inflammatory bowel disease can lead to clinical improvements without significant negative impacts on safety and tolerability.
- Hren et al state that with respect to complex patients with atopic dermatitis and psoriasis/psoriatic arthritis, and/or inflammatory bowel disease their research demonstrated that “dual biologic therapy can be prescribed, leading to a positive response, with only minor adverse events”, in a small retrospective study.

RDUR Criteria

- Time period: August 1, 2025 to January 31, 2026
- Identify members with more than one systemic medication (listed below), that overlap for 60 days or more.
- Report number of members, number of unique prescribers, and number of pharmacies.
- Drugs to included:

- Janus Kinase inhibitors: abrocitinib, ritlecitinib, baricitinib, upadacitinib, tofacitinib, deucravacitinib
- Biologics (include biosimilars): adalimumab, golimumab, sarilumab, tocilizumab, etanercept, abatacept, rilonacept, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, spesolimab, tildrakizumab, ustekinumab, dupilumab, lebrikizumab, tralokinumab, nemolizumab, mirikizumab, vedolizumab, infliximab, mepolizumab, benralizumab, tezepelumab, omalizumab
- Phosphodiesterase-4 inhibitor: apremilast
- Interleukin 1 antagonists: anakinra, canakinumab

Data

| Drug Combination | Iowa Total Care | Wellpoint | Molina | FFS |
|------------------------------|------------------------|------------------|---------------|------------|
| Xolair + Dupixent | 1 | 1 | 0 | 0 |
| Taltz + Xeljanz | 1 | 0 | 0 | 0 |
| Skyrizi + Otezla | 2 | 1 | 0 | 0 |
| Orencia Clickjet + Otezla | 1 | 0 | 0 | 0 |
| Rinvoq + Otezla | 1 | 0 | 0 | 0 |
| Humira + Dupixent | 1 | 2 | 0 | 0 |
| Orencia Clickjet + Xolair | 1 | 0 | 0 | 0 |
| Cosentyx + Xolair | 0 | 2 | 0 | 0 |
| Dupixent + Nucala | 0 | 2 | 0 | 0 |
| Humira + Otezla | 0 | 2 | 0 | 0 |
| Tremfya + Otezla | 0 | 2 | 0 | 0 |
| Dupixent + Fasenra | 0 | 1 | 0 | 0 |
| Dupixent + Stelara | 0 | 1 | 0 | 0 |
| Fasenra + Xolair | 0 | 1 | 0 | 0 |
| Humira + Tezspire | 0 | 1 | 0 | 0 |
| Humira + Skyrizi | 0 | 1 | 0 | 0 |
| Cosentyx + Otezla | 0 | 1 | 0 | 0 |
| Xeljanz + Otezla | 0 | 1 | 0 | 0 |
| Taltz + Otezla | 0 | 1 | 0 | 0 |
| Rinvoq + Tremfya | 0 | 1 | 0 | 0 |
| Rinvoq + Skyrizi | 0 | 1 | 0 | 0 |
| Fasenra + Dupixent + Actemra | 0 | 0 | 1 | 0 |
| Kineret + Ilaris + Xeljanz | 0 | 0 | 1 | 0 |
| Total Members | 8 | 22 | 2 | 0 |
| Total Prescribers | 15 | 37 | 5 | 0 |

Next Steps

1. Send letters to identified prescribers to call attention to combination therapy?
And/or ask about treatment plan and rationale?
2. DUR Digest Article?
3. Other?

References

- Advancements in dual biologic therapy for inflammatory bowel diseases: efficacy, safety, and future directions. Adam Fabisiak, Mitoz Caban, Patrycja Dudek, Aleksandra Strigac, Ewa Matecka-Wojcieszko, Renata Talar-Wojnarowska. Published January of 2025 in Therapeutic Advances in Gastroenterology, DOI <https://journals.sagepub.com/doi/10.1177/17562848241309871>.
- Efficacy and Safety of Omalizumab and Dupilumab in Pediatric Patients with Skin Diseases: An Observational Study. F Galletta, L Rizzuti, S Passanisi, E Rosa, L Caminiti, S Manti. Published February of 2025 in Journal of Personalized Medicine, DOI <https://www.mdpi.com/2075-4426/15/2/64>.
- Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease. Mary Grace Hren, Sophie Guenin, Saakshi Khattri. Published July of 2024 in Journal of the American Academy of Dermatology, DOI [https://www.jaad.org/article/S0190-9622\(24\)00492-4/fulltext](https://www.jaad.org/article/S0190-9622(24)00492-4/fulltext).
- Dual Therapy in Inflammatory Bowel Disease, G Altieri, A Zilli, TL Parigi, M Allocca, F Furfaro, G Fiorino, C Cicerone, L Peyrin-Biroulet, S Danese, F D'Amico. Published February of 2025 in Biomolecules, DOI <https://www.mdpi.com/2218-273X/15/2/222>.

Extended-Release ADHD Stimulants in Children Younger than 6 Years RetroDUR Proposal

Purpose

Identify and evaluate the use of extended-release (ER) stimulant medications for attention deficit/hyperactivity disorder (ADHD) in children younger than 6 years of age.

Background

- In June 2025, the U.S. Food and Drug Administration (FDA) issued a [Drug Safety Communication](#) announcing required labeling updates for all ER stimulant formulations indicated for ADHD, including amphetamine and methylphenidate products.
- The labeling updates warn of an increased risk of clinically significant weight loss, $\geq 10\%$ decrease in the Centers for Disease Control and Prevention (CDC) weight percentile, and other adverse reactions in patients younger than 6 years of age receiving these medications.
- The FDA reviewed data from clinical trials of ER formulations and determined that patients younger than 6 years of age have higher plasma exposures and higher rates of adverse effects compared to older children receiving the same dosages.
- For patients younger than 6 years experiencing weight loss or other adverse reactions while taking ER stimulants, consideration should be given to discontinuing the medication and/or switching to an alternative treatment (e.g. immediate-release stimulant).

Proposed RDUR Criteria

- Time period: February 1, 2026 through April 30, 2026
- Members < 6 years at the time of the pharmacy claim
- At least one pharmacy claim for an ER stimulant
 - ER methylphenidate products
 - ER amphetamine products
- Report total number of members and number of prescribers
 - Also break out by ER methylphenidate products and ER amphetamine products

**CGRP Inhibitor Therapeutic Duplication
RetroDUR
Proposal**

Purpose: Identify members with duplicate calcitonin gene-related peptide (CGRP) inhibitor treatment for migraines that overlap more than 60 days to determine if clinically appropriate.

Background: The most recent advances in migraine treatment involve two new subclasses of drugs. “Gepants” and “Monoclonal antibodies” (MAB). These treat migraine headaches by targeting calcitonin gene-related peptide (CGRP) for acute treatment or preventative treatment. The table below lists the available products, the subclass they belong to, the mechanism of action, type of migraine treatment, Iowa Medicaid preferred drug list formulary designation and administration details.

Iowa Medicaid has two prior authorization (PA) forms for migraine treatment. One for acute treatment and one for preventive treatment. Nurtec ODT can be used for both acute and prophylaxis treatment and is on both prior authorization forms. In addition, Vypti is only administered intravenously and requires coverage and reimbursement on the medical benefit, causing another avenue of potential inadvertent drug duplication. The PA form titles with their corresponding CGRP inhibitors are:

- 1) Acute Migraine Treatment: Nurtec ODT, Ubrelvy, Zavzpret
- 2) Selective Preventative Migraine Treatment: Aimovig, Ajovy, Emgality, Nurtec ODT, Qulipta

According to Shah, et al:

- Both “Gepants” and “MABs” have been shown to be effective for migraine when used individually. There have been no robust clinical trials studying use of both.
- The use of multiple “Gepants” or multiple “MABs” at the same time is not supported, and this represents duplication of therapy or utilization beyond what is supported by FDA labeling and recommendations.
- Combining a “Gepant” for acute treatment with a “MAB” for migraine prevention is slowing gaining support.

Reference:

(1) Tulsi Shah, Kate Bedrin, Amanda Tinsley. Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini review. Front Pain Research (Lausanne). 2023 Mar 17;4:1130239. Link : [Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review.](#)

Table 1. CGRP Antagonist Table

| Brand name | Subclass | MOA | Type of Migraine | PDL status | Administration |
|---------------------------|-----------------|----------------------|-------------------------|--|---|
| Nurtec (Rimegepant) | Gepant | Blocks CGRP receptor | Acute and prophylaxis | Preferred | 75mg PO once PRN (NMT 18 doses/30 days) |
| Ubrelvy (Ubrogepant) | Gepant | Blocks CGRP receptor | Acute | Preferred | 50-100mg PO once. Second dose may be taken 2 hours later. Max 200mg/day (NMT 1600mg/30 days). |
| Qulipta (Atogepant) | Gepant | Blocks CGRP receptor | Prophylaxis | Nonpreferred | 60mg po once daily. |
| Zavzpret (Zavegepant) | Gepant | Blocks CGRP receptor | Acute | Nonpreferred | 10mg into one nostril as single dose. Max 10mg/day (NMT 80mg/30 day) |
| Aimovig (Erenumab) | MAB | Blocks CGRP receptor | Prophylaxis | Preferred | 70mg SQ once monthly, up to 140mg SQ once monthly. |
| Ajovy (Fremenezumab) | MAB | Binds CGRP ligand | Prophylaxis | Preferred | 225mg SQ once monthly or 675mg every 3 months. |
| Emgality (Galcanzumab) | MAB | Binds CGRP ligand | Prophylaxis | Preferred | 240mg SQ once loading dose then 120mg SQ once monthly; cluster HD 300mg SQ once monthly. |
| Vyepti (Eptinezumab) | MAB | Binds CRGP ligand | Prophylaxis | Not on PDL—must be covered through medical benefit | 100mg IV q 3 months * Note: Vyepti is covered on medical benefit. |

RDUR Criteria

- Member continuously eligible from November 1, 2025, to April 30, 2026
 - Exclude TPL (where Medicaid is secondary payor)
- Time Period:
 - Pharmacy claim lookback: November 1, 2025, to April 30, 2026
 - Medical claim lookback: November 1, 2025, to April 30, 2026
- Report:
 - Review pharmacy claims and report out # of members on 2 distinct “GEPANT” agents overlapping ≥ 60 days. (List above). List the combinations found with each.
 - Review medical claims and pharmacy claims and report out # of members on 2 distinct “MAB” agents overlapping ≥ 60 days. List the combinations found with each.
 - Vyepti j-code is J3032.

Apolipoprotein C-III (ApoC-III) Inhibitors Prior Authorization Criteria Review

Background

Redemplo (plozasiran) is an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA) approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome (FCS). This is the second agent approved for this indication. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide (ASO), is also approved for the same indication. Prior authorization (PA) criteria for Tryngolza (olezarsen) are being updated to incorporate Redemplo (plozasiran) and rename the form. Both agents are also currently undergoing clinical trials for additional lipid-related indications: Redemplo is being studied in severe hypertriglyceridemia ($TG \geq 500$ mg/dL) and hypertriglyceridemia ($TG \geq 150$ mg/dL and ≤ 499 mg/dL), while Tryngolza is being studied in severe hypertriglyceridemia. In addition, there are other apoC-III targeting agents currently in development.

The [2026 ACC/AHA Multisociety Dyslipidemia Guideline](#) recommends treatment with olezarsen, as an adjunct to diet, in adults with FCS and a fasting TG ≥ 1000 mg/dL to lower TG levels and reduce the risk of pancreatitis. Plozasiran is not addressed in the guidelines. Standard lipid lowering therapies are minimally effective in FCS patients.

Dosage and Administration

- 25 mg injected subcutaneously once every 3 months

Dosage Forms and Strengths

- 25 mg/0.5 mL single-dose pre-filled syringe

Contraindications

- None

Adverse Reactions

- Most common (incidence $\geq 10\%$ of patients treated and $> 5\%$ more frequently than with placebo): hyperglycemia, headache, nausea, and injection site reaction.

Clinical Trials

The efficacy of Redemplo was established in a randomized, placebo-controlled, double-blind study in 51 adult patients with genetically confirmed or clinically diagnosed FCS maintained on a low-fat diet (≤ 20 g fat per day). A fasting TG level ≥ 880 mg/dL was required. At study entry, patients were treated with statins (43%), omega-3 fatty acids (29%), fibrates (69%), or no background TG lowering therapies (25%). Patients were randomized to receive Redemplo or placebo. Patients in the Redemplo group had a

baseline mean TG level of 2,008 mg/dL, compared with 2,053 mg/dL in the placebo group. The primary endpoint was percent change in fasting TG from baseline at month 10.

- The median difference between Redemplo and the placebo group in percent change in fasting triglyceride levels from baseline to month 10 was -58.7% (95% CI: -89.6, -27.9; $p < 0.0001$).
- Over the 12-month treatment period, the numerical incidence of acute pancreatitis in patients treated with Redemplo was lower compared with placebo (8% of patients in the Redemplo group compared with 20% of patients in the placebo group).

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for olezarsen (Tryngolza). Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agent(s) would be medically contraindicated. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following conditions are met:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) confirmed by genetic testing, (e.g., biallelic pathogenic variants in FCS-causing genes [*LPL*, *GPIHBP1*, *APOA5*, *APOC2*, or *LMF1*]) (attach genetic testing results); and
3. The patient has a current fasting triglyceride level of 880 mg/dL or greater (attach current lipid panel obtained within the past 30 days); and
4. The patient will use medication in combination with a low-fat diet (≤ 20 grams of total fat per day); and
5. Is prescribed by or in consultation with a cardiologist, an endocrinologist, or a provider who specializes in lipid management.

If the criteria for coverage are met, initial requests will be given for 6 months. Requests for continuation of therapy will be considered at 12-month intervals under the following conditions:

1. Documentation of a decrease in fasting triglyceride level from baseline (attach current lipid panel obtained within the past 30 days); and
2. Patient continues to use medication in combination with a low-fat diet (≤ 20 grams of total fat per day); and
3. Is prescribed by or in consultation with a cardiologist, an endocrinologist, or a provider who specializes in lipid management.

Proposed Clinical Prior Authorization Criteria (changes highlighted/italicized and/or stricken)

Prior authorization (PA) is required for *apoC-III inhibitors* *elezarsen* (Tryngolza). Requests for non-preferred agents may be considered when documented evidence is provided that the use of the preferred agent(s) would be medically contraindicated. Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following conditions are met:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of familial chylomicronemia syndrome (FCS) confirmed by genetic testing, (e.g., biallelic pathogenic variants in FCS-causing genes [*LPL*, *GPIHBP1*, *APOA5*, *APOC2*, or *LMF1*]) (attach genetic testing results); and
3. The patient has a current fasting triglyceride level of 880 mg/dL or greater (attach current lipid panel obtained within the past 30 days); and
4. The patient will use medication in combination with a low-fat diet (≤ 20 grams of total fat per day); and
5. *Medication will not be used concomitantly with other apoC-III inhibitors; and*
6. Is prescribed by or in consultation with a cardiologist, an endocrinologist, or a provider who specializes in lipid management.

If the criteria for coverage are met, initial requests will be given for 6 **12** months. Requests for continuation of therapy will be considered at 12-month intervals under the following conditions:

1. Documentation of a decrease in fasting triglyceride level from baseline (attach current lipid panel obtained within the past 30 days); and
2. Patient continues to use medication in combination with a low-fat diet (≤ 20 grams of total fat per day); and
3. Is prescribed by or in consultation with a cardiologist, an endocrinologist, or a provider who specializes in lipid management.

References

Redempho. Package insert. Arrowhead Pharmaceuticals, Inc.; November 2025.

Blumenthal R.S., Morris P.B., Guadino M., Johnson H.M. 2026
ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026.

Biologicals for Hidradenitis Suppurativa Prior Authorization Review

Background

Multiple written comments regarding the prior authorization (PA) criteria for biologic treatment of hidradenitis suppurativa (HS) were submitted in advance of the February 2026 DUR meeting. A recurring concern among these comments was the requirement for a lesion count of ≥ 3 and the need for documented failure with multiple agents, specifically topical clindamycin, a combination of oral clindamycin plus rifampin, and tetracyclines before initiating biologic therapy. Commenters argued that these requirements delay access to biologic treatment and do not align with current clinical evidence or national guideline recommendations. Based on these comments, the Commission requested that PA criteria be added to a future agenda for further discussion and potential revision.

HS is a chronic, follicular, occlusive disease characterized by inflammatory nodules, skin tunnels, and scarring, most commonly occurring in intertriginous areas. Patients frequently experience pain, chronic drainage, odor, and disfigurement. Treatment goals include reducing the development of new inflammatory lesions, skin tunnels, and scarring; managing existing lesions and associated symptoms; and minimizing the psychological burden of the disease.

The Hurley staging system is used as a method for classifying HS severity and guiding treatment; it does not specify exact lesion counts.

- Hurley Stage I - Mild Disease
 - Isolated inflammatory nodules or abscesses
 - No sinus tracts, minimal or no scarring
 - Often confined to one area
- Hurley Stage II - Moderate Disease
 - Recurrent abscesses and nodules
 - Early sinus tract formation and scarring
 - Lesions affect more than one area
- Hurley Stage III - Severe Disease
 - Multiple interconnected abscesses and nodules
 - Interconnected sinus tracts, extensive scarring
 - Diffuse or near-diffuse involvement

Clinical trials for all three FDA-approved therapies indicated for the treatment of moderate to severe HS (adalimumab, bimekizumab -bkzx, and secukinumab) required a minimum lesion count for study enrollment. Inclusion thresholds ranged from at least 3 lesions in the adalimumab trials to at least 5 lesions in the bimekizumab and secukinumab trials.

The recommended initial therapy for moderate to severe HS is oral antibiotics, for 10 to 12 weeks.

- Oral tetracyclines – Recommended for cases consistent with Hurley Stage II disease
- Oral clindamycin plus rifampin – Recommended for cases consistent with Hurley Stage III disease

For patients whose disease does not respond to oral antibiotic therapy, biologic therapy is recommended over other treatment modalities.

Clinical guidelines from the American Academy of Dermatology (AAD) are currently in development and expected in the fourth quarter of 2026.

Items to Consider

- Removal of topical clindamycin requirement
- Reduce the number of oral antibiotic trials
 - *Patient has documentation of an adequate trial and therapy failure with at least one oral antibiotic/oral antibiotic combination (doxycycline, clindamycin, rifampin)*
- Remove requirement of 3 abscesses or inflammatory nodules
- Update renewal criteria requiring a documentation of positive response to therapy (versus a defined clinical response)
 - *Additional authorizations will be considered upon documentation of a positive response to therapy.*

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for biologicals FDA approved or compendia indicated for the treatment of Hidradenitis Suppurativa (HS). Payment for non-preferred biologic agents will be considered only for cases in which there is documentation of a previous trial and therapy failure with a preferred biologic agent. Payment will be considered under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of moderate to severe HS with Hurley Stage II or III disease; and
3. Patient has at least three (3) abscesses or inflammatory nodules; and
4. Patient has documentation of adequate trials and therapy failures with the following:
 - a. Daily treatment with topical clindamycin;
 - b. Oral clindamycin plus rifampin;
 - c. Maintenance therapy with a preferred tetracycline.

If criteria for coverage are met, initial requests will be given for 4 months. Additional authorizations will be considered upon documentation of clinical response to therapy. Clinical response is defined as at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count from initiation of therapy.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Proposed Clinical Prior Authorization Criteria - #1 (removal of topical clindamycin only)

Prior authorization (PA) is required for biologicals FDA approved or compendia indicated for the treatment of Hidradenitis Suppurativa (HS). Payment for non-preferred biologic agents will be considered only for cases in which there is documentation of a previous trial and therapy failure with a preferred biologic agent. Payment will be considered under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of moderate to severe HS with Hurley Stage II or III disease; and
3. Patient has at least three (3) abscesses or inflammatory nodules; and
4. Patient has documentation of adequate trials and therapy failures with the following:
 - a. ~~Daily treatment with topical clindamycin;~~
 - b. Oral clindamycin plus rifampin;
 - c. Maintenance therapy with a preferred tetracycline.

If criteria for coverage are met, initial requests will be given for 4 months. Additional authorizations will be considered upon documentation of clinical response to therapy. Clinical response is defined as at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count from initiation of therapy.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Proposed Clinical Prior Authorization Criteria - #2 (all changes under items to consider)

Prior authorization (PA) is required for biologicals FDA approved or compendia indicated for the treatment of Hidradenitis Suppurativa (HS). Payment for non-preferred biologic agents will be considered only for cases in which there is documentation of a previous

trial and therapy failure with a preferred biologic agent. Payment will be considered under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient has a diagnosis of moderate to severe HS with Hurley Stage II or III disease; and
3. ~~Patient has at least three (3) abscesses or inflammatory nodules; and~~
4. Patient has documentation of *an* adequate trials and therapy failures with *at least one oral antibiotic/oral antibiotic combination (e.g., doxycycline, clindamycin, rifampin)*. the following:
 - a. ~~Daily treatment with topical clindamycin;~~
 - b. ~~Oral clindamycin plus rifampin;~~
 - c. ~~Maintenance therapy with a preferred tetracycline.~~

If criteria for coverage are met, initial requests will be given for 4 months. Additional authorizations will be considered upon documentation of *clinical a positive* response to therapy. ~~Clinical response is defined as at least a 50% reduction in total abscess and inflammatory nodule count with no increase in abscess count and no increase in draining fistula count from initiation of therapy.~~

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

References

UpToDate: Ingram JR. Hidradenitis suppurativa: Management. UpToDate. Last updated February 2026. Accessed March 26, 2026.

Humira. Package Insert. AbbVee Inc; December 2025.

Bimzelx. Package Insert. UCB Inc; November 2024.

Cosentyx. Package Insert. Novartis Pharmaceuticals Corporation; March 2026.

Dupilumab (Dupixent) Prior Authorization Review

Background

Dupilumab (Dupixent) received approval for a new indication for the treatment of adult and pediatric patients with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. This is the first FDA-approved biologic approved for this indication.

- AFRS is progressive and distinct type of chronic rhinosinusitis (CRS) with type 2 inflammation, characterized by nasal polyposis, production of thick eosinophilic mucin, and expansile changes of the involved sinuses.
- The mainstay of management has been surgery, but it is not curative; up to 28.7% of patients need revision surgery. The goals of surgery include:
 - Clearing eosinophilic mucin that harbors the fungi triggering and perpetuating inflammation
 - Removing nasal polyps to improve nasal congestion
 - Opening the sinus cavities, making them available for sinus irrigations and topical therapy (corticosteroids)
- This surgical goal remains difficult to achieve because the affected sinus cavities can enlarge beyond the reach of standard surgical instruments, and the challenge is further intensified by the exceptionally sticky nature of the mucin.
- Systemic corticosteroids may be given preoperatively but are widely used postoperatively.
- Topical corticosteroids are initiated after surgery. Use of topical corticosteroids prior to surgery have demonstrated limited effectiveness due to the affected sinus cavities.

Clinical Studies

The approval of Dupixent for the new indication was based on a randomized, double-blind, placebo-controlled study in 62 adult and pediatric patients aged 6 years and older with AFRS. Patients were randomized to receive either Dupixent or placebo for 52 weeks. Rescue with systemic corticosteroids or surgery was allowed during the study at the investigator's discretion. The primary endpoint was the change from baseline in sinus opacification assessed by the Lund Mackay (LMK) sinus CT scan score at week 52. The LMK sinus CT scan score evaluated the opacification of each sinus using a 0 to 2 scale (0 = normal; 1 = partial opacification; 2 = total opacification) deriving a maximum score of 12 per side and a total maximum score of 24 (higher scores indicate more opacification).

- The least-squares mean change in LMK sinus CT scan score was -9.17 with Dupixent vs. -1.81 with placebo (difference -7.36, 95% CI: -9.38, -5.35).

Dose and Administration for AFRS (subcutaneous injection; no loading dose)

- Adults – 300 mg every 2 weeks
- Pediatric patients (6-17 years)
 - 15 kg to < 30 kg – 300 mg every 4 weeks
 - 30 kg to < 60 kg – 200 mg every 2 weeks
 - 60 kg or more – 300 mg every 2 weeks

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for Dupixent (dupilumab). Payment for non-preferred agents will be considered when there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered when patient has an FDA approved or compendia indication for the requested drug under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient's current weight in kilograms (kg) is provided; and
3. Patient has a diagnosis of moderate-to-severe atopic dermatitis; and
 - a. Patient has failed to respond to good skin care and regular use of emollients; and
 - b. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; and
 - c. Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
 - d. Patient will continue with skin care regimen and regular use of emollients; or
4. Patient has a diagnosis of moderate to severe asthma with an eosinophilic phenotype (with a pretreatment eosinophil count ≥ 150 cells/mcL within the previous 6 weeks) or with oral corticosteroid dependent asthma; and
 - a. Has a pretreatment forced expiratory volume in 1 second (FEV₁) $\leq 80\%$ predicted in adults; $< 90\%$ predicted in adolescents 12 to 17 years of age; and $< 95\%$ predicted in children 6 to 11 years of age; and
 - b. Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (e.g. long-acting beta₂ agonist [LABA], or leukotriene receptor antagonist [LTRA]) for a minimum of 3 consecutive months. Patient must be compliant with therapy, based on pharmacy claims; and
 - c. Patient must have one of the following, in addition to the regular maintenance medications defined above:
 - i. One (1) or more exacerbations in the previous year or
 - ii. Require daily oral corticosteroids for at least 3 days; or
5. Patient has a diagnosis of inadequately controlled chronic rhinosinusitis with

- nasal polyposis (CRSwNP); and
- a. Documentation dupilumab will be used as an add-on maintenance treatment; and
 - b. Documentation of an adequate trial and therapy failure with at least one preferred medication from each of the following categories:
 - i. Nasal corticosteroid spray; and
 - ii. Oral corticosteroid; or
6. Patient has a diagnosis of eosinophilic esophagitis (EoE); and
- a. Patient has ≥ 15 intraepithelial eosinophils per high-power field (eos/hpf) as confirmed by endoscopic esophageal biopsy (attach results); and
 - b. Patient has signs and symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, food refusal, abdominal pain, heartburn regurgitation, chest pain and/or, odynophagia); and
 - c. Documentation of previous trials and therapy failures with all of the following:
 - i. High dose proton pump inhibitor (PPI) for at least 8 weeks; and
 - ii. Swallowed topical corticosteroid (e.g., fluticasone propionate, oral budesonide suspension); and
 - iii. Dietary therapy; or
7. Patient has a diagnosis of moderate to severe prurigo nodularis (PN); and
- a. Patient has experienced severe to very severe pruritus, as demonstrated by a current Worst Itch-Numeric Rating Scale (WI-NRS) ≥ 7 ; and
 - b. Patient has ≥ 20 nodular lesions (attach documentation); and
 - c. Documentation of a previous trial and therapy failure with a high or super high potency topical corticosteroid for at least 14 consecutive days; or
8. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype; and
- a. Patient has moderate to severe airflow limitation, measured within the past 12 months, as evidenced by both of the following:
 - i. FEV1/FVC ratio < 0.7 , and
 - ii. FEV1 % predicted between 30% to 79%; and
 - b. Patient has a minimum blood eosinophil count of 300 cells/mcL, measured within the past 12 months; and
 - c. Patient has documentation of maximal inhaled therapy for 3 or more months and an inadequate response to:
 - i. Triple therapy with all of the following treatments:
 1. Long-acting muscarinic antagonist/anticholinergic (LAMA); and
 2. Long-acting beta agonist (LABA); and
 3. Inhaled corticosteroid (ICS); or
 - ii. Double therapy with both of the following if ICS is contraindicated
 1. LABA; and
 2. LAMA; and
 - d. Patient has history of at least 2 moderate or 1 severe exacerbation(s) in the previous 12 months despite receiving maximal triple therapy or double therapy (defined above). Moderate exacerbation is defined as patient

- required treatment with systemic corticosteroids and/or antibiotics and severe exacerbation is defined as hospitalization or observation for over 24 hours in an emergency department or urgent care facility; and
- e. Patient will continue to receive maintenance therapy (as documented above) concomitantly with dupilumab; or
9. Patient has a diagnosis of chronic spontaneous urticaria (CSU) with no known cause; and
 - a. Patient has documentation of an adequate trial and therapy failure with a preferred second generation H1 receptor antihistamine for at least 2 weeks; or
 10. Patient has a diagnosis of bullous pemphigoid (BP); and
 - a. Is initiated with a tapering course of oral corticosteroids.

If criteria for coverage are met, initial authorization will be given for 6 months for all the above indications, except for COPD, CSU, and BP which will receive an initial authorization of 12 months to assess the response to treatment. Request for continuation of therapy will require documentation of a positive response to therapy and continued use of add-on maintenance therapy, where indicated.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

Proposed Clinical Prior Authorization Criteria (changes italicized, highlighted, and/or stricken)

Prior authorization (PA) is required for Dupixent (dupilumab). Payment for non-preferred agents will be considered when there is documentation of a previous trial and therapy failure with a preferred agent. Payment will be considered when patient has an FDA approved or compendia indication for the requested drug under the following conditions:

1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and
2. Patient's current weight in kilograms (kg) is provided; and
3. Patient has a diagnosis of moderate-to-severe atopic dermatitis; and
 - a. Patient has failed to respond to good skin care and regular use of emollients; and
 - b. Patient has documentation of an adequate trial and therapy failure with one preferred medium to high potency topical corticosteroid for a minimum of 2 consecutive weeks; and
 - c. Patient has documentation of a previous trial and therapy failure with a topical immunomodulator for a minimum of 4 weeks; and
 - d. Patient will continue with skin care regimen and regular use of emollients; or
4. Patient has a diagnosis of moderate to severe asthma with an eosinophilic phenotype (with a pretreatment eosinophil count \geq 150 cells/mcL within the

- previous 6 weeks) or with oral corticosteroid dependent asthma; and
- a. Has a pretreatment forced expiratory volume in 1 second (FEV₁) ≤ 80% predicted in adults; < 90% predicted in adolescents 12 to 17 years of age; and < 95% predicted in children 6 to 11 years of age; and
 - b. Symptoms are inadequately controlled with documentation of current treatment with a high-dose inhaled corticosteroid (ICS) given in combination with a controller medication (e.g. long-acting beta₂ agonist [LABA], or leukotriene receptor antagonist [LTRA]) for a minimum of 3 consecutive months. Patient must be compliant with therapy, based on pharmacy claims; and
 - c. Patient must have one of the following, in addition to the regular maintenance medications defined above:
 - i. One (1) or more exacerbations in the previous year or
 - ii. Require daily oral corticosteroids for at least 3 days; or
5. Patient has a diagnosis of inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP); and
- a. Documentation dupilumab will be used as an add-on maintenance treatment; and
 - b. Documentation of an adequate trial and therapy failure with at least one preferred medication from each of the following categories:
 - i. Nasal corticosteroid spray; and
 - ii. Oral corticosteroid; or
6. Patient has a diagnosis of eosinophilic esophagitis (EoE); and
- a. Patient has ≥ 15 intraepithelial eosinophils per high-power field (eos/hpf) as confirmed by endoscopic esophageal biopsy (attach results); and
 - b. Patient has signs and symptoms of esophageal dysfunction (e.g., dysphagia, food impaction, food refusal, abdominal pain, heartburn regurgitation, chest pain and/or, odynophagia); and
 - c. Documentation of previous trials and therapy failures with all of the following:
 - i. High dose proton pump inhibitor (PPI) for at least 8 weeks; and
 - ii. Swallowed topical corticosteroid (e.g., fluticasone propionate, oral budesonide suspension); and
 - iii. Dietary therapy; or
7. Patient has a diagnosis of moderate to severe prurigo nodularis (PN); and
- a. Patient has experienced severe to very severe pruritus, as demonstrated by a current Worst Itch-Numeric Rating Scale (WI-NRS) ≥ 7; and
 - b. Patient has ≥ 20 nodular lesions (attach documentation); and
 - c. Documentation of a previous trial and therapy failure with a high or super high potency topical corticosteroid for at least 14 consecutive days; or
8. Patient has a diagnosis of chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype; and
- a. Patient has moderate to severe airflow limitation, measured within the past 12 months, as evidenced by both of the following:
 - i. FEV₁/FVC ratio < 0.7, and

- ii. FEV1 % predicted between 30% to 79%; and
- b. Patient has a minimum blood eosinophil count of 300 cells/mcL, measured within the past 12 months; and
- c. Patient has documentation of maximal inhaled therapy for 3 or more months and an inadequate response to:
 - i. Triple therapy with all of the following treatments:
 - 1. Long-acting muscarinic antagonist/anticholinergic (LAMA); and
 - 2. Long-acting beta agonist (LABA); and
 - 3. Inhaled corticosteroid (ICS); or
 - ii. Double therapy with both of the following if ICS is contraindicated
 - 1. LABA; and
 - 2. LAMA; and
- d. Patient has history of at least 2 moderate or 1 severe exacerbation(s) in the previous 12 months despite receiving maximal triple therapy or double therapy (defined above). Moderate exacerbation is defined as patient required treatment with systemic corticosteroids and/or antibiotics and severe exacerbation is defined as hospitalization or observation for over 24 hours in an emergency department or urgent care facility; and
- e. Patient will continue to receive maintenance therapy (as documented above) concomitantly with dupilumab; or
- 9. Patient has a diagnosis of chronic spontaneous urticaria (CSU) with no known cause; and
 - a. Patient has documentation of an adequate trial and therapy failure with a preferred second generation H1 receptor antihistamine for at least 2 weeks; or
- 10. Patient has a diagnosis of bullous pemphigoid (BP); and
 - a. Is initiated with a tapering course of oral corticosteroids; or
- 11. *Patient has a diagnosis of allergic fungal rhinosinusitis (AFRS); and*
 - a. *Patient has a history of sino-nasal surgery.*

If criteria for coverage are met, initial authorization will be given for 6 months for all the above indications, except for COPD, CSU, ~~and~~ BP, *and AFRS* which will receive an initial authorization of 12 months to assess the response to treatment. Request for continuation of therapy will require documentation of a positive response to therapy and continued use of add-on maintenance therapy, where indicated.

The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated.

References

Dupixent subcutaneous injection [prescribing information]. Tarrytown, NY: Regeneron/Sanofi-Aventis; February 2026.

Chua AJ, Jafar A, Luong AU. [Update on allergic fungal rhinosinusitis](#). Ann Allergy Athma Immunol. 2023; 131 (3): 300-306.

UpToDate: Schlosser RJ. Allergic fungal rhinosinusitis. UpToDate. Last updated May 2025. Accessed March 23, 2026.

Idiopathic Pulmonary Fibrosis and Related Lung Diseases (formerly Pirfenidone [Esbriet]/Nintedanib [Ofev]) Prior Authorization Review

Background

Jascayd was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients and for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

See the attached new drug overview for clinical information. Current guidelines have not been updated to include Jascayd. The prior authorization (PA) criteria are being revised to streamline requirements and incorporate Jascayd.

Current Clinical Prior Authorization Criteria

Prior authorization (PA) is required for pirfenidone (Esbriet) and nintedanib (Ofev). Dosing outside the FDA approved dosing will not be considered. Concomitant use of pirfenidone and nintedanib will not be considered. Payment will be considered for patients when the following criteria are met:

1. Patient meets the FDA approved age; and
2. Is prescribed by a pulmonologist; and
3. Patient does not have hepatic impairment as defined below:
 - a. Nintedanib – Patient does not have moderate or severe hepatic impairment (Child Pugh B or C); or
 - b. Pirfenidone – Patient does not have severe hepatic impairment (Child Pugh C); and
4. Patient does not have renal impairment as defined below:
 - a. Nintedanib – Patient does not have severe renal impairment (CrCl <30 ml/min) or end-stage renal disease; or
 - b. Pirfenidone – Patient does not have end-stage renal disease requiring dialysis; and
5. Patient does not utilize non-prescribed inhalants, such as vaping or other inhaled tobacco products, prior to initiating therapy and has been instructed to avoid tobacco products while using pirfenidone or nintedanib; and
6. Patient has a diagnosis of idiopathic pulmonary fibrosis (nintedanib or pirfenidone) as confirmed by one of the following (attach documentation):
 - a. Findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP); or
 - b. A surgical lung biopsy demonstrating usual interstitial pneumonia (UIP); and
 - c. Prescriber has excluded other known causes of interstitial lung disease (ILD) such as domestic and occupational exposures, connective tissue disease, and drug toxicity; and

- d. Patient has documentation of pulmonary function tests within the prior 60 days with a forced vital capacity (FVC) $\geq 50\%$ predicted; and
 - e. Patient has a carbon monoxide diffusion capacity (%DLco) of $\geq 30\%$ predicted; or
7. Patient has a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) (nintedanib) as confirmed by the following (attach documentation):
- a. Documentation of a chest high resolution computed tomography (HRCT) scan showing fibrosis affecting $\geq 10\%$ of the lungs; and
 - b. Patient has documented pulmonary function tests within the prior 60 days showing FVC $\geq 40\%$ predicted; and
 - c. Patient has a carbon monoxide diffusion capacity (%DLco) of $\geq 30-89\%$ predicted; or
8. Patient has a diagnosis of chronic fibrosing interstitial lung disease with a progressive phenotype (nintedanib) and confirmed by the following (attach documentation):
- a. Documentation of a chest high resolution computed tomography (HRCT) scan showing fibrosis affecting $\geq 10\%$ of the lungs; and
 - b. Patient has documented pulmonary function tests within the prior 60 days showing FVC $\geq 45\%$ predicted; and
 - c. Patient has a carbon monoxide diffusion capacity (%DLco) of $\geq 30-79\%$ predicted; and
 - d. Patient has at least one sign of clinical progression for interstitial lung disease within the last 24 months despite standard treatment with an agent other than nintedanib or pirfenidone:
 - i. A relative decline in the FVC of at least 10% predicted; or
 - ii. A relative decline in the FVC of 5-9% predicted combined with at least one of the following:
 - 1. Worsening respiratory symptoms; or
 - 2. Increased extent of fibrosis on HRCT; or
 - iii. Worsening respiratory symptoms and an increased extent of fibrotic changes on HRCT only.

If the criteria for coverage are met, initial requests will be given for 6 months. Additional authorizations will be considered at 6 month intervals when the following criteria are met:

- 1. Adherence to pirfenidone (Esbriet) or nintedanib (Ofev) is confirmed; and
- 2. Documentation of a positive response to therapy, defined as meeting at least one of the following:
 - a. Rate of lung function decline slowed; or
 - b. Improved or no worsening of symptoms of cough, shortness of breath; and
- 3. Documentation is provided that the patient has remained tobacco-free; and
- 4. ALT, AST, and bilirubin are assessed periodically during therapy.

Proposed Clinical Prior Authorization Criteria (changes highlighted/italicized and/or stricken)

Prior authorization (PA) is required for *medications used to treat idiopathic pulmonary fibrosis and related lung diseases*. ~~pirfenidone (Esbriet) and nintedanib (Ofev). Dosing outside the FDA approved dosing will not be considered. Concomitant use of pirfenidone and nintedanib will not be considered. Payment for non-preferred agents will be authorized only for cases in which there is documentation of a previous trial and therapy failure with a preferred agent that is FDA approved or compendia indicated for the submitted diagnosis, when applicable.~~ Payment will be considered for patients when the following criteria are met:

1. *Request adheres to all FDA approved labeling including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations* ~~Patient meets the FDA approved age; and~~
2. Is prescribed by a pulmonologist; and
3. ~~Patient does not have hepatic impairment as defined below:~~
 - a. ~~Nintedanib — Patient does not have moderate or severe hepatic impairment (Child Pugh B or C); or~~
 - b. ~~Pirfenidone — Patient does not have severe hepatic impairment (Child Pugh C); and~~
4. ~~Patient does not have renal impairment as defined below:~~
 - a. ~~Nintedanib — Patient does not have severe renal impairment (CrCl <30 ml/min) or end-stage renal disease; or~~
 - b. ~~Pirfenidone — Patient does not have end-stage renal disease requiring dialysis; and~~
5. Patient does not utilize non-prescribed inhalants, such as vaping or other inhaled tobacco products, prior to initiating therapy and has been instructed to avoid tobacco products while using *requested medication(s)* ~~pirfenidone or nintedanib; and~~
6. ~~Concomitant use of nintedanib and pirfenidone will not be considered; and~~
7. ~~Documentation of an inadequate response to monotherapy with nintedanib or pirfenidone, at up to maximally indicated doses, is required prior to combination therapy with nerandomilast; and~~
8. Patient has a diagnosis of idiopathic pulmonary fibrosis (*nerandomilast, nintedanib, or pirfenidone*) as confirmed by one of the following (attach documentation):
 - a. Findings on high-resolution computed tomography (HRCT) indicating usual interstitial pneumonia (UIP); or
 - b. A surgical lung biopsy demonstrating ~~usual interstitial pneumonia (UIP); and~~
 - c. Prescriber has excluded other known causes of interstitial lung disease (ILD) such as domestic and occupational exposures, connective tissue disease, and drug toxicity; and

- d. Patient has documentation of pulmonary function tests within the prior 60 days with a forced vital capacity (FVC):
 - i. $\geq 50\%$ predicted *for nintedanib or pirfenidone*; or
 - ii. $\geq 45\%$ predicted *for nerandomilast*; and
 - e. Patient has a carbon monoxide diffusion capacity (%DLco):
 - f. $\geq 30\%$ predicted *for nintedanib or pirfenidone*; and
 - g. $\geq 25\%$ predicted *for nerandomilast*; or
9. Patient has a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) (nintedanib) as confirmed by the following (attach documentation):
- a. Documentation of a ~~chest high resolution computed tomography (HRCT)~~ scan showing fibrosis affecting $\geq 10\%$ of the lungs; and
 - b. Patient has documented pulmonary function tests within the prior 60 days showing FVC $\geq 40\%$ predicted; and
 - c. Patient has a ~~carbon monoxide diffusion capacity (%DLco)~~ of $\geq 30-89\%$ predicted; or
10. Patient has a diagnosis of chronic fibrosing interstitial lung disease with a progressive phenotype (*progressive pulmonary fibrosis [PPF]*) (nintedanib *or nerandomilast*) and confirmed by the following (attach documentation):
- a. Documentation of a ~~chest high resolution computed tomography (HRCT)~~ scan showing fibrosis affecting $\geq 10\%$ of the lungs; and
 - b. Patient has documented pulmonary function tests within the prior 60 days showing FVC $\geq 45\%$ predicted; and
 - c. Patient has a ~~carbon monoxide diffusion capacity (%DLco)~~ of:
 - i. $\geq 30-79\%$ predicted *for nintedanib*; or
 - ii. $\geq 25\%$ predicted *for nerandomilast*; and
 - d. Patient has at least one sign of clinical progression for interstitial lung disease within the last 24 months ~~despite standard treatment with an agent other than nintedanib or pirfenidone~~:
 - i. A relative decline in the FVC of at least 10% predicted; or
 - ii. A relative decline in the FVC of 5-9% predicted combined with at least one of the following:
 - 1. Worsening respiratory symptoms; or
 - 2. Increased extent of fibrosis on HRCT; or
 - iii. Worsening respiratory symptoms and an increased extent of fibrotic changes on HRCT only.

If the criteria for coverage are met, initial requests will be given for 6 months. Additional authorizations will be considered at 6-month intervals when the following criteria are met:

- 1. Adherence to *medication* ~~pirfenidone (Esbriet) or nintedanib (Ofev)~~ is confirmed; and
- 2. Documentation of a positive response to therapy, defined as meeting at least one of the following:
 - a. Rate of lung function decline slowed; or

- b. Improved or no worsening of symptoms of cough, shortness of breath; and
- ~~3. Documentation is provided that the patient has remained tobacco-free; and~~
- ~~4. ALT, AST, and bilirubin are assessed periodically during therapy.~~

References

Jascayd Package insert. Boehringer Ingelheim Pharmaceuticals, Inc; December 2025.

New Drug Overview

Jascayd (nerandomilast)

PDL Category: Idiopathic Pulmonary Fibrosis

Introduction

Disease Background:

- Idiopathic pulmonary fibrosis (IPF) is a distinct kind of idiopathic interstitial pneumonia, a category of conditions that cause interstitial lung disease (ILD). IPF is classified as a chronic fibrosing interstitial pneumonia, that is a progressing disease limited to the lung and results from an abnormal wound healing activity causing a deposition of changed extracellular matrix as well as scarring and disturbance of alveolar design (*Richeldi et al 2025*).
 - It is a serious long-term disease where the tissue around the air sacs in the lungs are affected. Tissue in the lung becomes thick and stiff, which can result in persistent scarring in the lungs (fibrosis). Fibrosis, or this permanent scarring, results in having a harder time in breathing (*NIH 2023*).
- IPF generally affects adults 55 to 75 years of age, and affects men more than women. Risk factors for IPF include cigarette smoking, older age, being male, family history, exposure to certain environments (such as livestock or pine wood dust), or exposure to certain viral proteins and antibodies to viruses, among others (*Richeldi et al 2025*).
- Typically non-specific symptoms of the pulmonary system are observed, including chronic dry cough and dyspnea. Fatigue may also occur (*Richeldi et al 2025*).
 - The progression of IPF varies for each patient, with scarring that may happen quickly in some or slowly in others. The disease may stay stable for long periods of time in some or gets worse quickly in others (*NIH 2023*).
 - Acute exacerbations are seen in 5-20% of patients. Acute exacerbations are characterized as worsening of clinical symptoms, as well as objective findings that may include fever or worsening of oxygenation and radiographic discoveries. During the period of the disease, acute exacerbations can occur at any time. (*Richeldi et al 2025*).
- There is currently no cure for IPF; however, supportive care strategies such as smoking cessation, pulmonary rehabilitation, and vaccination for respiratory infections are suggested (*King 2026, NIH 2023*). Two antifibrotic medications FDA-approved in 2014 are available and appear to be associated with slowing progression of the disease and reducing acute exacerbation frequency. There may also be a mortality benefit (*King 2026*).
- Progressive pulmonary fibrosis (PPF) is a specific type of progressive and fibrotic disease that occurs in cases of ILD other than in IPF that is described per clinical symptoms, lung function, and imaging of the chest irrespective of the underlying disorder (*Kang and Song 2023*).
 - It is an ILD that results in signs of fibrosis with confirmation of progression over time.
 - It is estimated that about 13% to 40% of non-IPF fibrosing ILDs progress within 2 years, even with appropriate management of the disease.
- Jascayd was FDA approved in 2025.

Pharmacology/Usage

- Jascayd (nerandomilast) is a phosphodiesterase 4 (PDE4) inhibitor, with at least nine-fold preferential inhibition of the PDE4B isoenzyme over PDE4A, PDE4C, and PDE4D. PDE4 hydrolyzes and inactivates cyclic adenosine monophosphate (cAMP). Nerandomilast exerts both anti-fibrotic and immunomodulatory effects as PDE4B inhibition elevates intracellular cAMP levels and reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, which are overexpressed in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

Indications

Table 1. Food and Drug Administration Approved Indications

| Indication | Jascayd (nerandomilast) |
|---|-------------------------|
| <ul style="list-style-type: none"> For the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. For the treatment of progressive pulmonary fibrosis (PPF) in adult patients. | ✓ |

(Prescribing information: Jascayd 2025)

- Information on indications, mechanism of action, pharmacokinetics, dosing, safety, and clinical efficacy summary has been obtained from the prescribing information for the individual products, except where noted otherwise.

Dosing and administration

Table 2. Dosing and Administration

| Drug | Available Formulations | Route | Usual Recommended Frequency | Comments |
|-------------------------|------------------------|-------|--|--|
| Jascayd (nerandomilast) | Film-Coated Tablets | Oral | BID, approximately 12 hours apart, with or without food. | <ul style="list-style-type: none"> Do not reduce dosage when used concomitantly with pirfenidone Reduce dosage to 9mg BID for patients who are unable to tolerate the 18mg BID dose, except in patients who concomitantly use with pirfenidone. Swallow tablets whole or disperse in water. If a dose is missed, advise the patient to take the next dose at the next scheduled time. Do not make up for a missed dose. Jascayd use is not recommended in patients with end stage renal disease or severe hepatic impairment. |

See the current prescribing information for full details.

Clinical Efficacy Summary

- The efficacy of Jascayd for IPF was assessed in two randomized, double-blind, placebo-controlled trials (FIBRONEER-IPF and Trial 2).

Data as of February 4, 2026. KAC/RC

Page 2 of 7

This information is considered confidential and proprietary to Iowa Medicaid's PBM provider and property of Iowa Medicaid, which may not be reproduced without permission. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the new drug overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

- FIBRONEER-IPF included adult patients with IPF (N=1,177) with or without background antifibrotic treatments (nintedanib or pirfenidone).
 - They were randomized to receive Jascayd (9mg BID or 18mg BID) or placebo until the last patient received treatment for 52 weeks (blinded trial duration up to 91 weeks; end of trial duration up to 109 weeks). Randomization was stratified by the presence or absence of background antifibrotic treatments (nintedanib or pirfenidone) at baseline
 - This trial included patients with a mean age of 70 years (range 42 to 90 years) who were mostly males (83%) and White (68%).
 - At baseline, the mean forced vital capacity (FVC) was 78% of predicted normal. In addition, 78% were on stable antifibrotic treatment (nintedanib 46%, pirfenidone 32%) and 22% were not on either treatment (15% treatment naïve, 7% previously discontinued treatment).
- Trial 2 was a 12-week trial that enrolled adult patients (N=147) with IPF with or without background antifibrotic treatments (nintedanib or pirfenidone).
 - They were randomized to receive Jascayd 18mg BID or placebo for 12 weeks. Randomization was stratified by the presence or absence of background antifibrotic treatments (nintedanib or pirfenidone) at baseline
 - This trial included patients with a mean age of 70 years (range 40 to 85 years) who were mostly male (77%) and White (78%).
 - At baseline, the mean FVC was 78% of predicted normal. In addition, 50% of the patients were on stable antifibrotic treatment (nintedanib 29%, pirfenidone 21%).
- In both studies, patients were required to have a diagnosis of IPF based on ATS/ERS/JRS/ALAT criteria. The diagnosis was confirmed by the investigator based on chest high-resolution computed tomography (HRCT) scan and, if available, lung biopsy, and usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with the clinical diagnosis of IPF.
 - Patients were also required to be greater than or equal to 40 years of age with an FVC \geq 45% of predicted and a carbon monoxide diffusing capacity (DLCO, corrected for hemoglobin) \geq 25% of predicted.
 - Prior to visit 1 and during screening, patients had to be on stable treatment with nintedanib or pirfenidone (no dose changes for at least 12 weeks) and planned to stay on this background antifibrotic treatment after randomization. Alternatively, patients were required to be naïve to or have previously discontinued nintedanib or pirfenidone for at least 8 weeks and did not plan to start or restart background antifibrotic treatment.
- The primary endpoint in FIBRONEER-IPF was the absolute change from baseline in FVC in milliliters (mL) at 52 weeks.
 - In this study population, there was less decline in absolute change from baseline in FVC in patients who received Jascayd as compared with patients who received placebo (accounting for mortality), and this reduction in decline was statistically significant.
 - The adjusted mean decline in patients receiving Jascayd 18mg or Jascayd 9mgs was -106ml and -122ml, respectively, whereas in the placebo group, an adjusted mean decline of -170ml was observed. The respective treatment differences compared with the placebo group were 64ml and 48ml.
 - In this trial, the results of the primary endpoint across subgroups by background antifibrotic treatment (nintedanib, pirfenidone, or none) for Jascayd 18mg vs placebo were consistent with the overall population. Efficacy was not observed in patients who received Jascayd 9mg BID with pirfenidone as background antifibrotic treatment.
- In Trial 2, patients taking Jascayd 18mg BID compared to placebo, with or without background antifibrotic treatments, had a reduction in FVC decline at week 12 of 91ml.
- The key secondary endpoint in the FIBRONEER-IPF trial was time to first occurrence of any of the components of the composite endpoint over the blinded duration of the trial (up to 91 weeks): acute IPF exacerbation, hospitalization for respiratory cause, or death.
 - Acute IPF exacerbation was defined as acute worsening or development of dyspnea typically less than one month duration, computed tomography with new bilateral ground-glass opacity, and/or consolidation superimposed on a

- background pattern consistent with IPF, and deterioration not fully explained by cardiac failure or fluid overload. Neither acute IPF exacerbations nor respiratory hospitalizations were adjudicated.
- Overall, there was no statistically significant treatment difference in hazard ratio (HR) for the Jascayd 18mg or 9mg groups compared to placebo for the key secondary composite endpoint (Jascayd 18mg and 9mg respectively: HR 1.17 and HR 1.03).
 - An event occurred in 21.7% of the Jascayd 18mg group, 20.2% in the Jascayd 9mg group, and 20.4% in the placebo group (*Richeldi et al 2025a*)
 - Survival was assessed.
 - In the FIBRONEER-IPF study population, the HR for all-cause mortality, assessed until the end of trial (up to 109 weeks), did not demonstrate a significant treatment difference for Jascayd 18mg or 9mg compared to placebo (HR 0.66 and HR 0.95, respectively).
 - The efficacy of Jascayd for PPF was assessed in a randomized, double-blind, placebo-controlled trial (FIBRONEER-ILD).
 - This study enrolled adult patients (N=1,178) with PPF with or without background treatment with nintedanib who were randomized to Jascayd 9mg BID, Jascayd 18mg BID, or placebo until the last patient received treatment for 52 weeks (blinded trial duration up to 109 weeks; end of trial duration up to 114 weeks). Randomization was stratified by the presence or absence of nintedanib therapy and by HRCT pattern using central review.
 - Enrolled patients had a mean age of 66 years (range 26 to 88), while 56% were male and 58% were White. At baseline, the mean FVC was 70% of predicted normal, 44% were on stable treatment with nintedanib, and 56% of patients were not treated with nintedanib (44% were treatment naïve and 12% previously discontinued nintedanib treatment).
 - On baseline HRCT, 71% of patients had UIP or UIP-like fibrotic pattern and 29% of patients had other fibrotic patterns. The underlying clinical IDL diagnoses were autoimmune ILDs (28%), hypersensitivity pneumonitis (20%), unclassifiable idiopathic interstitial pneumonia (20%), idiopathic nonspecific interstitial pneumonia (19%), and other ILDs (14%).
 - Patients with PPF were enrolled if they had relevant fibrosis (greater than 10% fibrotic features) on HRCT and presented with clinical signs of progression. Patients were required to be ≥18 years of age and to have an FVC ≥45% of predicted and a DLCO ≥25% of predicted. Prior to visit 1 and during screening, patients had to be on stable therapy with nintedanib and planned to stay on this background PPF therapy after randomization. Alternatively, patients were required to be naïve to or have previously discontinued nintedanib for at least 8 weeks and did not plan to start or restart background PPF treatment.
 - The primary endpoint in this study was the absolute change from baseline in FVC in mL at 52 weeks.
 - In this study population, there was less decline in absolute change from baseline in FVC in patients who received Jascayd compared with patients who received placebo (accounting for mortality), and this reduction in decline was statistically significant. The adjusted mean decline in patients receiving Jascayd 18mg or Jascayd 9mg was -86mL and -69mL, respectively, whereas in the placebo group, an adjusted mean decline of -152mL was observed. The respective treatment difference compared with the placebo group was 65mL and 83mL. FVC results across relevant subgroups were similar.
 - The key secondary endpoint in this trial was the time to the first occurrence of any of the components of the composite endpoint over the blinded duration of the trial (up to 109 weeks): acute ILD exacerbation, hospitalization for respiratory cause, or death.
 - Acute ILD exacerbation was defined as acute worsening or development of dyspnea typically less than 1 month duration, computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with fibrosing ILD, and deterioration not fully explained by cardiac failure or fluid overload. Neither acute ILD exacerbations nor respiratory hospitalizations were adjudicated.

- Overall, there was no statistically significant treatment difference in the hazard ratio (HR) for the Jascayd 18mg or 9mg groups compared to placebo for the key secondary composite endpoint (Jascayd 18mg or 9mg groups, respectively, compared to placebo: HR 0.77 and HR 0.88).
- In this study population, the HRs for all-cause mortality, assessed until the end of the trial, for Jascayd 18mg and 9mg compared to placebo were 0.51 and 0.51, respectively. These results were not prespecified for multiplicity control.

Clinical guidelines

- Note that guidelines do not include Jascayd as the guidelines were published prior to Jascayd being FDA approved.
- **Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Association Latino Americana de Torax (ALAT) Clinical Practice Guideline** (*Raghu et al 2022*).
 - Recommendations include not using antacids for respiratory outcome improvements in patients with IPF.
 - Treatment considerations for IPF include nintedanib and pirfenidone, while non-pharmacologic considerations include oxygen supplementation and pulmonary rehabilitation.
 - It is recommended to obtain further data on pirfenidone efficacy and safety for non-IPF interstitial lung disease (ILD) manifesting progressive pulmonary fibrosis (PPF) in general and specific types of non-IPF ILD manifesting PPF, as well as for nintedanib for specific types of non-IPF ILD manifesting PPF.
 - Nintedanib use is suggested for PPF treatment if patients have failed standard management for fibrotic ILD, other than IPF.
- **An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline** (*Raghu et al 2015*).
 - It is recommended against using certain treatments for IPF, including anticoagulants, imatinib, ambrisentan, and the combination of prednisone, azathioprine, and N-acetylcysteine.
 - The authors recommend using nintedanib and pirfenidone for treatment of IPF.

Safety summary

- **Contraindications:** None.
- **Box Warning:** None.
- **Warnings and precautions:** None.
- **Common adverse drug reactions:**
 - Listed % incidence for adverse drug reactions= reported % incidence for drug (Jascayd 18mg BID) minus reported % incidence for placebo in patients with IPF. Please note that an incidence of 0% means the incidence was the same as or less than placebo.
 - The most frequently reported adverse events included diarrhea (25%), COVID-19 (1%), upper respiratory tract infection (3%), depression (2%), weight decreased (3%), decreased appetite (4%), nausea (1%), fatigue (1%), headache (2%), vomiting (1%), back pain (2%), and dizziness (0%).
 - Listed % incidence for adverse drug reactions= reported % incidence for drug (Jascayd 9mg BID) minus reported % incidence for placebo for all grades in patients with IPF. Please note that an incidence of 0% means the incidence was the same as or less than placebo.

- The most frequently reported adverse events included nausea diarrhea (14%), COVID-19 (4%), upper respiratory tract infection (1%), depression (1%), weight decreased (2%), decreased appetite (4%), nausea (2%), fatigue (2%), headache (1%), vomiting (0%), back pain (1%), and dizziness (1%).

- **Drug interactions:**

- Nerandomilast is a CYP3A substrate.
 - Reduce the dosage to 9mg BID when used concomitantly with strong CYP3A inhibitors.
 - Avoid the use of Jascayd with strong or moderate CYP3A inducers.
- Concomitant use of Jascayd with pirfenidone decreases exposure of nerandomilast. When Jascayd was used concomitantly with pirfenidone in patients with IPF in a phase-3 study, efficacy was not observed with the Jascayd 9mg BID dosage.
 - The recommended dosage of Jascayd is 18mg BID when used concomitantly with pirfenidone. Do not reduce the dosage to 9mg BID.

- **Special populations:**

- There is no pregnancy category for this medication; however, the risk summary indicates that there are no available data on use in pregnant women to assess for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are maternal and fetal risks associated with untreated IPF and PPF during pregnancy. Based on findings from animal studies, Jascayd may increase the risk for fetal loss. Advise pregnant women and females of reproductive potential of the potential risk of fetal loss.
- The safety and efficacy of use have not been established in the pediatric population.

Conclusion

- Idiopathic pulmonary fibrosis (IPF) is a distinct kind of idiopathic interstitial pneumonia, a category of conditions that cause interstitial lung disease (ILD). IPF is classified as a chronic fibrosing interstitial pneumonia, that is a progressing disease limited to the lung and results from an abnormal wound healing activity causing a deposition of changed extracellular matrix as well as scarring and disturbance of alveolar design (*Richeldi et al 2025*).
- Progressive pulmonary fibrosis (PPF) is a specific type of progressive and fibrotic disease that occurs in cases of ILD other than in IPF that is described per clinical symptoms, lung function, and imaging of the chest irrespective of the underlying disorder (*Kang and Song 2023*).
- Jascayd is a PDE4 inhibitor indicated for:
 - The treatment of IPF in adult patients.
 - The treatment of PPF in adult patients.
- The efficacy of Jascayd for IPF was assessed in two randomized, double-blind, placebo-controlled trials.
 - FIBRONEER-IPF included adult patients (N=1,177) with IPF with or without background antifibrotic treatments (nintedanib or pirfenidone) who were randomized to receive Jascayd 9mg or 18mg, or placebo.
 - The primary endpoint was the absolute change from baseline in FVC at 52 weeks.
 - Results suggested that there was less decline in absolute change from baseline in FVC in the Jascayd group compared to placebo, and this reduction in decline was statistically significant.
 - Note that efficacy was not observed in patients who received Jascayd 9mg BID with pirfenidone as background antifibrotic treatment. Thus, the recommended dosage of Jascayd is 18mg BID when used concomitantly with pirfenidone.
 - The main secondary endpoint was time to first occurrence of any of the components of the composite endpoint over the blinded duration of the trial: acute IPF exacerbation, hospitalization for respiratory cause, or death.

- Overall, there was no statistically significant treatment difference in HR for the Jascayd 18mg or 9mg groups compared to placebo for this endpoint (HR 1.17 and HR 1.03, respectively).
- The HR for all-cause mortality, a secondary endpoint, did not demonstrate a significant treatment difference for Jascayd 18mg or 9mg as compared with placebo.
- Trial 2 was a 12-week trial that included adults (N=147) with IPF with or without background antifibrotic treatments who were randomized to Jascayd 18mg or placebo.
 - Patients in the Jascayd 18mg group compared to placebo, with or without background antifibrotic treatments, had a reduction in FVC decline at week 12 of 91mL.
- The efficacy of Jascayd for PPF was assessed in one randomized, double-blind, placebo-controlled trial.
 - The study enrolled adults with PPF with or without background treatment with nintedanib, and the primary endpoint was the absolute change from baseline in FVC in mL at 52 weeks.
 - Results suggested that there was less decline in absolute change from baseline in FVC in patients receiving Jascayd compared with placebo, and this reduction in decline was statistically significant.
- Guidelines do not currently include Jascayd (nerandomilast) but do recommend pirfenidone or nintedanib.
- Jascayd offers providers another treatment option, and use has been studied with and without background antifibrotic treatments (nintedanib or pirfenidone). Comparator treatments with Jascayd include Ofev (nintedanib) and Esbriet (pirfenidone).
- There is no evidence to suggest that Jascayd is safer or more effective than other currently preferred, more cost-effective medications. It is therefore recommended that Jascayd remain non-preferred and require prior authorization and be available to those who are unable to tolerate or who have failed on preferred medications.
- **PDL Placement:**
 - Preferred
 - Non-Preferred with Conditions

References

- Jascayd Package insert. Boehringer Ingelheim Pharmaceuticals, Inc; December 2025.
- Kang HK, Song JW. Progressive pulmonary fibrosis: where are we now? *Tuberc Respir Dis.* 2023; 82(2): 123-133.
- King Jr. TE. Treatment of idiopathic pulmonary fibrosis. UpToDate Web site. Updated February 2, 2026. Accessed February 3, 2026. www.uptodate.com.
- National Institute of Health (NIH). National Heart, Lung, and Blood Institute. What is idiopathic pulmonary fibrosis. Updated June 26, 2023. Accessed February 3, 2026. [Pulmonary Fibrosis - What Is Idiopathic Pulmonary Fibrosis? | NHLBI, NIH](https://www.nhlbi.nih.gov/health-topics/idiopathic-pulmonary-fibrosis).
- Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an Update) and Progressive Pulmonary Fibrosis in adults: An official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med.* 2022; 205(9):e18-e48. doi: 10.1164/rccm.202202-0399ST.
- Raghu G, Rochweg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT Clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med.* 2015; 192(2):e3-19.
- Richeldi L, Trow TK, Qaseem A. Idiopathic pulmonary fibrosis. Dynamed Web site. Updated December 22, 2025. Accessed February 3, 2026. www.dynamed.com.
- Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. *NEJM.* 2025a; 392(22); 2193-2202. doi: 10.1056/NEJMoa2414108.

Publication Date: February 2026.

2026
Vol. 38
No. 2



*The Bulletin of
Medicaid Drug
Utilization Review
in Iowa*

DUR Commission Members

Melissa Klotz, PharmD, Chairperson ♦ Jason Kruse, DO, Vice-Chairperson
Rhea Hartley, MD ♦ Holly Randleman, PharmD ♦ Jennifer Johnson, PharmD ♦ Bryon Schaeffer, MD
Charles Wadle, DO ♦ Caitlin Reinking, PharmD ♦ Jordan Thoman, PharmD ♦ Abby Cate, PharmD

DUR Professional Staff

Pamela Smith, RPh, DUR Project Coordinator

Optimizing SGLT2 Inhibitor Use in Chronic Kidney Disease

Chronic kidney disease (CKD) affects millions of adults and is associated with risks of kidney failure, cardiovascular disease, and hospitalization. Sodium glucose cotransporter-2 (SGLT2) inhibitors have emerged as foundational therapy in CKD management, with strong evidence demonstrating renal and cardiovascular protection independent of glycemic control. Current guidelines now recommend SGLT2 inhibitors as first-line therapy in eligible patients with CKD at risk of progression, with or without diabetes.

Guideline Recommendations at a Glance

[Kidney Disease: Improving Global Outcomes \(KDIGO\) 2024 Clinical Practice Guideline](#)

- Recommend initiating an SGLT2 inhibitor in adults with CKD and albuminuria, with or without diabetes
- Initiate with an estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m²
- Continue even if eGFR falls below 20 mL/min/1.73 m²

[American Diabetes Association \(ADA\) Standards of Care in Diabetes – 2026](#)

[Chronic Kidney Disease and Risk Management](#)

- Recommend initiating an SGLT2 inhibitor with demonstrated benefit in adults with type 2 diabetes (T2D) with CKD and albuminuria (irrespective of A1C)
- Initiate at an eGFR ≥ 20 mL/min/1.73 m²
- Continue until dialysis or transplant

SGLT2 Inhibitors with Kidney Outcome Data

- Canagliflozin (Invokana)
- Dapagliflozin (***Farxiga***)
- Empagliflozin (***Jardiance***)

Notes

- Glucose-lowering effect is minimal at an eGFR < 45 mL/min/1.73 m²
- SGLT2 inhibitors should not be used in type 1 diabetes (T1D)
- Preferred agents (as of [January 1, 2026 PDL](#)) are shown in bold and italicized text
- No prior authorization is required for preferred agents

The DUR Commission recently identified members with a diagnosis of CKD without an SGLT2 inhibitor in their pharmacy claims. Despite robust evidence demonstrating renal protection and guideline directed recommendations for use, data suggests that uptake with these agents in the Iowa Medicaid population has been slow. In an effort to share this information with prescribers, DUR letters were sent recommending the addition of an SGLT2 inhibitor when appropriate and outlining the [Preferred Drug List](#) (PDL) status of SGLT2 agents.

Below is a list of all single agent SGLT2 inhibitors and their FDA-approved indications. Preferred agents (as of January 1, 2026) are shown in bold and italicized text.

Single Agent SGLT2 Inhibitors and their FDA-Approved Indications

| Medication | FDA-Approved Indications |
|--|--|
| Dapagliflozin <i>(Farxiga)</i> | <ul style="list-style-type: none"> • Type 2 diabetes (adults and children ≥ age 10) • Heart failure (regardless of ejection fraction) • CKD with or without diabetes |
| Empagliflozin <i>(Jardiance)</i> | <ul style="list-style-type: none"> • Type 2 diabetes (adults and children ≥ age 10) • Cardiovascular death risk reduction in T2D + CVD • CKD risk reduction |
| Canagliflozin (Invokana) | <ul style="list-style-type: none"> • Type 2 diabetes (adults) • Cardiovascular death risk reduction in T2D + CVD • Diabetic kidney disease with albuminuria: delay CKD progression and reduce heart failure |
| Ertugliflozin (Steglatro) | <ul style="list-style-type: none"> • Type 2 diabetes (adults) |

CKD – chronic kidney disease; CVD – cardiovascular disease; T2D – type 2 diabetes

FDA Warning about Vitamin B6 Deficiency and Associated Seizures for Carbidopa/Levodopa Drug Containing Products

The U.S. Food and Drug Administration (FDA) is requiring the addition of a warning to the prescribing information for carbidopa/levodopa agents to inform clinicians that these agents may cause vitamin B6 deficiency and vitamin B6 deficiency-associated seizures.

Clinicians should evaluate vitamin B6 levels before starting treatment with these agents, and if symptoms of vitamin B6 deficiency appear during treatment. Higher doses of carbidopa/levodopa have been associated with an increased risk of vitamin B6 deficiency. Seizures associated with the use of these products do not respond to traditional anti-seizure medications but are resolved after administration of vitamin B6.

[Drug Safety Communication](#)

**Medicaid Statistics for Prescription Claims
March through May 2026**

| | FFS | Wellpoint | Iowa Total Care | Molina Healthcare |
|--|------------|------------------|------------------------|--------------------------|
| Total \$ Paid | | | | |
| # Paid Claims | | | | |
| Unique Users | | | | |
| Avg Cost/Rx | | | | |
| Top 5 Therapeutic Class by RX Count <small>Therapeutic class taxonomy may differ among each plan</small> | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Top 5 Therapeutic Class by \$ Amount <small>(pre-rebate) Therapeutic class taxonomy may differ among each plan</small> | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Top 5 Drugs by Prescription Count | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Top 5 Drugs by Paid Amount <small>(pre-rebate)</small> | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |